UBC DEPARTMENT OF MEDICINE
2005
ANNUAL REPORT
TABLE OF CONTENTS
MESSAGE FROM DR. GRAYDON MENEILLY….….….….………………………………3 MISSION STATEMENT.……………………………………………………...……………….7 ORGANIZATION CHART.………………………………………………...………………….9 UBC DEPARTMENT OF MEDICINE COMMITTEE STRUCTURES………………..…11 UBC DEPARTMENT OF MEDICINE ADMINISTRATIVE OFFICE...………………….13 UBC DEPARTMENT OF MEDICINE COMMITTEES..………………………………….. 15 Department Heads, Associate Heads, UBC Division Heads, Educational Program Directors & Associate Directors.………………………………………… 17 Research………………………………………………………………………………………….19 Committee for Appointments, Reappointments, Promotion and Tenure.………………………. 21 Teaching Effectiveness Office.…………………………………………………………………..25 DIVISION REPORTS.…………………………………………………………………………27 Allergy & Immunology.………………………………………………………………………… 29 Cardiology.……………………………………………………………………………………….33 Critical Care Medicine.…………………………………………………………………………..45 Dermatology.……………………………………………………………………………………. 49 Endocrinology.………………………………………………………………………………….. 55 Gastroenterology.…………………………………………………………………………….…. 59 General Internal Medicine.……………………………………………………………………… 63 Geriatric Medicine.……………………………………………………………………………… 67 Hematology.…………………………………………………………………………………….. 71 Infectious Diseases.………………………………………………………………………………75 Medical Oncology.……………………………………………………………………………… 81 Nephrology.…………………………………….……………………………………………..… 87 Neurology.……………………………………….…………………………………………….... 93 Occupational Medicine…………………………………………………………………………109 Physical Medicine & Rehabilitation.…………………………………………………………...113 Respiratory Medicine.…………………………………………………………………………..117 Rheumatology.………………………………………………………………………………….121 EDUCATIONAL PROGRAMS.…………………………………………………………….. 127 Clinical Investigator Program.…………………………………………………………………. 129 Continuing Medical Education Program..……………….…………………………..………… 135 Graduate Studies Program in Experimental Medicine….……………………………………… 137 HIV/AIDS Research Program..…………………………………………………………………141 Postgraduate Education Program.……………………………………………………………… 147 Undergraduate Education Program.……………………………………………………………. 151 PUBLICATIONS….………………………………………………………………………….. 153 GRANTS AND RESEARCH AWARDS.………………………………………………..….. 208
UBC Department of Medicine Page 1 Annual Report 2005
Message From Dr Graydon Meneilly
Graydon S. Meneilly, MD, FRCPC Eric W. Hamber Professor & Head UBC Department of Medicine
I am pleased to provide this overview for the 2005 annual report on behalf of the UBC Department of Medicine. This report is also available on the internet at www.medicine.ubc.ca
Overview
The UBC Department of Medicine provides research, teaching and clinical services related to the nature, cause and prevention of adult diseases. We are the largest Department in the Faculty of Medicine and we consist of 18 divisions: Allergy and Immunology, Cardiology, Community Internal Medicine, Critical Care, Dermatology, Endocrinology, Gastroenterology, Geriatric Medicine, Internal Medicine, Hematology, Infectious Diseases, Medical Oncology, Nephrology, Neurology, Occupational Medicine, Physical Medicine and Rehabilitation, Respiratory Medicine and Rheumatology.
Members
As you read through this document you encounter the many different aspects of our Department and the things we have achieved over the past year. I would like to take this opportunity to highlight some of the many wonderful accomplishments of our members. In particular I would like to highlight the contributions of Dr Paul Man, Associate Head of Medicine at UBC and Chair, Department of Medicine at Providence Health Care. He is absolutely integral to the function of the Department and all of our strategic initiatives.
Recruitment and retention are a large part of our business. We have appointed 4 Professors, 3 Associate Professors, 1 Assistant Professor, 2 Clinical Professors, 1 Clinical Associate Professor, 21 Clinical Assistant Professors, 8 Clinical Instructors, 1 Adjunct Professor and 1 Associate Member. We have promoted 23 Faculty members effective July 1, 2005.
UBC Department of Medicine Page 3 Annual Report 2005 Our faculty received 5 CIHR Scholarship/Scientist awards, 16 Michael Smith Scholarships/Scientist awards, 7 CRC Scientist awards and 6 Scholarship/Scientist awards from other peer reviewed agencies.
Dr Harvey Lui stepped down as Associate Head of Medicine, UBC and Vancouver Acute, on August 31, 2005. I wish to express a sincere thank you to Harvey for all his efforts on behalf of myself and the department. I am pleased to announce that Dr Michael Barnett was appointed Associate Head of Medicine, UBC and Vancouver Acute effective September 1, 2005.
I am particularly pleased to announce the appointment of Dr Janet McElhaney, Head, UBC Division of Geriatric Medicine from October 1, 2005. Dr. McElhaney received her medical training at the University of Alberta and completed her residency in Internal Medicine and Geriatric Medicine at that institution. She was previously on staff at the University of Connecticut Health Centre, in Hartford.
Dr John Fleetham stepped down as Division Head for the UBC Division of Respiratory Medicine on June 30, 2005. His stewardship and support of departmental priorities have been exemplary and I wish to express a sincere thank you for all his efforts on behalf of myself and the department. Dr Paul Man was appointed Acting Head, UBC Division of Respiratory Medicine July 1, 2005.
Awards
The Department extends its warmest congratulations to these outstanding individuals who received the following Departmental awards: The Fay R. Dirks Awards for Excellence in Teaching were awarded to Drs. Roger Wong (Geriatric Medicine) and Rose Hatala (General Internal Medicine); The Martin M. Hoffman Awards for Excellence in Research were awarded to Drs. Diane Lacaille (Rheumatology) and Don Sin (Respiratory); The Donald M. Whitelaw Awards for Outstanding Grand Rounds were given to Drs. Heather Finlayson, Andrew Travlos & Russell O’Connor (Physical Medicine & Rehabilitation) and Julio Montaner (Infectious Diseases); The Master Teacher Awards were given to Drs. Jeff Beckman (Neurology) and Barry Kassen (General Internal Medicine).
In addition, members of the department were recognized by the faculty and other bodies for their excellence in teaching and research: Dr. G. B. John Mancini (Cardiology) was appointed an Elite Reviewer for the Journal of the American College of Cardiology; Dr. Dwight Peretz (Cardiology) was elected to Mastership by the Board of Regents of the American College of Physicians, Internal Medicine; Dr John Esdaile (Rheumatology) received the Canadian Rheumatology Association Distinguished Investigator Award; Dr Juan Ronco (Critical Care Medicine) received a commendation for contributions to the 2004 Acute Critical Events Simulation (ACES) Program; Dr Harvey Lui was elected as President of the Canadian Dermatology Association; Dr Alastair McLeod (Dermatology) was appointed as Honorary Member of the Canadian Medical Association; Dr Jolanda Cibere (Rheumatology) received the Networks of Centres of Excellence Young Innovators Award; Dr Gordon Page (General Internal Medicine) received a 2005 Award for Outstanding Achievement in the Evaluation of Clinical Competence by the Medical Council of Canada; Drs. Robert Brunham & Neil Reiner (Infectious Diseases) received a BC Genome Award; Dr Dean Johnston (Neurology) received the Roche UBC Department of Medicine Page 4 Annual Report 2005 Award for Excellence in Clinical Skills Teaching; Dr Hugh Chaun (Gastroenterology) received an Award of Excellence of the College of Physicians and Surgeons of BC; Dr Isabella Tai (Gastroenterology) was awarded a Michael Smith Foundation for Health Research Career Investigator Senior Scholar Award for Biomedical Research; Dr John Gill (Nephrology) was awarded a Michael Smith Foundation for Health Research Career Investigator Scholar Award for Health Sciences Research and a Michael Smith Clinical Investigator Award; Dr Jim Busser (General Internal Medicine) received the Bobby Miller Award for Excellence in Teaching; Dr Yu Tian Wang (Neurology) was awarded the UBC Killam Research Prize in Junior Science; Dr Peter Pare (Respiratory Medicine) was awarded the UBC Killam Research Prize in Senior Science; Dr Stephan van Eeden (Respiratory Medicine) received the William Thurlbeck Distinguished Researcher Award; Dr Kenneth Blocka (Rheumatology) received the Clinical Faculty Award for Excellence in Teaching; Dr Barry Koehler (Rheumatology) and Dr Ted Wilkins (Endocrinology) both received UBC Career Awards for Excellence in Teaching; and Dr Richard Klasa (Medical Oncology) received a PAR-BC Residents’ Advocate Award.
One of the Department's most important strategic initiatives is the creation of the Academic Enhancement Endowment Fund and the Academic Enhancement Fund competition process. These awards are provided in an effort to ensure greater protected research time for individuals undertaking meritorious research. This fund has taken on greater importance as the endowment has grown and as the awards have increased. The recipients of the Academic Enhancement Endowment Fund awards in 2005 were Drs. Jason Barton (Neurology), Victoria Cook (Respiratory) and Sharlene Gill (Medical Oncology). Recipients are termed Departmental Scholars.
Clinical
The foundation of all activities in a Department of Medicine is exemplary patient care. Maintaining the highest quality of care has been challenging due to resource constraints, but our members continue to provide excellent care to the citizens of Vancouver and the province of British Columbia. The Regional Medical Council has made some progress in this regard. Our efforts have resulted in a modest increment in medical beds, a regional stroke initiative, improved access to interventional cardiology in our health region, new programs for the frail elderly and an innovative hostel unit for intravenous drug users who require prolonged antibiotic therapy.
Research
Once again the department was extremely successful in attracting research support. The department received $ 25,561,231.00 in peer reviewed grants and $ 26,727,911.00 in non-peer reviewed grants.
The number of high profile peer reviewed papers by members of the department continues to increase. The department published more than 680 peer reviewed papers in the last year in journals of the highest impact including the New England Journal of Medicine, JAMA and many others. These research contributions highlight the fact that many groups within the department are among the best in the world in their area of expertise.
UBC Department of Medicine Page 5 Annual Report 2005 Teaching
Our medical school will double in size in the next few years and we have implemented a unique model of distributed education. Our department has performed pilot clerkships in Victoria, Prince George and other venues in the province and we look forward to implementation of the distributed curriculum in the fall. Our postgraduate training programs continue to thrive. Our core and subspecialty programs have doubled in size. We continue to attract the highest quality trainees from around the country. Our resident research day is outstanding in size, scope and quality. Thanks to the efforts of Dr Roger Wong and our postgraduate team, we have implemented a new curriculum for teaching quality improvement to our residents. We are excited about our plan to implement a research track for our core program in the next academic year. We hope this will help to address the looming shortage of clinical investigators in the near future.
Summary
In closing I would like to take this opportunity to once again acknowledge the contributions of all Faculty and Staff and to thank them for their hard work, outstanding achievements and dedication to the success of the Department of Medicine.
Sincerely,
Graydon S. Meneilly, MD, FRCPC Eric W. Hamber Professor & Head UBC Department of Medicine
UBC Department of Medicine Page 6 Annual Report 2005
MISSION STATEMENT
We, the members of the Department of Medicine of the University of British Columbia, will work with all our partners to provide the highest possible standard of excellence in patient care, teaching and research. We will pursue this mission while emphasizing open communication and ethical behavior, and while recognizing that it is a privilege to provide responsible and innovative stewardship of human, financial and all other resources. We will always:
• respect the dignity, individuality and needs of our patients,
• strive to discover new knowledge that will advance state-of-the- art care,
• ensure effective and innovative teaching of our students,
• optimize our organization to promote both professional and personal fulfillment,
• value the efforts and achievements of teams and individuals who work to face the challenges of modern medicine.
These activities will ensure the respect of our peer organizations and recognition as a world-class Department of Medicine.
UBC Department of Medicine Page 7 Annual Report 2005
ORGANIZATION CHART
Dean UBC Faculty of Medicine
Head UBC Department of Medicine
Associate Heads, Heads & Directors of Divisions UBC Dept. of Medicine & Programs of UBC Heads, Hosp. Dept. of Medicine Department of Medicine
Heads & Directors of Divisions & Programs of the Hospital Departments of Medicine
Members, Divisions & Programs of the Hospital Departments of Medicine
UBC Department of Medicine Page 9 Annual Report 2005
UBC DEPARTMENT OF MEDICINE COMMITTEE STRUCTURES
Head UBC Department of Medicine
Academic Appointments Executive Committee UBC Quarterly / Reappointments Promotion & Tenure Committee
Teaching Effectiveness UBC Division Heads UBC Educational All Faculty Committee Program Directors
Allergy & Immunology Infectious Diseases Continuing Medical Education
Cardiology Medical Oncology Graduate/Experimental Medicine
Critical Care Medicine Nephrology Postgraduate
Endocrinology Neurology Undergraduate
Gastroenterology Occupational Medicine Clinical Investigator Program
General Internal Physical Medicine & Medicine Rehabilitation
Geriatric Medicine Respiratory Medicine
Hematology Rheumatology
UBC Department of Medicine Page 11 Annual Report 2005
UBC DEPARTMENT OF MEDICINE – ADMINISTRATION OFFICE
Department Head Division Heads Associate Heads
Administration Undergraduate Postgraduate Experimental Clinical Continuing Director Program Program Medicine Program Investigator Medical Director Director Director Program Education Directors Director
Associate Information Human Finance Undergraduate Program Continuing Technology Resources Manager Program Directors Medical Systems Manager Administrator Education Consultant Administrator Postgraduate Faculty Hires Finance Clerk Admin. Asst. Undergraduate Administrator Experimental Clinical & Promotions (UBC) Program Medicine Investigator Coordinator Secretary (VGH) Program Program Secretary Secretary (SPH) (40%) HR Assistant STI Clerk Admin. Asst. Undergraduate Postgraduate (Staff) (60%) (Hospital) Program Program Secretary (SPH) Assistant
HR Assistant (Faculty) CV Postgraduate Secretary / Program Secretary, Secretary Assoc. Head, Receptionist Research Postgraduate Program Secretary (SPH) (40%) UBC DIVISIONS
Allergy & Immunology Critical Care Medicine General Internal Medicine Infectious Diseases Neurology Respiratory Medicine Cardiology Endocrinology Geriatric Medicine Medical Oncology Occupational Medicine Rheumatology Community Internal Medicine Gastroenterology Hematology Nephrology Physical Med & Rehab
UBC Department of Medicine Page 13 Annual Report 2005
UBC DEPARTMENT OF MEDICINE COMMITTEES
UBC Department of Medicine Page 15 Annual Report 2005
DEPARTMENT HEADS, ASSOCIATE HEADS, UBC DIVISION HEADS, EDUCATIONAL PROGRAM DIRECTORS & ASSOCIATE DIRECTORS
DEPARTMENT HEADS
Graydon S. Meneilly, MD, FRCPC Eric W. Hamber Professor & Head Department of Medicine UBC & VGH
S. F. Paul Man, MD, FRCPC Chair, Department of Medicine Providence Health Care
UBC ASSOCIATE HEADS
Dr. Harvey Lui, Associate Head of Medicine, Vancouver Acute (Jan - Aug 31, 2005) Dr. Michael Barnett, Associate Head of Medicine, Vancouver Acute (Sept 1, 2005 - ) Dr. S. F. Paul Man, Associate Head of Medicine, Providence Health Care Dr. Doris Doudet, Associate Head Research, Vancouver Acute Dr. Peter Pare, Associate Head Research, Providence Health Care
UBC DIVISION HEADS
Allergy & Immunology Dr. Robert Schellenberg Cardiology Dr. Chris Buller Critical Care Medicine Dr. John Fenwick Dermatology Dr. Harvey Lui Endocrinology & Metabolism Dr. David Thompson Gastroenterology Dr. Urs Steinbrecher General Internal Medicine Dr. Iain Mackie, (Acting) Geriatric Medicine Dr. Larry Dian, (Acting) (Jan 1 - Sept 30, 2005) Dr. Janet McElhaney (Oct 1, 2005 - ) Hematology/Bone Marrow Transplantation Dr. Michael Barnett Infectious Diseases Dr. Neil Reiner Medical Oncology Dr. Joseph Connors, (Acting) (Jan 1 - Feb 28, 2005) Dr. Susan O'Reilly (on sabbatical) (Jan 1 - Feb 28, 2005) Nephrology Dr. Paul Keown Neurology Dr. Howard Feldman Physical Medicine & Rehabilitation Dr. Theo Van Rijn Respiratory Medicine Dr. John Fleetham (Jan - June 2005) Dr. Paul Man (Acting) (July 1, 2005 - ) Rheumatology Dr. John Esdaile
UBC Department of Medicine Page 17 Annual Report 2005 EDUCATIONAL PROGRAM DIRECTORS & ASSOCIATE DIRECTORS
Clinical Investigator Program Directors Dr. Anita Palepu Dr. Adeera Levin
Continuing Medical Education Director Dr. G. B. John Mancini
Graduate Studies Program in Dr. Vince Duronio Experimental Medicine Director
HIV/AIDS Research Program Director Dr. Julio Montaner
Postgraduate Education Program Dr. J. Mark Roberts Director
Associate Directors Dr. Roger Wong Dr. Rose Hatala Dr. Barry Kassen
Undergraduate Education Program Director Dr. Grant Stiver
Associate Directors Dr. Jim Dunne, 3rd year, St Paul's Dr. Jim Busser, 3rd year, VGH Dr. Reva Adler, 4th year Dr. Janet Kushner-Kow, Expansion & New Programs
UBC Department of Medicine Page 18 Annual Report 2005 RESEARCH
Doris J. Doudet Professor & Associate Head
In July 2004, Dr. Doris J. Doudet accepted the position of Associate Head, Research. As a prolific investigator and having experienced firsthand the obstacles that challenge anyone embarking on a career in research, her desire is to facilitate and promote research activity within the Department.
It was in this spirit that she undertook the formidable task of creating a web-based guide, targeted specifically for new investigators, but useful for experienced investigators as well as it contains many useful links. The guide provides investigators with critical information on the research application process, taking the wealth of information available from a variety of sources and organizing it in a logical and accessible format. The guide also provides useful links and basic information, such as setting up a campus-wide log-in account and preparing a CV. Since its implementation in October 2005, the guide has been a great resource for new and experienced investigators alike.
Dr. Doudet has also laid the groundwork for the creation of a web-based database containing the research interests of all faculty members. Once this database is set up, it will be made available to all new investigators to assist them in networking with faculty members who share their research interests, as well as to potential students and residents looking for research mentors. Currently, Dr. Doudet is exploring avenues for hosting this database in a friendly web-based system.
Finally, Dr. Doudet has formed a Research Strategic Committee with the objective of increasing the profile of research in the Department. The Committee held its first meeting in December 2005.
UBC Department of Medicine Page 19 Annual Report 2005
COMMITTEE FOR APPOINTMENTS, REAPPOINTMENTS, PROMOTION AND TENURE
Chair: Dr. G. S. Meneilly, Professor Administrative Secretary: Jeannie Brown
Dr. Noel Buskard, Clinical Professor - Hematology January 2005 to June 2005 Dr. John Cairns, Professor - Cardiology January 2005 to December 2005 Dr. Doris Doudet, Professor - Neurology January 2005 to December 2005 Dr. John Esdaile, Professor - Rheumatology January 2005 to December 2005 Dr. Karen Gelmon, Clinical Professor - Medical Oncology January 2005 to June 2005 Dr. Paul Hoskins, Clinical Professor - Medical Oncology January 2005 to December 2005 Dr. Simon Huang, Clinical Associate Professor - Rheumatology June 2005 to December 2005 Dr. Keith Humphries, Professor - Hematology January 2005 to December 2005 Dr. Paul Keown, Professor - Nephrology January 2005 to December 2005 Dr. Nasreen Khalil, Clinical Professor - Respiratory Medicine June 2005 to December 2005 Dr. Barry Koehler, Clinical Professor - Rheumatology January 2005 to December 2005 Dr. Harvey Lui, Professor - Dermatology January 2005 to June 2005 Dr. John Mancini, Professor - Cardiology January 2005 to December 2005 Dr. Nevin Murray, Clinical Professor - Medical Oncology January 2005 to December 2005 Dr. Donald Ricci, Clinical Professor - Cardiology January 2005 to December 2005 Dr. Robert Schellenberg, Professor - Allergy and Immunology June 2005 to December 2005
This dedicated group of committed Departmental members is charged with facilitating the career advancement of our members while upholding consistent and rigorous standards as set out by UBC. As usual, this Committee invested a great deal of thoughtful energy to support the additions and promotions listed below. We are very proud of the following:
NEW APPOINTMENTS
Badii, Maziar – Rheumatology - Clinical Assistant Professor Baruni, Rida - Physical Medicine and Rehabilitation - Clinical Assistant Professor Blackwell, Margaret - Community Internal Medicine - Clinical Instructor Cass, Aaron – Nephrology - Clinical Assistant Professor
UBC Department of Medicine Page 21 Annual Report 2005 Cashman, Neil – Neurology - Professor Choi, Hyon – Rheumatology - Associate Professor Cohen, Richard - Respiratory Medicine - Clinical Assistant Professor Cowan, Bryce – Dermatology - Clinical Instructor Curt, Armin – Neurology - Associate Professor Da Roza – Nephrology - Clinical Assistant Professor Foltz, Lynda – Hematology - Clinical Instructor Gill, Shavinder - Community Internal Medicine - Clinical Assistant Professor Gross, Lyle - Physical Medicine and Rehabilitation - Adjunct Professor Henderson, William, Critical Care Medicine – Clinical Instructor Hogg, Robert - Professor Isac, George - Critical Care Medicine - Associate Member Kerr, Thomas - Infectious Diseases - Clinical Assistant Professor Lansdorp, Peter – Hematology - Professor Laskin, Janessa - Medical Oncology - Clinical Assistant Professor Lefebvre, Yvonne - Clinical Professor Lohrisch, Caroline - Medical Oncology - Clinical Assistant Professor Lysyshyn, Mark - General Internal Medicine - Clinical Instructor Ma, Irene - General Internal Medicine - Clinical Assistant Professor MacRitchie, Donald - Community Internal Medicine - Clinical Instructor Maung, Tun Zan - Community Internal Medicine - Clinical Assistant Professor Mayo, John - Cardiology - Associate Professor McElhaney, Janet - Geriatric Medicine - Professor Miller, David - Community Internal Medicine - Clinical Assistant Professor Min, Simon - Community Internal Medicine - Clinical Assistant Professor Mirzanejad, Yazdan - Infectious Diseases - Clinical Instructor Mitenko, Paul - General Internal Medicine - Clinical Professor Moore, David - Infectious Diseases - Clinical Assistant Professor Moss, Robert – Cardiology - Clinical Assistant Professor Offer, Robert – Rheumatology - Clinical Associate Professor Petrossian, Caroline - Geriatric Medicine - Clinical Instructor Pillay, Willie – Geriatric Medicine – Clinical Assistant Professor Ramanathan, Krishnan - Cardiology - Clinical Assistant Professor Sherk, Peter – Community Internal Medicine – Clinical Assistant Professor Singh, Andrew - Clinical Assistant Professor Tebbutt, Scott - Respiratory Medicine - Clinical Assistant Professor Williams, Dave - Clinical Assistant Professor Zypchen, Leslie - Hematology, Clinical Instructor
PROMOTIONS
Professor: Levy, Robert - Respiratory Medicine Van Eeden, Stephanus - Respiratory Medicine
Associate Professor: Sandford, Andrew - Respiratory Medicine UBC Department of Medicine Page 22 Annual Report 2005 Clinical Professor: Nevill, Thomas - Hematology Webb, John - Cardiology Wong, HC George - Allergy and Immunology
Clinical Associate Professor: Beckman, Jeff- Neurology Forrest, Donna -Hematology Keyes, Robert - Neurology Klinkhoff, Alice - Rheumatology Magee, Laura - General Internal Medicine Toze, Cynthia - Hematology Van Rijn, Theo - Physical Medicine and Rehabilitation
Clinical Assistant Professor: Copland, Michael - Nephrology Devonshire, Virginia - Neurology Ellard, Susan - Medical Oncology Gill, Sabrina - Endocrinology and Metabolism Hughes, Barbara - Physical Medicine and Rehabilitation Koo, David - Physical Medicine and Rehabilitation Sirrs, Sandra - Endocrinology and Metabolism Underwood, Heather - Physical Medicine and Rehabilitation Wilson, Jennifer - Respiratory Medicine Woolfenden, Andrew - Neurology
REAPPOINTMENTS
Ayas, Najib - Respiratory Medicine - Assistant Professor Dorscheid, Delbert - Critical Care Medicine - Assistant Professor Gill, John - Nephrology - Assistant Professor Grigg, Michael - Infectious Diseases - Assistant Professor Humphries, Karen - Cardiology - Assistant Professor
EMERITUS STATUS Beattie, Lynn – Geriatric Medicine – Professor Emeritus Wilkins, Graeme – Endocrinology – Clinical Professor Emeritus
UBC Department of Medicine Page 23 Annual Report 2005
TEACHING EFFECTIVENESS OFFICE
Dr. James Busser Chair; Member, UBC Division of General Internal Medicine
Mrs. Jennifer Golinski Administrator; Undergraduate Education, UBC Department of Medicine
Ms. Katya Leonardia Assistant to Department Head’s Secretary, UBC Department of Medicine
Reports to:
Committee for Appointments, Reappointments, Promotions and Tenure
Functions:
1. Provides Faculty member with "Guidelines" for producing necessary back-up documentation to Teaching Dossier.
2. Meets with Faculty member to discuss necessary back-up documentation and process involved in review for promotion/tenure/reappointment.
3. Liaises with various program offices: Undergraduate, Postgraduate, Continuing Medical Education, Graduate Studies to obtain information regarding teaching effectiveness of candidate. Where necessary, requests additional peer review of teaching.
4. Reviews teaching dossier, back-up documentation, peer review and prepares draft report for Committee for Appointments, Reappointments, Promotions and Tenure.
5. Forwards draft report to Faculty member to ensure that important information has not been omitted.
6. Finalizes report and forwards to Committee for Appointments, Reappointments, Promotions and Tenure.
In the year 2004, the Teaching Effectiveness Committee prepared 18 letters on behalf of GFT and Clinical Faculty. Subsequent promotions for these faculty have included:
(4) Professor (1) Associate Professor (2) Clinical Professor (5) Clinical Assistant Professor (4) Clinical Associate Professor
UBC Department of Medicine Page 25 Annual Report 2005 In the year 2005 we met with another 28 faculty, and have prepared 28 letters to support their review and/or consideration of promotion.
UBC Department of Medicine Page 26 Annual Report 2005
DIVISION REPORTS
UBC Department of Medicine Page 27 Annual Report 2005
ALLERGY & IMMUNOLOGY
Dr. R. Robert Schellenberg Professor & Head
Faculty Members
Professor & Head Schellenberg, Dr. Robert SPH Clinical Professor Wong, Dr. HC George VA Clinical Associate Professor Mandl, Dr. Michael SPH Clinical Associate Professor Stark, Dr. Donald SPH Clinical Instructor Kanani, Dr. Amin Vancouver Associate Member Stephenson, Dr. Mary
Divisional Overview
Our small division is involved in providing clinical teaching in allergy and immunology at all levels. This includes major initiatives in patient education, CME programs for physicians, and elective rotations for residents and medical students. Despite not offering a training program at UBC, members are involved nationally in the nucleus committee of the Royal College as well as the examination committee for our subspecialty. Members are actively involved with lay organizations in medical advisory positions as well as in educational initiatives.
Teaching
All members of the Division are actively involved in teaching students, residents, community physicians and lay persons.
Dr. Schellenberg provides an introductory lecture to Medicine I students on the basic mechanisms of allergic inflammation as well as teaches in the Pathology 521 course. All members actively participate in case-based subspecialty teaching seminars for Med III / IV students and provide individual office-based teaching of students who have chosen an elective rotation in the subspecialty. In addition, each member teaches in the Clinical Skills block for Med I students and conducts Bedside teaching sessions with Med II students.
The month-long elective rotation for residents in Internal Medicine and its subspecialties has become increasingly popular in recent years. Members commit a half to a full day per week of
UBC Department of Medicine Page 29 Annual Report 2005
their office practice for each resident and Dr. Schellenberg has one on one teaching sessions two half days each week with the resident.
Major initiatives have been undertaken in community medical education to physicians, other health care professionals and to the lay public. CME programs organized by Dr. George Wong through the auspices of the UBC Community Programs are given in various communities in British Columbia and the Northwest Territories. These have received excellent evaluations and are highly appreciated by physicians in outlying areas. Each member contributes to these programs.
Despite semi-retirement, Dr. Michael Mandl has continued his asthma education program initiated through the Health Transition Fund to raise awareness and specific information in management of asthma in communities in BC. Five geographical sites have been targeted for evaluation of the effectiveness of this intensive education program to the public.
Dr. George Wong has developed specific expertise in evaluation of complementary and alternative medicine practices and has presented a number of interesting papers on these aspects at meetings in the USA and Canada, as well as to the BC Qualified Acupuncturists and Traditional Chinese Medicine Practitioners Association. This August he was invited by the Ningxia Medical School and the Public Health Bureau of Ningxia Hui Region to deliver 6 lectures to their members.
All members have been actively involved in providing teaching seminars in various communities in British Columbia. Examples include Grand Rounds presentations at Kelowna General, Surrey Memorial and Royal Jubilee Hospitals on topics of immune deficiency and management of difficult asthma.
Research
The members at St. Paul’s hospital have a major interest in management of primary immune deficiency and have initiated a number of research projects as well as interactions with the lay organizations, Canadian Immune Deficiency Patient Organization and the Jeffrey Modell Foundation. Dr. Amin Kanani is the principal investigator on a grant-in-aid (co-investigators Dr. Stark and Dr. Schellenberg) from Bayer Inc. study evaluating the quality of life and health outcome parameters of patients with primary immunodeficiency using two different dosing regimens of IVIG to determine optimal dosing requirements. Preliminary results suggest very interesting findings that may form the basis of modifications to present clinical recommendations.
Dr. Stark is the principle investigator in a study evaluating a new IV immunoglobulin product and he has submitted a unique proposal (Dr. Kanani and Schellenberg are co-investigators) to assess subcutaneous administration of the IVIG product which would allow home-based therapy.
Dr. Wong is conducting studies assessing the use and potential harmful effects of herbal and Chinese medicines.
UBC Department of Medicine Page 30 Annual Report 2005
Clinical Services
All members are actively involved in providing clinical consultative services in Allergy and Immunology to the community. Dr. Mandl has outreach clinics in Dease Lake, Stewart, Hazelton, Bella Bella, Campbell River, Parksville and Bamfield. Dr. Stark provides outreach clinics in Prince George and Sechelt. He has been active with the hospitals in establishing protocols for the management of latex allergy in hospitals. Dr. Wong has had a specific interest in complimentary medicine practices and the potential harmful effects of specific treatments.
A major initiative at St. Paul’s Hospital to improve the care of patients with primary immunodeficiency is being led by Drs. Kanani, Stark and Schellenberg in conjunction with Debbie Laflamme (Supervisor of Outpatient Services) and Darryl Gouthro (Manager of the Blood Bank). This entails the establishment of an outpatient clinic and registry to provide service to these patients and initiate home subcutaneous or intravenous immunoglobulin therapy. The goal of this project is to have a provincial centre and resource for all patients with primary immune deficiency and link registries with others across Canada and globally.
National and International Initiatives
Drs. Stark and Schellenberg are very involved with the national programs for Allergy and Clinical Immunology.
Dr. Stark chairs the Nucleus Committee for Clinical Immunology and Allergy of the Royal College of Physicians and Surgeons of Canada and is a Past-President of the Canadian Society of Allergy and Clinical Immunology.
Dr. Schellenberg completed his 2-year term as president of the Canadian Society of Allergy and Clinical Immunology in October ’04 and remains on its Board of Directors. He is also the deputy chair of the Royal College Examination Committee for this subspecialty and is the program director for the annual scientific meeting of the Canadian Society of Allergy and Clinical Immunology. In addition, he is a member of the Medical Advisory Committee of the Canadian Immune Deficiency Patient Organization.
Dr. Stark and Dr. Schellenberg are members of the Board of Directors for the Canadian Foundation for Allergy and Clinical Immunology, a charitable organization of which Dr. Stark was the founder.
All members are actively involved in local, national and international committees dealing with their areas of interest.
Future Directions
A major initiative of the division is the development of a Comprehensive Care Program for patients with Primary Immune Deficiency in British Columbia. We are working collaboratively with groups across the country to establish a registry of these patients for improved care and opportunities for multi-centred research initiatives. Locally we are working to have a specific out-patient clinic where management can be better coordinated, especially as we move to home UBC Department of Medicine Page 31 Annual Report 2005
immunoglobulin replacement therapy. We are the first adult centre to initiate this and are developing a business plan to the Ministry of Health to make this a provincial resource that would allow better standardized care at lower cost.
Due to our limited numbers and the expanding requests for elective rotations in our subspecialty, we plan to increase our membership by adding excellent clinical faculty from the community. Some already contribute significantly to our ongoing teaching programs.
UBC Department of Medicine Page 32 Annual Report 2005
CARDIOLOGY
Dr. Christopher E. Buller Professor & Head
Faculty Members
Professor & Head1 Buller, Dr. Christopher SPH/VA Professor Cairns, Dr. John VA Professor Kerr, Dr. Charles SPH Professor Mancini, Dr. G B John VA/SPH Professor Rabkin, Dr. Simon VA Associate Professor (Honorary) Henning, Dr. Hartmut VA Assistant Professor Humphries, Dr. Karin SPH Clinical Professor Bernstein, Dr. Victoria VA Clinical Professor Dodek, Dr. Arthur SPH Clinical Professor Hamburger, Dr. Jaap VA/SPH Clinical Professor Huckell, Dr. Victor VA Clinical Professor Penn, Dr. Ian VA Clinical Professor Ricci, Dr. Donald VA Clinical Professor2 Webb, Dr. John SPH Clinical Associate Professor Carere, Dr. Ronald SPH Clinical Associate Professor Fung, Dr. Anthony VA Clinical Associate Professor Gin, Dr. Kenneth VA Clinical Associate Professor Ignaszewski, Dr. Andrew SPH Clinical Associate Professor Kiess, Dr. Marla SPH Clinical Associate Professor MacDonald, Dr. Ian SPH Clinical Associate Professor Thompson, Dr. Christopher SPH Clinical Associate Professor Yeung-Lai-Wah, Dr. John SPH Clinical Assistant Professor Aymong, Dr. Eve SPH Clinical Assistant Professor Chan, Dr. Sammy SPH Clinical Assistant Professor Heilbron, Dr. Brett SPH Clinical Assistant Professor Isserow, Dr. Saul VA Clinical Assistant Professor Jue, Dr. John VA
1 Promoted 1 July 2004, confirmed August 2005 2 Promoted 1 July 2005
UBC Department of Medicine Page 33 Annual Report 2005
Clinical Assistant Professor Lee, Dr. Pui-Kee VA Clinical Assistant Professor3 Moss, Dr. Robert SPH Clinical Assistant Professor Rabinowitz, Dr. Alan SPH Clinical Assistant Professor4 Ramanathan, Dr. Krishnan SPH/VA Clinical Assistant Professor Saw, Dr. Jacqueline VA Clinical Assistant Professor Straatman, Dr. Lynn SPH Clinical Assistant Professor Wong, Dr. Graham VA Clinical Instructor Munt, Dr. Bradley SPH Clinical Instructor Tung, Dr. Stanley SPH Adjunct Professor Lear, Dr. Scott SPH Professor (Emeritus) Boone, Dr. John SPH Professor (Emeritus) Kavanagh-Gray, Dr. Doris SPH Professor (Emeritus) Mizgala, Dr. Henry Vancouver Professor (Emeritus) Peretz, Dr. Dwight West Vancouver Clinical Professor (Emeritus) Shaw, Dr. Melville Vancouver Clinical Professor (Emeritus) Walters, Dr. Max
Divisional Overview
The UBC Division of Cardiology consists of 36 active faculty (including 6 full-time faculty and 29 clinical faculty distributed over two large tertiary programs at St. Paul’s Hospital and Vancouver Acute (including UBC site). Eight additional members enjoy emeritus, honorary or adjunct status. In 2005, Dr. Christopher Buller entered his second year as Head, UBC Division of Cardiology and Sauder Family Heart & Stroke Foundation Chair in Cardiology, as well as Head, Division of Cardiology, Vancouver Acute.
The UBC Division of Cardiology provides a comprehensive range of tertiary and quaternary cardiology sub-specialty services and programs, including ambulatory and inpatient consultative cardiology, specialized clinics including heart function, cardiac intensive care, electrodiagnostics, cardiac ultrasound, interventional cardiology, electrophysiology, nuclear cardiology, adult congenital heart disease, cardiac transplantation and ventricular assist, atherosclerosis risk reduction and cardiac rehabilitation, and advanced cardiac imaging.
Teaching
Undergraduate:
Cardiovascular clinical assessment constitutes a core skill set for general physicians and many specialists and thus undergraduate teaching of the cardiovascular history and physical examination constitutes a substantial teaching load. The Division of Cardiology provided 117 hours of structured bedside teaching, 39 hours in seminars, lectures and case-based learning sessions and an additional 21 hours were contributed to undergraduate OSCE examinations during 2005. Reflecting the make-up of our Division, the substantial majority of this teaching was provided by our clinical faculty. Beginning in 2003, Dr. Saul Isserow has developed and
3 New faculty member 2005, recommended for Clinical rank 4 New faculty member 2005, recommended for Clinical rank UBC Department of Medicine Page 34 Annual Report 2005
implemented standardized instruction in the method of clinical examination for the undergraduate curriculum. To further advance undergraduate clinical skills teaching, the Division supports creating Directors of Undergraduate Education within Divisions or groups of Divisions carrying large undergraduate teaching loads. These positions would be responsible not only for optimizing the clinical content of the curriculum, but also for improving teaching effectiveness and consistency through application of objective metrics.
Identifying a dedicated individual to assume overall responsibility for undergraduate teaching was a goal in 2005. The Division expects to complete recruitment to this position in early 2006. The individual identified brings formal expertise in medical education, educational metrics and teaching through simulation technology.
Postgraduate:
The UBC Postgraduate Program in Cardiology (Ken Gin, Director) continues to expand with 6 Ministry funded residents and 8 externally funded residents. In 2005, the Division itself funded one additional resident using internal resources, and negotiated the creation of another 3-year position through partnership with the Healthy Heart Society. In all, our program enjoys 14 core residents in cardiology distributed over the three-year Royal College Program.
Academic aspects of the program continue to strengthen with an extensive weekly curriculum of structured bedside teaching, internal and guest faculty lectures, resident-led presentations, and journal club reviews of contemporary literature, compromising 6—10 hours of structural teaching weekly. Research mentoring has been enhanced by the appointment of two hospital- based postgraduate research directors, Drs. John Jue and Sammy Chan. The program has raised over $20,000.00 to support resident research. In 2005, an associate program director based at St. Paul’s Hospital position was created and filled by Dr. Krishnan Ramanathan.
A Royal College Internal Review highlighted the many strengths of the program with only minor deficiencies noted. The surveyors thought the program was in excellent shape for the formal Royal College Review to be held in 2007.
All UBC candidates who took the Royal College examination in Cardiology were successful. Moreover, all of our core program graduates from 2005 have secured positions for subspecialty training or staff positions.
The subspecialty programs continue to include Interventional Cardiology, Electrophysiology, Echocardiography and Heart Function/Transplant.
Continuing Medical Education
Internal Rounds
Across sites, the Division of Cardiology presents a rich curriculum of regular lectures and rounds. Cardiology Grand Rounds is presented weekly at each hospital. In addition, a variety of city-wide and hospital-based rounds are held regularly as follows:
UBC Department of Medicine Page 35 Annual Report 2005
Interventional Cardiology (weekly, city-wide) Combined Cardiology/Cardiac Surgery (weekly, both sites) M&M (weekly at SPH, monthly at VH) Echocardiography (weekly, VGH) Resident Noon rounds (weekly, SPH) Research Rounds (bi-weekly, SPH) Journal Club (monthly, city-wide) UBC City-Wide Rounds (bi-monthly)
Distinguished Speakers in Cardiovascular Medicine
2005 saw the second year of the Distinguished Speakers in Cardiovascular Medicine series held monthly during the academic year. Hosted jointly with the UBC Division of Cardiac Surgery, this program is directed by Drs. Ken Gin and Andrew Ignaszewski and brings prominent cardiovascular academics to Vancouver for 1 or 2 days of focused activity and interaction including research seminars, resident teaching, and the Distinguished Speaker Lecture itself. A broad range of tertiary and community cardiovascular specialists and researchers attend these lectures. They afford an important opportunity for basic scientists, clinical and academic physicians, cardiac surgeons, as well as faculty and staff from pharmacy and other allied health disciplines to meet and interact.
A key goal of this guest lecture series is to maintain complete academic independence with respect to the choice of speakers and topics. Funding it, however, requires industry support. To resolve this paradox, the cardiac pharmaceutical and device industry was approached at large by the Divisional leadership to provide shared funding without any input regarding content. In 2005, 8 industry partners supported Distinguished Speakers through this arms length funding arrangement.
Course & Convention Leadership
The 14th Annual Whistler Course (January 2005) Christopher Buller, Donald Ricci and Ian Penn, Course Co-Directors
This 3-day course aimed at Interventional Cardiologists and allied Cardiac Catheterization laboratory staff from across Canada was held at Chateau Whistler. The curriculum emphasizes advances in technical and technological aspects of the specialty. Faculty included both UBC and other leading Canadian and US interventionalists.
The 7 th Annual Excellence in Interventional Cardiology Course (December 2005) Ronald Carere, Course Co – Director with Dr Eric Cohen, University of Toronto
This 3-day course for Interventional Cardiologists attracts attendees from across Canada. The curriculum emphasizes novel topics relevant to interventional cardiology including advances in evidence-based practice and public policy challenges.
Annual Practical Cardiology Course Vancouver (September 2005) Brett Heilbron, Course Director UBC Department of Medicine Page 36 Annual Report 2005
This one-day course serves as a Cardiology update for family physicians and general internists. Chaired by Dr. Bernstein for more than a decade, this year saw the baton pass to Dr. Brett Heilbron. Dr. Heilbron (Clinical Assistant Professor) has developed an enviable reputation in BC for clinical cardiology and for translation of advances in evidence based cardiovascular medicine to the community physician. The curriculum showcased our diverse Divisional faculty. Always well subscribed, this conference consistently receives outstanding reviews and serves as an important linkage between our Division and the primary care community.
Hot Topics in Cardiology (April 2005) UBC Division of Cardiology CME Committee / Simon Rabkin, Chair
This one-day UBC Division of Cardiology CME event was held in downtown Vancouver and targeted clinical cardiologists and general internists. The curriculum was designed as a topical update emphasizing new clinical science in areas of rapid clinical change. Faculty was drawn entirely from within the UBC Division. Approximately 100 physicians from throughout BC attended.
Research
Dr. Eve Aymong has successfully submitted abstracts on clinical outcomes of diabetics undergoing coronary angioplasty, complementing work as SPH Principal Investigator for the multicenter FREEDOM trial. Another subset of particular interest is patients with previous CABG. She was part of a successful team applying for funds from the AHA for research in patients with metabolic syndrome, currently enrolling in New York. Work investigating a variety of biomarkers of the now completed multicenter SHOCK-2 clinical trial continues. In addition, she has ongoing collaborations with Vancouver investigators on several studies that are currently under review by CIHR. She is active on several DSMCs and is a reviewer for several cardiology journals and meetings.
Dr. Victoria Bernstein continues to be actively involved in research. Ongoing studies include: STICH; Magnesium study - Assessment of i/v magnesium for decrease in atrial arrhythmias after heart surgery; BEAUTIFUL study - Ivabradine vs.. placebo CAD with LV dysfunction; ONTARGET - Telmisartan/Ramipril or combination in high risk cardiac patients; AF-CHF- Rate control vs.. rhythm control in patients with LV dysfunction and paroxysmal AF; AUDITOR - Rimonabant in the regression of arteriosclerosis disease. Studies completed include: SIMPATICO- Immune modulation in patients with severe intermittent claudication; ACCLAIM - Immune modulation in patients with class III & IV CHF; IMAGINE - Use of Quinapril in early post operative patients undergoing CABG; RUTH - Assessment of Raloxifene in women with ASHD; HOPE TOO; AMADEUS. Dr. Bernstein also serves on events committees for the following studies: ONTARGET; ACCLAIM; IMAGINE; HOPE TOO
Dr. Christopher Buller is active in numerous clinical trials and in outcomes research. His interest in occluded coronary arteries and the ‘open artery hypothesis’ has led to his participation on the Executive Steering Committee, Operations Committee and Publications Committee of the NIH/NHLBI funded Open Artery Trial, an international multi-center clinical trial initiated in 1998 and will be presenting its primary results at the American Heart Association Annual Scientific Sessions in November 2006. Dr. Buller directs aspects of the trial related to PCI (the UBC Department of Medicine Page 37 Annual Report 2005
experimental strategy), is Co-Director of the Core Angiographic Laboratory. He is also Co- principal Investigator of the NIH/NHLBI funded angiographic substudy of the Open Artery Trial, TOSCA-2. Dr. Buller is also the Canadian Principal Investigator for the NIH/NHLBI funded FREEDOM trial, a 140 centre international trial comparing drug eluting stents to coronary bypass surgery in patients with diabetes and multi-vessel coronary heart disease. In the area of acute myocardial infarction, Dr. Buller has also been active as a member of the executive steering committee of the Which ST-Elevation Therapy (WEST) study presented at the Canadian Cardiovascular Society in October 2005.
Dr Ronald Carere’s research interest is predominantly in the area of population based and outcomes research. This includes use of the BC Cardiac Registry in determining population rates of cardiac procedures, exploring access issues and projections for procedure demand. He is a collaborative in several projects with other Canadian centers doing similar work and a co- investigator with Dr McManus and others in the Genome BC project seeking non invasive markers for transplant rejection.
Dr. Sammy Chan is active in clinical trials and mechanistic research. His area of interest is preventive cardiology and endothelial function. He is the St. Paul's Hospital site investigator for the CRESCENDO study investigating the potential role of Rimanobant in reducing adverse cardiovascular outcomes. He was awarded a 2 year grant in aid from the Heart & Stroke Foundation of BC and Yukon for a proposal involving aging, endothelial progenitor cells and endothelial function.
Dr. Anthony Fung was appointed as the Director of Interventional Cardiology Research at the Vancouver General Hospital in 2003. This busy unit coordinates local investigators' initiated research and participates in multi-center clinical trials. In 2005, we had 7 full time employees, and coordinated 15 clinical trials. Dr. Fung initiated the BRIEF-PCI trial in 2005. This is a double blind randomized trial comparing a brief infusion of eptifibatide versus prolonged infusion in preventing ischemic events following percutaneous coronary intervention. By December, 2005, more than 200 patients were enrolled.
Dr. Jaap Hamburger is centrally involved in translational research addressing myocardial repair by autologues bone marrow stem cells in both small (mouse) and large (pig) animal models. This project operates in collaboration with the Terry Fox laboratory (BC Cancer Agency), the Jack Bell Laboratory and iCAPTURE. During 2005 new imaging results indicated the presence of connexin 43 protein in transplanted BMSC, thus suggesting a mechanism for cell to cell communication in regenerated myocardial tissue.
A second translational project, in collaboration with Dr. K. Qayumi, was initiated under the title "The use of Trans Guidewire Therapy for reduction of reperfusion injury during direct PCI”. The animal phase of this project established the safety and feasibility of a trans guidewire strategy aimed at blocking reactive oxygen species formation during reperfusion of acutely occluded coronary arteries.
Dr. Ken Gin has served as reviewer for a number of journals during 2005: Journal of American Cardiology; Thorax; Canadian Journal of Cardiology; Journal of Emergency Medicine; as well as serving as abstract reviewer for the Canadian Cardiovascular Society. Dr. Gin has been the UBC Department of Medicine Page 38 Annual Report 2005
Primary Investigator on multiple studies including Timi 25/Extract; Prevention of MI Early Remodelling (PREMIER); Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE); Aggressive Reduction of Inflammation Stops Events ( ARISE); Comprehensive rimonabant evaluation study of cardiovascular endpoints and outcomes (CRESCENDO); and Co-PI on CANPANP. In addition, Dr. Gin serves as a member on several steering committees including Magnesium for the Prevention of Atrial Arrhythmias after Cardiac Surgery (MPAACS); Validation of Chest Pain: Rule out ACS Rule; Aminophylline in and out of hospital brady/PEA onset (ABBA) and the Canadian Outpatient Self Monitoring Study.
Dr. Karin Humphries' areas of interest include sex differences in CVD presentation, treatment and outcomes; Health Services research focused on secondary prevention; population-based rates of treatment, including PCI, CABG, and pharmacological therapy; and atrial fibrillation. Dr. Humphries has led B.C.'s team of contributors to the Canadian Cardiovascular Outcomes Research Team (CCORT) project and GENESIS - Gender and Sex Differences in Cardiovascular Disease - and Inter-disciplinary Capacity Enhancement Team funded by CIHR. A growing area of interest for Karin is investigator-driven randomized controlled trials. With her advanced theoretical and extensive practical knowledge, she supports and informs many such initiatives within the Division. As Principal Investigator, Dr. Humphries presently holds a Scholar Award from the Michael Smith Foundation as well as funding from the Heart and Stroke Foundation and CIHR .
Dr. John Jue continues to add to his echo database which currently has 70,000 studies. Current research work includes dilated coronary sinus – associated echo findings. Pulmonary hypertension in aortic stenosis. Intravenous contrast agents and hand-held portables. Tissue doppler following coversion of atrial fibrillation to sinus. Surveillance of mechanical mitral valves by echocardiography.
Dr. Charles Kerr is a clinical electrophysiologist and carries out an active research program in cardiac arrhythmia management. His main area of interest has been atrial fibrillation (AF). He has directed the Canadian Registry of Atrial Fibrillation since 1990. CARAF I has followed 1100 patients from their initial diagnosis of AF over 10 years, providing insight into progression of disease and clinical and laboratory outcomes. CARAF II has followed a more recent cohort to more carefully evaluate medical therapy provided by community physicians. He is also involved in drug trials of new antiarrhythmic and antithrombotic agents, as well as research trials of pacemakers and defibrillators. Dr. Kerr was invited by the Division to present a lecture as part of the UBC Division of Cardiology Distinguished Speaker series. He presented his talk in November 2005 entitled "Atrial Fibrillation: A Quarter of a Century Later" which was very well received.
Dr. G. B. John Mancini has been active in clinical trials through his Cardiovascular Imaging Research Core Laboratory (CIRCL)which provides measurements of endothelial dysfunction (brachial artery ultrasound), carotid ultrasound, quantitative coronary intravascular ultrasound and quantitative coronary angiography(QCA). In addition, Dr. Mancini has expanded his research interests to include both clinical and molecular projects attempting to unravel the interplay between pulmonary diseases and cardiovascular events. Clinical projects assessing the impact of Chronic Positive Airway Pressure on carotid atherosclerosis and endothelial dysfunction in patients with Obstructive Sleep Apnea are underway. Cellular and molecular UBC Department of Medicine Page 39 Annual Report 2005
projects assessing the effects of statins and angiotensin receptor blockers on animal models and in-vitro cellular models of lung injury are also underway. The ACROSS-Cypher® trial assessing the efficacy of sirolimus eluting stents in chronic total occlusions was started in 2005. Terje Steigen, Senior interventionalist at the University Hospital of Northern Norway, is a fellow in the laboratory pursuing collaborative projects assessing myocardial perfusion grading in the OAT trial. CIRCL has completed the QCA analyses for the WEST, SMARTFED, and STREAM trials in the last year. The M-CHAT carotid ultrasound study was also completed.
Dr. Krishnan Ramanathan was recruited from New York in May 2005. He is actively involved in trying to better understand the complex interplay between coronary artery disease (CAD), Diabetes mellitus and or reno-vascular disease through international multi-centre clinical trails and local research. He is also collaborating with prominent genetic researchers from Boston University to determine if a genetic marked exists for the high incidence of premature CAD in South Asians. His experience in clinical trial has to his inclusion on Steering / Operations Committees, Data and Safety Monitoring Boards and Writings Committees. He was also the inaugural recipient of the St Paul’s Hospital Foundation Physicians Scholars Award.
Dr. Jacqueline Saw arrived as a recruit from the Cleveland Clinic in 2004. She has research interests in several areas of cardiovascular medicine. She is the PI of 2 locally designed studies. Aspirin and clopidogrel resistance is being evaluated in a substudy of BRIEF-PCI (a locally developed multicenter RCT). The ELAPSE study is evaluating the development of resistance to long-term clopidogrel administration, which is at the midpoint of patient enrollment since starting in 2005. She is also involved in evaluating the interaction of clopidogrel and statin in a posthoc analysis of CHARISMA, and also evaluating the PCI outcomes of patients with peripheral arterial disease in a pooled analysis. Dr. Saw is also involved in local outcome studies evaluating both co-morbidities and therapies in patients undergoing percutaneous peripheral arterial and carotid revascularization procedures.
Dr. John Webb is Director of Interventional Cardiology Research at St. Paul’s hospital. The newly developed procedure of percutaneous transarterial aortic valve implantation has proven very successful. St. Paul's Hospital has the first and largest experience worldwide for this new procedure and is the sole training centre with a large number of prominent international visitors and new programs proctored by St. Paul's cardiologists in several countries. In addition to arterial access valve replacement, the first successful transapical access procedures were performed this year further expanding the potential role of catheter valve replacement for aortic stenosis. 2005 saw 10 peer reviewed journal publications from Dr. Webb as well as two future 1st author manuscripts and accompanying editorials in Circulation.
Dr. Graham C. Wong is active in clinical trials of acute coronary care with a particular focus on optimizing epicardial reperfusion. He is also interested in population-based outcomes following mechanical and pharmacological reperfusion for ST elevation myocardial infarction. Dr. Wong is currently the principal investigator for the inflammatory markers substudy of the BRIEF PCI study comparing an abbreviated versus a standard infusion of eptifibatide following percutaneous coronary intervention. Dr. Wong sits on the National Steering Committee for the GRACE 2 Registry of acute coronary syndromes. He currently heads the Clinical Trials Group for the Coronary Care Unit at VGH.
UBC Department of Medicine Page 40 Annual Report 2005
Dr. John Yeung has a major research interest in the mechanisms of clinical arrhythmias and in developing the techniques for both mapping and ablating complex myocardial arrhythmic circuits. As a result of his work, St. Paul’s Hospital Electrophysiology Laboratory is recognized as a Centre of Excellence for the use of the 3D mapping system. It is thus a training centre attracting international cardiac electrophysiologists interested in this field. He continues to evaluate the modulation of vagus nerve inputs to the left atrium in patients who undergo linear pulmonary vein ablation for atrial fibrillation. Other interests include the role of implantable cardioverter defibrillator (ICD) devices and biventricular pacing (cardiac re-synchronization).
Clinical Sub-Programs
• Healthy Heart Program (risk reduction and rehabilitation) o Andrew Ignaszewski** Saul Isserow* • Cardiac Electrodiagnostics o Marla Kiess** John Jue* • Acute Coronary Care o Alan Rabinowitz** Graham Wong* • Interventional Cardiology & Cardiac Catheterization o John Webb** Anthony Fung* • Cardiac Ultrasound o Christopher Thompson** John Jue* • Heart Function and Cardiac Transplantation o Andrew Ignaszewski** • Adult Congenital Heart Disease o Marla Kiess** • Arrhythmia Management o Charles Kerr** • Clinical & Consultative Cardiology o Saul Isserow*
** SPH Director *VGH Director
Advanced Cardiac Imaging
A revolution in cardiac imaging is occurring as the capabilities to image the moving heart at high resolution with CT and MR technology, and in three dimensions with ultrasound (3D Echo) mature to a state of clinical applicability. Models for institutional participation in this field vary widely, and collisions between radiology and cardiology interests are common. Both VA and SPH Cardiac Sciences programs have enjoyed positive working relationships with their respective Departments of Radiology, and both are fashioning cooperative relationships to bring these technologies to patient care and research.
The UBC Division of Cardiology proposed the cross-appointment of Dr. John Mayo (UBC Department of Radiology) in early 2005 and will be completing this novel arrangement in early 2006. Dr. Mayo will begin his position as Director, Advanced Cardiac Imaging at VA for a three year term in January 2006. His mandate will include the development of an interdisciplinary
UBC Department of Medicine Page 41 Annual Report 2005
program including the recruitment of both Cardiology and Radiology stream specialists in Advanced Cardiac Imaging at Vancouver Acute.
There are ongoing discussions at SPH between radiology, nuclear medicine and cardiology to further develop this field. Dr Jen Ellis from radiology is being supported by PHC and her department to do an additional 6 months of MRI training directed at the complex congenital heart disease. A successful clinical collaboration with Dr John Mawson from the department of radiology at BC Womens and Children’s is also in place
Administration - UBC Divisional Leadership in Context
The human and monetary cost of cardiovascular disease in our society has spawned a complicated matrix of university, hospital, regional and provincial governance structures each of which bears directly on the activity, clinical planning and academic development within the UBC Division of Cardiology. Division Head positions exist for the UBC Division overall and for each of our two teaching hospitals. Cardiac Science Program Director positions also exist for each teaching hospital. A newly formed regional cardiac sciences program designed to advise and coordinate activities at all Vancouver Coastal hospitals is chaired by a Regional Cardiac Sciences Director. Finally, province-wide tertiary cardiac services (of which our teaching hospitals provide more than 50% of all activity) are now directly funded through the Provincial Health Services Authority. Medical input to this planning and funding body occurs through a committee constituted with representatives from each tertiary centre. This committee, the Provincial Panel on Cardiac Health, includes both influential chair and subcommittee leadership positions.
Within this complicated context, 2005 saw several changes in leadership roles within our Divisional and Cardiac Science Programs that were intended to improve the alignment of academic and operational responsibilities. Dr. Buller resigned the position of Head, Division of Cardiology, St. Paul’s Hospital in order to assume the position of Medical Director, Cardiology, Vancouver Acute. Dr. Andrew Ignaszewski (Clinical Associate Professor) has assumed the position of Acting Head, Division of Cardiology, St. Paul’s Hospital; a search for a permanent Head is underway. Dr. Donald Ricci (Clinical Professor) resigned the position of Medical Director, Cardiac Sciences, Vancouver Acute after more than 10 years of committed leadership. Dr. Ronald Carere (Clinical Associate Professor) continues his successful tenure as Medical Director, St. Paul’s Heart Centre and as Regional Director, Cardiac Sciences, Vancouver Coastal Health. Dr. Charles Kerr (Professor) continues to bring skill and experience to the position of Chair, Provincial Panel on Cardiac Health.
Future Directions
As indicated in previous UBC Division of Cardiology annual reports, organization of tertiary cardiac services in VCH remains a subject of active formal and informal discussion and at times some controversy due to different perspectives and priorities. The professional and academic activity of most of our faculty members is closely linked to their participation or leadership in specific tertiary cardiac services. Continued activity within these services is often central to the realization of legitimate career ambitions and academic development. Equally important to most of our Division members is their participation in, and contributions to, a comprehensive and UBC Department of Medicine Page 42 Annual Report 2005
vibrant cardiac sciences program. Thus discussions regarding greater centralization of cardiac services offer both new opportunity but also understandable concerns amongst faculty members. Whereas increasing centralization of tertiary cardiac activity in one hospital (SPH or VA) has potential advantages with regard to coordination, critical mass and efficiency, the negative implications to the alternate hospital are potentially profound. Both VA and SPH care for the most complex patients in the province. The feasibility of caring for complex and critically ill patients without a full range of cardiac consultative, diagnostic and therapeutic services has been called into question. An alternative proposal for enhanced coordination of tertiary cardiac services would see the development of centralized cardiac program governance, but with many tertiary services remaining distributed at both hospitals. Effective centralized governance, however, would require reorganization of cardiac budgets, administrative structures and reporting lines, and professional reporting lines, all of which are presently hospital-based.
In order to advance the Divisional dialogue on this challenging subject, formal facilitated discussions have been initiated.
Special Honours and Awards 2005
Dr. Christopher Buller • “Best Presentation at Academic Half Day by a Staff Member” UBC Postgraduate Program in Cardiology - June 2005 Dr. John Cairns • Fellow of the Canadian Academy of Health Sciences Dr. Ken Gin • UBC Postgraduate Program in Cardiology “Best Teacher during a Clinical or Research Rotation” 2004-2005 Dr. Saul Isserow • Master Teacher award - Anaesthesia Department • People's Choice award - VGH Medical Staff Dr. Charles Kerr • Canadian Cardiovascular Society Annual Meeting Chair • Co-Chair, Canadian Cardiovascular Congress • Chair, Provincial Advisory Panel on Cardiovascular Health
Dr. Marla Kiess • Member, Board of Directors, Canadian Adult Congenital Heart Network 1999-2005 • President, Canadian Nuclear Cardiology Society 2003-2005 • Member, Nuclear Cardiology Wait Time, Sub-Group of the Canadian Cardiovascular Society • Member, Writing Group, CCS Position Statement on Advanced Cardiac Imaging 2005- 2006 • Member, Organizing Committee, Annual Scientific Meetings, Canadian Society of Nuclear Medicine, Vancouver, May, 2005.
UBC Department of Medicine Page 43 Annual Report 2005
• Chair and Speaker, “Women and Coronary Heart Disease” Plenary Session, Annual Scientific Meetings of the Canadian Society of Nuclear Medicine, Vancouver, May 13, 2005. • Member, Organizing Committee, American Society of Nuclear Cardiology Annual Symposium and Scientific Sessions, Seattle, Washington, September, 2005. • Chair, Meet the Experts Session, “What’s the Best Test? Cardiac CT, Myocardial Perfusion Imaging (SPECT) and PET in the evaluation of CAD”, Canadian Cardiovascular Society Annual Scientific Sessions, Montreal, Quebec, October 25, 2005. • Chair, Robert J. Burns Memorial Lecture, Montreal, Quebec, October 25, 2005. • Co-Chair, “Adult Congenital Heart Disease”, Canadian Cardiovascular Society Annual Scientific Session, Montreal, Quebec, October 26, 2005. • Principle Co-Investigator, Open-label extension study to investigate the safety of Tracleer (Bosentan) in adult patients with pulmonary arterial hypertension related to Eisenmenger’s syndrome, Actelion Pharmaceuticals.
Dr. G. B. John Mancini • Completed term as President of the Canadian Society for Clinical Investigation (Sept 2004-5). • Canadian Society for Clinical Investigation Past-President (Sept 2005-6).
UBC Department of Medicine Page 44 Annual Report 2005
CRITICAL CARE MEDICINE
Dr. John Fenwick Clinical Assistant Professor & Head
Faculty Members
Clinical Assistant Professor & Head Fenwick, Dr. John VA Professor Russell, Dr. James SPH Professor Walley, Dr. Keith SPH Associate Professor Dodek, Dr. Peter SPH Assistant Professor Dorscheid, Dr. Delbert SPH Clinical Associate Professor Tsang, Dr. John VA Clinical Assistant Professor Chittock, Dr. Dean VA Clinical Assistant Professor Dhingra, Dr. Vinay VA Clinical Assistant Professor Forrest, Dr. David VA Clinical Assistant Professor Grant, Dr. Gregory SPH Clinical Assistant Professor Henderson, Dr. William RCH Clinical Assistant Professor Keenan, Dr. Sean SPH Clinical Assistant Professor Ronco, Dr. Juan VA Clinical Instructor Craig, Dr. Katherine RCH/VA Clinical Instructor Isac, Dr. George VA
Divisional Overview
The UBC Division of Critical Care Medicine is multidisciplinary in structure, with 15 faculty members, all qualified critical care specialists from Medicine, Surgery, Anaesthesia and Emergency Medicine backgrounds participating in patient care at St. Paul’s Hospital, Royal Columbian Hospital, Richmond General Hospital, Nanaimo Regional Hospital and Vancouver Hospital. The Division continued to expand in 2005 with the addition of Dr. William Henderson and Dr. George Isac as new faculty members. The two-year Critical Care Medicine subspecialty-training program is fully accredited and accepts two trainees per year. The Research Program in Critical Care Medicine is comprehensive, spanning from molecular and cellular biology through large animal models to clinical research in critically ill adults. The basic science research program is based in the Cardiopulmonary Laboratories at St. Paul’s Hospital. The clinical research program is focused in the intensive care units of St. Paul’s Hospital, Royal Columbian Hospital and Vancouver Hospital.
UBC Department of Medicine Page 45 Annual Report 2005
Teaching
The University of British Columbia Adult Critical Care Medicine Training Program, under the direction of Dr. Katherine Craig, continued at the British Columbia Children’s, St. Paul’s and Vancouver Hospitals. In 2005 there were 5 trainees in the Adult Critical Care Medicine Fellowship Training Program. Trainees completing the program in 2005 will be the first to receive subspecialty certification through examination by the Royal College of Physicians and Surgeons of Canada. The ICU rotations for speciality residents from Medicine, Anaesthesia and Surgery continued to be highly rated at both St. Paul’s and Vancouver Hospital. Under the direction of Dr.Vinay Dhingra, participation in the SCCM Critical Care Support Course has now expanded to include core residents from all UBC Departments.
Research
The Research Program in Critical Care Medicine is comprehensive, spanning from molecular and cellular biology through large animal models to clinical research in critically ill adults. The basic science research program is based in the Cardiopulmonary Laboratories at St. Paul’s Hospital. The clinical research program is focused in the intensive care units of St. Paul’s, Royal Columbian and Vancouver Hospitals.
The basic science research program continues to investigate corticosteroid and ischemia/reperfusion induced airway epithelial cell apoptosis (Dr. Dorscheid), stem cell repair of RSV induced airway injury (Dr. Dorscheid), endothelins and the mechanism of hypoxemia and pulmonary hypertension in acute pulmonary embolism (Dr.Tsang), the molecular and cellular biology of leukocyte induced myocardial dysfunction in septic shock (Dr. Walley), immunomodulation in the treatment of sepsis and acute lung injury (Drs. Russell and Walley) and mathematical modelling of tissue oxygen uptake (Dr. Walley).
The clinical research program remains strong at St. Paul’s and Vancouver Hospital with studies on the role of genotype and phenotype in sepsis and systemic inflammatory states (Drs. Walley and Russell), clinical trials and epidemiology of organ dysfunction in critical illness (Dr. Russell), exercise induced hypoxemia (Dr. Russell), glucose control and outcomes in the critically ill (Drs. Dhingra, Chittock, Ronco, Dodek, Henderson and Fenwick), recognition, quantification and treatment of delirium in the ICU (Dr. Chittock), the role of organizational factors and organizational culture in outcomes of critical care (Drs. Dodek, Keenan and Henderson), treatment of catheter related bloodstream infections (Drs. Ronco and Dhingra), role of non-invasive ventilation in critical illness (Dr. Keenan), effect of sedation and agitation on duration of mechanical ventilation (Dr. Chittock), adrenal function in sepsis (Drs. Fenwick, Chittock and Ronco), communication and decision making in end of life care (Dr. Dodek), ventilator associated pneumonia (Dr. Dodek), fluid resuscitation in septic shock (Dr. Dhingra), patient safety teams and determinants of outcome in ICU (Drs Dodek, Chittock and Keenan), vasopressin in septic shock (Drs. Russell, Walley, Chittock and Ronco) and blood transfusion and cerebral oxygenation in head injury (Drs. Chittock and Fenwick).
UBC Department of Medicine Page 46 Annual Report 2005
Clinical Services
The ICUs at St. Paul’s and Vancouver Hospital continued to experience an increase in occupancy and workload with over 1700 admissions at the two sites. The ICUs at St. Paul’s Hospital and Vancouver General Hospital have continued to grow, reaching 15 and 27 beds in size respectively. Division members from St. Paul’s, Vancouver General and Richmond General Hospitals participated as members of the Regional Critical Care Council and continue to develop and implement strategies to improve the delivery of critical care services within the region.
Future Directions
In 2005, under the direction of Dr. Dean Chittock, the Division will hold the third annual Canadian Critical Care Conference at Whistler, BC. Under the direction of Dr. Vinay Dhingra, the Division will continue to expand the implementation of the SCCM Fundamentals in Critical Care Medicine Support Course as part of the core residency training program. It is anticipated that the SCCM course will, in the future, become a successful CME activity within the Department of Medicine, attracting critical care providers from around the province. Drs. Ronco and Dhingra, in collaboration with the Center for Excellence in Surgical Education and Innovation, continue to develop simulator models for the teaching of technical and patient management skills to critical care trainees. The Division continues to explore, as part of the regional critical care mandate, the possibility of Departmental status within the region as well as within the Faculty of Medicine.
Special Honours and Awards
Dr. Dean Chittock was appointed the Regional Head of Critical Care Medicine and served as organizer and session moderator at the Canadian Critical Care Conference, Whistler, BC.
Dr. Katherine Craig was appointed Training Program Director of the UBC Adult Critical Care Medicine Training Program.
Dr. Vinay Dhingra was appointed to the Medical Advisory Committee of the BC Transplant Society, and was appointed a Forum Member of the Canadian Council for Donation and Transplantation.
Dr. Peter Dodek was an invited speaker at the Toronto Critical Care Medicine Symposium, Toronto, Ontario, the Rocky Mountain Critical Care Conference, Vernon, BC, the Canadian Critical Care Conference, Whistler, BC, the Penticton Conference on Death with Dignity, Penticton, BC, and the Canadian Collaborative to Improve Patient Care and Safety in ICU, Winnipeg, Manitoba.
Dr. Del Dorscheid was an invited speaker at the 1st International Pan-Arab Critical Care Medicine Congress, Talif, Saudi Arabia, served as Chair of the 2005 VanSeaPort Respiratory Research Conference, Whistler, BC, and was reappointed, Assistant Professor, UBC Department of Medicine.
UBC Department of Medicine Page 47 Annual Report 2005
Dr. Sean Keenan was an invited speaker at the American College of Chest Physicians Annual Meeting, Montreal, Quebec, The Toronto Critical Care Medicine Symposium, Toronto, Ontario, the American Thoracic Society Annual Meeting, San Diego, California, and the 6th Annual Advances in Respiratory and Critical Care Medicine Conference, Whistler, BC.
Dr. Juan Ronco received the Master Teacher award from the UBC Department of Anesthesia and was appointed Vice Chair, Examination Board in Critical Care Medicine, Royal College of Physicians and Surgeons Canada.
Dr. John Tsang was appointed an Affiliate Associate Professor, Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington.
Dr. Keith Walley was an invited speaker at the Lilly Critical Care Global Medical Conference, Belgium, Brussels, the 25th International Symposium on Intensive Care and Emergency Medicine, Belgium, Brussels and the 2005 Annual Scientific Meeting, Joint Faculty of Intensive Care Medicine, Auckland, New Zealand. Dr. Walley was appointed Senior Faculty Member, Faculty Appointments, Reappointments, Promotion and Tenure Committee, UBC Faculty of Medicine.
UBC Department of Medicine Page 48 Annual Report 2005
DERMATOLOGY
Dr. Harvey Lui Professor & Head
Faculty Members
Professor & Head Lui, Dr. Harvey VA Professor Ho, Dr. Vincent VA Professor McLean, Dr. David VA Professor Rivers, Dr. Jason VA Associate Professor Dutz, Dr. Jan VA Associate Professor Kitson, Dr. C. Neil VA Associate Professor Li, Dr. Gang VA Assistant Professor McElwee, Dr. Kevin VA Assistant Professor Zhou, Dr. Youwen VA Clinical Professor Carruthers, Dr. Alastair VA Clinical Professor Shapiro, Dr. Jerry VA Clinical Professor Warshawski, Dr. Laurence VA Clinical Associate Professor Conklin, Dr. Robert VA Clinical Associate Professor Crawford, Dr. Richard SPH Clinical Associate Professor Gallagher, Richard BCCH Clinical Associate Professor Haber, Dr. Richard Victoria Clinical Associate Professor Kunimoto, Dr. Brian VA Clinical Associate Professor Ongley, Dr. Roberta VA Clinical Associate Professor Schlappner, Dr. Otto SPH Clinical Associate Professor Prendiville, Dr. Julie BCCH Clinical Assistant Professor Bergman, Dr. James Vancouver Clinical Assistant Professor Gregory, Dr. Brian VA Clinical Assistant Professor Kenny, Dr. Patrick Royal Jubilee Clinical Assistant Professor Morton, Dr. Charles VA Clinical Assistant Professor Prihoda, Dr. Marie VA Clinical Assistant Professor Thomas, Dr. Richard VA Clinical Assistant Professor Tuyp, Dr. Evert VA Clinical Assstant Professor Zeng, Dr. Haishan BCCH Clinical Assistant Professor Zloty, Dr. David VA Clinical Instructor Amiss, Dr. John Victoria Clinical Instructor Au, Dr. Sheila VA
UBC Department of Medicine Page 49 Annual Report 2005
Clinical Instructor Cowan, Dr. Bryce VA Clinical Instructor Davis, Dr. Anne VA Clinical Instructor Hong, Chih-ho SPH Clinical Instructor Rossi, Dr. Sikina Victoria Clinical Instructor Shokravi, Dr. Mohammad North Vancouver Adjunct Professor Thewalt, Dr. Jenifer Burnaby Clinical Professor (Emeritus) Maddin, Dr. W. Stuart VA Clinical Professor (Emeritus) McLeod, Dr. William VA
Divisional Overview
2005 was a major transition year for the Division of Dermatology. The evolution towards formal departmental status that was begun in 2004 progressed through several stages. In May 2005 the Faculty of Medicine, at its Full Faculty meeting, voted to approve the establishment of the Department of Dermatology and Skin Science pending an external review. This review was conducted in August 2005 by Dr. Lorne Tyrell (former Dean of Medicine at the University of Alberta), Dr. John Voorhees (Chairman of the Department of Dermatology at the University of Michigan), and Dr. Paul Man (Chairman of the Providence Health Care Department of Medicine). Their unanimous recommendation was that the “Division of Dermatology be elevated to the Department of Dermatology and Skin Science by the Faculty of Medicine and the University of British Columbia”. Final ratification by the UBC Senate is expected in early 2006.
The faculty, trainees, students, and staff of the Division of Dermatology are deeply appreciative of the Department of Medicine for the excellent academic support and leadership that it has provided to us since the founding of UBC’s medical school 55 years ago. The new department looks forward to maintaining strong links to our parent department as well as nurturing new collaborations and opportunities.
In 2005 Dr. Bryce Cowan was welcomed as a new member of the Division of Dermatology. Dr. Cowan is a plastic surgeon who completed his micrographic surgery fellowship with Dr. Warshawski and Zloty at the VGH Skin Care Centre. His background in plastic surgery combined with the recent recruitment to the UBC Division of Plastic Surgery of an international wound healing expert, Dr. Aziz Ghahary, will help to strengthen academic and clinical ties between Plastic Surgery and Dermatology. Dr. James Bergman joined the Division from the University of San Diego where he had been a pediatric dermatologist. Dr. Bergman is triple certified in dermatology, pediatrics, and allergy/immunology. Dr. Mike Martindale and Dr. Sikina Rossi were appointed in 2005 as the new Dermatology Site Leaders for education in the Northern and Island Medical Programs respectively. Both leaders have been very active in the medical school expansion.
Teaching
Undergraduate: Dr. Jerry Shapiro, Director. The major undergraduate initiative this year has been related to the medical school expansion. Detailed videoconferencing plans, including contingencies, were put in place for delivering the Integument Block of the Second Year Phase II program over three separate sites (Vancouver, Victoria, and Prince George) by January 2006. Third Year Dermatology Clerkship Pilots were run as trials in Prince George and several sites in UBC Department of Medicine Page 50 Annual Report 2005
the Lower Mainland. Both the second and third year programs in integument and dermatology are required courses for all undergraduate UBC medical students. Accommodating more medical students in office-based teaching settings is a major challenge for our program, but fortunately we have been able to draw on significant goodwill and enthusiasm amongst our community- based dermatologists. Final implementation of the recognition and teaching compensation package by the Faculty of Medicine for clinical faculty members will go a long ways towards sustaining faculty commitment throughout the expansion and beyond.
Postgraduate: Director: Dr. Larry Warshawski. The residency training program underwent an Internal Royal College Review in November 2005. Program and rotation objectives were extensively reviewed and updated as were the processes for providing mutual feedback between residents and faculty supervisors. Support for resident training came from the BC Ministry of Health (via CARMS), the Province of Manitoba, and the Government of Kuwait. National manpower studies have demonstrated that there is insufficient capacity to train the number of dermatologists required to meet current needs in Canada. Our program is grateful to the Postgraduate Dean’s Office for assisting us with funding re-entry resident positions in 2005, and looks forward to being able to eventually double our postgraduate training slots in parallel with the medical school expansion. Our first resident rotation in Victoria was launched in 2005.
Our residency training program is complemented by advanced dermatology fellowship programs in skin surgery, hair disorders, dermatopathology, photomedicine/lasers with trainees coming from Germany, Korea, Bahrain, Calgary, Ontario, and New Brunswick.
Experimental Medicine: The ranks of dermatology graduate students continue to grow with MSc and PhD student placements in all five of our basic science laboratories. The quality of our graduate student research is reflected in numerous awards and scholarships (CIHR, NSERC, Michael Smith Foundation), publications in higher impact journals, and excellent presentations at the Annual Dermatology Research Day.
Continuing Medical Education: CME courses offerings for 2005 included:
Spring Dermatology Update for Family Physicians (Vancouver, March 4-5, 2005) Course Director: Dr. Brian Kunimoto
Conference for Pediatric Allergy and Dermatology (Whistler, April 16-17, 2005) Course Director: Dr. Jim Bergman
Dowling Club Meeting (Vancouver, May 27-28, 2005) Organizer: Dr. Jim Bergman
Dermatology Update 2005 (Montreal, October 27-29, 2005) Course Director: Dr. Stuart Maddin
Research
One of the research highlights was the 6th WHO World Congress on Melanoma that was hosted in Vancouver on September 6-10, 2005 by three of our faculty, Dr. Jason Rivers, Dr. Richard UBC Department of Medicine Page 51 Annual Report 2005
Gallagher, and Dr. David McLean. Plans are well underway for our next major dermatology conference to be hosted in 2007 by one of our faculty members, Dr. Jerry Shapiro: the International Congress of Hair Research.
All of our dermatology and skin research laboratories maintained national level (e.g. CIHR, NCIC) peer-reviewed funding in 2005. The fifth annual UBC Dermatology Research Day (March 12, 2005) was well attended by scientists, clinicians, clinical and graduate student trainees, as well as nurses and ancillary staff. Dr. Aziz Ghahary served as an invited external presenter.
There are now five independent basic research laboratories in addition to the clinical research that takes place at our teaching hospitals and community offices:
Laboratory of Skin Immunotherapeutics Dr. Jan Dutz
Laboratory for Advanced Medical Photonics (LaMP) Dr. Harvey Lui Dr. David McLean Dr. Haishan Zeng
Skin Cancer Biology Lab Dr. Gang Li Dr. Vincent Ho
Predictive Medicine and Therapeutics Laboratory Dr. Youwen Zhou
Hair Biology Research Laboratory Dr. Kevin McElwee Dr. Jerry Shapiro
Clinical Services
A new Vitiligo and Pigmentary Disorders Clinic was established at the VGH Skin Centre to provide access to advanced treatments and research into the biological basis of disorder skin pigmentation. New laser systems were acquired at the Lions Laser Skin Centre for vascular and melanotic lesions. Clinical expertise in psoriasis, eczema, skin cancer, vitiligo, alopecia, and skin rejuvenation amongst our faculty was featured in local and national media throughout 2005.
Dr. Otto Schlappner retired from teaching in the Division of Dermatology after a distinguished 19 year teaching career based at St. Paul’s Hospital.
Special Honours and Awards
Dr. James Bergman, Appointment as Clinical Assistant Professor
Dr. Jan Dutz, (1) Lectureship, Canadian Dermatology Foundation, (2) Resident Teaching Award, Division of Dermatology, and (3) Resident Teaching Award Residents & Fellows Section, Canadian Dermatology Association
Dr. Harvey Lui, President, Canadian Dermatology Association UBC Department of Medicine Page 52 Annual Report 2005
Dr. W. Alastair McLeod, (1) Honorary Membership, Canadian Medical Association and (2) Vice-Chair, Ethics Committee, Providence Health Care
Dr. Mike Martindale, Appointment as Dermatology Site Leader for Education, Northern Medical Program
Dr. Jason Rivers, Appointed Editor-in-Chief, Journal of Cutaneous Medicine and Surgery
Dr. Sikina Rossi, Appointment as Dermatology Site Leader for Education, Island Medical Program
Dr. Otto Schlappner, (1) Retirement as Clinical Associate Professor and (2) Practitioner of the Year, Dermatology Society of BC
Dr. Elizabeth Ross, Teaching Award, Residents & Fellows Section, Canadian Dermatology Association
Dr. Najwa Somani, Resident Award, Dowling Club & Dermatology Society of BC Joint Meeting
Ms. Alison Karst, Doctoral Research Award, Canadian Institutes of Health Research (Supervisor: Dr. Gang Li)
Mr. William Kuo, Graduate Student Award, Michael Smith Foundation for Health Research (Supervisor: Dr. Gang Li)
Mr. Philip Ng, Graduate Student Award, Michael Smith Foundation for Health Research (Supervisor: Dr. Gang Li)
UBC Department of Medicine Page 53 Annual Report 2005
ENDOCRINOLOGY
Dr. David Thompson Clinical Assistant Professor & Head
Faculty Members
Clinical Assistant Professor & Head Thompson, Dr. David VA Professor Prior, Dr. Jerilynn VA Clinical Associate Professor Tildesley, Dr. Hugh SPH Clinical Assistant Professor Bebb, Dr. Richard SPH Clinical Assistant Professor Dahl, Dr. Marshall VA Clinical Assistant Professor Elliott, Dr. Thomas VA Clinical Assistant Professor Gill, Dr. Sabrina SPH Clinical Assistant Professor Kendler, Dr. David VA Clinical Assistant Professor Kreisman, Dr. Stuart SPH Clinical Assistant Professor Sirrs, Dr. Sandra VA Clinical Assistant Professor Wallace, Dr. Clarissa VA Clinical Instructor Fung, Dr. Michelle VA Clinical Instructor Johnson, Dr. Michelle SPH Clinical Instructor Kong, Dr. Jason VA Clinical Instructor Mase, Dr. Robert SPH Associate Member Bondy, Dr. Greg SPH Associate Member Kitson, Dr. Hilary Associate Member Rothstein, Dr. Ralph C&W Health Centre Associate Member Stewart, Dr. Laura C&W Health Centre Adjunct Professor Finegood, Diane Burnaby Professor (Emeritus) Dawson, Dr. Keith Vancouver Clinical Professor (Emeritus) Wilkins, Dr. Graeme VA
Overview
The UBC Division of Endocrinology was active in a number of areas in 2005. There is increasing demand for clinical services in many areas at all sites. Planning is underway to accommodate the increased teaching demand required by the medical school expansion. The number of clinical research studies continues to grow.
UBC Department of Medicine Page 55 Annual Report 2005
Teaching
Undergraduate: The major responsibilities of the division at present are to provide tutors and materials for the PBL course offered at the beginning of medical school as well as opportunities for students in their senior years to take electives in endocrinology. Some division members serve as attending physicians on CTU and are involved in teaching internal medicine to clinical clerks. The expansion of the medical school will require the appointment of new faculty members to accommodate the increased teaching demand as well as careful planning to provide endocrinology instruction in sites where there are no endocrinologists in practice.
Postgraduate: The UBC division is currently training a total of four fellows in endocrinology, the largest number the division has ever had. One fellow has had a unique program created that will result in a dual certification in endocrinology and nuclear medicine. We anticipate an increased number of funded positions for endocrinology fellows to be created with the medical school expansion. VGH and SPH provide rotations for core internal medicine residents every month. Careful planning is required to provide a thorough grounding in the principles of endocrinology within the constraints of a one-month rotation. The demand for rotations in endocrinology will increase with the increased number of internal medicine residents that will accompany the medical school expansion. We are currently planning how to best meet this increased demand.
Community
Our division provides an increasing number of educational activities to community physicians. We run annual courses such as the Diabetes Directors Symposium and BC Endocrine Days as well as participating in departmental courses such as the Annual Reviews of Internal Medicine. Division members continue to provide a large number of invited lectures to community physicians across the province. Dr. Prior published a book in 2005 and has a very active web- site that allows people all over the world to learn about her research.
Committees
Dr. Dahl serves on committees for the Canadian Medical Association as well as the Medical Services Commission of British Columbia. Several division members are involved in the preparation of the 2008 Canadian Diabetes Association’s Clinical Practice Guidelines: Dr. Thompson (Chair Diabetes in Pregnancy section, transplantation, steering committee), Dr. Dawson (aboriginal issues, steering committee), Dr. Tildesley (insulin therapy in type 1), Dr. Meneilly (diabetes in the elderly) and Dr. Bebb (erectile dysfunction). Dr. Sirrs is on the national committee for Fabry’s disease. Several division members serve as expert reviewers for medical journals and national grants competitions.
Research
Research presentations by our residents and fellows at the Resident Research Day continues to be highly rewarded with several awards, including for best overall presentation. Most division members are involved in a number of areas of clinical research with the major ones listed below: Dr. Dawson: diabetes care in First Nations communities, clinical trials UBC Department of Medicine Page 56 Annual Report 2005
Dr. Elliott: clinical trials, President of the BC Endocrine Research Foundation Dr. Fung: islet cell transplantation, inpatient diabetes care delivery Dr. Kong: diabetes in pregnancy, clinical trials Dr. Sirrs: adult metabolic disease, lipid disorders Dr. Prior: women’s health, osteoporosis Dr. Dahl: diabetes health care delivery, inpatient diabetes care Dr. Thompson: islet cell transplantation, diabetes in pregnancy Dr. Bebb: male reproductive health Dr. Tildesly: diabetes care, clinical trials Dr. Kreisman: thyroid disease, cystic fibrosis and diabetes Dr. Gill: women’s health Dr. Kendler: osteoporosis Dr. Johnson: pituitary disease
Future Directions
The division will be focusing on expanding the activities described above as well as recruiting new members to meet the increased teaching requirements needed for the medical school expansion. A search committee will begin the process of selecting a new division head for 2007.
UBC Department of Medicine Page 57 Annual Report 2005
GASTROENTEROLOGY
Dr. Urs Steinbrecher Professor & Head
Faculty Members Professor & Head Steinbrecher, Dr. Urs VA Professor Freeman, Dr. Hugh VA Associate Professor Salh, Dr. Baljinder VA Associate Professor Yoshida, Dr. Eric VA Assistant Professor Tai, Dr. Isabella VA Clinical Professor Halparin, Dr. Laurence SPH Clinical Associate Professor Byrne, Dr. Michael VA Clinical Associate Professor Carr, Dr. Donald † VA Clinical Associate Professor Gray, Dr. James VA Clinical Associate Professor Kwan, Dr. Peter VA Clinical Associate Professor Weiss, Dr. Alan VA Clinical Assistant Professor Amar, Dr. Jack SPH Clinical Assistant Professor Enns, Dr. Robert SPH Clinical Assistant Professor Erb, Dr. Siegfried VA Clinical Assistant Professor Telford, Dr. Jennifer SPH Clinical Assistant Professor Whittaker, Dr. Scott SPH Clinical Instructor Chatur, Dr. Nazira VA Clinical Instructor Fishman, Dr. Martin Richmond Clinical Instructor Lam, Dr. Eric SPH Clinical Instructor Ramji, Dr. Alnoor SPH Associate Member Gill, Dr. Sharlene BCCA Associate Member McManus, Dr. Bruce SPH Visiting Professor Gomez-Munoz, Dr. Antonio VA Professor (Emeritus) Anderson, Dr. Frank VA Professor (Emeritus) Chaun, Dr. Hugh SPH Professor (Emeritus) Macdonald, Dr. Walter VA Professor (Emeritus) Stordy, Dr. Stanford SPH
† deceased June 12, 2005
UBC Department of Medicine Page 59 Annual Report 2005
Divisional Overview
The UBC Division of Gastroenterology consists of 5 UBC full-time faculty members, 15 clinical faculty members, 2 associate members, 4 emeritus professors, and one visiting professor. These staff are based at St. Paul’s Hospital, Vancouver General Hospital, UBC Hospital, Vancouver Cancer Centre, and Richmond General Hospital. There are active gastroenterology inpatient/consult services at Vancouver General Hospital and St. Paul’s Hospital as well as a liver transplant unit at Vancouver General Hospital. At VGH, nine gastroenterologists or hepatologists and two GI surgeons are based in the GI outpatient clinic and clinical research center in the Willow Chest Centre. All 8 gastroenterologists at St. Paul’s Hospital recently relocated to a new office and clinical research facility at 770 - 1190 Hornby St. The GI subspecialty training program currently has 5 trainees. In addition, there is a liver transplant fellow and an advanced therapeutic endoscopy fellow. The basic research themes in the division include oxidized LDL as an activator of growth signals in macrophages, molecular and biochemical abnormalities underlying chemotherapy resistance in GI cancer, and mucosal signal transduction mechanisms in models of inflammatory bowel disease and colon cancer. The division is also engaged in an active and multifaceted clinical research and clinical trials program.
Teaching
Undergraduate: The GI Division plays a key role in the enhancement and ongoing improvement of the GI block in phase II of the undergraduate curriculum. In addition to updates and revisions to the cases, lectures, and labs, priorities for 2006 are to plan for the expansion of the medical school class size over the next 4 years, to increase the quality, quantity, and accessibility of exhibits associated with the block cases, and to renew online resources for the block. Dr. Nazira Chatur was appointed Undergraduate Program Director for GI.
Postgraduate: Dr. Peter Kwan is Director of the GI training program, and Dr. Chatur serves as Co-director. The division is proud of the excellent trainees currently enrolled in the program. The GI trainees are Drs. Henry Chung, Jin-Kee Ho and Nasser Al-Masri for 2004-2006, and Drs. Iman Zandieh and Pongphob Intaraprasong for 2005-2007. Dr. Wichian Apiratpracha is the Transplant Hepatology fellow for 2005-2006, and Dr. Jaber Al-Ali is the Therapeutic Endoscopy fellow.
Experimental Medicine: Dr. Bill Salh coordinates the GI components of the Experimental Medicine Program. There are currently 4 graduate students from the GI Division registered in Experimental Medicine. In addition, two summer students, and two post-doctoral fellows are supervised by GI division members.
Continuing Medical Education: In 2005, the UBC GI Division organized the ninth Annual Digestive Disease Week Review Course for subspecialists. The Dr. Rob Enns chaired the Annual GI Forum. Both were well-attended and highly-rated events. The BC Hepatitis Program organized a Hepatitis B Conference in April for the Chinese Canadian Medical Society, Vancouver Chapter. The BC Hepatitis Program also created an educational website this year with the aid of a grant from the Community Care Foundation of BC. Many division members
UBC Department of Medicine Page 60 Annual Report 2005
participated in other regional and national CME events, including the Dept. of Medicine/ABIM Annual Course and the St. Paul’s Family Practice Annual Course.
Research
Division members generated more than 50 publications in peer-reviewed journals in 2004, and associate members added an additional 15 papers. Several division members including Drs. Salh, Steinbrecher, and Tai conduct active basic research programs supported by national and regional granting agencies (CIHR, HSFC, CCFC, and Canadian Society for Intestinal Research). The Division is expanding clinical research and clinical trials activities, and is involved in more than 30 trials in a variety of clinical areas including viral hepatitis, liver transplantation, inflammatory bowel disease, esophageal reflux disease, peptic ulcer disease, and functional bowel disorders. There are three main sites for clinical trials activities, the Drs. Anderson, Enns, Yoshida, Gray, Kwan, and Whittaker have been particularly active in clinical trials. As a result of recruitment initiatives over the past year, we have attracted three new clinician-investigators to the division's faculty (Drs. Chatur, Ramji, and Telford) who will build on existing clinical research strengths in the division.
Administration and Future Directions
Dr. Steinbrecher completed his term as division head. After an international search, Dr. Eric Yoshida was offered the position. He will take over as Head of the UBC and VGH/UBCH Divisions of Gastroenterology effective February 1, 2006.
Special Honours and Awards
Dr. Michael Byrne was appointed to the Editorial Boards of the World Journal of Gastroenterology and the Internet Journal of Gastroenterology. He was also Editorial Consultant for the Physicians' Information and Education Resource published by the American College of Physicians. Dr. Nazira Chatur was the recipient of the Astra-Zeneca Teaching Award. Dr. Hugh Chaun is Secretary-General, Bockus International Society of Gastroenterology and served as Chair, Press and Congress News Committee, 2005 World Congress of Gastroenterology Canadian Organizing Committee. He is also Governor of the American College of Gastroenterology representing the region of the Western Provinces, and Chair, Governing Board, Canadian Digestive Health Foundation. Dr. Chaun was a recipient of the inaugural Award of Excellence which is a new annual award presented by the College of Physicians and Surgeons of British Columbia. Dr. Rob Enns is Chair, Canadian Association of Gastroenterology Endoscopy Committee, served on the Presidential Abstract Selection Committee and the Scientific Organizing and Endoscopy Organizing Committees for the 2005 World Congress of Gastroenterology, and is a member of the Canadian Digestive Disease Health Foundation Committee. Dr. Enns is an Associate Editor of the Canadian Journal of Gastroenterology. Dr. James Gray is President, B.C. Society of Gastroenterology. Dr. Eric Yoshida is a Councillor of the Canadian Association for the Study of the Liver (CASL), and was on the organizing committee of the inaugural CASL Conference. Dr. Yoshida is an Associate Editor of the Canadian Journal of Gastroenterology and is also on the Editorial Boards of the World Journal of Gastroenterology and the Internet Journal of Gastroenterology. Dr. Urs Steinbrecher is Chair,
UBC Department of Medicine Page 61 Annual Report 2005
CIHR Metabolism Grant Panel, Chair, Heart and Stroke Foundation of B.C. and Yukon Research Committee, and Chair, AHFMR Clinical Investigator Review.
In Memoriam
Dr. Donald M. Carr died on June 12th, 2005 of a rapidly progressive malignancy. He had been a member of the GI Division for more than three decades. During his career he made tremendous contributions in clinical practice and teaching of gastroenterology and was a pioneer in therapeutic endoscopy, which was his passion. He was an outstanding clinician, an inspiring teacher, and a genuinely compassionate and generous individual. He was also a strong supporter of academic development and research in the division. Throughout his career, Dr. Carr earned the admiration and respect of his patients, colleagues and coworkers. He will be greatly missed.
To sustain his vision for progress in the division, his colleagues and patients established The Dr. Donald M. Carr Gastrointestinal and Liver Disease Fund. Proceeds from this fund will be used to support research and education in gastroenterology and liver disease at VGH and UBCH, including the introduction and evaluation of new endoscopic technologies. Contributions may be directed to the VGH/UBCH Foundation.
UBC Department of Medicine Page 62 Annual Report 2005
GENERAL INTERNAL MEDICINE
Dr. Iain Mackie Clinical Professor & Acting Head
Faculty Members
Clinical Professor & Acting Head Mackie, Dr. Iain VA Professor Page, Dr. Gordon VA Associate Professor Palepu, Dr. Anita SPH Associate Professor Studney, Dr. Donald VA Clinical Professor Mitenko, Dr. Paul Nanaimo Clinical Associate Professor Hatala, Dr. Rose SPH Clinical Associate Professor Kassen, Dr. Barry VA Clinical Associate Professor Kennedy, Dr. James SPH Clinical Associate Professor Magee, Dr. Laura C&W Health Centre Clinical Associate Professor Onrot, Dr. John SPH Clinical Assistant Professor Arseneau, Dr. Richard SPH Clinical Assistant Professor Ayotte, Dr. Brian Shuswap Lake Clinical Assistant Professor Baillie, Dr. Hector Nanaimo Clinical Assistant Professor Busser, Dr. James VA Clinical Assistant Professor Dunne, Dr. James VA Clinical Assistant Professor Ma, Dr. Irene VA Clinical Assistant Professor Ong-Lam, Dr. May SPH Clinical Assistant Professor Richmond, Dr. Allister Chilliwack Clinical Assistant Professor Wakefield, Dr. Robert VA Clinical Assistant Professor Ward, Dr. John SPH Clinical Instructor Auersperg, Dr. Edward Maple Ridge Clinical Instructor Broder, Dr. Sarah Penticton Clinical Instructor Caswell, Dr. Sherri VA Clinical Instructor Chan, Dr. Alex Chong Hen VA Clinical Instructor Cunningham, Dr. Kenneth SPH Clinical Instructor Deutscher, Dr. Timothy Nanaimo Clinical Instructor Duke, Dr. Stephen Victoria Clinical Instructor Ervin, Dr. Francis (Frank) Maple Ridge Clinical Instructor Hawley, Dr. Phillipa VA Clinical Instructor Holmes, Dr. Cheryl Kelowna Clinical Instructor Kenyon, Dr. Michael Nanaimo
UBC Department of Medicine Page 63 Annual Report 2005
Clinical Instructor Khan, Dr. Nadia SPH Clinical Instructor Kincade, Dr. David Kamloops Clinical Instructor Lai, Dr. Kevin Nanaimo Clinical Instructor Lysyshyn, Dr. Mark SPH Clinical Instructor McKay, Dr. Rhonda SPH Clinical Instructor Purkiss, Dr. Susan C&W Health Centre Clinical Instructor Roberts, Dr. James Mark VA Clinical Instructor Son, Dr. Wai Kong Chilliwack Clinical Instructor Sunderwood, Dr. Jennifer VA Clinical Instructor Winkler, Dr. Lawrence Nanaimo Clinical Instructor Wong, Dr. Steven VA Professor (Emeritus) Paige, Dr. Bruce VA Professor (Emeritus) Sanders, Dr. Harvey Professor (Emeritus) Schulzer, Dr. Michael VA Associate Professor (Emeritus) Rangno, Dr. Robert SPH
Divisional Overview
The UBC Division of General Internal Medicine is a large division within the Department of Medicine consisting of faculty with a variety of generalist and subspecialty interests. The faculty function at the four major teaching hospitals as well as in community hospitals throughout the province. Faculty are heavily involved in the teaching programmes of the Undergraduate and Postgraduate Programmes of the Faculty of Medicine, and a number of members play major leadership roles within those programmes. The Internal Medicine Programme Director and two of the three Associate Directors are members of the Division. Division members are site directors for the undergraduate programme. Research is concentrated at St. Paul’s Hospital (SPH) and BC Women’s Hospital (BCWH). The Division is home to a number of award- winning teachers and a number of its members have national reputations for their involvement with Internal Medicine and General Internal Medicine at a national level. New recruits to the Division in 2005 included Dr. Irene Ma at Vancouver Hospital & Health Sciences Center (VHHSC) and Dr. Mark Lysyshyn at SPH. Dr. Ma has a MSc. in clinical epidemiology and is interested in population health and ethnicity and disease. Dr. Lysyshyn has expertise in eating disorders and inner city health/addictions medicine. He has an MPH degree from Harvard, completed in 2005.
Teaching
The Division plays a major role in undergraduate teaching on the Clinical Teaching Units of Vancouver Hospital and St. Paul’s Hospital. Dr. Jim Busser and Dr. Jim Dunne are Internal Medicine Site Directors for the Undergraduate Programme in Internal Medicine. The medical school expansion and its effect on both the undergraduate and postgraduate teaching programmes has resulted in an expansion of the CTUs and the development of innovative ways to structure the CTUs to deal with increasing numbers of students.
One of the major foci of the Division is Postgraduate Education. This training is focused on the CTUs as well as ambulatory clinics at Vancouver General Hospital (VGH) and St. Paul’s Hospital. Several members of the Division have expertise in the development of evaluation UBC Department of Medicine Page 64 Annual Report 2005
systems and have introduced novel evaluation tools (i.e. the mini-CEX examination) to the ongoing evaluation of core Internal Medicine residents. This interest has led to research that will have a national impact on the evaluation of residents at both the local and Royal College levels.
Members of the Division are recognized for their expertise in clinical teaching and have won numerous teaching awards (see section on Awards).
Research
While many Division members are engaged in research, the main research foci are at SPH and BCWH. Dr. Anita Palepu continues to be a nationally recognized researcher in Population Health, focusing on areas related to HIV. She holds numerous grants from CIHR, the NIH and the Michael Smith Foundation. Dr. Palepu sits as Associate Senior Scientific Editor for the Canadian Medical Association Journal and functions as a peer reviewer for numerous medical journals and granting agencies. In 2005 she became the Co-director for the UBC Department of Medicine Clinical Investigator Programme. She remains a strong advocate for the supervised injection facility in the Vancouver Downtown East-side. Her advocacy and research gathered national prominence in 2005 with a national CBC interview.
Dr. Nadia Khan continues her research in population health. She is the recipient of a number of major peer reviewed grants from the CIHR and Michael Smith Foundation.
Drs. Rose Hatala, Barry Kassen (both from SPH) and Mark Roberts and Iain Mackie (both from VGH) undertook a major study of the mini-CEX examination and compared its outcome to that of the Royal College Internal Medicine oral examination. As a result of the study, mini-CEX examinations have become standard evaluation tools for trainees in the residency training programme. Drs. Hatala and Kassen are also involved in collaborative research with faculty from the University of Miami on the role of simulators in oral clinical examinations.
Dr. Laura Magee continues to provide expertise and research skills in her role as an expert in Maternal Medicine at BCWH. She, too, holds major grants from the CIHR and Michael Smith Foundation for her work in hypertension in pregnancy and interventions to improve maternal outcomes in deliveries under 29 weeks.
Administration
As mentioned above, members of the Division play major administrative roles within the university and nationally.
Dr. Iain Mackie continued as the Acting Division Head and Division Head at Vancouver Hospital & Health Sciences Center. He is a member of the Oral Examination Board for the Royal College of Physicians & Surgeons of Canada and acts as a surveyor for the RCPSC in the accreditation of postgraduate training programmes.
Dr. Barry Kassen is the Division Head at SPH and has major administrative roles as Associate Head of the St. Paul’s Hospital Department of Medicine and is CTU Director. He is the Programme Director for the GIM Fellowship Programme. Dr. Kassen is also an Associate UBC Department of Medicine Page 65 Annual Report 2005
Director for the IM Residency Training Programme, being responsible for the development of community training programmes. Nationally, Dr. Kassen is the Chair of the Internal Medicine Examination Board for the RCPSC and sits on the Royal College Nucleus Committee for Internal Medicine.
Dr. Mark Roberts acts as the CTU Director at VGH. He is the Programme Director for the Internal Medicine Residency Training Programme, having taken over from Dr. Iain Mackie in late 2004. Dr. Roberts is also a member of the Oral Examination Board of the RCPSC.
Dr. Rose Hatala is Associate Director for the IM Residency Training Programme, responsible for evaluation. She sits, nationally, on the Examination Committee for Internal Medicine at the RCPSC and is a member of the Oral Examination Board.
Dr. Robert Rangno continued his role as a member of the Therapeutics Initiative – Education Working Group. Dr. Tom Perry also has a significant administrative role with the Therapeutics Initiative.
Future Directions
The expansion of the medical school and an increased number of residency positions will challenge the Division to develop innovative teaching methods and improve the quality of teaching on the Clinical Teaching Units. Recruitment in 2006 will take place in a number of areas, including a major emphasis on recruitment at VHHSC. Division members will continue to expand their research focus and the recruitment of faculty with special expertise in medical education. Population health and perioperative evaluation will be a major priority.
Honours and Awards
Dr. Rose Hatala won the Fay Dirks Award for Excellence in Teaching at St. Paul’s Hospital.
Dr. Anita Palepu won the Howard Stein Master Teacher Award at St. Paul’s Hospital.
Dr. Iain Mackie was nominated for the Killam Prize at the University of British Columbia.
Dr. Nadia Khan won the Shelly Naiman Award, given by the residents in the IM Residency Training Programme.
Dr. Barry Kassen won the Master Teacher Award at St. Paul’s Hospital.
UBC Department of Medicine Page 66 Annual Report 2005
GERIATRIC MEDICINE
Dr. Janet E. McElhaney Dr. Larry Dian, Clinical Associate Professor & Head Professor & Acting Head (October 1, 2005 – present) (January 1 – September 30, 2005)
Faculty Members
Professor & Head McElhaney, Dr. Janet SPH/VA Professor Meneilly, Dr. Graydon VA Assistant Professor Madden, Dr. Kenneth VA Clinical Associate Professor Adler, Dr. Reva VA Clinical Associate Professor Dian, Dr. Larry VA Clinical Associate Professor Martini, Dr. Janet VA Clinical Assistant Professor Chung, Dr. Maria VA Clinical Assistant Professor Hill, Dr. Amanda VA Clinical Assistant Professor O'Connor, Dr. Peter RCH Clinical Assistant Professor Rauscher, Dr. Christopher VA Clinical Assistant Professor Wong, Dr. Roger VA Clinical Instructor Barnett, Dr. Kim Richmond Clinical Instructor Bater, Dr. Marilyn Victoria Clinical Instructor Bell, Dr. Kathryn VA Clinical Instructor Cook, Dr. Wendy SPH Clinical Instructor King, Dr. Kim Nanaimo Clinical Instructor Kushner-Kow, Dr. Janet SPH Clinical Instructor Lee, Dr. Philip SPH Clinical Instructor Malone, Dr. Marilyn Victoria Clinical Instructor Menezes, Dr. Janice SPH Clinical Instructor Petrossian, Dr. Caroline SPH Clinical Instructor Ranchod, Dr. Hetesh SPH Clinical Instructor Williams, Dr. Dorothy SPH Professor (Emeritus) Beattie, Dr. Lynn VA
UBC Department of Medicine Page 67 Annual Report 2005
Divisional Overview
The Division of Geriatric Medicine currently has 15 faculty within Vancouver Acute (VA) and Providence Health Care (PHC) and 4 faculty in distributed sites. The Division provides a wide range of clinical services across these sites, including active geriatric consultation services, in- patient acute care for elders (ACE), geriatric activation and assessment beds, geriatric day hospitals and multiple outpatient clinics. Clinical services provided as an outreach to the community are gradually being integrated into the Community Health Centers of VCH. The strategic plan for the Division is moving forward under the Responsive Acute Care for Elders (RACE) initiative and is undertaking a process that will improve outcomes of seniors accessing the acute care system. The academic and clinical missions of the Division will role out under the Vancouver Initiative To Add Life to Years (VITALiTY). The Division’s major areas of research emphasis in health services research and active research programs in diabetes, dementia, osteoporosis, falls prevention, cardiovascular disease, inflammation, immunosenescence and vaccination provide a foundation for the scholarship and service that will promote health and wellness, functional vitality and social engagement for seniors in the community of Vancouver Coastal Health and British Columbia.
Teaching
Undergraduate: Dr. Reva Adler coordinates Phase V for the Undergraduate Education Committee of the Department of Medicine and will coordinate this phase for the medical school expansion. Dr. Janet Kushner-Kow is the Representative for the undergraduate teaching program for the UBC Division of Geriatric Medicine and also has a role in the medical school expansion that went live in September 2005. She has recently revised the undergraduate curriculum for second year bedside teaching in Geriatric Medicine and is also actively involved in the Brain and Behaviour Week in PBL. The Division met with geriatricians from other parts of the province to discuss the impact and opportunities related to the medical school expansion, particularly in view of the fact that geriatrics will be a focus of the Island medical program.
Postgraduate: Under the leadership of Dr. Larry Dian, our training program continues to be actively involved in the teaching of internal medicine residents and fellows in the principles of the care of the frail elderly. Our Division members also participate in the clinical teaching units and noon rounds for medical residents. Drs. Reva Adler and Janet Kushner-Kow have created an inter-professional educational program for geriatrics using case-based scenarios that are being used in universities and community health throughout British Columbia. Dr. Roger Wong is Associate program director, postgraduate medical education, Department of Medicine UBC. The postgraduate program includes three residents, including one gulf state resident, and one resident will start in July 2006. The program successfully underwent an internal review in May 2005. Fellowship academic sessions covering ethics, communications and core topics were instituted in 2005. Further linkages between the division, Geriatric Psychiatry and Care for the Elderly programs and trainees are being made.
Continuing Medical Education: In 2005 the Division members were active participants in numerous CME events including programs in osteoporosis, falls and fractures, dementia, diabetes and other topics. The Division Seminar Program takes place weekly during the academic year, ably directed by Dr. Phil Lee. The Division will host the 2006 Canadian UBC Department of Medicine Page 68 Annual Report 2005
Geriatrics Society Annual Scientific Meeting in Vancouver with Dr. Roger Wong as the Conference Chair, and with preparations largely complete, registrations have already surpassed the attendance in previous years.
Research
Dr. Meneilly continues his research program in diabetes in the elderly and is also actively involved in the islet transplant program. Dr. Ken Madden received a CIHR grant to conduct a randomized, controlled trial of aerobic, strength to measure its effect on arterial stiffness and the cardiovascular control measures that prevent syncope during upright tilt (recruitment began at the beginning of February, 2006). Dr. McElhaney is establishing her research program in Vancouver based on her NIH-funded research on the effect of aging and heart failure on immunologic responsiveness to influenza vaccination. Dr. Wendy Cook presented the results of her study on gaps in care for osteoporosis in rural community nursing homes at a session chaired by Dr. Larry Dian at an international osteoporosis and renal disease conference in Toronto. Dr. Dian has received funding from the Michael Smith Foundation to develop guidelines for rational pharmacotherapy in rural nursing homes. Dr. Roger Wong continues to conduct research in medical education. He is currently investigating the role of electronic academic detailing in teaching medical concepts to physicians. He is also involved in clinical outcomes research on the measurement and determinants of physical function in acutely ill seniors in the ACE unit. Dr. Beattie is involved in multiple research projects related to dementia and is Chair of the Research Policy Committee for the Alzheimer Society of Canada and the BC Network for Aging Research, and a member of the CIHR Gender, Sex and Health Committee. Dr. Reva Adler has represented Canada at a number of international conferences on genocide that results from her work under a Fulbright scholarship over the past three years. She is also funded by the Vancouver Foundation to study access to health services for older immigrants to Canada. Dr. Janice Menezes has a research focus within PHC to conduct performance and continuous quality improvement reviews with ongoing evaluation of service delivery. Dr. Wendy Cook is evaluating risk factors for falls in different populations of older adults including those with end- stage renal disease on hemodialysis and peritoneal dialysis or presenting to the Emergency Department with falls, and collaborates with the Bone Health Research Group focusing on falls prevention at VA. Dr. Philip Lee has completed a CIHR Fellowship Behavioral Neurology and Dementia and is initiating a study on delirium in hospitalized older adults with the recent award of a Physician Scholar Award from the Providence Health Care Foundation. Dr. Hill is involved in interventions and health care delivery research in the areas of management of congestive heart failure and delirium. Drs. Phil Lee and Ken Madden are collaborating with Dr. McElhaney in interventions for delirium at PHC and VA as well.
Clinical Services
At both PHC and VA, clinical activities continue to increase and a Sub-Acute for Frail Elderly (SAFE) unit operates at the UBC hospital site. The Division is actively involved in patient assessment and management at the VGH STAT Centre and is providing outreach through community-based services within Vancouver Community Health.
UBC Department of Medicine Page 69 Annual Report 2005
Administration
The leadership Structure of the UBC and PHC Division has undergone a significant change over the past year. Dr. Janet McElhaney was recruited back to Canada from the United States as Head, Division of Geriatric Medicine for both UBC and PHC. She is also Physician Program Co-Director for Elder Care Program with responsibilities for geriatric and rehabilitation medicine at St. Paul’s, Mount St. Joseph and Holy Family Hospitals. At VA, Dr. Meneilly is Chair for the Department of Medicine at both VA and UBC. Dr. Larry Dian is the VA Division Head for Geriatric Medicine. Dr. Janice Menezes is the Physician Operations Leader at St. Paul’s. Dr. Reva Adler is Medical Director of the VGH STAT Centre. Dr. Amanda Hill continues in her role as Medical Director, Community and Specialty Medicine. Dr. Roger Wong continues his roles as Medical Director, Geriatric Consultation Program and Medical Manager, ACE unit at VA. Dr. Maria Chung is Medical Director, UBC Hospital.
Special Honours and Awards
Dr. Graydon S. Meneilly, Eric W. Hamber Professor & Head, Department of Medicine, UBC & Vancouver Acute
Dr. Janet E. McElhaney, Allan M. McGavin Chair in Research Geriatrics and UBC and PHC Head, Division of Geriatric Medicine
Dr. Larry Dian, Vancouver Acute Head, Division of Geriatric Medicine
Dr. Ken Madden was awarded 3-year CIHR grant for the project entitled “Exercise and Cardiovascular Control During Upright Tilt in Older Adults with Type 2 Diabetes.
Dr. Roger Wong was awarded the Fay R. Dirks award for excellence in teaching by the Department of Medicine UBC, and received with Dr. Kerry Wilbur the Canadian Society of Hospital Pharmacists: BC Branch practice award.
Dr. Janet McElhaney received the Competing Renewal of her NIH grant titled “T-Cell Responses Predict Influenza Risk in Older Adults” from the National Institute of Allergy and Infectious Diseases.
UBC Department of Medicine Page 70 Annual Report 2005
HEMATOLOGY
Dr. Michael Barnett Clinical Professor & Head
Faculty Members Clinical Professor & Head Barnett, Dr. Michael VA/BCCA Professor Eaves, Dr. Allen BCCA Professor Humphries, Dr. Richard BCCA Professor Lansdorp, Dr. Peter BCCA Professor Schrader, Dr. John UBC Associate Professor Smith, Dr. Clayton VA/BCCA Clinical Professor Ballem, Dr. Penny C&W Health Centre Clinical Professor Hogge, Dr. Donna VA/BCCA Clinical Professor Nevill, Dr. Thomas VA/BCCA Clinical Associate Professor Benny, Dr. Barrett VA Clinical Associate Professor Forrest, Dr. Donna VA/BCCA Clinical Associate Professor Nantel, Dr. Stephen VA/BCCA Clinical Associate Professor Shepherd, Dr. John VA/BCCA Clinical Associate Professor Sutherland, Dr. Heather VA/BCCA Clinical Associate Professor Toze, Dr. Cynthia VA/BCCA Clinical Associate Professor Vickars, Dr. Linda SPH Clinical Assistant Professor Leitch, Dr. Heather SPH Clinical Assistant Professor Li, Dr. Charles SPH Clinical Instructor Broady, Dr. Raewyn VA Clinical Instructor Foltz, Dr. Lynda Clinical Instructor Galbraith, Dr. Paul SPH Clinical Instructor Lavoie, Dr. Julye VA/BCCA Clinical Instructor Leger, Dr. Chantal SPH Clinical Instructor Petraszko, Dr. Tanya VA Clinical Instructor Song, Dr. Kevin VA/BCCA Clinical Instructor Sreenivasan, Dr. Gayatri VA Clinical Instructor Tsang, Dr. Peter VA Clinical Instructor Zypchen, Dr. Leslie VA Clinical Professor (Emeritus) Buskard, Dr. Noel VA
UBC Department of Medicine Page 71 Annual Report 2005
Divisional Overview
The UBC Division of Hematology includes 26 staff and 3 associate staff members based at the Vancouver General Hospital (VGH), the Vancouver Cancer Centre (VCC) and the Terry Fox Laboratory (TFL) of the British Columbia Cancer Agency, St. Paul’s Hospital (SPH), BC Women’s & Children’s Hospital and UBC. In 2005, laboratory research programs at TFL and UBC brought in peer-reviewed operating support of $3.8 million and CFI equipment funds of $1.3 million and clinical research at VGH and SPH brought in $432,336. There was a total of 40 peer-reviewed publications. Training and patient care remained at the forefront of clinical activities. Trainees in the Division as a whole included 5 Hematology fellows, 6 Leukemia/BMT fellows, 16 laboratory post-doctoral fellows and 11 graduate students.
Teaching
Undergraduate: This was the 7th year of the Blood & Lymphatics Block in the Problem Based Learning course.
Postgraduate: A total of 24 Residents in the Internal Medicine Program took hematology-based electives during the past year. These were one or two month blocks spent on the Hematology Consultation Service at VGH or SPH.
Subspecialty Training: Five General Hematology fellows were based at VGH. Rotations included the General Hematology Consultation Service, Leukemia/BMT Service, Blood Transfusion Service, Cell Separator Unit, Out-patient Clinics and Hematopathology. Rotations were also taken at SPH, VCC, BC Women’s and Children’s Hospital. These positions were filled by Dr. Mohammed Al Belowi, Dr. Lynda Foltz, Dr. Yulia Lin, Dr. Carolyn Owen, and Dr. Paul Yenson.
Leukemia/Bone Marrow Transplantation Fellowship: The Leukemia/BMT Program had six positions available for clinical training in the management of patients with leukemia and those undergoing hematopoietic stem cell transplantation. These positions were filled by Dr. Yasser Abou Mourad, Dr. Genevieve Gallagher, Dr. David Irvine, Dr. Prabodh Das, Dr. Fat-hia Al Qurashi, and Dr. Maryse Power.
Postdoctoral Training: Division Members conducting bench research at the TFL and UBC trained 16 postdoctoral fellows, of whom 13 were PhD’s and 3 were MD’s.
Doctoral Training: The Terry Fox Lab accommodated 11 graduate students.
Continuing Medical Education: Division Members attended numerous national and international meetings both as attendees and speakers.
Research
Clinical research continued to be focused on hematological malignancies at VGH/VCC and thrombosis at SPH. As well as in-house studies, significant contributions were made to national and international trials. Laboratory research based at the TFL involved the regulation of normal UBC Department of Medicine Page 72 Annual Report 2005
and malignant hematopoietic cell growth and differentiation with special emphasis on the myeloid leukemias, Hox genes and telomeres. The molecular characterization of regulatory pathways was the focus at UBC.
Clinical Services
The clinical services at VGH/VCC and SPH continued to cope with a high workload in terms of both inpatient and outpatient activities.
Dr. Noel Buskard retired from the Division in the summer of 2005. Over a period spanning 27 years, Dr. Buskard gave sterling service as a clinician, taught with panache and played a leadership role in a number of national and international societies.
In the autumn, after a Thrombosis fellowship in Ottawa, Dr. Leslie Zypchen was appointed a staff hematologist at VGH.
Administration
Dr. Linda Vickars (Head of Hematology at SPH), Dr. Clayton Smith (Director of the Leukemia/BMT Program at VGH and BCCA), Dr. Stephen Nantel (Director of the Clinical Practice Unit for Hematology/BMT at VGH), Dr. Barrett Benny (Director of the Cell Separator Unit at VGH), Dr. Peter Tsang (Director of the Hematology Training Program) and Dr. Charles Li (Coordinator of Undergraduate Teaching) continued in leadership positions.
Future Directions
The main research goals will be to enhance activity at the laboratory/clinical interface in hematological malignancy and to expand efforts in thrombosis. Accordingly, new initiatives, e.g., development of a Hematology Clinical Trials Unit and collaborations, e.g., with the Centre for Blood Research at UBC will be pursued. In regard to clinical services, a priority will continue to be the achievement of a full complement of appropriately funded staff.
Special Honours and Awards
Dr. Penny Ballem – Women’s Executive Network, Award for “Canada’s Most Powerful Women: Top 100” in the Public Sector Leaders Category
UBC Department of Medicine Page 73 Annual Report 2005
INFECTIOUS DISEASES
Dr. Neil E Reiner Professor and Head
Dr. H Grant Stiver Professor and Assistant Head
Faculty Members
Professor & Head Reiner, Dr. Neil VA Professor Bowie, Dr. William VA Professor Brunham, Dr. Robert UBC/BCCDC Professor Chow, Dr. Anthony VA Professor Montaner, Dr. Julio SPH Professor Stiver, Dr. Grant VA Associate Professor Av-Gay, Dr. Yossef VA Associate Professor Phillips, Dr. Elizabeth SPH Associate Professor Tyndall, Dr. Mark SPH Assistant Professor Cherkasov, Dr. Artem VA Assistant Professor Grigg, Dr. Michael VA Assistant Professor Hmama, Dr. Zakaria VA Assistant Professor Steiner, Dr. Theodore VA Clinical Professor Burdge, Dr. David C&W Health Centre Clinical Professor Chan, Dr. Robert SPH Clinical Professor Phillips, Dr. Peter SPH Clinical Professor Rekart, Dr. Michael BCCDC Clinical Assistant Professor Harrigan, Dr. Richard SPH Clinical Assistant Professor Kerr, Dr. Thomas SPH Clinical Assistant Professor Montessori, Dr. Valentina SPH Clinical Assistant Professor Moore, Dr. David SPH Clinical Assistant Professor Press, Dr. Natasha SPH Clinical Assistant Professor Wood, Dr. Evan SPH Clinical Instructor Mirzanejad, Dr. Yazdan Surrey Clinical Instructor Reynolds, Dr. Robert VA Associate Member Isaac-Renton, Dr. Judith BCCDC Associate Member Jewesson, Dr. Peter Associate Member Marra, Dr. Fawziah BCCDC Associate Member McElhaney, Dr. Janet SPH Associate Member McMaster, Dr. Robert VA Associate Member Money, Dr. Deborah C&W Health Centre Associate Member Patrick, Dr. David BCCDC UBC Department of Medicine Page 75 Annual Report 2005
Visiting Assistant Professor Naserpour Farivar, Dr. Taghi VA Visiting Scientist Lam, Dr. Bing VA Visiting Scientist Lopez, Dr. Martin VA Visiting Scientist Papavinasasundaram, Mr. VA Kadambavanasundar Visiting Scientist Petchkovski, Dr. Dmitri VA Visiting Scholar Rios, Dr. Lilia VA Adjunct Professor Sanghera, Dr. Jasbinder Vancouver
* Inactive member/Assistant Professor de Haan, Dr. Marie VA
Divisional Overview
2005 was an unprecedented year for growth and significant achievements for the Division of Infectious Diseases. The core Division is now comprised of 18 MD and 7 PhD faculty who oversee programs in patient care, education and research at three teaching hospitals located at Vancouver General (VGH), St. Paul’s (SPH), and BC Children’s and Women’s Hospitals as well as the UBC/BC Centre for Disease Control. Along with the highly active clinical faculty are nationally and internationally recognized investigators with expertise and interests in areas including molecular microbial pathogenesis, host defense, microbial genomics, HIV, clinical epidemiology, sexually transmitted diseases, respiratory, urinary tract, fungal infections, and vaccine studies. More about these research activities as well as a major multi million dollar award from Genome Canada/BC for research in Emerging Infectious Diseases will be described further along in this report.
Faculty at St. Paul’s welcomed three AIDS researchers who joined the BC Centre for Excellence in HIV/AIDS as Clinical faculty. Dr. David Moore, MD, is working in Uganda on clinical monitoring strategies for the use of antiretroviral therapy in African countries as well as conducting research on the HIV/AIDS Drug Treatment Program. Dr Thomas Kerr, PhD, has a focus on epidemiology, evaluation of health services and health psychology pertaining to injection drug use and HIV/AIDS treatment. Dr Evan Wood has a PhD in Epidemiology, with an HIV epidemiology focus. In addition, Dr Yazdan Mirzanejad, an experienced ID specialist and intensivist who is consulting at Surrey Memorial and Royal Columbian Hospitals also joined the Division this year. Dr. Janet McElhaney, the new Head of Geriatric Medicine and respected influenza researcher, became an associate member of the Division.
Teaching
Teaching continues to be a major strength of the Division of Infectious Diseases. Members of the Division make substantial contributions to the education of undergraduate and postgraduate students, residents and fellows from the Faculty of Medicine. In addition, 15 visiting undergraduate and postgraduate medical students and residents representing most Canadian medical schools, and Jichi University in Japan, received elective training in Infectious Diseases at VGH and SPH this year.
Undergraduate: The Division’s significant commitment to undergraduate teaching includes the highly regarded Host Defense Infection Block in the Problem Based Learning course. Clinical UBC Department of Medicine Page 76 Annual Report 2005
Clerkship Half Days and inpatient rotations are also highly regarded by students. Dr. Grant Stiver continues his significant contribution to the Program as Director of Undergraduate Education for the Faculty of Medicine.
Postgraduate: Following seven very successful years as Program Director of the Residency Training Program, Dr. Valentina Montessori handed the role over to Dr. Natasha Press in the fall. Dr. Press, who completed the UBC Infectious Diseases Subspecialty Training Program in 2000, will be an equally effective Program Director. The two-year Royal College Subspecialty Training Program provides high quality clinical and research training in order to equip fellows for an academic career in infectious diseases. Currently, there are a total of six fellows in the Program.
Graduate Students: Through Experimental Medicine as well as the Departments of Laboratory Medicine and Microbiology and Immunology, Infectious Diseases Faculty supervised 20 graduate students and 13 post doctoral research fellows at VGH, BCCDC and SPH.
UBC MD/PhD Program: Dr. Anthony Chow is Director of the UBC MD/PhD Program jointly administered by the Faculty of Medicine and the Faculty of Graduate Studies. This integrated combined degree Program prepares the students to pursue a research-intensive track of residency and postdoctoral training in a specialty or discipline of their choice, ultimately leading to an independent clinician-investigator career. The program enrolled 13 trainees during 2005. MD/PhD students have won numerous awards from external agencies including the Canadian Society for Clinical Investigation, BC Research Institute, Vancouver Coastal Health Research Institute, CIHR-UBC- TRID, and the Michael Smith Foundation for Health Research.
TRID Program: Dr. Anthony Chow is also Director of the CIHR-UBC Strategic Training Program for Translational Research in Infectious Diseases (TRID). This innovative and successful training program has brought together basic, clinical and population-based researchers, and has created unparalleled opportunities for translational and trans-disciplinary research training not available from classical training programs. TRID has a multidisciplinary Faculty drawn from both clinical and basic science departments with a common interest in infectious diseases, microbiology and public health. In 2005 the Program administered 28 TRID studentships, 5 PhD and 1 MD/PhD awards, and 5 postdoctoral research fellowships. TRID trainees published 17 and submitted 6 peer-reviewed manuscripts, and presented 30 papers at national and international conferences. TRID held two thematic research symposia “Emerging and Re-emerging Infectious Diseases”, and “Innate Immunity and Immuno-modulation in Infectious Diseases”. Among the 19 students who recently completed their undergraduate degrees, 10 have entered medical school, and 7 have entered graduate studies.
Research
Recognition of the quality of the highly active and innovative research programs undertaken by Division faculty at all sites is illustrated by the total grant funding awarded for the year which reached an all time high, at $6.9 M. Not included in this amount, and without a doubt the highlight of the year, was the awarding of $5.76 M for three years by Genome BC and Genome Canada to Neil Reiner, Robert Brunham and Brett Finlay for their innovative research project called PREPARE, Proteomics for Emerging Pathogens and Response. Division members Art UBC Department of Medicine Page 77 Annual Report 2005
Cherkasov and Robert McMaster are also involved with this integrated research program to study protein interaction networks and apply computational genomics to identify novel, high quality drug targets in microbial pathogens.
Immunity and Infection Research: The Division maintains an active basic research program in molecular microbial pathogenesis and host defense at VGH. Pathogens under study included M. tuberculosis, Leishmania, Toxoplasma, E. coli, Staphylococci, Streptococci and Chlamydia. In addition to addressing mechanisms of pathogenesis, ongoing research is concerned with both innate and acquired immune responses to infection including vaccine development. The Division’s research program has an important bioinformatics focus with additional state-of-the art expertise in molecular modeling and computer-aided drug design.
HIV/AIDS Research Program: The AIDS Research Program, which involves seven faculty members at the St. Paul’s site, is nationally and internationally recognized for work in all facets of HIV. The main areas of research encompass epidemiology, clinical management and basic sciences. The epidemiology group has been actively developing and maintaining long-term analyses of drug treatment programs in Vancouver, including harm reduction strategies to prevent HIV transmission. The group has been investigating the natural history of injection drug use including: study of HIV and Hepatitis C and other adverse consequences related to injection drug use, the scientific evaluation of North America’s first supervised injection site, examination of illicit opiate addiction, as well as treatment and policy in Canada. A special focus during 2005 included new cohort studies involving commercial sex workers and street youth. The clinical science research focuses on issues important to the medical management of patients with HIV including multidrug-resistant virus, pharmacokinetics of antiretrovirals, and adherence to antiretroviral therapy regimens, drug toxicities, viral co-infections and primary care initiatives. The basic science program has a major focus on HIV resistance to antiretroviral therapy and mechanisms of toxicity.
Clinical Research: Dr. Grant Stiver continued his timely research in respiratory tract infections, particularly influenza and influenza FluInsure vaccine efficacy. Current other trials include assessment of a new antibiotic Telavacin against MRSA skin and soft tissue infections and Gram positive nosocomial pneumonia, as well as further studies on oral gel formulations to treat C. difficile colitis. The Oak Tree Program at Children’s and Women’s Health Centre of BC has a collaborative clinical research program led by Dr David Burdge. The program focuses on women/gender issues in HIV with clinical studies in HIV infected women, pregnant women and children.
Epidemiological Research: ID Faculty at the UBC CDC have a wide range of goals including STD prevention, control and service delivery; control of emerging infectious diseases, particularly from respiratory pathogens; assessment of the human papillomavirus infection (HPV) status in BC and provision of province wide diagnostic and treatment services; reduction of antimicrobial misuse as linked to the emergence of resistant organisms; detection and description of unique outbreaks such as Cryptococcus gattei disease; and early interruption of transmission of diseases from infected food products. Drs. Michael Rekart and Bill Bowie are involved in CIDA funded projects concerning STD, HIV, TB prevention and care in Vietnam and Guyana, and ecosystem health in Ecuador.
UBC Department of Medicine Page 78 Annual Report 2005
Clinical Services
The Division maintains two highly active consultation services, one located at SPH and one at VGH. The volume of consultations at VGH has doubled since 2000 including increases of 15% each year for the past three years. The consultation services see the usual full range of general ID cases. At the same time, there is a particular wealth of clinical material related to reconstructive orthopedics including spine, neurosurgery, bone marrow and solid organ transplant, tuberculosis, infections related to IVDU and infections in other marginalized populations. There is also an AIDS inpatient ward based at SPH which continues to be extremely busy. The capacity is expected to increase to 20 beds early in 2006.
Administration
In August, Dr Julio Montaner, who is also Physician Program Director for HIV/AIDS, Providence Health Care became Director of the BC Centre for Excellence in HIV/AIDS.
Dr. David Patrick, Director, Communicable Disease Epidemiology, UBC CDC, and his team have been recognized for developing a valuable template for communicable disease control organization. Since the SARS outbreak, they have received guests from all over the world who wish to study this model. They have been recognized in Dr. David Naylors’ report on the future of public health in Canada. “We see the rationale for single-focus agencies and commend the work of British Columbia’s Centre for Disease Control as a provincial examplar in the infectious disease field.”
Special Honours and Awards
Yossi Av-Gay: Chairman; Proteomic of host response to viral infection. 3rd International Consortium of Anti Virals meeting, Trent University, Ontario
William Bowie: Invited Speaker for the Vancouver Institute Fall Series: Emerging epidemics and pandemics: Are they inevitable and catastrophic? Tom Marrie Lecturer, Dalhousie University, May 2005
Robert Brunham: CIHR Partnership Award, SARS Accelerated Vaccine Initiative; Along with David Patrick, addressed the visiting delegation from Guandong, China on Infectious Disease Control.
Tony Chow: Member, CIHR Infection & Immunity Pilot Project Grants Committee
Julio Montaner: Mark Wainberg Lecture (Research Award). 14th Annual Canadian Conference on HIV/AIDS Research, Vancouver, May 2005; Donald Whitelaw Award for Outstanding Grand Rounds (St. Paul’s Hospital Department of Medicine), June 2005
David Patrick: Emerging Infectious Diseases: UBC’s Interdisciplinary Attack. Plenary talk and meetings during the opening of UBC’s Pacific Rim Regional Office in Hong Kong, May 2005 UBC Department of Medicine Page 79 Annual Report 2005
Elizabeth Phillips: Invited speaker: Abacavir Hypersensitivity. Towards diagnostic precision and preventive screening. British Association for HIV Research, London, UK
Neil Reiner: Invited Speaker, American Society for Microbiology, Symposium on TB pathogenesis, Atlanta, GA; Elected to Council, Society for Leucocyte Biology
UBC Department of Medicine Page 80 Annual Report 2005
MEDICAL ONCOLOGY
Dr. Susan E. O'Reilly Clinical Professor & Head
Faculty Members
Clinical Professor & Head O'Reilly, Dr. Susan BCCA/Vancouver Clinical Professor & Acting Head Connors, Dr. Joseph BCCA/Vancouver Assistant Professor Chi, Dr. Kim BCCA/Vancouver Assistant Professor Chia, Dr. Stephen BCCA/Vancouver Assistant Professor Gill, Dr. Sharlene VA Assistant Professor Savage, Dr. Kerry VA Clinical Professor Gelmon, Dr. Karen BCCA/Vancouver Clinical Professor Hoskins, Dr. Paul BCCA/Vancouver Clinical Professor MacLean, Dr. Grant BCCA/Victoria Clinical Professor Murray, Dr. Robert Nevin BCCA/Vancouver Clinical Professor Shah, Dr. Amil BCCA/Vancouver Clinical Professor Swenerton, Dr. Kenneth BCCA/Vancouver Clinical Professor Weinerman, Dr. Brian BCCA/Victoria Clinical Associate Professor Coppin, Dr. Christopher BCCA/Fraser Valley Clinical Associate Professor Klasa, Dr. Richard BCCA/Vancouver Clinical Associate Professor Klimo, Dr. Paul Lion's Gate Hospital Clinical Associate Professor Murphy, Dr. Kevin BCCA Clinical Associate Professor Ragaz, Dr. Joseph BCCA Clinical Associate Professor Wilson, Dr. Kenneth BCCA/Victoria Clinical Assistant Professor Allan, Dr. Sharon BCCA/Victoria Clinical Assistant Professor Anderson, Dr. Helen Victoria Clinical Assistant Professor Bernstein, Dr. Vanessa BCCA/Victoria Clinical Assistant Professor Bryce, Dr. Cicely BCCA/Vancouver Clinical Assistant Professor Ellard, Dr. Susan VA Clinical Assistant Professor Gill, Dr. Karamjit Surrey Clinical Assistant Professor Khoo, Dr. Kong BCCA/Kelowna Clinical Assistant Professor Knowling, Dr. Margaret (Meg) BCCA/Fraser Valley Clinical Assistant Professor Laskin, Dr. Janessa BCCA Clinical Assistant Professor Lee, Dr. Ursula BCCA/Fraser Valley Clinical Assistant Professor Lohrisch, Dr. Caroline BCCA Clinical Assistant Professor Macpherson, Dr. Nicol BCCA/Victoria
UBC Department of Medicine Page 81 Annual Report 2005
Clinical Assistant Professor Melosky, Dr. Barbara BCCA/Vancouver Clinical Assistant Professor Noble, Dr. R. Michael RCH Clinical Assistant Professor Norris, Dr. Brian BCCA/Fraser Valley Clinical Assistant Professor Sawhney, Dr. Ravinder BCCA/Fraser Valley Clinical Assistant Professor Sehn, Dr. Laurie BCCA/Vancouver Clinical Assistant Professor Shenkier, Dr. Tamara BCCA/Vancouver Clinical Assistant Professor Stuart, Dr. David Burnaby Clinical Assistant Professor Taylor, Dr. Marianne BCCA/Victoria Clinical Instructor Bouttell, Dr. Elaine Kelowna Clinical Instructor Fenton, Dr. David BCCA/Kelowna Clinical Instructor Fitzgerald, Dr. Catherine BCCA/Victoria Clinical Instructor Lee, Dr. Christopher BCCA/Fraser Valley Clinical Instructor MacNeil, Dr. Mary BCCA/Victoria Clinical Instructor Martin, Dr. Lee Ann BCCA/Fraser Valley Clinical Instructor Martins, Dr. Heidi BCCA/Victoria Clinical Instructor Souliere, Dr. Sheila Victoria Clinical Instructor Sutherland, Dr. Judith BCCA/Kelowna Associate Member Brigden, Dr. Malcom Victoria Associate Member Ling, Dr. Victor BCCRC Honorary Professor (Emeritus) Bruchovsky, Dr. Nicholas BCCA Clinical Professor (Emeritus) Goldie, Dr. James BCCA Clinical Professor (Emeritus) Klaassen, Dr. David BCCA Clinical Professor (Emeritus) Plenderleith, Ian BCCA Clinical Professor (Emeritus) Silver, Dr. Hulbert BCCA
Divisional Overview
The Division of Medical Oncology, UBC, comprises the medical oncology and scientific staff at the Vancouver Center, Fraser Valley Center, Surrey, Vancouver Island Center, Victoria and the Center for the Southern Interior, Kelowna, as well as community oncologists in Burnaby, North Vancouver, Nanaimo and the Royal Columbian Hospital, New Westminster.
In addition to the clinical division, there is a laboratory section (Advanced Therapeutics), which is located in the British Columbia Cancer Research Center. It comprises four senior scientists and six clinical investigators who have appointments at the Vancouver Cancer Center, Department of Medical Oncology.
Medical Oncology clinical services are organized as a Provincial Systemic Therapy Program reaching across the Province of British Columbia including the four cancer centers and outreach programs in more than twenty additional community hospitals in smaller urban centers. Undergraduate teaching occurs in the Vancouver, Victoria and Fraser Valley Cancer centers. Postgraduate teaching occurs primarily at the Vancouver Cancer Center with additional elective opportunities available at all four cancer centers including Victoria, Fraser Valley and Kelowna. UBC clinical faculty at all centers participate in undergraduate teaching modules.
The next five years will pose some exciting challenges and opportunities. More medical oncologists and hematologists specializing in neoplastic diseases will be recruited to address the UBC Department of Medicine Page 82 Annual Report 2005
rising incidence of cancer, related to the aging population and, even more importantly, the increasingly complex treatment programs incorporating new targeted small molecules and immunotherapeutic agents. Expanded opportunities for clinical and translational research is readily available based on the rapid emergence of new knowledge in cancer biology, especially insights derived from molecular oncology, genomic and gene expression studies.
The new $100,000,000 B.C. Cancer Research Center building opened in early 2005. This state- of-the-art research facility houses a wide range of laboratory research programs including molecular oncology, the Terry Fox Laboratory focusing on hematologic cellular biology and leukemias and core programs in genomic analysis, gene expression profiling, novel imaging and tumor modeling and population based epidemiology and biostatics. The BC Cancer Agency Genome Sciences Centre has moved into a large laboratory facility nearby but continues to forge collaborative projects with several tumor groups within Medical Oncology including breast cancer, gastrointestinal cancer and lymphoproliferative neoplasms.
Teaching
The Medical Oncology Undergraduate Training Committee, chaired by Dr. Amil Shah, is active in providing and planning teaching modules and clinical bedside teaching in Internal Medicine. An elective in Medical Oncology is available to UBC and visiting medical students.
The Postgraduate Training Committee, chaired by Dr. Tamara Shenkier, offers popular two- month electives in Medical Oncology to internal medicine residents from UBC and other universities. Approximately 10-16 residents per year from these and other specialty disciplines spend elective periods at the Vancouver Cancer Center. Opportunities are available for electives at all of our regional cancer centers and some financial support for travel and accommodation is available for residents choosing one of these options.
The Postgraduate Training Committee also plans and supervises the two-year subspecialty- training program in Medical Oncology. This program is based at the Vancouver Cancer Center with elective opportunities at all other centers and in community oncology practice. The four- month elective period may also be applied to laboratory or clinical research. One or two month electives at centers elsewhere in Canada or in other countries may also be considered. This program, now one of the largest programs in Canada, has expanded to enroll four first year and four second year residents and is fully approved by the Royal College of Physicians and Surgeons of Canada and has consistently received excellent reviews. Additional training positions for overseas residents result in eight or nine trainees participating in this two-year program at any one time. Currently, residents participate in academic oncology training with excellent exposure to clinical practice, ambulatory care and clinical trials. Residents are expected to conduct clinical research and have a number of publications and presentations to their credit. At least half of our residents from each year recently have competed successfully for post-residency academic subspecialty fellowships that have launched them on promising academic careers. Opportunities to pursue laboratory research projects are available.
UBC Department of Medicine Page 83 Annual Report 2005
Continuing Medical Education
All medical staff are active in continuing medical education courses organized by the British Columbia Cancer Agency, other provincial, national and international bodies. Several of our faculty members have emerged as international leaders in their field and are actively sought out to provide leadership within the major international societies including the American Society of Clinical Oncology, the American Society of Hematology and the American Association for Cancer Research in addition to their contributions to the National Cancer Institute of Canada and its Clinical Trials Group.
Research
Members of the Division are involved in a wide variety of phase I, II, III and IV clinical trials. These include the development of new anti-cancer drugs, the evaluation of new doses schedules and combinations of drugs in the phase II setting and the participation in multi-institutional phase III studies and post marketing phase IV trials evaluating effective new treatments on specific categories of malignancy.
Our phase I investigational new drug program has grown rapidly as a reflection of the energy and enthusiasm of the scientists and physicians in the Advanced Therapeutics section of Medical Oncology and in response to the increasing availability of new agents for testing in North America. We are currently expanding clinical and translational research in a new unit at the Vancouver Cancer Centre.
Our Advanced Therapeutics section is able to evaluate new biological response modifiers, gene therapy and pharmaceutical agents through all stages from in-vitro testing in the laboratory to evaluation in human volunteers. The Vancouver Cancer Center has the only Clean Room in an academic center in Canada that is equipped and licensed for the packaging and formulation of pharmaceutical agents in small quantities for clinical testing.
At the pre-clinical level, studies are being carried out in evaluating anti-angiogenesis agents, gene modifiers, enzyme inhibitors, experimental drug modulators, pre-clinical drug toxicities and molecularly targeted agents such as the new tyrosine kinase inhibitors, immunotherapeutic agents targeted against breast cancer, colorectal cancer, lung cancer and lymphomas.
Currently, our oncologists partner with scientists, pathologists and epidemiologists in winning research grants for collaborative population-based and translational research. The BCCA manages its own grants and these are not listed in this report.
Clinical Services
The four B.C. Cancer Centers now provide medical oncology consultations for 9,000 new patients annually with more than 62,000 ambulatory care visits to these centers.
UBC Department of Medicine Page 84 Annual Report 2005
Administration
The Provincial Systemic Therapy Program, headed by Dr. Susan O’Reilly, manages the $100,000,000 oncology drug budget, which supports the care of more than 26,000 patients annually, both within BCCA centers and in community hospitals and plans and delivers clinical services in BCCA Centers. Opportunities for health services research projects are available and linkages with the Provincial Tumour Registry and Vital Statistics are readily available. We are uniquely positioned to further develop province-wide population-based research in health outcomes for cancer patients and regularly take advantage of this special opportunity.
Future Directions
The major academic goal of the Division is to continue to build an outstanding translational research unit that combines the excellent basic science research at the British Columbia Research Center, the input from the Genome Science Centre, the resources of our academic medical oncologists and the participation of our large patient population.
British Columbia has consistently shown the best cancer survival statistics in Canada and we are in a unique position to carry out province-wide treatment programs in both clinical and translational research. We are continuously expanding our research agenda in these areas and in those of health outcomes and economic analyses.
UBC Department of Medicine Page 85 Annual Report 2005
NEPHROLOGY
Dr. Paul Keown Professor & Head
Faculty Members
Professor & Head Keown, Dr. Paul VA Professor Quamme, Dr. Gary UBC Professor Wong, Dr. Norman UBC Assistant Professor Gill, Dr. John SPH Clinical Professor Chan-Yan, Dr. Clifford SPH Clinical Professor Levin, Dr. Adeera SPH Clinical Professor Werb, Dr. Ronald SPH Clinical Associate Professor Chan, Dr. Victor RCH Clinical Associate Professor Landsberg, Dr. David SPH Clinical Associate Professor Shapiro, Dr. R Jean VA Clinical Associate Professor Taylor, Dr. Paul SPH Clinical Associate Professor Yeung, Dr. Choi Kit VA Clinical Assistant Professor Cass, Dr. Aaron RCH Clinical Assistant Professor Chiu, Dr. Anthony SPH Clinical Assistant Professor Copland, Dr. Michael VA Clinical Assistant Professor Da Roza, Dr. Gerald RCH Clinical Assistant Professor De Luca, Dr. Linda SPH Clinical Assistant Professor Duncan, Dr. John VA Clinical Assistant Professor Jastrzebski, Dr. Jacek VA Clinical Assistant Professor Karim, Dr. Mahmud RCH Clinical Assistant Professor Kiaii, Dr. Mercedeh SPH Clinical Assistant Professor Singh, Dr. Rajinder Suneet VA Clinical Instructor Jamal, Dr. Abeed SPH Clinical Instructor Jung, Dr. Beverly SPH Professor (Emeritus) Cameron, Dr. Eugene VA Professor (Emeritus) Price, Dr. John VA Professor (Emeritus) Rae, Dr. Angus SPH
UBC Department of Medicine Page 87 Annual Report 2005
Divisional Overview
The Division of Nephrology includes 27 members based at four principal sites: St. Paul’s Hospital, Vancouver General Hospital, the UBC Hospital and the Royal Columbian Hospital, who provide provincial leadership in research, education, and clinical care within the field of renal medicine. The Division has a strong clinical base and provides integrated and decentralized nephrology care throughout Vancouver Coastal Health, including Richmond, North Vancouver and coastal areas, with a strong working collaboration with Fraser Health. The Division has an important role in the UBC undergraduate medical curriculum, has a mature nephrology postgraduate training program, and participates actively in the Experimental Medicine and Clinical Investigator programs of the Department of Medicine. Research activities encompass both laboratory and clinical sciences, and combine genetic and molecular research, pharmacology and therapeutics, epidemiology and clinical trials, and population health and outcomes/economic investigations in renal disease and transplantation. Members of the Division assume leadership roles in the advancement of nephrology at provincial, national and international levels through their positions in the BC Provincial Renal Agency, BC Transplant Society, the VCH Regional Renal Program, the Kidney Foundation of Canada, the Canadian and International Societies of Nephrology, the International Transplantation Society, and US National Kidney Foundation.
Teaching
The UBC Division of Nephrology is a key component of the tertiary education program for medicine and related health sciences for the Greater Vancouver region, and has established undergraduate, graduate, post-graduate and continuing medical education sections. The Vancouver General Hospital, St. Paul’s Hospital/Providence Healthcare and BC Children’s Hospital have formalized education programs for UBC medical students, interns, residents, sub- specialty residents in nephrology, rotating trainees in general medicine, anaesthesia and other relevant disciplines, and for clinical and research fellows. These educational programs attract trainees from across Canada, from Europe, Asia and the Middle East for post-graduate training. The Richmond General Hospital and Lion’s Gate Hospital as yet provide no formal educational program, but will increasingly provide a platform for community nephrology training as the Division extends to these locations. Continuing education funds are available for all renal programs allocated from UBC, through the value added agreements in the BCPRA provincial contracts, and from other contributions through the Division of Nephrology. The primary sites for undergraduate and graduate training are at VGH, SPH/Providence Healthcare and the BC Children’s Hospital. Education in pharmacy and allied health disciplines occurs in the same sites under the auspices of UBC and related professional bodies. Divisional program directors include: Dr. Suneet Singh (Undergraduate Programs), Dr. John Duncan (Postgraduate Programs), Dr. Adeera Levin (Continuing Medical Education), and Dr. David Landsberg (Fellowship Programs).
Undergraduate: The Division of Nephrology has contributed significantly to implementing the medical school’s distributed curriculum in 2004/05 and is actively involved in all areas of education throughout the undergraduate program. Dr. Suneet Singh is the Director of Undergraduate Education for the Division of Nephrology, supported by Drs. Copland, White, Levin, Chan-Yan, Jamal and other members of the Division. Nephrology subspecialty residents UBC Department of Medicine Page 88 Annual Report 2005
are actively involved in the clinical case sessions. Dr. Singh and Dr. Levin coordinate medical student rotations through Nephrology at the VGH and SPH sites respectively. Dr. Jamal and the administration staff at both sites serve as the student contact for electives and selectives. These rotations receive excellent evaluations and many students return as residents.
Postgraduate: Dr. John Duncan is Director of the Postgraduate Education Program, which is widely recognized for the excellence of its clinical training. This highly-structured program encompasses the broad range of basic and clinical renal sciences through formal educational sessions and weekly resident and fellow’s rounds. The Program has 7 trainees currently enrolled in the first and second years of core nephrology training and has an outstanding record of successful Royal College examinations. Elective opportunities are provided for subspecialty residents to pursue training in particular aspects of renal medicine, including histopathology, glomerular diseases, community nephrology, dialysis or transplantation, and other components according to their needs and interests. Residents and fellows are encouraged to be active in clinical research throughout their core years, with submissions to and presentations at meetings of the Canadian and American Societies of Nephrology, the American Society of Transplantation, and the Canadian Transplant Society.
Graduate: The Division has an active fellowship education program under the direction of Dr. David Landsberg, which offers advanced and specialist training in clinical or laboratory sciences in many areas of renal medicine including chronic kidney disease, dialysis, transplantation, immunology and genetics/genomics. This training may be combined with formal graduate course work leading to Masters or Doctoral degrees in Experimental Medicine, Health Care and Epidemiology or related disciplines through the Faculty of Graduate Studies.
Continuing Medical Education: Members of the Division participate actively in Continuing Medical Education activities at the local, provincial, national and international levels, and in so doing bring an important measure of prestige to the Department and University. UBC Division of Nephrology rounds are held twenty times per year, alternating between Vancouver General and St. Paul’s Hospital sites, with distinguished speakers invited from throughout North America and Europe. Distinguished Visiting Professors also visit the Division on a frequent basis to present individual seminars or conferences and interact with the members, trainees and staff during their visit. Drs. Levin, Keown and Gill maintain active speaking schedules in national and international meetings, presenting both reviews of key topics and original research, and other members of the Division are gradually acquiring national and international recognition in additional aspects of nephrology.
Research
The Division has a strong and internationally-recognized translational research program in both renal disease and transplantation. Members of the Division currently hold $3.2 million in grant support including grants from Genome Canada, the CIHR, the MSFHR and other peer-review agencies, and generated more than 30 scientific articles in 2005. The UBC Division of Nephrology research program is working to: (a) optimize the ongoing academic activities of current members by fostering effective collaboration, (b) ensure effective mentoring for new recruits to maximize their opportunities for academic success and (c) provide formal graduate and post-graduate scientific training for residents and fellows in Medicine, Nephrology and other UBC Department of Medicine Page 89 Annual Report 2005
disciplines, and for students from the Experimental Medicine and Clinical Investigator programs. The Renal Sciences Program integrates members from the VGH and SPH Providence Healthcare sites to ensure full participation and collaboration, and to ensure appropriate academic space and resources for the proposed research at both principal hospital sites. The program is funded from all relevant sources including normal peer review agencies, private research contributions, corporate partnerships and the creation of a strong industrial-academic interface. The principal components of the program are outlined below:
Laboratory Sciences: Dr. Quamme’s research is focused on differential expression analyses that identify novel genes involved with magnesium transport and metabolism in human kidney. Using expression systems his group has experimentally characterized these transcripts offering novel clinical approaches to diagnoses of diseases. Dr. Quamme continues this line of investigation through identification of key molecular targets, regulation of gene expression, and cell signaling events. Dr. Wong’s research activity continues to explore the role of vasocative peptide in regulating the expression of vasopressin V2 receptor expression in the inner medullary collecting duct of the kidney, and of other vasoactive peptides including endothelin and AQP4 on the kidney, heart and brain. Dr. Keown's research has targeted the mechanisms, modulation and consequences of the immune response in organ transplantation and autoimmune disease, combining studies in molecular genetics, cell biology, pharmacokinetics and dynamics. Dr. Keown currently co-leads a Genome Canada-funded ($9.1 million) search for predictive biomarkers of acute and chronic allograft rejection in heart, kidney and liver transplant recipients. Dr. Gill has pioneered the investigation of alloimmunity following transplantation with the monitoring of anti-donor HLA antibodies using novel solid-phase fluorescent methods for antibody detection. Continuing research will build upon these studies using newly established DNA/RNA banking facilities, signal analysis and high-throughput genomics and proteomic methods for molecular targeting, to investigate disease risk and therapeutic response genes, immuno pharmacodynamics /pharmacogenomics and measures of operational tolerance.
Clinical Sciences: Dr. Levin’s research encompasses the broad range of epidemiology, outcomes, and health policy in chronic kidney disease. Particular interests include the impact of anemia on renal co-morbidity, analysis of cardiovascular disease risk in patients with impaired renal function, strategies for and benefits of co-ordinated care for chronic kidney disease, the role of vitamin D in bone health and clinical outcome, measures of renal function, and societal measures of renal disease burden. Dr. Levin holds a MSHRF planning award for additional research into complex disorders. Dr. Gill has established an important platform of clinical research in the epidemiology of renal transplantation which has examined the impact of increased donor age and recipient waiting times on outcomes of renal transplantation, the potential survival advantage of pre-emptive transplantation, the progression of kidney disease in native and grafted organs, and the incidence and consequences of cardiovascular disease during the waiting period. He is the recipient of a major CIHR award to further this research base. Drs. Kiaii and Jastrzebski have focused on dialysis research related to vascular access and the clinical and economic impact of anemia management in dialysis recipients, while Dr. Duncan has examined gender relationships within the context of renal failure care, and the incidence, severity and functional impact of renal artery stenosis in patients with cardiovascular disease. Dr. Shapiro is engaged in studies of neurocognition in chronic renal failure and transplantation, and Dr. Landsberg has pioneered investigation of living altruistic organ donation and pursued clinical trials of therapeutic immunosuppression. The Division has a strong commitment to clinical and UBC Department of Medicine Page 90 Annual Report 2005
therapeutic trials, with many continuing single and multicentre Phase I - Phase IV studies. Further integration of the clinical research program will enable the introduction of advanced study methods and trial designs, and will permit all members of the division to become actively involved in the evaluation of new and innovative treatments.
Clinical Services
The renal services provided by the Division of Nephrology operate within a broad provincial context with established clinical guidelines, provincial contracts, information systems, central administration and co-ordination for education and other projects. This affords Division an opportunity to be both a key contributor to and a beneficiary of provincial policies, projects and experience. British Columbia is widely recognized to be at the forefront of renal care delivery, with active programs for the early detection of renal disease in the population, multidisciplinary coordination of care, delivery of dialysis therapy in the community or at home, and novel approaches to renal transplant donation. The BC Provincial Renal Agency (BCPRA) coordinates the development and integration of renal services, funding, establishment of standards and guidelines, and works in collaboration with each of the health authorities to ensure equal access to care for all patients living with kidney disease. The BC Transplant Society coordinates the funding and oversight of renal and other solid organ transplant services and the retrieval of cadaveric organs and tissues.
Within this framework, renal care delivery is based on established principles of integrated chronic disease management through a combination of institutional, community and home-based programs. Three tertiary care teaching hospitals, the Vancouver General Hospital (VGH), St. Paul’s Hospital (SPH Providence Healthcare) and BC Children’s Hospital (BCCH), collaborate to provide ambulatory chronic renal disease care, in-patient management, hospital dialysis and renal transplantation, and home hemo- and peritoneal dialysis for adult and pediatric patients with renal disease throughout the Vancouver Coastal Health region. Community hemodialysis is conducted as an integrated program in six units, three of which are freestanding and three hospital-based, and renal consultation is provided in two large community hospitals, at Lion’s Gate Hospital and Richmond General Hospital. Almost 3 000 patients with chronic renal disease currently receive care within VCH, of whom over 1,000 have progressive CKD, almost 800 are on dialysis, and a further 800 have a functioning renal transplant. Recent figures estimate that many more subjects within this region may have chronic renal dysfunction without knowledge of the fact so that further innovation, coordination and integration of services will be essential to meet the impending challenge over the next decade and to improve maintain the standards of care already established by the Division.
Administration
Dr. Paul Keown, Professor of Medicine, continued in 2005 as Head of the Division of Nephrology and Director of the VCH Regional Renal Program. The Division has moved to build an effective administrative infrastructure to support continuing growth and development commencing with the appointment of Mr. Shawn Jorgensen as Executive Administrator followed by Ms. Heather Chitty as Administrative Assistant for Educational Programs. Additional administrative personnel will be added throughout the coming year to fulfill the goals and objectives of the Division in the fields of clinical service, teaching and research. UBC Department of Medicine Page 91 Annual Report 2005
Future Directions
The Division will continue to build on its strengths to ensure the highest quality of academic and clinical activity for the University, the health system, and the community. Recruitment of two new academic nephrologists is planned for July 2006 to complement the services in the principal university-affiliated hospitals and to expand the activities of the Division to the Richmond Health region. Completion of the new Academic Ambulatory Care Centre at the VGH site will enable consolidation of divisional offices, administration and activities, and co-ordination of out- patient care, education and research. Development of a formal research plan for the next 5 years will enable the Division to integrated existing activities in the fields of laboratory and clinical sciences and expand into novel areas of cutting-edge research, and allocation of new research space at both SPH/PHC and VGH through the new ambulatory care centre provide outstanding opportunities for this expansion. The Division will continue to take a major role in the teaching of Renal Sciences within the University, continue its leadership position in nephrology postgraduate education, and introduce innovative initiatives in the delivery of integrated regional care for patients with renal disease.
Special Honours and Awards
Dr. Michael Copland Master Teacher Award, UBC Department of Anaesthesia 2005 Dr. John Gill Michael Smith Foundation for Health Research, Scholar Award (July 2005) Dr Paul Keown Genome Canada Award for Biomarker research in Transplantation Member of Council, Executive, the Transplantation Society Dr Adeera Levin Michael Smith Health Research Foundation Team Planning Award 2005 Council member, International Society of Nephrology Michael Smith Foundation for Health Research, Postdoctoral Trainee Fellowship (July 2005) Kidney Foundation, Biomedical Fellowship (July 2005)
UBC Department of Medicine Page 92 Annual Report 2005
NEUROLOGY
Dr. Howard Feldman Professor & Head
Faculty Members
Professor & Head Feldman, Dr. Howard VA Professor Barton, Dr. Jason VA Professor Cashman, Dr. Neil VA Professor Doudet, Dr. Doris VA Professor Oger, Dr. Joel VA Professor Pelech, Dr. Steven VA Professor Stoessl, Dr. Jon VA Professor Tsui, Dr. Joseph VA Professor Wang, Dr. Yu Tian VA Associate Professor Curt, Dr. Armin VA Associate Professor Kastrukoff, Dr. Lorne VA Associate Professor McKeown, Dr. Martin VA Assistant Professor Hsiung, Dr. Ging-Yuek Robin SPH Assistant Professor Lee, Dr. Chong Sik VA Assistant Professor Spacey, Sian VA Assistant Professor Traboulsee, Dr. Anthony VA Assistant Professor Tremlett, Dr. Helen VA Clinical Associate Professor Beckman, Dr. Jeff VA Clinical Associate Professor Hooge, Dr. John SPH Clinical Associate Professor Javidan, Dr. Manouchehr VA Clinical Associate Professor Jones, Dr. Michael VA Clinical Associate Professor Keyes, Dr. Robert SPH Clinical Associate Professor Krieger, Dr. Charles VA Clinical Associate Professor Robinson, Dr. Gordon VA Clinical Assistant Professor Briemberg, Dr. Hannah VA Clinical Assistant Professor Clarke, Dr. Stephen SPH Clinical Assistant Professor Devonshire, Dr. Virginia VA Clinical Assistant Professor Foti, Dr. Dean VA Clinical Assistant Professor Gibson, Dr. Gillian VA Clinical Assistant Professor Johnston, Dr. Dean SPH Clinical Assistant Professor Martzke, Dr. Jeffrey VA
UBC Department of Medicine Page 93 Annual Report 2005
Clinical Assistant Professor Mezei, Dr. Michelle VA Clinical Assistant Professor Prout, Dr. Alister SPH Clinical Assistant Professor Teal, Dr. Philip VA Clinical Assistant Professor Thiessen, Dr. Brian VA Clinical Assistant Professor Woolfenden, Dr. Andrew VA Clinical Instructor Bozek, Dr. Christopher Burnaby Clinical Instructor Chapman, Dr. Kristine SPH Clinical Instructor Costantino, Dr. Anthony VA Clinical Instructor Hallam, Dr. Bradley VA Clinical Instructor Murphy, Dr. Colleen VA Clinical Instructor Smyth, Dr. Penelope VA Clinical Instructor Tai, Dr. Charles SPH Clinical Instructor Tessler, Dr. Barry RCH Clinical Instructor Varelas, Dr. Michael VA Associate Member Anderson, Dr. Duncan VA Associate Member Forwell, Dr. Susan VA Associate Member Graeb, Dr. Douglas VA Associate Member Hurwitz, Dr. Trevor VA Associate Member Leavitt, Dr. Blair VA Associate Member Li, Dr. David VA Associate Member Moore, Dr. Wayne VA Associate Member Raymond, Dr. Lynn VA Associate Member Sadovnick, Dr. Adele VA Associate Member Stowe, Dr. Robert VA Associate Member Wilkinson, Dr. Rosemary VA Adjunct Professor Bub, Dr. Daniel U Victoria Adjunct Professor Ruth, Dr. Thomas VA Professor (Emeritus) Calne, Dr. Donald VA Professor (Emeritus) Eisen, Andrew VA Professor (Emeritus) Kim, Dr. Seung VA Professor (Emeritus) Pate, Dr. Brian VA Professor (Emeritus) Sweeney, Dr. Vincent VA Clinical Professor (Emeritus) Anzarut, Dr. Andre SPH Clinical Professor (Emeritus) Bratty, Dr. Paul VA Clinical Professor (Emeritus) Hashimoto, Dr. Stanley VA Clinical Associate Professor (Emeritus) Jones, Dr. David VA Clinical Associate Professor (Emeritus) Wong, Dr. Milton SPH
Divisional Overview
The Division of Neurology is the largest division within the Department of Medicine. It has its major teaching, research and clinical activities at Vancouver General Hospital, UBC Hospital and St. Paul’s Hospital. There are 43 Neurology faculty members whose primary appointment is in the Division, with another 11 appointed as associate members, 2 as adjunct professors and 10 as emeritae.
UBC Department of Medicine Page 94 Annual Report 2005
The Division is nationally and internationally recognized for its clinical and research programs in neurodegenerative, demyelinative, neuromuscular and cerebrovascular diseases. It has been consistently very productive in obtaining peer-reviewed grant funding, and makes important contributions to both basic neuroscience and clinical neurological literature. This past year divisional members published more than 126 papers in peer-reviewed journals an increase of almost 30 publications from last year. The Division provides neurological care province wide including tertiary and quaternary care for a variety of neurological disorders. The division has clinical outreach to many communities around the province. Faculty are actively involved in teaching and supervising all levels of students and trainees from undergraduate to post doctoral fellows.
Amongst the highlights for the Division in the past year has been the recruitment and arrival of a number of full-time faculty who will be adding their clinical, teaching and research expertise to the division. Dr. Neil Cashman was recruited from the University of Toronto to UBC in August 2005 to take up an appointment as Tier I Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases. His research activities will center on mechanisms and strategies of protein misfolding in neurodegenerative diseases particularly in prion diseases, but also more broadly in Alzheimer’s disease, Parkinson’s disease, and ALS. In his clinical activities he will provide leadership to the ALS program. Dr. Armin Curt was recruited to UBC from the University of Zurich to take up an endowed Chair in Spinal Cord Research with ICORD. His research interest focuses on both injury and recovery of spinal cord diseases. Clinically he will be actively involved in the Spinal Cord Unit at VGH as well as in neuro-rehabilitation at GF Strong.
Major events within the division this past year included the launching of an expanded clinical and research program in ALS at GF Strong. Drs. Charles Krieger, Gillian Gibson and Andrew Eisen were all very active in the reconfiguration of the Clinic and in the development of an Endowment for the ALS program. In March the program settled into its new physical space at GF Strong. At years end Dr. Neil Cashman received the news that his application to lead a National Centers of Excellence program in Prion Science had been approved with committed funding of $35 million over the next 7 years. A number of co-investigators and collaborators within UBC contributed to this successful application which will be centered at the UBC campus but which will involve activities across the country. The Division received final approval of the funding and endowment of the Sauder Family and BC Heart and Stroke Professorship in Stroke Research and the Fisher Family and Alzheimer Society of BC Professorship in Alzheimer’s disease research. These positions were being advertised and interviewed for at years end with the anticipation that appointments will take place in 2006. The Division actively participated in an LEFF application for funding of the second phase of the Brain Research Center which will focus on translational research with planning to develop a fully functional integrated clinical and research center for brain disorders at UBCH.
Teaching
Undergraduate: Division members continue to be involved as PBL facilitators and teachers in the Brain and Behaviour block during 2nd year, providing lectures and bedside sessions in clinical skills. The Division is particularly grateful to the community neurologists who have faithfully supported this teaching activity. UBC Department of Medicine Page 95 Annual Report 2005
This year volunteer patients were recruited from the many ambulatory care clinics within the Division. This removed much of the pressure of finding suitable patients on the in-patient unit and allowed better quality teaching for students in their Clinical Skills sessions.
Seminars and bedside sessions were provided for 3rd year and a 4th year clerkship as elective/selective. The clerkship is based on an inpatient and outpatient experience allowing students to take advantage of all of the resources within the Division. In addition to UBC students the clerkship attracts students from other medical schools in Canada and other countries.
Divisional members are an integral part of Phase VI providing curricula designed to encourage critical evidence-based management of clinical problems.
Postgraduate: The Post-Graduate Residency Training in Neurology is fully accredited with the Royal College of Physicians and Surgeons. It currently has 19 residents at various levels of training from PGY1 to PGY5. In the first two years of the program, the residents rotate through various subspecialties in Internal Medicine, ICU, Emergency, as well as doing their first Neurology rotations. The PGY3-5 years are core Neurology training years. Residents do their inpatient training at Vancouver General Hospital and St. Paul's Hospital. Many outpatient subspecialty clinics are done at UBC Hospital. During their training the residents in Neurology are actively involved in various research projects. In 2005 there were 3 resident poster presentations at various international meetings and 2 papers published in peer-reviewed journals. Dr. Manu Mehdiratta, the chief resident in Neurology was awarded a Resident Scholarship Award for the American Academy of Neurology Annual Meeting in 2005 and the Ludmila and Henry Zeldowicz Award for accomplishment in research for the academic year 2005-6.
Dr. Colleen Murphy undertook a new teaching initiative within the Division in 2005, developing a new 32-hour course lecture series in Neuroanatomy with clinical correlations and has also developed a 4 hour lecture series in medical ethics.
Fellowship Training and Awards
The Division of Neurology appointed the following individuals to fellowship and post-doctoral fellowship training in 2005:
Alzheimer’s Disease and Related Disorders: Dr. Najeeb Qadi (Clinical Fellow), Dr. Michael Woodward (Clinical Fellow), Dr. Claudia Jacova (CIHR and Michael Smith Health Research Foundation Post-doctoral Fellow).
Parkinson’s Disease and Movement Disorders (Pacific Parkinson’s Research Center): Dr. Abduraheem Al Shehri, Dr. Andre Troiano (clinical fellow).
Neuro-ophthalmology: to June 2005 - Dr. Rashmin Khari and Dr. Nipat Au-aree; from July 2005 to June 2006- Dr. Rashmin Khari and Dr. Briar Sexton.
UBC Department of Medicine Page 96 Annual Report 2005
Vancouver General Hospital Neurology Service (Clinical Teaching Unit)
The in-patient service at VGH consists of a 14 bed unit located on T5-B of the Pattison Pavilion. This unit is the only dedicated in-patient Neurology clinical teaching unit (CTU) in the province and has within its mandate the provision of tertiary care for complex neurological disorders. The inpatient program features a specialized epilepsy monitoring unit (2 beds) and Acute Stroke Unit (2 beds). Life and Limb policies are in place for accepting acute stroke patients, as well as neuromuscular disorders requiring plasmapheresis.
Over the last year substantial improvements to stroke care have been made within VGH. A large percentage of all stroke patients presenting or referred to VGH are now admitted to the Neurology service for acute management during the first 5-7 days of their post stroke care. From there the stroke pathway includes transfer to the UBCH Subacute Stroke Unit or other appropriate rehabilitation facilities or home. This has resulted in an increase in the number of stroke patients cared for on neurology with the elimination in patients requiring a prolonged stay on the unit.
The VGH and UBCH neurologists provide important consultation services within Vancouver Acute. Neurological diagnostic services at VGH include electroencephalography (EEG), intraooperative monitoring (IOM) and electromyography (EMG) are based at VGH.
Ambulatory services provided include subspecialty clinics for Movement Disorders, Multiple Sclerosis, Alzheimer’s Disease and dementias, Stroke, Neuromuscular Disease, and Neuro- oncology. These clinics integrate with a strong research environment for each of these programs, which in turn forms the core of the academic mission of the Division. The clinics also provide important post-graduate educational activities for trainees within the Division. There are also subspecialist clinical neurologists within the division dedicated to care of patients with headache (Dr. Gordon Robinson), pregnancy complications (Dr. Robert Keyes) and HIV (SPH).
St. Paul's Hospital Division of Neurology
The St. Paul’s Hospital Division of Neurology is an important part of the clinical and teaching program of the UBC Division of Neurology. Dr. Robert Keyes is the division head of SPH. This division provides tertiary referral care for the Providence Health Care network as well as to the province more widely. The SPH division participates in an important and extensive outreach program to communities in northern BC and the Yukon territory. It is additionally involved in providing inpatient consultation services to the Mount St. Joseph’s Hospital site and Women’s Hospital. The division has opened an outpatient neurology clinic at the Mount St. Joseph’s Hospital Site to meet the needs of the patient population it serves. At SPH there is a Rapid Access Neurology Clinic where patients requiring urgent but not emergent care are seen and provide clinical service especially to the patient population arising from the downtown core.
The members of the Division of Neurology at SPH includes a wide cross section of subspecialty interests including clinical neurophysiology, neuromuscular disease, multiple sclerosis, neurological diseases in pregnancy, cerebrovascular disease and neurological diseases in HIV and AIDS. A close link between the Division of Neurology at SPH and the Department of UBC Department of Medicine Page 97 Annual Report 2005
Pediatrics and the Department of Obstetrics continues by virtue of the subspecialty interests of Dr. Keyes. The appointment of Dr. Robin Hsiung has added expertise in neurogenetics especially in neurodegenerative disease. Dr. Hsiung conducts his lab research in collaboration with the I-Capture Center at SPH and his dry lab research at UBCH.
Alzheimer’s Disease and Related Disorders
Clinical Activities: The Clinic for Alzheimer Disease and Related Disorders at UBCH is the main tertiary care referral center in BC for dementia assessment and management. It is one of the largest and most respected dementia clinics in Canada. New referrals to the clinic receive a range of multidisciplinary assessments including Genetics, Social Work, Neuropsychology, Geriatric Psychiatry and Neurological/Medical which make seminal contributions to the multifaceted clinical care needed for dementia patients and their families.
In 2005, the Clinic undertook an increased level of clinical activity evaluating > 1200 patients. This increased activity was possible as the result of the multidisciplinary recruitments to the Clinic of Drs. Philip Lee (Geriatrics), Dr. Robin Hsiung (Neurology) and Dr. Kiran Rabheru (Geriatric Psychiatry). Their expertise was added to the Clinic clinical and research capacity. In July 2005, Dr. Howard Feldman took over the role of Clinic Director in succession of Dr. Lynn Beattie who had been the Director since the Clinic inception in the early 1980s. Her dedication and commitment to the evolving mandate of the Clinic is recognized with appreciated as it forged the solid foundation that the Clinic functions with today. A 10 year comparative review of clinic demographics and diagnoses undertaken in 2005 revealed that the mix of referred patients has changed to a younger patient population, to one with more disorders of mild cognitive impairment and to more atypical dementias. This has changed the nature of the assessments that are undertaken and the needs of the clinic patient population.
Research: In 2005, the research activities of the Clinic included a mix of peer reviewed funded research projects from the Canadian Institutes of Health Research (CIHR), the National Institutes of Health (NIH), and clinical trials both investigator-initiated as well as industry sponsored. Major research initiatives were launched in 2005 in the frontotemporal dementias, particularly the form of FTD with ubiquinated inclusions, in primary prevention of dementia, and in biomarker development. Ongoing research areas include the development of volumetric analytic techniques for MRI in mild cognitive impairment, and the long-term characterization of clinical outcomes in mild cognitive impairment and dementia syndromes through the ACCORD cohort study.
The development of a data management core for investigators at the Brain Research Center has been a major initiative for the research group in 2005. The data management group has been coordinating the data management and studies across a range of neurologic and psychiatric illnesses at UBCH including manic depressive illness, multiple sclerosis as well as dementia. The research unit appointed 3 fellows who were each active in 2005; Dr. Claudia Jacova (post- doctoral fellow funded through a Neurobiology Training Grant of CIHR and MSHRF), Dr. Michael Woodward (clinical research fellow from the University of Melbourne) and Dr. Najeeb Qadi (clinical fellow Saudi Arabia). Dr. Dessa Sadovnick’s program of genetic research continued to attract grant funding for genomic studies with MIRAGE and continued to provide comprehensive genetic counseling to all patients referred to the Clinic. Dr. Beattie has continued UBC Department of Medicine Page 98 Annual Report 2005
her work on Quality of Life studies in the Clinic and has been active in developing the BC Network of Aging Research.
Clinical trials have continued to focus in the past year on studies of mild cognitive impairment as a precursor state to AD, with completion of a series of large clinical trials investigating the potential for delay of time to the diagnosis of AD with seminal study results published on a study of donepezil in the New England Journal of Medicine. The Clinical Trials program benefits from a core group of very experienced research coordinators and research assistants who are critical to the programmatic success.
Teaching and Education: The Clinic has been very active in providing teaching to trainees of multiple disciplines at many levels. A formal one-day preceptorship training program for family physicians and specialists is in place. Clinic members participated extensively in CME activities, and on expert national international working groups and advisory committees. The Clinic is very active in public education and its clinicians have also been called on to have a high profile in national and international public policy in dementia care. Within the Clinic, Dr. Foti has made a notable contribution to the Neurology residency training program through his teaching activities and clinical mentoring.
Stroke and Cerebrovascular Program
The VGH serves as the tertiary referral centre for stroke and cerebrovascular diseases in B.C. To support this clinical role the VGH Stroke Program maintains a dedicated on-call system with the commitment of six neurologists. A “Stroke Hot Line” pager system is available 24/7 to triage patients from around the lower mainland and southern British Columbia. The VGH Stroke Team consists of stroke neurologists, diagnostic and interventional neuroradiologists, neurointerventional/neurovascular neurosurgeons, and vascular surgeons. The program provides state-of-the-art care to cerebrovascular patients. Neuroradiology provides superb diagnostic and interventional services. In cooperation with the BC Bedline the program has successfully developed an acute stroke referral system for the provision of thrombolytic and interventional stroke care.
In 2005 the organization of the delivery of stroke care at VGH changed. All stroke patients were seen by the Neurology service with a larger portion of patients being admitted under the care of Neurology to both the Stroke Unit and the Neurology ward service. The Stroke Unit provided intensive care nursing for the treatment of acute stroke patients who are critically ill or who have received interventional therapies while the ward provided the subsequent first week of care to stroke patients. A Subacute Stroke Unit to Rehab pathway was established at UBCH with transfer of stroke care at 5-7 days of care. Efforts are now underway to develop a British Columbia Stroke Strategy in collaboration with the Heart and Stroke Foundation, and Vancouver Coastal Health.
The Stroke Prevention Clinic continued to provide same day clinical and diagnostic services to patients seen in its twice weekly clinics. These clinics provide a critical resource for patients at risk of stroke and to emergency departments and physicians. Prompt and expert care reduces the need for hospitalization through the rapid evaluation of patients.
UBC Department of Medicine Page 99 Annual Report 2005
The VGH Stroke Program undertook its well subscribed Annual Western Canada Stroke Conference again. This program has been highly successful in its mission to provide stroke education to neurologists from B.C. and western Canada. Weekly stroke rounds are held to provide education to residents and medical students. Residents and students spend time in the Stroke Prevention Clinic evaluating and making decisions on urgent cases. The Stroke neurologists continue to give Grand Rounds, medical rounds and talks at CME events to educate physicians around the province. Public forums have been held by the Heart and Stroke Foundation with the participation of stroke neurologists and others. On an international level, members of the Stroke Program delivered posters and platform presentations at the American Stroke Association meeting, the Canadian Congress of Neurological Sciences, the American Academy of Neurology, and the European Stroke Conference.
Multiple Sclerosis
The 2005 census of Clinic activity included active charts with 2717 patient Clinic visits and 648 research visits during the year and with 230 new patients confirmed to have Multiple Sclerosis. Dr. V. Devonshire has become the Clinical Team Leader of the Multiple Sclerosis Clinic succeeding Dr. J. Oger while Dr. Tony Traboulsee has accepted the position of Director of Clinical Trials. An active recruitment process is underway to fill an Endowed Chair in Multiple Sclerosis as well as to replace Dr. Don Paty in providing academic leadership to the program.
The clinic has now a complement of 7 neurologists (Drs. V. Devonshire, S. Hashimoto, J. Hooge, L. Kastrukoff, J. Oger, P. Smythe and (A) T. Traboulsee) together with 3 neuro- opthalmologists (Drs. D. Anderson, J. Lindley and K. Wade) The Clinic continues to maintain important interdepartmental collaborations to provide best care to affected patients. In particular the close collaborations with Dr.(A) D. Sadonick (genetics counseling), Dr. A. Jiwa and J. Tham (psychiatric care), Dr. S. Elliot (sexual medicine care) and Dr. Fenster for neuro-urology are vital.
The clinic provides outreach to 3 satellite clinics in Victoria (1000 patients registered), Kelowna (700 patients), and Prince George (300 patients), as well as providing outreach through clinic activities in Comox. Each clinic is organized within the local hospital under the umbrella of the local health board around a full time coordinating nurse. The UBC consultants come to these clinics as visiting experts and work with the local neurologists in providing the highest quality MS care within a multidisciplinary setting that includes critical contributions from Physiotherapy, Occupational Therapy and Social work. Dr. J. Hooge has accepted to become the clinical team leader for the Prince-George MS clinic.
In collaboration with Pharmacare and with educational funding from the pharmaceutical industry it has been possible to continue the valuable “MS Special Therapy” program to help educate patients in the choice and management of adverse effects of Disease Modifying Therapies (DMT). There are now over 1500 treated patients being followed in this program.
The MS clinical trial group: Through this research program of the Clinic MS clinic patients can participate in innovative clinical trials that have resulted in major advances in therapy. In 2005 clinical trials included 648 trial visits.
UBC Department of Medicine Page 100 Annual Report 2005
Rehabilitation Programs: The MS rehabilitation team continues to be very active nationally and internationally in maintaining the website of the International Consortium of MS Centers (T. Jiwa), as well as providing representation on the Editorial Board of the Journal of MS Care (S. Forwell). S. Forwell has received her PhD in OT at UCSF using fatigue in the population of the MS clinic as a focus for her studies.
Research Highlights: Drs. Oger and Tremlett were recipients of a research grant from the MS Society of Canada. The Neuroimmunology lab of Dr. Oger has added two new assays to measure antibodies to Interferons fufilling a need identified by the Canadian Network of MS clinics to have this testing available for clinical use in Canada. Assays to measure antibodies against Glatiramer Acetate have also been developed. Dr. Sadovnick, a Michael Smith Distinguished Scholar, received a $ 3 million grant from the MS Foundation of Canada to pursue further studies on the genetic susceptibility to MS. She has also initiated a North American pregnancy registry under the auspices of the Consortium. She will be soon co-operating with the European database in a trial on prevention of post-partum relapses in MS. The MS/MRI Research Group, directed by Drs. Li and Traboulsee, continues to provide internationally recognized high quality MRI analyses for multicentre research as well as developing a 4-terabyte database for future natural history studies. Innovative analytic techniques have been developed that allow semi- automated lesion load and brain volumetric measures. In collaboration with the Consortium of MS Centers, Drs. Li and Traboulsee have developed international guidelines for clinical MR imaging in the diagnosis and management of Multiple Sclerosis. The MS/MRI Research Group has fostered translational research in MS by supporting basic physics research (Alex MacKay) and pathological correlation studies (Drs. Moore and Dorovini-Zis).
Neurogenetics
The initiatives in Neurogenetics have brought together a group of researchers including Dr. Sian Spacey, Dr. Michelle Mezei, Dr. Blair Leavitt, Dr. Robin Hsiung, Dr. Dessa Sadovnick, Dr. Lynn Raymond and a group of genetic counselors.
At the UBCH the Neurogenetics clinic is a referral center for British Columbia providing over 400 outpatient visits in 2005. The patients seen have a wide range of inherited peripheral and central CNS disorders the most common include the ataxias, channelopathies, hereditary spastic paraparesis, the phakomatoses, myotonic dystrophy, CMT, ALS, and mitochondrial disease. Many of these patients are participants in genetic research run through the UBC Neurogenetics Unit and have donated DNA to the clinic DNA bank. As well there are Neurogenetic arms of the Alzheimer and MS Clinics which provide genetic counseling to patients and families with these disorders.
Research Highlights: Dr. Spacey was awarded an operating grant from the CIHR to investigate the genetics and pathogenic mechanism of the paroxysmal dyskinesias. To date this work has resulted in the identification of a new gene locus for paroxysmal non-kinesigenic dyskinesia, and a new gene for the kinesigenic form of this disease. Dr. Blair Leavitt’s lab has directed attention at identifying novel forms of CAG repeat disorders and he has been involved in ongoing clinical trials looking for novel biomarkers and new therapeutic agents. Dr. Mezei is currently involved in a number of research projects including predictive testing in SOD-1 familial ALS, and MR
UBC Department of Medicine Page 101 Annual Report 2005
spectoscopy with measurement of brain myelin content in individuals with cognitive deficits related to phenylketonuria.
Neuromuscular Diseases Program
The Vancouver Coastal ALS Centre officially opened at the GF Strong site in March 2005 under the direction of Dr. Charles Krieger working with Drs Hannah Briemberg and Dr. Andrew Travlos. This continues to be one of the few multidisciplinary ALS clinics in Canada.
Dr. Neil Cashman will take over the directorship of the Vancouver Coastal ALS centre at some time in 2006.
Dr. Hannah Briemberg has established an excellent muscle biopsy service at VGH and has taken over the supervision of the monthly muscle pathology rounds. Her active research projects include an NIH funded pilot study for the Use of Etanercept in Dermatomyositis and a clinical trial of prednisone in Ocular Myasthenia Gravis. Dr. Kristine Chapman and Dr. Gillian Gibson are investigators in several diabetic neuropathy treatment trials and a soon to commence clinical trial for traumatic nerve injury. Dr. Krieger continues with his active research in the murine mouse model of ALS. Dr. Michelle Mezei continues in her active role as the Director of the residency training program in neuromuscular diseases and EMG, both for the neurology and psychiatry residents. Her research interests are in the fields of mitochondrial myopathy and myasthenia gravis. Dr. Mezei will an investigator in the upcoming NIH trial of Thymectomy in non-Thymomatous MG patients.
Neuro-Oncology Program
The Neuro-Oncology program is a multidisciplinary program involving members of the Divisions of Neurology, Radiation Oncology, Neurosurgery and Medical Oncology. Its goal is to provide comprehensive care for patients with CNS malignancies and establish both clinical and translational research programs in Neuro-Oncology.
In the realm of patient care, the program has continued to supply patients with advanced surgical and radiotherapeutic management of brain tumors including a well-established linear accelerator based stereotactic radiation program. Molecular diagnostic technology has advanced our understanding of oligodendrogliomas and improved our management and chemotherapeutic strategies for these tumors.
Over the 2005 year, grant supported research into molecular genetic changes in oligodendroglioma and other gliomas is ongoing with grant support from the Brain Tumour Foundation of Canada.
Ongoing clinical research trials include a phase II trial of a novel tyrosine kinase inhibitor GW572016 for relapsed glioblastoma multiforme. Upcoming clinical trials include a phase III trial comparing radiotherapy to temozolomide chemotherapy in low grade gliomas (NCIC CE5), and a neurosurgical trial exploring the use of Transmid fusion protein in relapsed glioblastoma multiforme.
UBC Department of Medicine Page 102 Annual Report 2005
Neuro-Ophthalmology
Clinical service: The UBC Neuro-ophthalmology division provides clinical teaching and research services at Providence Health Care (St. Paul’s Hospital site), VHHSC (Eye Care Centre) and UBC Hospital. Consulting services are also provided at GF Strong Rehab and BC Children’s Hospital. Duncan Anderson has stepped down as UBC Director of Neuro- ophthalmology and Jason Barton (Division of UBC Neurology) has taken over as Director.
St. Paul’s site has 4-5 neuro-ophthalmology clinics per week staffed by Duncan Anderson (3 clinics) and Janette Lindley (1-2 clinic). VGH Eye Care Centre has 6 clinics per week staffed by Duncan Anderson (4 clinics) and Jason Barton (2 clinics). UBC has 2 clinics per week in the Multiple Sclerosis Clinic staffed by Duncan Anderson, Janette Lindley, as well as occasionally by Kevin Wade and Jason Barton. Botulinum toxin injection clinics are provided by Janette Lindley and Kevin Wade.
A new venture was the establishment of two satellite MS/neuro-ophthalmology clinics, one at Burnaby staffed by Duncan Anderson, and one at the Royal Jubilee Hospital in Victoria staffed by Ray Bell (director), Jason Barton, and David Wakelin.
During the year 2367 patients were seen at PHC site, 640 UBC site, 2080 ECC site, and 840 at Kevin Wade’s office, for a total of 5927 patient visits per year.
Teaching
a. Residents and students Medical students, ophthalmology and neurology residents and fellows rotate through the neuro- ophthalmology service and are supplied we supply approximately 60 hours of clinical teaching per week. In addition, Kevin Wade supervises the neuro-ophthalmologic component of journal clubs.
b. Fellowship The division had two clinical fellows from Jul 04 to Jun 05 (Rashmin Khair and Nipat Au-aree) and also from Jul 05 to Jun 06 (Rashmin Khair and Briar Sexton). c. Guest speakers, local lectures, and other educational offerings Neuro-ophthalmology have hosted three guest speakers: Charles Maxner, Professor of Neurology and Ophthalmology, Dalhousie University H Stanley Thompson, Professor Emeritus of Ophthalmology, University of Iowa Marlene Behrmann Professor of Psychology, Carnegie Mellon University
d. Website The neuro-ophthalmology division also received a grant to set up and host a case-based educational website for Canadian neuro-ophthalmology, which started in Aug 05: www.neuroophthalmology.ca
UBC Department of Medicine Page 103 Annual Report 2005
Research
Programs currently in progress in the division include: a. Prospective Evaluation of Optic Nerve Head and Retinal Nerve Fiber Layer in various Optic Neuropathies and of the Macula in Immune Reconstitution Uveitis and in Neuro-ophthalmic Disease (JL) b. Inter-trial contextual effects of saccades: inhibition, plasticity and prediction in controls and schizophrenic patients (JB) c. Face processing: mechanisms of expression and identity perception in behavioural studies of controls and stroke patients, and fMRI (JB) d. HRT monitoring of swollen optic nerves, including papilledema in IIH (KW)
Funding sources for research have included CRC Tier II, CFI, CIHR, MSFHR and NIMH (R01).
Pacific Parkinson’s Research Centre
Teaching: The Movement Disorders Clinic provides ambulatory teaching to medical students and to residents in neurology, geriatrics, psychiatry and family medicine. Two clinical fellows completed their training during 2005. One of these has returned to a Movement Disorders clinic in Canada and the other to a faculty position at the National Neuroscience Institute in Singapore.
Faculty members of the Pacific Parkinson’s Research Centre participate in the Brain & Behaviour course and provide training to multiple trainees at the MSc and PhD levels in the Graduate Neuroscience program. Dr. McKeown runs the Motor Systems module of the Systems Neuroscience (Neuroscience 501) core course in the Graduate Neuroscience program. Faculty members within the Centre serve as mentors in the CIHR-funded Neuroscience Training Initiative and serve on numerous supervisory, comprehensive and examination committees.
Research: During the past year, Centre investigators were awarded a number of CIHR grants, including a pilot project on the effects of ECT in a rodent model of Parkinson’s (Dr. Doudet), studies on disease and treatment-induced changes in levodopa-derived dopamine kinetics and dopamine transporter expression in a rodent model of Parkinson’s (Dr. Sossi) and on expectation, the placebo effect and dopamine release in Parkinson’s disease (Dr. Stoessl). The placebo grant was the highest ranked proposal of 49 reviewed by that committee.
Centre investigators had 19 PubMed listings during 2005, including papers in Annals of Neurology, Brain, Biological Psychiatry, Journal of Cerebral Blood Flow and Metabolism, Neuroimage, Neurology, Pain, Physics in Medicine and Biology and Journal of the American Chemical Society.
The backbone of the Centre’s research program continues to be the close partnership with the UBC-TRIUMF PET program. During 2005, the high-resolution, high sensitivity human research tomograph was made operational and human studies have begun. The small animal microPET scanner was upgraded.
In addition to our basic and imaging research program, a number of clinical trials have been conducted. In 2005, the Centre was selected as the only site for functional imaging studies to UBC Department of Medicine Page 104 Annual Report 2005
assess the benefits of a novel gene therapy for Parkinson’s disease. Patients for this study are referred from Chicago and California.
Clinical: The Movement Disorders Clinic provided more than 3,400 outpatient visits in 2004. The majority of these are for patients with Parkinson’s disease or focal dystonia. The program continues to be heavily supported by nurse coordinators, who provide education and counseling to patients, families and other health care professionals. In 2005, the clinic added a 0.5 time physiotherapist, funded by a Centre of Excellence award from the National Parkinson Foundation (Miami).
Epilepsy
This was another very busy clinical year for which the Seizure Investigation Unit which ran at full capacity investigating patients with both difficult diagnostic problems as well as intractable epilepsy for potential seizure surgery. Approximately 30 patients were operated on out of about 80 patients that were assessed. Other key team members on the Epilepsy service include Dr. David Katz (Neuropsychologist) who not only assesses patients pre-surgically as well as from the vocational and psychosocial viewpoints and Janice Henrikson nurse clinician,.
After a lag of about a year the program is back doing the “Wada test” again using the medication Propofol instead of Amytal.
Basic Neurosciences
The lab of Dr. Yu Tian Wang has continued to receive international accolades with outstanding academic productivity. Dr. Wang’s research focuses on understanding the molecular mechanisms responsible for regulating the function and intracellular trafficking of neurotransmitter receptors critical for brain functions such as learning, memory and cognition. He is investigating the manner by which these mechanisms may be altered in central nervous disease processes. His goal is to be able to treat central nervous disorders such as stroke, epilepsy and drug addiction by designing new therapeutics which specifically target these receptors and their pathways. Amongst his current lab projects is a study of the molecular mechanisms mediating neuronal death following stroke. A major research focus of this project is to develop new therapeutic agents that will interfere with cell-death inducing glutamate receptor signaling pathways by disrupting interactions of the glutamate receptors, particularly the NMDA subtype (NMDAR), with scaffolding and signaling proteins. His lab has been a strong training environment with 1 post doctoral fellow and three graduate students appointed in 2005.
Appointments and Promotions
Dr. Armin Curt was appointed to the rank of Associate Professor with effect from July 1, 2005.
Dr. Jeff Beckman was promoted from the rank Clinical Assistant Professor to Clinical Associate Professor with effect from July 1, 2005.
Dr. Robert Keyes was promoted from the rank of Clinical Assistant Professor to Clinical Associate Professor with effect from July 1, 2005. UBC Department of Medicine Page 105 Annual Report 2005
Dr. Anthony Traboulsee was promoted from the rank Clinical Assistant Professor to Assistant Professor with effect from January 1, 2006. Dr. Virginia Devonshire was promoted from the rank Clinical Instructor to Clinical Assistant Professor with effect from July 1, 2005.
Dr. Andrew Woolfenden was promoted from the rank Clinical Instructor to Clinical Assistant Professor with effect from July 1, 2005.
Special Honours and Awards
Dr. Duncan Anderson served a term as President, Canadian Orthoptic Society in 2005.
Dr. Armin Curt was Organizer and Chair of the first meeting of the European Clinical Trials Network in SCI (EUCTN-SCI) held on March 18th University of Zurich, Switzerland.
Dr. Dean Johnston was awarded the Roche Award for Excellence in Clinical Skills Teaching 2005.
Dr. David Li - Keynote Address. European Society of Magnetic Resonance in Medicine and Biology, Basle, CH. Assessment of Treatment by MRI, Cellular and Experimental to Clinical Trials: Neurological example
Kinexus Bioinformatics Corporation, the biotechnology company that Dr. Pelech founded and of which he is the president and chief scientific officer, was selected Red Herring Magazine as within the top 100 private companies in high tech in North America in 2005.
Dr. Thomas Ruth - Patent: Simple method for determining the proton energy from an accelerator; with J. Publicover and S Lapi; Provisional Filed in September 2005.
Dr. Dessa Sadovnick - Michael Smith Distinguished Scholar. She was an invited speaker at the reunion commune avec le Club de la Sclerose en Plaques, Marseilles, France, April 2005, as well as being the chair and speaker at a workshop on Pregnancy and MS, Consortium of MS Clinics (CMSC), Orlando, Florida, June 2005. She was an invited plenary speaker at Multiple Sclerosis, RIMS, Tallinn, Estonia, May 2005.
Dr. Tony Traboulsee was Member at Large, Consortium of MS Centers Board of Directors and co-chair, Fellowship Committee, Canadian Network of MS Centers.
Dr. Helen Tremlett was awarded a travel bursary for young investigators by the World Congress of Neurology organising committee to attend the conference in Sydney, Australia 2005, and a travel grant for young investigators (Euro400) by the ACTRIMS-ECTRIMS Scientific Committee to attend the annual conference in Thessaloniki, Greece 2005.
Dr. Andrew Woolfenden – Chair, Acute Stroke Session, International Stroke Society Meeting, New Orleans, February 2005.
UBC Department of Medicine Page 106 Annual Report 2005
Dr. Jason Barton was awarded the 2005 Norman Geschwind Prize in Behavioural Neurology, American Academy of Neurology.
Dr. Jeff Beckman was awarded the Master Teacher Award in the UBC Department of Medicine for 2005.
Dr. Joel Oger - Opening remarks at the ECTRIMS scientific session Thessaloniki, Greece 2005. Tribute to Dr.Donald Paty.
Erika Basile was awarded a travel grant for young investigators (Euro400) by the ACTRIMS- ECTRIMS Scientific Committee to attend the annual conference in Thessaloniki, Greece 2005.
UBC Department of Medicine Page 107 Annual Report 2005
OCCUPATIONAL MEDICINE
Dr. Annalee Yassi Professor & Acting Head
The Division of Occupational Medicine was conceived and approved by the department in the late fall of 2005, and is preparing for a formal official launch in 2006.
Dr. Annalee Yassi, MD, MSc, FRCPC (Community Medicine), FRCPC (Occupational Medicine) and a Tier 1 Canada Research Council chair-holder, has been serving as Acting Division Head until the new Division is officially launched. An initial list of approximately a dozen faculty members was submitted to the Department, with suggested ranks and roles. The process for appointment for several of these is now beginning. These include Royal College Fellows in Occupational Medicine itself, as well as Fellows whose primary affiliation is another division within the department but who have a strong interest in occupational medicine. Also included are faculty members (including research scientists), some with primary affiliations in other departments, as well as physician specialists in occupational medicine who are recent arrivals to BC, and not yet university affiliated, but who have an interest in the new Division.
Divisional Overview
The vision for the new Division is to strengthen the teaching of occupational medicine at the undergraduate, postgraduate and continuing medical education level; to capitalize on the immense research opportunities in this area; to contribute to world knowledge; and improve service provision in BC in this field. There are only 50 Royal College of Physicians and Surgeons of Canada specialists in Occupational Medicine in Canada, with only a tiny number in BC (7) plus a handful of American Board certified physicians who specialize in this field. Thus, this specialty is under-developed in Canada relative to the vast majority of other countries, and is particularly under-developed in BC. Many primary care physicians have become certified by the Canadian Board of Occupational Medicine to help fill the gap, but there is widespread recognition, especially within industry and the insurance sector, that BC physicians are not optimally trained or providing optimal service in this area.
The Royal College has recently confirmed its decision to make Occupational Medicine a Sub- Specialty of Medicine, with entry at the PGY4 year. The emerging new Division of Occupational Medicine is therefore planning to become accredited and ready for PGY4 intake for July 2007. In concert with a Royal College accredited program, the vision calls for the development of a provincial referral centre to reduce morbidity from occupational and
UBC Department of Medicine Page 109 Annual Report 2005
environmental disease and occupational injury through prompt and accurate diagnosis and evidence-based management. The size, scope, programs, program directors, services, affiliations etc. will be elaborated in a business plan that will be submitted in 2006.
Teaching
Undergraduate teaching: As more than half the Occupational Medical specialists in BC live on Vancouver Island, the Island medical program has had the most active involvement of prospective division members, including Dr. Doug Hamm MD, MSc, FRCPC (Occ Med) who, along with Dr. Yassi, has been teaching DPAS, and Dr. Patricia Sparks (recent immigrant from the US) who has been teaching in the PBL program. The Medical Services unit of WorkSafeBC (The Worker’ Compensation Board of BC), managed by Dr. Celina Dunn (the Director of Clinical Services in Dr. Don Graham), has expressed an interest in contributing to undergraduate teaching, although the details have yet to be worked out.
Postgraduate teaching: Dr. Yassi holds an occupational medicine referral teaching clinic – in which she provides clinical teaching to residents (usually Family Practice residents or Community Medicine residents on elective rotation with her). Occasionally graduate students from related disciplines, such as Occupational Hygiene, join the clinical teaching. Most patients are referred from their family physicians, but some are referred from internists, or from the workers compensation board (WorkSafeBC). Other prospective affiliated division members, including Dr. Maziar Badii of the Division of Rheumatology, provide clinical teaching, as do many others in their current practices. Dr. Sami Youakim, another FRCPC in Occupational Medicine has also been contributing to resident teaching. In addition, more administrative and research-oriented electives are being offered to residents, mostly from other departments (e.g. Community Medicine residents and Family Practice residents) or Occupational Medicine visiting fellows from other jurisdictions. The Occupational Health and Safety Agency for Healthcare (OHSAH) has been the home-base for these rotations, which generally combine clinical work with a major research project that the resident undertakes.
Continuing Education: OHSAH has a partnership with all the Health Authorities in BC, in a variety of important initiatives, including the case management of healthcare workers who have sustained occupational injuries or developed occupational illnesses. The Prevention and Early Active Return-to-Work Safely (PEARS) program requires the involvement of knowledgeable medical practitioners to provide appropriate clinical treatment and workplace modification advice. OHSAH is interested in exploring further links in this regard with the Division of Occupational Medicine, in conjunction with other divisions in the Department (e.g. Division of Physical Medicine and Rehabilitation). The Division also plans to work closely with WorkSafeBC and the UBC Department of Family Practice to provide continuing education for family physicians and other physicians in the community.
Research
The Division is expected to have an extremely strong research agenda, and has already been acknowledged as a world leader in the prevention of illnesses, injury and disability in healthcare workers. The focus of the research will likely be clinical intervention studies to determine the best treatment approach to decreasing morbidity from occupational disease and injury as well as UBC Department of Medicine Page 110 Annual Report 2005
their ensuing psychological, social and financial costs. It is expected that over a million dollars of CIHR funds will be brought into the Division in 2006, in addition to provincially-funded research.
The Division will also conduct research on a global level, having strong ties to World Health Organization initiatives, and there are already-funded projects in several developing countries, most notably Ecuador, where projects to improve the diagnosis and management of occupational diseases (e.g. pesticide poisoning, heavy metal poisoning, etc.) are underway.
The Division also hopes to embark on collaborative research with other Divisions, such as the Division of Respiratory Medicine, with whom some joint grants are already being held, and new initiatives with the Division of Physical Medicine and Rehabilitation, among others.
Clinical Services
As noted above, this will be a strong focus of the new Division – with the intent to establish a provincial referral centre, and a network of recognized providers who have links to the Division, so as to best monitor, evaluate and enhance the quality of the service provided. The referral centre envisioned would be inter-disciplinary in scope, including not only occupational medical and physical rehabilitation specialists, but also other occupational clinicians, such as occupational clinical psychologists (perhaps under the direction of psychologist and researcher, Dr. Elizabeth Smailes). It would respond to the need for expertise on occupational and environmental clinical assessment and management, known to be of considerable need in BC, as illustrated by the increasing number of individuals inappropriately receiving non-evidence-based treatments (e.g. chelation therapy), and the absence of a centre of excellence to which community physicians can refer patients for expert comprehensive diagnostic or treatment advice. Links will be formed with physicians who have obtained their Certificate from the Canadian Board of Occupational Medicine (CBOM) and other physicians with interests in occupational medicine but without FRCPCs, will be encouraged.
Administration
At the moment, the Division has no funding. A Business Plan is being developed, with the hope of attracting some financial resources for the administrative needs of the Division.
Future Directions
As noted above, this new Division is early in its planning phases, but aims to become a world- class research, teaching and service centre for occupational medicine, building on other strengths in BC – such as OHSAH (winner of CIHR’s Inaugural Knowledge Translation Award), a very strong School of Occupational and Environmental Hygiene, the work of Dr. Ray Copes and his initiatives at BCCDC in environmental health, and the interests of the Ministry and WorkSafeBC.
UBC Department of Medicine Page 111 Annual Report 2005
PHYSICAL MEDICINE & REHABILITATION
Dr. Theo van Rijn Clinical Associate Professor & Head
Faculty Members
Clinical Associate Professor & Head van Rijn, Dr. Theo VA Clinical Associate Professor Anton, Dr. Hubert VA Clinical Associate Professor Hahn, Dr. George VA Clinical Associate Professor Schamberger, Dr. Wolfgang Burnaby Clinical Associate Professor Travlos, Dr. Andrew VA Clinical Assistant Professor Baruni, Rida VA Clinical Assistant Professor Dhawan, Dr. Pankaj VA Clinical Assistant Professor Hirsch, Dr. Gabriel VA Clinical Assistant Professor Hughes, Dr. Barbara VA Clinical Assistant Professor Koo, Dr. David VA Clinical Assistant Professor Mortifee, Dr. Peter VA Clinical Assistant Professor Townson, Dr. Andrea VA Clinical Assistant Professor Underwood, Dr. Heather VA Clinical Assistant Professor Vondette, Dr. Michael VA Clinical Assistant Professor Weeks, Dr. Claire VA Clinical Instructor Adrian, Dr Mark VA Clinical Instructor Crossman, Dr. Mark Vancouver Clinical Instructor Dawson, Dr. Andrew VA Clinical Instructor Lau, Dr. Herman SPH Clinical Instructor O'Connor, Dr. Russell VA Clinical Instructor Reebye, Dr. Nittin VA Clinical Instructor Weiss, Dr. Elliott SPH Clinical Instructor Willms, Dr. Rhonda VA Clinical Instructor Yao, Dr. Jennifer VA Honorary Professor Kaplan, Dr. Paul USA Associate Member Eng, Dr. Janice Vancouver Associate Member Miller, Mr. William VA Associate Member Yassi, Dr. Annalee Vancouver Professor (Emeritus) Murray, Dr. Duncan Clinical Professor (Emeritus) Robinson, Dr. Cecil Clinical Associate Professor (Emeritus) Pinkerton, Dr. Alexander
UBC Department of Medicine Page 113 Annual Report 2005
Divisional Overview
The UBC Division of Physical Medicine & Rehabilitation currently has twenty-four active faculty members who are involved with patient care, teaching and research. Our members consult and provide rehabilitation services to persons ranging from the very young to the very old. We manage inpatient and outpatient programs for persons who have suffered spinal cord injury, acquired brain injury, neuromuscular abnormalities and cardio/pulmonary dysfunction. Inpatient services are provided at several sites, including Vancouver Acute/GF Strong Rehab Center, St. Paul’s Hospital, Holy Family Hospital, Eagle Ridge Hospital, Sunny Hill Health Center, as well as consultation services to the Vancouver teaching hospitals, BC Children’s Hospital, Royal Columbian Hospital and Burnaby General Hospital. Our staff is actively involved in teaching of residents and undergraduate students, as well as undergraduate students in related disciplines. Research activity deals with disease specific issues related to our patient population, as well as disability issues for the population at large. Dr. Jennifer Yao continues to serve as Program Director. Dr. David Koo continues to serve as Undergraduate Coordinator. Dr. Russell O’Connor has taken over the duties of Continuing Medical Education Coordinator.
Teaching
Ten members of our Division participated in the Undergraduate curriculum including half-day lectures on disability, activity limitations and participation restrictions, problem-based learning, MSK clinical skills sessions, mentorship and specialty-specific discussions on impairment and disability. Our Division continues to be actively involved in teaching elective medical students who have an interest in our specialty. The Division participated in the teaching of 11 medical students during the 2005 calendar year. The Division completed a very successful project of an enhanced MSK skills session prior to the final second year examinations for a select body of students. Those students who participated in the session were thus able to achieve a ‘higher’ score on their MSK related OSCE station. An Undergraduate Committee now meets quarterly to discuss Undergraduate teaching issues and future service provision.
There were nine active residents in the program at the end of 2005. All residents from PGY2 onwards have a formal half day of research experience throughout their academic years. Resident teaching is done at the bedside and in ambulatory clinics. Formalized seminars are undertaken during weekly Academic Half Days as well as selected times throughout the week. Residents continue to participate in a scheduled monthly Journal Club supervised by members of the Division, in order to develop skills in the critical assessment of journal articles.
Our Division provides needs-based weekly CPD meetings attended by Division and non- Division members who have an interest in topics presented. The CPD Committee meets at least bi-annually to review upcoming CPD activities and to formulate ways to enrich ongoing education of our membership. The CPD committee continues to encourage members to develop innovative teaching methods, as well as utilizing panel discussions and experts from other sub- specialties for broader educational experience.
UBC Department of Medicine Page 114 Annual Report 2005
Research
Caroline Abramson and Catherine Tadey served as Research Coordinators for Divisional Research and Research activities during the year.
Dr. Hugh Anton served as the Research Coordinator and Chair of the UBC/PM&R Divisional Research Committee and helped organize monthly Committee meetings for the Division. Collectively the Division continues to embark on several projects that share common interest to our members. He was the primary investigator in a study assessing fatigue in persons with spinal cord injury, as well as co-investigator in a summer student project dealing with fatigue in medical training.
Dr. David Koo was a presenter of one study involving spinal epidural abscess at the Asia Conference in Dallas, Texas, at the Inter-Urban SCI Conference in Kingston, Ontario, and the ICORD Annual Meeting in Vancouver.
Dr. Andrea Townson was co-investigator of 2 research projects dealing with issues regarding spinal cord dysfunction. She was the supervisor of a medical student project regarding fatigue in medical training. Dr. Townson is also co-investigator in developing spinal cord injury evidence- based review of best practices.
Dr. Barbara Hughes was the principal investigator of a project regarding rehabilitation therapy and outcome following spinal cord injury, as well as being co-investigator in another project dealing with genetic markers in recovery from spinal cord injury.
Dr. Claire Weeks was co-investigator in a study regarding rehabilitation therapy and outcome following spinal cord injury.
Dr. Pankaj Dhawan was co-investigator of a study looking at early rehabilitation intervention following mild traumatic brain injury.
Dr. Andrei Krassioukov, PGY4, was the primary investigator or presenter of six research projects dealing with neurological dysfunction following brain and/or spinal cord injury.
Clinical Services
Many members of our Division continue to provide consultation services to Vancouver Acute, St. Paul’s Hospital, as well as other hospitals in the Fraser Health Authority. Dr. Elliot Weiss is the leader for rehabilitation of Providence Health Care. Dr. Travlos and team members continue to provide clinical services and direction to the rehabilitation programs for persons suffering from ALS. Drs. Rhonda Willms and Heather Underwood continue to participate in services for persons requiring orthotics and/or prosthetics. Dr. George Hahn continues to provide consultation services for the BC Children’s Hospital, Vancouver Acute, and Sunnyhill Health Center.
UBC Department of Medicine Page 115 Annual Report 2005
Administration
Dr. Andrew Travlos served as a Chair of Specialty Committee in Physical Medicine & Rehabilitation of the Royal College of Physicians and Surgeons of Canada.
Dr. Hugh Anton served as examiner for the Specialty of PM&R at the Royal College.
Dr. Gabriel Hirsch served as Chair of the Section of PM&R for the BC Medical Association.
Dr. Theo van Rijn served as the Medical Director of Rehabilitation and Ambulatory Care Services, Vancouver Acute – Vancouver Coastal Health.
Drs. Andrea Townson, Andrew Travlos, and Rida Baruni served as medical managers assisting in program related issues at G.F. Strong Rehabilitation Center.
Special Honours and Awards
Drs. Heather Finlayson (PGY5), Andrew Travlos, and Russell O’Connor won the Donald M. Whitelaw Award for Outstanding Grand Rounds in 2005.
Drs. Russell O’Connor, Andrew Travlos and Jennifer Yao were presented Bill Fraser awards for research at G.F. Strong.
Dr. Jennifer Yao received the Dr. Duncan Murray Teaching Award.
Future Directions
Following a successful retreat in November 2005, the Division plans to develop expertise with other Faculty of Medicine departments regarding multiple sclerosis, cancer rehab, cardiopulmonary rehab, sports rehab and athletic injuries (especially for the disabled) and autonomic dysfunction.
The Division will begin to co-develop a Canada-wide post-graduate education/teaching initiative to promote academic excellence in our specialty.
The Division will be developing long-term initiatives regarding rehabilitation education and research in overseas countries.
UBC Department of Medicine Page 116 Annual Report 2005
RESPIRATORY MEDICINE
Dr. S. F. Paul Man Dr. John Fleetham Professor & Acting Head Professor & Head (July 1, 2005 – present) (January 1, 2005 – June 30, 2005) Faculty Members
Professor & Acting Head Man, Dr. S.F. Paul SPH Professor Bai, Dr. Tony SPH Professor Duronio, Dr. Vincent VA Professor FitzGerald, Dr. J. Mark VA Professor Fleetham, Dr. John VA Professor Lam, Dr. Stephen VA Professor Levy, Dr. Robert SPH Professor Ostrow, Dr. David VA Professor Pare, Dr. Peter SPH Professor Road, Dr. Jeremy VA Professor Van Eeden, Dr. Stephan SPH Associate Professor Ryan, Dr. Francis (Frank) VA Associate Professor Sandford, Dr. Andrew SPH Associate Professor Sin, Dr. Donald SPH Associate Professor Ward, Dr. Helen VA Associate Professor Wilcox, Dr. Pearce SPH Assistant Professor Ayas, Dr. Najib VA Assistant Professor Cook, Dr. Victoria VA Assistant Professor Tebbutt, Dr. Scott UBC Assistant Professor Champion, Dr. Paul VA Clinical Professor Khalil, Dr. Nasreen BCCDC Clinical Professor Lawson, Dr. Lindsay SPH Clinical Associate Professor Elwood, Dr. Kevin BCCDC Clinical Associate Professor Nakielna, Dr. Barbara SPH
UBC Department of Medicine Page 117 Annual Report 2005
Clinical Assistant Professor Cohen, Dr. Richard North Vancouver Clinical Assistant Professor Fera, Dr. Tharwat VA Clinical Assistant Professor Turner, Dr. Mark VA Clinical Assistant Professor Wilson, Dr. Jennifer VA Honorary Professor Lertzman, Dr. Morley VA Honorary Professor Tan-Hogg, Dr. Wan SPH Associate Member Brauer, Dr. Michael Vancouver Associate Member Lowe, Dr. Alan Vancouver Associate Member Muller, Dr. Nestor VA Associate Member Roberts, Dr. Clive Vancouver Visiting Scientist De Jong, Dr. Pieter SPH Visiting Scientist Morimoto, Dr. Kiyoshi SPH Visiting Scientist Tamagawa, Dr. Eiji SPH Professor (Emeritus) Abboud, Dr. Raja VA Professor (Emeritus) Bates, Dr. David Professor (Emeritus) Yeung, Dr. Moira VA Professor (Emeritus) Allen, Dr. Edward
Divisional Overview
The UBC Respiratory Division consists of 31 faculty members who are located at Vancouver Acute (Vancouver General Hospital, UBC Hospital), Providence Health Care (St. Paul’s Hospital, Mt. St. Joseph Hospital), Vancouver Cancer Centre, BC Centre for Disease Control and BC Transplant Society. There are active respiratory medicine in-patient and ambulatory care programs at Vancouver General Hospital and St. Paul’s Hospital. The two-year subspecialty respiratory medicine training program accepts one provincially funded trainee per year. The UBC Respiratory Division will expand the number of trainees to two per year starting in 2006. Respiratory Medicine is considered a centre of research excellence at both Providence Health Care and Vancouver Acute. Respiratory Research is a major component in the iCapture Centre (Cardio-respiratory research) at St. Paul’s Hospital. Respiratory Research is the primary component of the Lung and Critical Care Research Program at Vancouver Coastal Health Institute. During the tenure of Dr. Fleetham, the UBC Respiratory Division developed a strategic plan for clinical care, research and teaching of Respiratory Medicine within the Vancouver Coastal Health Authority, which incorporates a proposal for an academic funding contract for all divisional members.
Teaching
Undergraduate: The UBC Respiratory Division continues to have a major responsibility for the five-week pulmonary block in the undergraduate curriculum. Dr. Frank Ryan continues as chair of the pulmonary block. Dr. D. Ostrow, Dr. N. Khalil, Dr. S. Lam and Dr. P. Wilcox also participate as week chairs. Division members participate in undergraduate teaching either as tutors or clinical skills instructors.
Postgraduate: The UBC Respiratory Medicine Training Program, directed by Dr. P. Wilcox, continues to attract a large number of highly qualified applicants from across Canada. The program has full approval from the Royal College. This two year clinical program is based at UBC Department of Medicine Page 118 Annual Report 2005
both Vancouver General Hospital and St. Paul’s Hospital. There are elective opportunities at community based centres throughout BC and the program offers an optional third year of research training. Our current trainees are Dr. M. Al Ajmi (Kuwait) Dr. M. Molavi (trained in Iran and US, a Canadian Citizen), Dr. N. Al Lawati (Oman), Dr. A. Al Talag (Saudi Arabia), Dr. A. Al Jabbary (Saudi Arabia).
After twelve years of exemplary service, Dr. Pearce Wilcox stepped down as Director of the UBC Respiratory Medicine Training Program on December 31st 2005 and Dr. Jennifer Wilson assumed the role January 1st 2006.
Experimental Medicine: The UBC Respiratory Division continues to make significant contributions to the Departmental Experimental Medicine program with MSc. and PhD students being trained in both the Jack Bell Research Laboratory at Vancouver General Hospital and the iCapture Centre at St. Paul’s Hospital.
Continuing Medical Education: The annual UBC Respiratory Research retreat in June of each year is a highly successful event attracting the majority of the UBC Respiratory Faculty as well as a large number of community-based respirologists. The goal is to share state-of-the-art research being conducted within the UBC respiratory academic community with colleagues. This was initially organized by Dr. Bob Levy and more recently by Dr. Pearce Wilcox.
The annual Case Challenge and CME attracts the majority of BC academic and community respirologists in January each year and this is facilitated on an annual basis by Dr. Kevin Elwood. It is held in collaboration with the BC Society of Allergists and funded by an unrestricted grant from GSK. This is a venue in which respirologists throughout BC have been eager and happy participants.
The UBC Annual Respiratory Symposium has been held for seven years in Whistler. In an attempt to make it more accessible to allied health professionals, the conference has now been moved to Vancouver. It provides a state-of-the-art review of respiratory medicine. This symposium has been organized expertly by Dr. Mark FitzGerald.
Research
Respiratory Medicine is considered a centre of research excellence at both Providence Health Care and Vancouver Acute. The iCapture Centre was created with CFI funds to examine how abnormal genes change the structure and function of cells, tissues and organs to cause lung disease. Recently, the Division has added substantial strengths to epidemiology and translational research at the Centre. The major respiratory medicine research interests at the VCHI Lung and Critical Care Research Program are respiratory sleep and neuromuscular disease, environmental and occupational lung disease and airways disease. An emerging program of research in respiratory health outcomes in these different disease categories is also being developed in collaboration with the Centre for Clinical Epidemiology and Evaluation. The prevention and early diagnosis of lung cancer is the primary research focus at the Vancouver Cancer Centre and research into tuberculosis and mycobacterial disease is the major interest at the BC Centre for Disease Control. Research in lung transplantation takes place at both Vancouver Acute and the BC Transplant Society. Finally, there is a strengthened research relationship with critical care UBC Department of Medicine Page 119 Annual Report 2005
medicine, and members are now holders of a joint Michael Smith Foundation grant on patient safety in Critical Care Units.
Clinical Services
Active respiratory medicine in-patient and ambulatory care programs continue at both Vancouver General Hospital and St. Paul’s Hospital. Both sites are developing specialty clinics (eg. COPD, asthma, etc) with a major emphasis on overlapping best practices clinical care with clinical & translational research. As well, research databases are being developed to anchor clinical research at both sites.
Administration
The Division is in a state of transition for leadership. Dr. John Fleetham stepped down as the Head of the UBC Respiratory Division in 2005 after 11 years of outstanding leadership and guidance. Dr. Paul Man has been serving as Acting Head of the Division since July 1, 2005 until a new Head is appointed in the spring of 2006. Dr. Mark Fitzgerald is Head of the Vancouver Acute Respiratory Division. Dr. Robert Levy is Head of the Providence Health Care Respiratory Division. Dr. Pearce Wilcox completed his tenure as Director of the UBC Respiratory Medicine Training Program December 31, 2005 and Dr. Jennifer Wilson will assume these responsibilities effective January 2006. Bernice Robillard continues to work to support the administrative activities of the UBC Respiratory Division with major responsibilities for the postgraduate program. Lianne Kinnaird has ably helped the Division in its transition.
Future Directions
The Division will continue to develop its clinical program with a strong emphasis on further increasing ambulatory capacity. At Vancouver Acute, subject to issues related to lease options, the Division will move into a state-of-the-art Academic and Ambulatory Care Centre in September of 2006. The Division has, and will continue to take an active and leadership role in the development of increased research capacity through Michael Smith Foundation for Health Research as well as national initiatives in funding infrastructure for research.
Promotions
The following members received promotions in 2005: Dr. Robert Levy was promoted to Professor. Dr. Stephan Van Eeden was promoted to Professor. Dr. Andrew Sandford was promoted to Associate Professor. Dr. Scott Tebbutt was promoted to Assistant Professor. Dr. Nasreen Khalil was promoted to Clinical Professor. Dr. Jennifer Wilson was promoted to Clinical Assistant Professor.
UBC Department of Medicine Page 120 Annual Report 2005
RHEUMATOLOGY
Dr. John M. Esdaile Professor & Head
Faculty Members
Professor & Head Esdaile, Dr. John VA Professor Chalmers, Dr. Andrew VA Associate Professor Choi, Dr. Hyon VA Assistant Professor Cibere, Dr. Jolanda VA Assistant Professor Lacaille, Dr. Diane VA Clinical Professor Blocka, Dr. Kenneth VA Clinical Professor Koehler, Dr. Barry Richmond General Clinical Associate Professor Huang, Dr. Simon SPH Clinical Associate Professor Klinkhoff, Dr. Alice VA Clinical Associate Professor Offer, Dr. Robert Penticton Clinical Associate Professor Patterson, Dr. Alice VA Clinical Associate Professor Reid, Dr. Graham VA Clinical Associate Professor Shojania, Dr. Kamran VA Clinical Associate Professor Wade, Dr. John VA Clinical Assistant Professor Badii, Dr. Maziar VA Clinical Assistant Professor Ensworth, Dr. Stephanie VA Clinical Assistant Professor Kelsall, Dr. John SPH Clinical Assistant Professor Shuckett, Dr. Rhonda SPH Clinical Instructor Fenton, Dr. Stanley RCH Clinical Instructor Gillies, Dr. Jean SPH Clinical Instructor Watterson, Dr. John VA Honorary Professor Stein, Dr. Howard Adjunct Professor Gross, Dr. Lyle Bowen Island Professor (Emeritus) Tsang, Dr. Ian VA
Divisional Overview
The UBC Division of Rheumatology has 20 active faculty members, one associate member, 4 emeritus members, and one honorary member. Rheumatology consultation services are offered at Vancouver Hospital & Health Sciences Centre, St. Paul’s Hospital, BC Women’s Hospital & Health Centre, and G.F. Strong Rehabilitation Centre. Ambulatory care services are available at
UBC Department of Medicine Page 121 Annual Report 2005
the Mary Pack Arthritis Centre, St. Paul’s Hospital, BC Women’s Hospital & Health Centre, and in private practices throughout Vancouver. The Arthritis Society (BC & Yukon Division) provides excellent patient education and resources available through the Learning Centre based at the Mary Pack Arthritis Centre.
Many divisional faculty are members of the Arthritis Research Centre of Canada, a multidisciplinary clinical research and clinical trials facility affiliated with both the University of British Columbia and the Vancouver Coastal Health Research Institute. The Arthritis Research Centre focuses on "Practical Research for Everyday Living" for people with arthritis.
The two-year Postgraduate Training Program in Rheumatology continues to be the second- largest clinical rheumatology training centre in Canada. The program accepts one Ministry- funded trainee every year and a matching trainee funded by The Arthritis Society of Canada if successful in a peer-review competition. Also, one or two internationally-funded trainees are considered. Active in-patient, ambulatory care and research training is done at Vancouver Hospital & Health Sciences Centre, St. Paul’s Hospital, G.F. Strong Rehabilitation Centre, BC Women’s Hospital & Health Centre, the Arthritis Research Centre, and in private practices throughout the Lower Mainland and elsewhere in the province.
New members of the Division in the past year included Dr. Maziar Badii who was appointed as Clinical Assistant Professor. Dr. Robert Offer was appointed a Clinical Associate Professor. He will provide valuable community practice experience for the trainees in Penticton.
Also this past year, The Mary Pack-Arthritis Society Chair in Rheumatology was taken up by Dr. Hyon Choi, formerly of the Harvard Medical School. Dr. Choi has been appointed Associate Professor of Medicine and joined the staff at Vancouver Hospital & Health Sciences Centre in July 2005. He was also appointed as a Research Scientist at the Arthritis Research Centre. Dr. Choi is internationally recognized for his pioneering research in gout and the treatment of rheumatoid arthritis.
Teaching
Dr. Simon Huang continues to direct the highly successful undergraduate rheumatology program. Dr. Rhonda Shuckett does a superlative job of leading the Rheumatology Problem- Based Learning for the second-year medical and dental class.
Dr. John Esdaile continues as the Program Director for the Postgraduate Training Program, and the hospital programs continue to be led by Drs. Kenneth Blocka, John Esdaile, and John Watterson at St. Paul’s Hospital, Vancouver Hospital & Health Sciences Centre and G.F. Strong Rehabilitation Centre, respectively.
The postgraduate program is currently comprised of two first-year residents, two second-year residents, one resident on maternity leave, and two doctoral candidates. The clinical trainees continue to be involved in outreach clinics in Trail, Cranbrook, Fort St. John and other rural communities throughout B.C. UBC provides support for travel and accommodation for these outreach clinics. The residents also participate in mandatory rotations at Vancouver Acute, St. Paul’s Hospital, G.F. Strong, BC Children’s Hospital, Allan McGavin Sports Medicine Centre, UBC Department of Medicine Page 122 Annual Report 2005
and in numerous drug/disease monitoring clinics and community rheumatology practices throughout their training.
For the fifth year, a basic skills course for rheumatology fellows was given in the first week of July to provide detailed instruction on the clinical examination of the musculoskeletal exam, as well as the essentials of emergency arthritis care. The course, organized by Dr. Kam Shojania, involved the majority of the divisional faculty. Approximately 20 rheumatology trainees from other programs across Canada attended the course.
Continuing Medical Education for Rheumatology is led by Dr. Kam Shojania.
In May 2005, Dr. Mary-Ann Fitzcharles from McGill visited to perform mock oral examinations for the clinical fellows. Dr. John Kelsall acted as the Co-Examiner.
Dr. Howard Stein continues to volunteer his time teaching the clinical fellows every week at the weekly Academic Half-Day. The clinical fellows has also benefited from weekly guest speakers from many other divisions at their Academic Half-Day. As well, both the Division and the postgraduate program have benefited from a number of visiting professors including Drs. Boulos Haraoui (University of Montreal), Rob Rottapel (University of Toronto), Mary-Ann Fitzcharles (McGill University), Marvin Fritzler (University of Calgary), Ewa Roos (Lund University, Sweden), and Hani El-Gabalawy (University of Winnipeg).
Research
Members of the Division continue to be active in the Arthritis Research Centre. The Arthritis Research Centre includes faculty from the Division of Rheumatology, the Department of Orthopedics, the Department of Health Care & Epidemiology, the Department of Pharmaceutical Sciences and the School of Rehabilitation Sciences, as well as from the Centre for Health Evaluation and Outcome Studies at St. Paul’s Hospital, and the Centre for Clinical Epidemiology and Evaluation at Vancouver Acute.
Current research is funded by the Canadian Arthritis Network (a Networks of Centres of Excellence), The Arthritis Society of Canada, the Hecht Foundation, the Lupus Research Institute (US), and the Canadian Institutes of Health Research. Faculty members hold scholarships from The Molson Foundation, the J. W. McConnell Foundation Family Trust, the UBC Department of Medicine Academic Enhancement Fund, The Michael Smith Foundation for Health Research, The Arthritis Society of Canada, and the Canadian Institutes of Health Research.
The Canadian Arthritis Network was successful in receiving renewal funding ($16.2 million over the next four years) from the Networks of Centres of Excellence. Dr. John Esdaile formed part of a small team that was responsible for the renewal application. The Division, through the Arthritis Research Centre, assisted in the successful Research Hospital Fund application to the Canada Foundation for Innovation for the Centre for Hip Health, which will commence building in 2006.
UBC Department of Medicine Page 123 Annual Report 2005
Drs. Kenneth Blocka, Andrew Chalmers, John Kelsall, Alice Klinkhoff, Nima Shojania and Kam Shojania are leading clinical trials at the Arthritis Research Centre. The group’s research focuses on the study of new biological agents.
Clinical Services
The Mary Pack Arthritis Centre (operated by Vancouver Coastal Health; Director, Dr. Alice Klinkhoff) runs extensive drug and disease monitoring clinics. This program coordinates the travel of divisional faculty to provide consultation and treatment services in 28 remote locations across the province.
Ambulatory care clinics offered at St. Paul’s Hospital include those for scleroderma (Director, Dr. James Dunne), low back pain (Director, Dr. Jean Gillies) and a rapid-access program (Director, Dr. John Kelsall). Dr. Stephanie Ensworth, in addition to directing the Lupus Clinic at the Mary Pack Arthritis Centre, directs the Reproductive Rheumatology Clinic (one of only two such clinics in Canada) and the Rheumatic Diseases in Pregnancy Program at BC Women’s Hospital & Health Centre.
The G.F. Strong Rehabilitation Centre’s Arthritis Unit (Director, John Watterson) offers post- operative and rehabilitative services to rheumatology patients along with specialized physiotherapy, occupational therapy and vocational counseling. In-patient services are offered at Vancouver Acute, St. Paul’s Hospital, and BC Women’s Hospital & Health Centre.
Administration
Dr. John Esdaile is Head of the UBC Division of Rheumatology, the Vancouver Acute Division of Rheumatology, and the UBC Postgraduate Training Program in Adult Rheumatology. Dr. Ken Blocka is the Head of the St. Paul’s Hospital Division of Rheumatology and also oversees the hospital training program there. Dr. John Watterson oversees the hospital training program at G.F. Strong Hospital. Dr. Alice Klinkhoff is Director of the Mary Pack Arthritis Centre. Dr. John Esdaile is the Scientific Director of the Arthritis Research Centre.
Future Directions
In 2006, the Division will continue to pursue excellence in research, teaching and clinical care. A rapid-access clinic for early rheumatoid arthritis patients is under consideration. The Arthritis Research Centre is looking forward to breaking ground for the new Centre for Hip Health in the summer of 2006.
Distinctions and Awards
Dr. Ken Blocka received the UBC Clinical Faculty Award for Excellence in Teaching.
Dr. John Esdaile received the Canadian Rheumatology Association Distinguished Investigator Award.
Dr. Alice Klinkhoff was promoted to Clinical Associate Professor of Medicine. UBC Department of Medicine Page 124 Annual Report 2005
Dr. John Kelsall was appointed an Internal Medicine Examiner for the Royal College of Physicians and Surgeons of Canada.
Dr. Raheem Kherani, a rheumatology fellow, received the award for the Overall Best presentation by a trainee from the Canadian Rheumatology Association. He also received the Stefan Gryzbowski Prize for the Best Research Project by a Fellow at the annual UBC Resident Research Day.
Dr. Barry Koehler was promoted to Clinical Professor Emeritus. Also, he received the Faculty of Medicine’s Career Award for Excellence in Clinical Teaching.
Dr. Jacek Kopec, an Associate Member of the Division, was promoted to Associate Professor (Health Care & Epidemiology).
Dr. Diane Lacaille was awarded the Martin M. Hoffmann Award for Excellence in Research by the UBC Department of Medicine.
Dr. Ian Tsang received the prestigious Distinguished Rheumatologist Award from the Canadian Rheumatology Association.
Dr. John Watterson was promoted to Clinical Assistant Professor of Medicine.
UBC Department of Medicine Page 125 Annual Report 2005
EDUCATIONAL PROGRAMS
UBC Department of Medicine Page 127 Annual Report 2005
CLINICAL INVESTIGATOR PROGRAM
Dr. Adeera Levin Dr. Anita Palepu Clinical Professor & Co-Director Associate Professor & Co-Director
The Clinical Investigator Program (CIP) program is an integral component of the Department of Medicine. Its main goals are to integrate promising medical students, residents and fellows into an academic environment that sustains and nurtures academic interests. Drs. Palepu and Levin, in their role as co-directors of this program, have been advocating for young investigator participation and interest in research activities. The CIP program is a resource, which permits divisions within the DOM to leverage funding opportunities in order to support the academic endeavors of those divisions.
The Faculty Clinical Investigator Program is a 2-year program, which has the potential to fund at least 4 individuals each year. Current CIP young investigators enrolled in the DOM CIP program from 2005 include:), Dr. John Swiston (1st year) Respirology, Dr Mark Hull (1st year) Infectious Diseases, Dr. Greg Haljan (1st year) Critical Care Medicine, Dr. Nadia Zalunardo (2nd year) Nephrology. From the 2006 Faculty CIP competition, Dr Jag Gill (Nephrology) was awarded a position.
Accomplishments of those individuals are listed in the appendix below.
Given the importance of the CIP program to the growth and sustainability of research programs, the co-directors have been more formally integrated into key activities of the DOM. This has included presentations to the DOM business meetings at both PHC and VGH sites, and ongoing interaction with Division Heads at the UBC DOM Division Heads meeting held monthly.
There is currently a dedicated office administrative assistant, who works in conjunction with the other staff in the DOM administrative offices at both sites, to facilitate communication and serve as a resource for the enrollees.
UBC Department of Medicine Page 129 Annual Report 2005
The CIP directors continue to survey the program and department heads to estimate the number of research fellows who are currently in the Faculty of Medicine. The intent is to learn of existing educational curricula and develop an abbreviated curriculum that would be useful to junior clinician researchers in training.
APPENDIX
Dr. Warren Davidson (Year 2 completed) Division of Respirology Supervisor: Dr. Tony Bai He has assumed a 50% research allocated position with the Department of Medicine, University of Calgary at the Rockyview Hospital.
Abstracts A Comparison of the Leicester Cough Questionnaire with the St. George’s Respiratory Questionnaire in the Evaluation of Treatment Response in Patients with Chronic Cough. ATS Meeting, May 2005.
Publications Davidson W. Helical Computed Tomography has a Role in the Screening of Lung Cancer: The Con Argument. Canadian Respiratory Journal 2004; 11(3): 217-218.
Davidson W, Bai T. Asthma: Clearing the Way. The Canadian Journal of Diagnosis, November 2003.
Presentations Davidson W, Patel M. Helical CT for Lung Cancer Screening - PRO/CON Debate. Canadian Thoracic Society - American College of Chest Physicians, Orlando. October 26, 2003.
Davidson W. A Comparison of the Leicester Cough Questionnaire with the St. George’s Respiratory Questionnaire in the Evaluation of Treatment Response in Patients with Chronic Cough. 12th Canadian Resident Fellow Competition in Respiratory Research. Montreal. November 29, 2004.
Degree Programs completed Master of Health Science Degree Department of Health Care & Epidemiology, UBC
Dr. Nadia Zalunardo (Year 2) Division of Nephrology Supervisor: Dr. Adeera Levin and Dr. Chris Buller
Abstracts Harris M, Zalunardo N, Yip B, Werb R, Valyi M, Hogg R, Montaner J. Nephrotoxicity of tenofovir DF. Canadian Journal of Infectious Diseases 2003; 14 (suppl. A): 31A. UBC Department of Medicine Page 130 Annual Report 2005
Harris M, Zalunardo N, Bonner S, Werb R, Valyi M, Montaner JSG. Use of estimated glomerular filtration rate to predict renal toxicity in patients receiving tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, February 8- 11, 2004. Abstract 750.
Publications Zalunardo N, Tuttle KR. Atherosclerotic renal artery stenosis: current status and future directions. Current Opinion in Nephrology and Hypertension. 2004; 13:613-21.
Zalunardo N, Lemaire M, Davids MR, Halperin ML. Acidosis in a patient with cholera: A need to redefine concepts. Quarterly Journal of Medicine 2004; 97:681-96.
Zalunardo N, Levin A. Anemia and the heart in chronic kidney disease. Semin Nephrol 2006; In press.
Cote HCF, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, Hogg R, Harrigan PR, Montaner JS. Exploring mitochondrial nephrology as potential mechanism of kidney dysfunction among HIV infected patients on highly active antiretroviral therapy. Antiviral Therapy 2006; In press.
Submitted Zalunardo N, Rose C, Ma I, Gill J, Levin A, Curhan GC, Altmann P. Elevated serum C-reactive protein is predictive of short and long-term outcomes in peritoneal dialysis-associated peritonitis.
Degree Programs completed Masters in Science, Epidemiology Harvard School of Public Health Completion June 2005
Grants applied for 2005-6 Kidney Foundation Fellowship Grant: awarded Michael Smith Fellowship Grant: awarded but declined
Dr. John Robert Swiston (1st year) Division: Respirology Supervisors: Dr Mark FitzGerald and Dr John Granton
Publications John Granton and John Swiston. Initial Evaluation and Management of Severe Community- Acquired Pneumonia. Critical Care Rounds 2005; 6 (4).
Abstracts Acute Pulmonary and Vascular Effects of Wildfire Smoke Inhalation. J.R. Swiston, W. Davidson, S. Attridge, G. Li, M. Brauer, and S.F. van Eeden. University of British Columbia, Vancouver, British Columbia, Canada. Submitted to the American Thoracic Society for presentation at the ATS 2006 Conference UBC Department of Medicine Page 131 Annual Report 2005
Research in Progress A Study of Right Ventricular Function and Sympathetic Nervous System Activity in Pulmonary Arterial Hypertension before and after Therapy with Bosentan. John Robert Swiston, John Parker, John Floras, Narinder Paul, and John Granton. University of Toronto, Toronto, Ontario, Canada.
Long-Term Mortality after Hospitalization for Community-Acquired Pneumonia. John Robert Swiston, Margaret McGregor, Mahyar Etminan, and Mark FitzGerald. University of British Columbia, Vancouver, British Columbia.
Degree Programs enrolled Masters in Science, Epidemiology Harvard School of Public Health Starting summer 2006
Dr Mark Hull (1st year) Division: Infectious Diseases Supervisor: Dr J.S.G. Montaner
Publications
Posters/Abstracts Hull M, Doyle P, Derban A, Chong T, Lau T, Bowie W. Development of a Pre-Discharge Influenza Assesment and Vaccination Protocol for Acute-Care Medical Inpatients at Vancouver General Hospital. 45th InterScience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C. December 16th- 19th 2005.
Hull M, Phillips E, Harris M, Leong P, Toy J, Hogg R, Singer J, Montaner J. High risk of unrecognized adrenal suppression and symptoms of steroid excess in HIV+ clinic patients exposed to ritonavir and topical fluticasone: results of a case-control study. Accepted for Presentation at 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, USA, February 5th- 9th, 2006.
Submitted Abstracts Hull M, Champagne S, Romney M. Characterization of Community-Associated MRSA amongst clinical isolates at Providence Health Care, Vancouver, BC. Submitted to the Association of Medical Microbiology and Infectious Diseases Canada.Victoria, BC, March 15th- 19th, 2006.
Degree Programs currently enrolled Masters of Health Science Department of Healthcare and Epidemiology University of British Columbia
Awards Canadian HIV Trials Network Postdoctoral Fellowship 2005-2006 (Funding declined). Conference on Retroviruses and Opportunistic Infections 2006 Young Investigator Award. UBC Department of Medicine Page 132 Annual Report 2005
Dr. Greg Haljan (Year 1 completed) Critical Care Supervisor: Dr. Keith Walley
Research In Progress Genetic determinants of cognitive dysfuntion following cardiopulmonary bypass. Greg Haljan, Jim Russell, John Murkin, and Keith Walley.
Confocal two-photon laser microscopy of cerebral microvasculature flow patterns: the response to the systemic inflammatory response syndrome. Greg Haljan, Kevin Hodgson, Jim Russell and Keith Walley.
Abstracts G Haljan, A Maitland, A Buchan, R Aurora, M King, J Haigh, B Culleton, P Faris, D Zygun. The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery. (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial. 26th International Symposium on Intensive Care and Emergency Medicine, Brussels, March 2006. (accepted)
G.J. Haljan, A.M. Sutherland, K. Lau, J.M. Murkin, and K.R. Walley. Neurologic outcome after coronary artery bypass surgery is associated with post-operative serum levels of Interleukin 1- Receptor Antagonist. American Thoracic Society International Conference, May 2006. (accepted)
G.J. Haljan, A.M. Sutherland, J.M. Murkin, and K.R. Walley. Serum Erythropoietin levels increase after coronary artery bypass surgery and are associated with neurological outcome at discharge from hospital. 62nd Annual Meeting of the Canadian Anesthesiologists’ Society, June 2006. (submitted)
UBC Department of Medicine Page 133 Annual Report 2005
CONTINUING MEDICAL EDUCATION PROGRAM
Dr. G.B. John Mancini Professor & Director
Hazel Wilcox Administrator
New Initiatives/Developments
This year, we, once again, co-sponsored along with the Cardiovascular Society of Arizona, the “Southwestern Cardiology Symposium” held in Phoenix on February 11 – 13, 2005. This was an excellent event and involved the participation of both Canadian and American speakers.
On April 23, 2005 we worked with the UBC Division of Cardiology and Dr. Simon Rabkin to develop the “1st Annual Hot Topics in Cardiology” Conference. This one day event was held at the Hyatt Regency with an attendance of 78 physicians - primarily Canadian. The event was well-received and plans are currently underway for the 2nd Annual event to be held on April 8, 2006 at the Coast Plaza Hotel & Suites.
Our “8th Annual Medicine in the 21st Century” Conference was held June 2 – 4, 2005 at the Hotel Vancouver. Thirty-three UBC Faculty participated in the course which was presented to 145 attendees primarily from Canada and the United States. Once again this event was extremely well-attended and the quality, as in past years, was rated highly. Plans are currently underway to run this event in 2006 at the Sutton Place Hotel June 8 – 10, 2006.
In December 2005 we began working with the UBC Division of Respiratory Medicine and Dr. Mark FitzGerald to offer a two-day update in Respiratory Medicine. This will be held March 3 – 4, 2006 at the Hotel Vancouver.
These CME conferences have generated significant funding for the Department of Medicine Academic Enhancement Fund. During this year we were able to donate $45,000 to the fund. This fund helps support junior faculty who need protected time and other resources to develop their academic credentials in teaching and research.
We would like to thank our many Faculty Members who have contributed their time by participating in our CME events. Without their continued support we would be unable to continue to offer high quality, well-attended CME events.
UBC Department of Medicine Page 135 Annual Report 2005
GRADUATE STUDIES PROGRAM IN EXPERIMENTAL MEDICINE
Dr. Vincent Duronio Professor & Director
Divisional Overview
Experimental Medicine is the UBC graduate studies program, within the Department of Medicine, which was developed to train individuals seeking a career in biomedical research. Students are enrolled in both MSc and PhD degree programs. Subspecialties within the Experimental Medicine Program include Cancer Biology, Cardiology, Dermatology, Gastroenterology, Haematology/Oncology, Immunology, Infectious Diseases, Molecular Biology, Nephrology, Neurology, Pediatrics, Physiotherapy and Respiratory Medicine. A substantial number of students in the program are under the supervision of faculty members outside of the department. In 2005, 38 new students were admitted to the program. At the end of 2005, there were 130 students registered in the program, 53 for MSc degrees and 77 for PhD degrees.
During 2005, a total of twenty-two students graduated, twelve at the May 2005 Convocation and nine at the November 2005 Convocation. Student names and thesis titles are listed below (research supervisor in parenthesis):
PhD Graduates 1. Maureen Ashe, Upper Limb Bone Health: Cadaveric, imaging and clinical studies with a special emphasis on Peripheral Quantitative Computed Tomography, (Dr. Karim Khan & Dr. Heather McKay) 2. Scott Cameron, Generation and Partial Characterization of a Regulatory T Cell Phenotype following repeated in vivo Treatment with the Staphylococcal Superantigen Toxic Shock Syndrome Toxin-1, (Dr. Anthony W. Chow) 3. Ehsan Davani, The role of ICAM-1 in myocardial depression during sepsis and ischemia reperfusion injury, (Dr. Keith Walley) 4. Michael Hughes, The Role of SHIP in Hematopoiesis (Dr. Gerry Krystal) 5. Bruno Larrivee, Effects of VEGFR-2 Signalling in Post-Natal Hematopoiesis and Vasculogenesis, (Dr. Aly Karsan)
UBC Department of Medicine Page 137 Annual Report 2005
6. Kevin Leong, Role of Notch Signaling In Angiogenesis and Breast Cancer, (Dr. Aly Karsan) 7. Jasmeen Merzaban, Formation of Functional Selectin Ligands on Activated T Cells and Thymic Progenitors: The Role of Core 2 beta-1,6-N-Acetylglucosaminyltransferases in the Control of Lymphocyte Trafficking and Thymic Progenitor Homing, (Dr. Hermann Ziltener) 8. Meena Sran, Manual Therapy and the Osteoporotic Spine, (Dr. Karim Khan & Dr. Thomas Oxland) 9. Alison Wallace, Genetic Risk Factors for Chronic Obstructive Pulmonary Disease, (Dr. Peter Paré) MSc Graduates 1. Tonya Coulthard, Small Airway Remodeling: Analysis of Growth Factor Gene Expression Following Exposure to Cigarette Smoke, (Dr. Andrew Churg) 2. Derek Lei Dai, Roles of Tumor Suppressor APAF-1, Oncogene ILK and AKT Expression in Human Melanoma Progression, (Dr. Gang Li) 3. Ron Do, Acid-Base Equilibrium in Exhaled Breath Condensate of Grain Elevator Workers, (Dr. Susan Kennedy) 4. Clement Ho, Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis, (Dr. Gang Li) 5. Bojana Jankovic, Quantitative Analysis of Hypoxia Markers in Cervical Cancer Biopsies, (Dr. Peggy Olive) 6. Zhiqi Jian, Involvement of 3-phosphoinositide-dependent kinase 1 (PDK1) in the regulation of nitric oxide expression in LPS-stimulated macrophages, (Dr. Bill Salh) 7. Jill Kucab, Targeting Akt signaling in breast cancer: expression of phosphorylated-Akt in breast tumors and the efficacy of Celecoxib analogues as potential inhibitors, (Dr. Sandra Dunn) 8. Sarah Manske, MRI as an Instrument to Assess the Association Between Femoral Neck Bone Geometry and Strength of the Proximal Femur, (Dr. Heather McKay) 9. John McDonough, Expression of Pro-fibrotic Factors in the Airways of Lungs from Patients with Chronic Obstructive Pulmonary Disease, (Dr. James Hogg & Dr. Shizu Hayashi) 10. Pooran Qasimi, Divergent Mechanisms Utilized by SOCS3 to Mediate IL-10 Inhibition of TNF-alpha and Nitric Oxide Production by Macrophages, (Dr. Alice Mui) 11. Solmaz Sobhanifar, Fluorescence Imaging of Tumour Hypoxia in Xenograft Tumour Models, (Dr. Peggy Olive) 12. Julian Vasilescu, Development of a Proteomic Approach for Identifying Protein-Protein Interactions, (Dr. J. Schrader and Dr. Juergen Kast) 13. Tianjiao Ida Zhang, Analysis of Mouse Prostate Development Using Serial Analysis of Gene Expression (SAGE), (Dr. Cheryl Helgason)
UBC Department of Medicine Page 138 Annual Report 2005
In 2005, 106 Experimental Medicine students surveyed reported a total of $2,008,015 in funding, an average of $19,881 per student. Research Supervisors provided $966,050 in Graduate Research Assistantships. Other funding sources included CIHR ($284,750), the Michael Smith Foundation ($297,700), NSERC ($95,800), the Heart and Stroke Foundation ($52,500), and the UBC Graduate Entrance Scholarship ($10,115).
There are 124 faculty members currently registered as Research Supervisors in the program. Faculty members from other departments also participate as course lecturers, thesis committee members, in research seminars and as examiners for internal examinations and theses defenses.
In the academic year 2005, the Experimental Medicine Program offered nine graduate courses. These included: MEDI 501 (Molecular & Cellular Biology), MEDI 502 (Methodology), MEDI 535 (Journal Club), MEDI 548 (Directed Studies in Experimental Medicine), MEDI 560 (Pulmonary Pathophysiology), MEDI 570 (Cardiology), MEDI 580 (Infectious Diseases) and MEDI 590 (Molecular Medicine).
The overall administration of the program is under the guidance of the Experimental Medicine Committee. The committee is composed of representatives from each subspecialty and one student representative. This committee meets at least once per year to discuss policy and procedures. Current members of the committee are: Dr. Anthony Chow (Infectious Diseases), Dr. Vincent Duronio (Respiratory Medicine and Director), Dr. R. Keith Humphries (Haematology/Oncology), Dr. Gang Li (Dermatology), Dr. Steve Pelech (Molecular Medicine), Dr. Bill Salh (Gastroenterology), Dr. Andrew Sandford (Respiratory Medicine, iCapture Centre), Dr. Yu Tian Wang (Neurology, Brain Research Centre), and Dr. Graydon Meneilly (ex-officio). The Experimental Medicine Program’s daily administration is through the director and one secretary.
The Experimental Medicine Program continues to sponsor an annual Student Research Day, which will now be held twice a year. The 2005 event was held on November 22, at the Paetzold Health Education Centre, VGH. 13 students gave oral presentations and 28 students participated in poster presentations. A total of $800 in cash prizes was presented this year. The prizes this year went to:
Natasha Crellin (PhD, Supervisor: Dr. Megan Levings) - $300 Best Overall Presentation
Jennifer Davis (MSc, Supervisor: Dr. Pierre Guy & Dr. Karim Khan) - $100 Best Oral Presentation
Ren Yuan (PhD, Supervisor: Dr. Peter Paré) - $100 Best Poster Presentation
Lynsey Huxham, Ainsley Sutherland, Ivan Waissbluth – $50 each for Honourable Mentions for Oral Presentation
Sima Allahverdian, Maziar Riazy, Mohammed Khan - $50 each for Honourable Mentions for Poster Presentation
UBC Department of Medicine Page 139 Annual Report 2005
Financial support for Student Research Day was provided by GlaxoSmithKline Inc., the Vancouver Coastal Health Research Institute, the Canadian Society of Biochemistry, Molecular and Cellular Biology, Hoffman La-Roche Ltd., Schering Canada Inc. and Janssen-Ortho Inc.
The Experimental Medicine Program continued to offer travel grants to students who had already used the travel grant provided by the Faculty of Graduate Studies.
The Experimental Medicine Office is located in Room S125, Koerner Pavilion, 2211 Wesbrook Mall, UBC Campus. The office telephone number is 604-822-7215, the fax number is 604-822- 7897 and e-mail address is [email protected].
UBC Department of Medicine Page 140 Annual Report 2005
HIV/AIDS RESEARCH PROGRAM
Dr. Julio Montaner Professor & Director
Overview
The AIDS Research Program continues to refine the role of antiretroviral therapy for the treatment of HIV infection. The main areas of research continue to be epidemiology, basic science and clinical science. In the following report we summarize the program's activities and areas of concern for the year 2005.
Epidemiological Research
The epidemiology group has again been very productive and continues to benefit from long-term analyses emerging from the VanGuard Project, the VIDUS, SEOSI, ACCESS, ARYS, and CEDAR cohorts under the leadership of Drs. Lampinen, Wood and Kerr, and Spittal, respectively. The Drug Treatment Program, under the leadership of Dr. Robert Hogg, has emerged as a key contributor to our understanding of the dynamics of the HIV epidemic as well as the effect of treatment. The Epidemiological Research group has published over 40 peer- reviewed scientific articles this last year, many of them in highly respected international journals. Members of our team have received funding from the Michael Smith Health Research Foundation and the Canadian Institutes of Health Research for senior scholar research (Robert Hogg), masters and doctoral training (Beth Rachlis, Shayesta Dhalla, Sarah Fielden, Karrisa Johnston, Elisa Lloyd-Smith, Cari Miller. Melanie Rusch, Kate Shannon), and post-doctoral training (Paula Braitstein ART-LINC). Dr. Hogg also holds the Michael O’Shaughnessy Chair in Population Health in the Department of Medicine at UBC. Grant funding was obtained from the Michael Smith Health Research Foundation, Canadian Institutes of Health Research, National Institutes of Health in the United States and a number of pharmaceutical companies.
Basic Science
The research laboratory based at the B.C. Centre for Excellence in HIV/AIDS has established itself not only as a leading force in Canada, but also as a centre with considerable international influence. During the year, the laboratory provided clinical services to the province of B.C. in the areas of HIV drug resistance testing and pharmacokinetic measurement. The clinical implications and predictors of HIV drug resistance continue to be investigated, both at the B.C. Centre for Excellence and as part of international collaborations. The research laboratory
UBC Department of Medicine Page 141 Annual Report 2005
continues to develop tools with clinical applications that may be employed in the near future. These include tools for monitoring the side-effects and degree of adherence to medications, as well as tracking variations in the HIV and human genomes which are associated with response to HIV therapy, and virus pathogenicity. In addition to providing HIV drug resistance testing as a clinical service to most of Canada and investigator driven trials, the research lab has also received peer-reviewed funding for several studies from the Canadian Institutes of Health Research, Michael Smith Health Research Foundation, and the Ontario HIV Treatment Network. Novel testing applications in the laboratory continue to provide testing support for Phase III clinical trials.
Clinical Science
Cutting-edge research continues by members of the clinical science group, focusing on the treatment of patients with multidrug-resistant virus, pharmacokinetics of antiretrovirals, optimizing adherence to antiretroviral therapy regimens, recognition and management of drug toxicities, management of viral co-infections, and primary care initiatives.
New and investigational agents continue to emerge which hold promise in the treatment of patients with multi-drug resistant HIV. In 2005, the clinical group pioneered the use of a novel gas-powered injection system for the subcutaneous administration of enfuvirtide, the first approved HIV fusion inhibitor. This technique has substantially improved the tolerability of this agent and based on the results of our studies (soon to be published in AIDS) this device is recommended in major U.S. HIV treatment guidelines. The clinical group has also actively participated in large international trials of a number of investigational drugs for use in treatment- experienced patients, including the protease inhibitors tipranavir and TMC114, the nonnucleoside reverse transcriptase inhibitor TMC125, and the CCR5 receptor antagonist maraviroc. Our group was the first in Canada and one of the first in the world to explore the use of two of these investigational drugs, TMC114 and TMC125, together in combination in the salvage therapy situation. Furthermore, studies implementing a new nucleoside and an integrase inhibitor in this setting will be underway shortly.
The clinical team continues to work in concert with the B.C. Centre for Excellence laboratory to study the complex issues of pharmacokinetic interactions between antiretroviral drugs. Results of studies in this area which were presented during 2005 include the impact of atazanavir and ritonavir dosage adjustments on plasma levels of atazanavir; the impact of TMC125 on levels of coadministered saquinavir, lopinavir, and ritonavir; and the effect of dosage adjustments to overcome the negative interaction between tipranavir and lopinavir/ritonavir. The Therapeutic Drug Monitoring program is accumulating a large database, which incorporates information on all HIV+ patients undergoing antiretroviral drug level testing in the province. Linkage of this information with the Drug Treatment Program database will enable us to explore the complex relationships between antiretroviral drug levels and drug efficacy and toxicity, with respect to demographic factors (e.g. gender, age, and ethnicity), comorbid conditions, concomitant medications, and other factors. A major focus of the centre has been the use and study of pharmacokinetics to optimize and individualize care. Ongoing research is exploring factors which impact variability in the pharmacokinetics of these drugs such as gender, age and co- infection with hepatitis C.
UBC Department of Medicine Page 142 Annual Report 2005
The issues surrounding adherence to antiretroviral drug regimens are a topic of active study by the Psychology Team. A number of studies have been completed. One focused on describing how patients who have sustained undetectable viral loads for over a year accounted for their success, while the other study explored barriers to initiating antiretroviral therapy when medically indicated. Current projects include: examining HCV treatment adherence in patients co-infected with HCV and HIV, developing a brief psychological intervention to facilitate adherence, creating an inclusive adherence model, and describing the multi drug rescue therapy experience from the perspectives of both patients and care providers. The common goal of the psychology team’s projects is to optimize patients’ ability to take their antiretrovirals.
Toxicities of antiretroviral therapy continue to be a major focus of research by the clinical group. Metabolic disorders including mitochondrial toxicity and dyslipidemia are being studied in conjunction with colleagues in the Healthy Heart Program and UBC. For example, a randomized clinical trial looking at the effect of rosiglitazone on lipid levels and other markers of cardiovascular disease risk in antiretroviral-treated patients completed enrolment at the end of 2005; follow-up is ongoing. Also actively enrolling during 2005 is a large cross-sectional study examining the incidence of osteoporosis and osteopenia among HIV+ patients, one of the aims of which is to delineate whether specific antiretroviral therapies are risk factors for bone disease in this population. Other studies are examining the risk factors for, and appropriate monitoring and management of kidney dysfunction in the HIV+ population. During 2005 a paper was accepted for publication based on work from our clinical group in conjunction with Helene Cote at UBC, demonstrating the relationship between nephrotoxicity and concurrent treatment with tenofovir and didanosine. Based on these findings, the provincial HIV treatment guidelines now recommend against the routine use of these two drugs together if safer alternatives exist. Also during 2005, the results of a study examining the safety of antiretroviral treatment interruptions with close monitoring in a selected patient population, as a means of reducing the overall cost and toxicity associated with antiretroviral treatment, was published in the Journal of Infectious Diseases. Drug interactions both between antiretroviral agents and concurrent therapy are important causes of patients’ morbidity. Ongoing studies are exploring linkages between the drug treatment program and provincial databases to develop better processes for identifying drug interactions. Studies on the clinical impact of key drugs interactions such as the interaction between inhaled steroids and ritonavir which can lead to adrenal suppression are ongoing. Pharmacogenetics is an emerging area of research. Cutaneous testing in the form of patch testing has emerged as a useful tool in the diagnosis of abacavir hypersensitivity syndrome which will be applied in a large multicentre trial. HLA typing is being validated and studied prospectively with the plan to implement HLA-B*5701 as a screening test for the diagnosis of abacavir hypersensitivity.
Co-infection with hepatitis B and C continues to have a major effect on the HIV-infected clinic population. Ongoing research in this area is examining the effect of tenofovir on hepatitis B viral load in individuals with HIV/hepatitis B co-infection, and CIHR funded research is examining the effect of mitochondrial toxicity in the liver caused by HIV and hepatitis C treatment. CIHR funding has also been obtained to examine the pharmacokinetics of protease inhibitors in patients co-infected with hepatitis C. In addition, a study is planned which will examine the issue of suboptimal adherence to anti-hepatitis C treatment in HIV-positive patients.
UBC Department of Medicine Page 143 Annual Report 2005
In 2005, the John Ruedy Immunodeficiency Clinic (IDC) entered its third year as a primary and specialty clinic for HIV infected patients. The clinic incorporates a multidisciplinary team with expertise in all areas of HIV care particularly primary care physicians, nurses, social workers, nutritionists, counselors and psychologists. As well, the IDC operates a number of specialty clinics in the fields of primary care, infectious diseases, lipid disorders, anal dysplasia, neurology, dermatology, nephrology, psychiatry, addictions medicine, hepatitis B and C coinfections, antiretroviral management and clinical trial operations.
The HIV positive patient population served by the IDC continues to expand and currently numbers approximately 600. The clinic operates 5 days a week with after-hours on call coverage. The comprehensive clinical team described above is available to all patients. A large database is maintained with information on primary care initiatives, allowing a comprehensive, up-to-date assessment of the patient’s health status as well as immunizations, serologies, co- morbidities, medications, substance use, and other factors of interest.
In partnership with the Vancouver Coastal Health Authority and the UBC skill enhancement program for Family Physicians, the IDC offers a 3-month post-graduate program for family doctors. The aim of the program is to enhance skills in the care and treatment of patients with HIV/AIDS. The clinic as well gives medical support and consultations to the Dr. Peter Residency patients. An Antiretroviral Outreach Program (ARV-ORO) as been established to help inform, support and evaluate activities in Vancouver's Downtown Eastside.
Current Areas of Active Clinical Research
• First-line antiretroviral therapy • Salvage therapy for patients with previous treatment failure and multiple drug-resistant HIV • Strategies for optimizing the use of investigational and newly available antiretroviral agents • Complications of antiretroviral therapy, including lipodystrophy, dyslipidemias, cardiovascular disease, mitochondrial toxicity, peripheral neuropathy, hepatotoxicity, nephrotoxicity, osteopenia/osteoporosis, hypersensitivity reactions • Effect of treatment interruptions on long-term outcomes of HIV disease • Assessing and optimizing adherence to antiretroviral regimens and hepatitis C therapy • Pharmacokinetics of antiretroviral drugs, achieving optimal therapeutic drug levels, and drug interactions • Treatment and complications of hepatitis B and C co-infections • Prevention and treatment of opportunistic infections
UBC Department of Medicine Page 144 Annual Report 2005
Students/Residents/Postdoctoral Research Fellows:
Student Name Program Type Dates Supervisor(s) Braitstein, Paula PhD, UBC 1999-2005 R. Hogg, J. Montaner, M. O’Shaughnessy
Brumme, Zabrina PhD, MSHRF, CIHR 2001-2006 R Harrigan, R. Hogg, J. Montaner (Experimental Medicine)
Christie, Timothy MSc 2003-present R. Hogg, J. Montaner
Cox, Michelle Health Care & Epidemiology, 2002 D. Patrick, M. Tyndall, M. Krajden M.S. Thesis Student
Dhalla, Shayesta PhD 2005 R. Hogg, T. Kerr
Fielden, Sarah Student Researcher 2005-present R. Hogg
Grebaly, Jason Pharmacology PhD 2004 B. Conway, M. Tyndall, M. Krajden Dissertation
Kaida, Angela PhD 2005 R. Hogg, J. Spiegel
Lampinen, Tom Post-Doc 2003-Present R. Hogg
Lloyd-Smith, Elisa Health Care & Epidemiology 2005 B. Hogg, M. Tyndall, E. Wood PhD Dissertation
Maas, Benjamin Research Assistant 2005-present T. Kerr, J. Montaner
Mehrabad, Azar MSc 2005 P. Spittal, M. Schechter, R. Hogg
Ng, Francisco Postdoctoral Research Fellow- 2005-present J. Montaner Health Professional
Penner, Jeremy Health Care & Epidemiology, 2003 M. Tyndall, P. Granger M.S. Thesis Student
Rachlis, Beth MSc 2005 R. Hogg, T. Kerr
Ramirez Moreno, Saby Postdoctoral Research Fellow- 2004-2005 J. Montaner Health Professional
Remple, Valencia Health Care & Epidemiology 2003 D. Patrick, M. Tyndall, A. Jolly PhD Dissertation
Rocha, Clara Postdoctoral Research Fellow- 2005-present J. Montaner Health Professional
Rusch, Melanie Student Researcher 2003-present R. Hogg
Health Care & Epidemiology, UBC Department of Medicine Page 145 Annual Report 2005
PhD Dissertation 2002 M. Tyndall, J. Shovellar, D. Patrick
Shannon, Kate Health Care & Epidemiology 2004 M. Tyndall, T. Kerr, C. Patton PhD Dissertation
Small, Will Health Care & Epidemiology 2005 M. Tyndall, T. Kerr, J. Shovellar PhD Dissertation
Steenbeek, Audrey PhD 2001-2005 M. Tyndall, R. Hogg
Tam, Lily BSc 2005 R. Hogg, R. Harrigan
Taylor, Darlene Health Care & Epidemiology 2004 M. Tyndall, D. Patrick MSc thesis Weber, Amy MD/PhD 2001-present M. Tyndall, R. Hogg, J. Montaner
Yau, Steven Student Researcher May-Aug 2005 R. Hogg, J. Montaner
Michael Perlman Residency-Infectious Diseases 2005 J. Montaner Dr. Richard Bedell & HIV/AIDS Anouf Nematallah Amin Buzaid Melanie Murray Abeer Alshukairi Nezar Bahabri Mark Hull Daniel Renouf David Prchal Holly Samm Ghassan Wali Raed Al Roughani Aleksandra Stefanovic Dr. Mirzanejad Victor Leung George Robbins Bradley Quon Mark Warwas Dr. Steven Reynolds Natalie Briscoe Aman Kaur
Dr. Wayne Ghesquiere Preceptorship (HIV Primary 2005 J. Montaner Dr. Carlos Zala Care and HIV/AIDS Specialty S. Guillemi Dr. Alejandro Ferro Clinic) Dr. Sara Villar del Saz Dr. Lynn Farrales Dr. Martina Scholtens Dr. Liliana Kordic Dr. Daphne Hart
UBC Department of Medicine Page 146 Annual Report 2005
POSTGRADUATE EDUCATION PROGRAM
Dr. James Mark Roberts Clinical Instructor & Director
New Initiatives/Developments
2005 was an extremely busy year for the Internal Medicine Residency Training Program. With the ongoing expansion of the medical school, the 2005/2006 academic year saw a record number of core residents in the program with 81 in the first three core years plus 4 in the fourth year.
Dr. Rose Hatala was instrumental with respect to two new assessment processes for the 2005/2006 academic year. First, the mini-Clinical Evaluation Exercise (mini-CEX), an observed history and physical examination with feedback, is now a mandatory part of each rotation. Residents are expected to successfully complete six mini-CEXs during the academic year as part of their assessment of clinical performance. Completed assessments are monitored and remediation will be offered for any resident with identified weaknesses. Second, a procedures log has been introduced via WebEval and residents are now logging their procedures in order to be granted “competence” for the Royal College mandated procedures.
Developed by Dr. Roger Wong the 2005/2006 year also saw the introduction of a Quality Improvement curriculum. All residents in the training program will be exposed to the foundational components of curriculum with the objective of covering the building blocks of quality improvement. The venue whereby this is delivered will be at Academic Half Day in the form of didactic lectures and interactive workshops. PGY-1 residents only are involved in an independent study component of the curriculum whereby teams of 3–4 residents will work on a self-selected quality improvement project at one of the two hospital sites. The outcome of this project is the presentation of data at a yearend quality improvement conference to be held in October 2006.
A curriculum map has been developed by Dr. Roger Wong which has aided in the construction of a three year curriculum. This was done by reviewing Noon Rounds at VGH and Academic Half Day sessions over the past three years along with the results of the ACP-ASIM Internal Medicine In-Training Exam – this aided in the development of topics by subspecialty. Topics were then cross-matched to see what is being delivered and what we haven’t been teaching.
Our CaRMS interview process was completely restructured for 2005. We held approximately 142 interviews over a three day period in January 2005 with 7 interviews and 14 interviewers UBC Department of Medicine Page 147 Annual Report 2005
running consecutively. Applicants were toured by our PGY-1s at one of the teaching hospitals and then met with the Program Directors and Administration for a Q&A session. Applicants were then treated to lunch prior to the interview process. This new system has been extremely well-received by faculty, applicants and the administrative office.
Once again, in March 2005 the Chief Residents coordinated the Annual Whistler Conference which was held over a two day period and attended by approximately 50 residents.
The 21st Annual Resident Research Day was held on May 18, 2005 at the Pan Pacific Hotel. A large number of residents participated this year with 32 podium and 27 poster presentations. We were pleased to welcome the podium adjudicators – Dr. Tim Meagher from McGill University; Dr. Mike Delorme, Hematologist from Kelowna, BC and Dr. Mark Turner, Respirologist from White Rock, BC. Our poster adjudicators were Dr. Stephen Chung, Professor of Surgery, UBC and Dr. Doris Doudet, Associate Head of Research, UBC Medicine. This event was, once again, moderated superbly by Dr. Anita Palepu.
In 2005 we were approached by the Ministry of Health to participated in the assessment of two International Medical Graduates. Their competency to sit the Royal College examinations was to be assessed and they each spent a total of six months in the program.
Under the guidance of Dr. Roger Wong, e-Res was developed by Resident Dr. Loay Al Riyami. This is a new Web CT learning resource specific for Department of Medicine Residents.
In September 2005 the program underwent an Internal Review in preparation for the 2007 Royal College Accreditation. The review team was lead by Dr. Jon Fleming from the Department of Psychiatry. Overall, the program received a stellar review.
In September 2005 the Annual Royal College Meeting was held in Vancouver. This year saw the introduction of an Administrators’ Track. Hazel Wilcox working co-jointly with the Administrator from the University of Alberta was instrumental in the development of this well- received program. Hazel Wilcox spoke to three small groups with respect to Web-Based Evaluation Systems.
With a view to expansion in November, Dr. Grady Meneilly along with Hazel Wilcox and members of the Undergraduate Program met with Dr. Brian Wienerman, Dr. Oscar Casiro and other representatives from the Vancouver Island Program in Victoria. Again, in November, Dr. Mark Roberts, Hazel Wilcox and members of the Undergraduate Program traveled to Prince George to meet with Dr. Don MacRitchie and other members of the Northern program.
Plans continue to evolve with respect to providing residents to the distributed sites and 2006 will see the implementation of these plans with respect to Victoria and Prince George. Both of these sites have had “pilot” projects with medical students and residents, and are developing their own specific experiences, which are complementary to the home-based sites.
The community and distributed side expansion is progressing. Presently Nanaimo, under the stewardship of Dr. Hector Baillie, is fully subscribed and reviewed as very successful by the
UBC Department of Medicine Page 148 Annual Report 2005
trainees. Our more traditional site of Kamloops continues to be popular. More sites will be added, as the need is increasing.
The experience of having 1st year residents spending 6 months at each base hospital is received well by faculty and residents. It is too early to evaluate but there has been enthusiasm for this model.
We anticipate the upcoming year will be filled with many challenges and we look forward to working towards further development of a strong training program.
UBC Department of Medicine Page 149 Annual Report 2005
UNDERGRADUATE EDUCATION PROGRAM
Dr. H. Grant Stiver Professor & Director
The Department of Medicine Undergraduate Education Program encompasses second, third and fourth year medical students.
January through May, second year UBC medical students participate in a four-week bedside teaching course. This course continues to be one of the highest rated courses in the undergraduate curriculum. Students are assigned a patient and perform a complete and focused history and physical examination, reviewed at the bedside by a clinician instructor who also critiques the student’s write-up of the case.
September to August, the third year clinical clerkship rotation consists of an eight-week rotation, including Thursday afternoon academic half-days. The written examination at the end of each clinical clerk’s rotation continues to be the National Board of Medical Examiners (NBME) shelf examination in Medicine. The performance of UBC first-time examinees of the NBME exam in Medicine (all clerkship rotations) during the 2004-05 academic year resulted in a mean subject exam test score of 75.9. The mean for North American medical schools which have an eight- week clerkship was 74.5. The performance of students beginning the clerkship at the end of Third Year generally increased compared with the performance of students beginning in September, reflecting the increased clinical experience acquired throughout the year.
In year four, UBC medical students undertake a series of selective and elective rotations from September to December and also in the month of April. Our program offers a wide range of sub- specialty rotations and approximately 70% of fourth year students take at least one of these sub- specialty rotations.
In 2005, the Department of Medicine Undergraduate Program had many accomplishments and achievements:
• In April 2005, Delaine Harper and Jennifer Golinski were each nominated for the Applegarth Staff Service Award. This award recognizes excellence in personal achievements and outstanding contributions to the Faculty of Medicine. • In June 2005, the Undergraduate Education Program welcomed Sandra Hopkins as the new Program Assistant in the Department of Medicine Undergraduate Office. Sandra’s
UBC Department of Medicine Page 151 Annual Report 2005
office is located in the Burrard Building at St. Paul’s Hospital.
Medical School Expansion
• In 2005, two pilot clerkship rotations took place: o February, 2005 - an eight week pilot clerkship rotation in Victoria, BC, where two 3rd year medical students undertook their medicine training. o October 2005 - a four-week pilot clerkship rotation at Royal Columbian Hospital, where two 3rd year medical students spent four weeks of their Internal Medicine clerkship. o Both pilot clerkship rotations were done in conjunction with an internal medicine resident rotation and went very well. • In April 2005 and September 2005, the Medical School Expansion Office organized a workshop for the Vancouver Fraser Medical Program with representatives from Royal Columbian Hospital, Lion’s Gate Hospital and Richmond General Hospital to initiate site-specific planning of the expanded undergrad and postgrad programs in the Vancouver Fraser Medical Program (VFMP). • In June 2005 and November 2005, Undergraduate Education Committee members went to Prince George to meet with local internists to discuss plans for a proposed pilot clerkship rotation in January 2006. • In November 2005, Undergraduate Education Committee members visited Victoria to discuss plans for expansion in September 2006.
In 2006, the Undergraduate Program will continue to collaborate with expanded programs in Prince George and in Victoria to establish clerkship rotations in September 2006. We will also be looking at expanding our teaching capabilities to match increases in student enrolment in the Second Year Bedside Teaching sessions and to expand the current Internal Medicine Electives’ Program to include additional sites throughout British Columbia.
UBC Department of Medicine Page 152 Annual Report 2005
PUBLICATIONS
UBC Department of Medicine Page 153 Annual Report 2005
ADMINISTRATION Towle, Dr. Angela Towle A, Godolphin W, Van Staalduinen S, Overgaard V. "Talk to Your Doc". Helping adolescents make health care transitions. Education Canada 2005; 45 (2): 29-30. Bates J, Casiro O, Fleming B, Frinton V, Towle A, Snadden D. Expanding undergraduate medical education in British Columbia: a distributed campus model. Canadian Medical Association Journal 2005;173(6) electronic supplement http://www.cmaj.ca/chi/content/full/173/6/589/DC1.
ALLERGY AND IMMUNOLOGY Wong, Dr. H. C. George Wong HCG. Doctors, lawyers, and sex. BC Med J 2005; 47(1):4. Wong HCG. Factitious anaphylaxis and prevarication anaphylaxis. J Allergy Clin Immunol. 2005; 116(3):710, available online June 30, 2005.
CARDIOLOGY Aymong, Dr Eve D Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, Mehran R. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. American Journal of Cardiology. 2005 Jan 1;95(1):13-9. Buller, Dr. Christopher E Pate GE, Lowe R, Buller CE. Fibromuscular dysplasia of the coronary and renal arteries? Catheter Cardiovasc Interv. 2005;64:138-45. Yee KM, Buller CE, Catellier D, et al. Effect of bare metal stenting on angiographic and clinical outcomes in diabetic and nondiabetic patients undergoing percutaneous coronary intervention of nonacute occluded coronary arteries: A report from the total occlusion study of Canada (TOSCA). Catheter Cardiovasc Interv 2005. Stigant C, Izadnegahdar M, Levin A, Buller CE, Humphries KH. Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era. Am J Kidney Dis 2005;45:1002-9. The Occluded Artery Trial (OAT) Research Group. Design and methodology of the Occluded Artery Trial (OAT). Am Heart J. 2005;150:627-42. Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation. 2005;111(11):1390-7. Gin, Dr. Kenneth G Al Shehri A, Gin K. "What is the sensitivity and specificity of transthoracic ECHO compared to right heart catheterization for PAH? Perspectives in Cardiology, October 2005. Taylor C, Ramanathan K, Gin K. Shot to the Heart: Cardiac Manifestation of SLE, Cardiocase of the month, Perspectives in Cardiology, November-December 2005.
Heilbron, Dr. Brett • Heilbron B, Klein G, Talajic M, Guerra P. Management of atrial fibrillation in the emergency
UBC Department of Medicine Page 155 Annual Report 2005
department and following acute myocardial infarction. Can J Cardiol 2005;21(Suppl B):61B-66B. • Mitchell B, Crystal E, Heilbron B, Page P. Atrial fibrillation following cardiac surgery. Can J Cardiol 2005;21(Suppl B):45B-50B. Humphries, Dr. Karin Kerr CR, Humphries KH, Taljic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, Dorian P, Newman D, Mooney S, Spinelli J. Rate of Progression and Predictors of Progression of Paroxysmal to Chronic Atrial Fibrillation Following the Initial Diagnosis of Paroxysmal Atrial Fibrillation: Results from the Canadian Registry of Atrial Fibrillation (CARAF) Am Heart J 2005;149(3):489-96. Humphries KH, Carere RG, Izadnegahdar M, Galbraith PD, Knudtson ML, Ghali WA. Cross-Provincial Utilization of Cardiac Services: The Importance of Data Sharing for Clinical Registries and Outcomes Research. Can J Cardiol 2005;21(3):267-72. Kerr, Dr. Charles R Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, Dorian P, Newman D. Progression to chronic atrial fibrillation following the intitial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149:489-496. McNeil E, Gagnon RE, Potts JE, Yeung-Lai-Wah JA, Kerr CR, Sanatani S. Cerebral oxygenation during defibrillator threshold testing of implantable cardioverter defibrillators. PACE 2005; 28:528- 533. Kerr CR, Roy D. Canadian Cardiovascular Society 2004 Consensus Conference: Atrial Fibrillation. Can J Cardiol 2005; 21(Suppl B):5B-73B. Gillis AM, Kerr CR, Crystal E. Pacing for the prevention of atrial fibrillation. Can J Cardiol 2005; 21 (Suppl B):41B-44B. Barlow MA, Qi A, Klein GJ, Boone JB, Connolly SH, Dorian P, Green M, Krahn AD, Talajic M, Sheldon R, Yee R, Kerr CR. Lone atrial fibrillation. Long-term clinical and echocardiographic follow-up. Under Revision. Mancini, Dr. G B John Mancini GBJ. The 'double dip' hypothesis: Simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockers. Can J Cardiol 2005;21(6):519-523. Mancini GBJ, Khalil N. Angiotensin II Type 1 Receptor Blocker Inhibits Pulmonary Injury. Clin Invest Med 2005;28(3):118-126. The Occluded Artery Trial (OAT) Research Group (Mancini GBJ, member). Design and methodology of the Occluded Artery Trial (OAT). Am Heart J 2005;150:627-42. Douglas J, Holmes D, Kereiakes D, Grines C, Block E, Ghazzal ZMB, Morris D, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GBJ, Weintraub W, for the Cilostazol for Restenosis Trial (CREST) Investigators. Coronary Stent Restenosis in Patients Treated With Cilostazol. Circulation, 2005;112:2826-2832. (accompanied by Editorial: Schömig, A, Kastrati A, Wessely R. Prevention of Restenosis by Systemic Drug Therapy. Back to the Future? Circulation, 2005;112:2759-2761).
Rabkin, Dr. Simon Kong JY, Klassen SS, Rabkin SW. Ceramide activates a mitochondrial p38 mitogen-activated protein kinase: a potential mechanism for loss of mitochondrial transmembrane potential and apoptosis. Molecular and Cellular Biochemistry 2005;278(1-2):39-51. Rabkin SW. The association of hypertension and aortic valve sclerosis. Blood Pressure 2005;14(5):264-72.
UBC Department of Medicine Page 156 Annual Report 2005
Kong JY, Klassen SS, Rabkin SW. The association of RhoB with caspase-2: Changes with lovastatin- induced apoptosis. Biochem and Cell Biology 2005;83(5):608-19. Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, Leiter LA, Lebel M, Herbert C, Schiffrin EL, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Dechamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Campbell NR, Arnold M, Moe G, Hill MD, Jones C, Larochelle P, Ogilvie RI, Tobe S, Houlden R, The Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol. 2005 Jun:21(8):657-72. Saw, Dr. Jacqueline Casserly IP, Abou-Chebl A, Fathi RB, Lee DS, Saw J, Exaire JE, Kapadia SR, Bajzer CT, Yadav JS. Slow-flow phenomenon during carotid artery intervention with embolic protection devices: predictors and clinical outcome. JACC 2005;46(8):1466-72. Abramson BL, Huckell V, Anand S, Forbes T, Gupta A, Harris K, Junaid A, Lindsay T, McAlister F, Roussin A, Saw J, Teo KK, Turpie AG, Verma S. Canadian Cardiovascular Society Consensus Conference: Peripheral Arterial Disease – Executive Summary. Can J Cardiol 2005;21(12):997-1006. Straatman, Dr. Lynn Malek F, Kaan A, Straatman L, Cheung A, Ignaszewski A. Timing of the first endomyocardial biopsy in heart transplantation after induction immunosuppressive therapy – experience from Canadain Heart Transplant Center. Cas Lek Cesk. 2005;144(8):507-9; discussion 509. Samman A, Imai C, Straatman L, Frolich J, Humphries K, Ignaszewski A. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. J Heart Lung Transplant 2005 Aug 24(8):1008-13. Webb, Dr. John G Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy 2005 Aug; 25(8):1095-103. Shalansky St, Pate G, Levin A, Webb J. N-acetylcysteine for prevention of radiocontrast-induced nephrotoxicity: The importance of dose and route of administration. Heart 2005; 91:997-999. Pate G, Munt B, Webb JG. Percutaneous closure of an aortic prosthetic paravalvular leak. Cathet Cardiovasc Interv 2005; 65:69-72. Stone GW, Webb JG, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff M, Gibbons R, Jones D, Lansky AJ. A randomized, controlled trial of distal microcirculatory protection during primary angioplasty in acute myocardial infarction. JAMA 2005; 293: 1063-72. Chandavimol M, McClure SJ, Carere R, Thompson CR, Ricci DR, MacKay M, Webb JG. Percutaneous aortic valve implantation: a case report. Can J Cardiol 2005 Pate GE, Wu V, Webb JG. Nickel Allergy: lack of correlation between systemic TH1 immune response and skin patch testing. J Invasive Cardiol 2005;17:574. Webb JG, Chandavimol M, Hamburger JN, Page G, Mc Manus B, Krucoff M, Mancini GBJ. Initial experience with a novel coronary rinsing and thrombectomy system.
CRITICAL CARE Dodek, Dr. Peter M Heyland DK, Groll D, Rocker G, Dodek P, Gafni A, Tranmer J, Pichora D, Lazar N, Kutsogiannis J, Shortt S, Lam M, for the Canadian Researchers at the End of Life Network (CARENET). End of Life
UBC Department of Medicine Page 157 Annual Report 2005
Care in Acute Care Hospitals in Canada: A Quality Finish? Journal of Palliative Care. 21:142-150, 2005. Keenan, Dr. Sean P Keenan SP, Powers C, McCormack DG. Nonivasive ventilation in milder COPD exacerbations: an RCT. Respiratory Care 2005 May;50(5):610-6. Alvarez CM, Tredwell S, Keenan SP, Beauchamp R, De Vera M, Choit R. Treatment of Idiopathic Clubfoot utilizing Botulinum A Toxin: a new method and its short term outcome. J Ped Ortho 2005 Mar-Apr;25(2):229-35. Russell, Dr. James A Sutherland AM, Walley KR, Manocha S, Russell JA. Interleukin 6 haplotype clades associated with increased mortality in critically ill adults. Arch Int Med 2005; 165: 75 - 82. Prasongsukarn K, Abel JG, Jamieson WRE, Cheung A, Russell JA, Walley KR, Lichtenstein SV. The effects of steroid on the occurrence of atrial fibrillation after coronary artery bypass grafting surgery. A prospective randomized trial. J Thorac Cardiovasc Surg 2005;130(1): 93-98 Sutherland A, Manocha S, Walley K, Russell JA. CD 14, mannose binding lectin and TLR 2 in severe sepsis. Crit Care Med 2005; 33:(3):638-644. Sutherland A, Russell JA. Issues with polymorphism analysis in sepsis. Clin Inf Dis 2005;41 (Suppl 7):S396-402 Wattanathum A, Manocha S, Russell JA, Walley KR. IL-10 haplotypes are associated with higher mortality in critically ill patients with pneumonia but not extra-pulmonary sepsis. Chest 2005; 128:1690-1698 Shaw D, Russell JA, Walley KR. Genetics of sepsis. Drug Development Reviews 2005;64: 181-194 Levy MM, Macias WL, Vincent J, Russell JA, Silva E, Trzaskoma BL, Willliams MD. Early changes in organ function predicts eventual survival in severe sepsis. Crit Care Medicine 2005; 33 (10): 2194- 2201. Tsang, Dr. John Y Tsang JY, Lamm WJE, Starr IR, Hlastala MP. Spatial pattern of ventilation perfusion mismatch following acute pulmonary thromboembolism in pigs. J Appl Physiol 2005; 98:1862-1898. Walley, Dr. Keith R Sutherland AM, Walley KR, Manocha S, Russell JA. Interleukin-6 haplotype clades associated with increased mortality in critically ill patients. Arch In Med 33(3):638-644, 2005. Sutherland AM, Walley KR, Russell JA. Polymorphisms in CD14, Mannose Binding Lectin and TLR2 are Associated with Increased Prevalence of Infection in Critically Ill Adults. Crit Care Med 33(3):638-644, 2005. Wattanathum A, Manocha S, Groshaus H, Russell JA, Walley KR. IL-10 Haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients extrapulmonary sepsis. Chest. 128(3):1690-8, 2005. Prasongsukarn K, Abel JG, Jamieson WR, Cheung A, Russell JA, Walley KR, Lichtenstein SV. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: A prospective randomized trial. J Thorac Cardiovasc Surg. 130(1):93-8, 2005. Shaw D, Russell JA, Walley KR. Pharmacogenomics in sepsis and septic shock. Drug Dev Res. 64:181-194, 2005. Walley KR. Microvascular resuscitation as a therapeutic goal in severe sepsis. Crit Care 9 Suppl 4:S27-32, 2005.
UBC Department of Medicine Page 158 Annual Report 2005
DERMATOLOGY Carruthers, Dr. Alastair Dover JS, Carruthers A, Carruthers J, Alam M. Clinical use of Restylane. Advances in Dermatologic Surgery 2005. Maddin S (Ed), Skin Therapy Letter, Vol. 10(1). Hong, Dr. Chih-ho H Silver SG, Hong C, Ting PT, Ball NJ. Kikuchi-Fujimoto's necrotizing lymphadenitis in association with discoid lupus erthematosus: A case report. J Cutan Med Surg 2005; Sprnger-Verlag (published online July 7/05). Silver SG, Hong HC, Ting PT, Ball NJ. "Kikuchi-Fujimoto's necrotizing lymphadenitis in association with discoid lupus erythematosus: A case report." J Cutan Med Surg 2005; 8(6):442-445.
Ho, Dr. Vincent Zhou Y, Dai D, Martinka M, Su M, Zhang Y, Campos E, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005. Lynde C, Barber K, Claveau J, Gratton D, Ho V et al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg 2005 (published online June 30/05). Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V et al. Integrating biologic agents into management of moderate-to-severe psoriasis: A consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg 2005 (published online May/05). Li, Dr. Gang Qiang L, Campos EI, Xiao H, Ho VC, Li G. Development of a pan-specific, affinity-purified anti-acetylated lysine antibody for detection, identification, isolation and intracellular localization of acetylated protein. J Immunoassay & Immunochem 2005;26:13-23. Karst AM, Dai DL, Martinka M, Li G. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 2005; 24:1111-1116. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: A clinicopathological study of 292 cases. J Clin Oncol 2005; 23:1473-1482. (Highlighted in Nature Clinical Practice Oncology Vol. 2, p280). Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Nelson C, Ho V, Li G. Osteopontin expression correlates with melanoma invasion and promotes cell growth. J Invest Dermatol 2005; 124:1044-1052. Lui, Dr. Harvey Hamzavi I, LUI H. Using light in dermatology: An update on lasers, ultraviolet phototherapy, and photodynamic therapy. Dermatol Clin 2005; 23:199-207. Alajlan A, Shapiro J, Rivers JK, MacDonald N, Wiggin J, LUI H. Paradoxical hypertrichosis and pseudo-hypertrichosis following laser epilation. J Am Acad Dermatol 2005; 53:85-88. Lau DP, Huang Z, LUI H, Anderson DW, Berean K, Morrison MD, Shen L, Zeng H. Raman spectroscopy for optical diagnosis in the larynx: preliminary findings. Lasers Surg Med 2005; 37:192-200. McElwee, Dr. Kevin J McElwee KJ, Freyschmidt-Paul P, Hoffmann R, Kissling S, Hummel S, Vitacolonna M, Zöller KJM. Transfer of CD8+ cells induce localized hair loss while CD4+/CD25- cells promote systemic alopecia areata and CD4+/CD25+ cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol 2005; 124: 947-57. PMID: 15854035. McElwee KJ, Yu M, Park SW, Ross EK, Finner A, Shapiro J. What can we learn from animal models of alopecia areata? Dermatology 2005; 211: 47-53. PMID: 15983437.
UBC Department of Medicine Page 159 Annual Report 2005
Freyschmidt-Paul P, McElwee KJ, Hoffmann R, Sundberg JP, Kissling S, Hummel S, Vitacolonna M, Kopp-Schneider A, Zoller M. Reduced Expression of Interleukin-2 Decreases the Frequency of Alopecia Areata Onset in C3H/HeJ Mice. J Invest Dermatol 2005; 125: 945-51. PMID: 16297194. McLean, Dr. David I Huang Z, LUI H, McLean DI, Korbelik M, Zeng H. Raman spectroscopy in combination with background near-infrared autofluorescence enhances the in vivo assessment of malignant melanoma. Photochem Photobiol 2005;81:1219-1226. Rivers, Dr. Jason K Tyler I, Rivers JK, Shoveller JA, Blum A. Melanoma detection in British Columbia. J Am Acad Dermatol 2005;52(1):48-54. Somani N, Rivers JK. Imiquimod 5% cream for the treatment of Actinic Keratoses. Skin Therapy Lett. 2005;10(2):1-6. Lee TK, Rivers JK, Gallagher RP. Site-specific protective effect of broad-spectrum sunscreen on nevus development among white schoolchildren in a randomized trial. J Am Acad Dermatol 2005;52:786-92. Alajlan A, Shapiro J, Rivers JK, MacDonald N, Wiggin J, Lui H. Paradoxical hypertrichosis after laser epilation. J Am Acad Dermatol 2005; 53:85-88. Shapiro, Dr. Jerry Ross EK, Shapiro J. Management of hair loss. Dermatologic Clinics 2005;23(2):227-43. Olsen EA, Messenger AG, Shapiro J, Bergfeld, MD, Hordkinsky MK et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005;52:301-11. Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol 2005;53(1):1-37; quiz 38-40. Alajlan A, Shapiro J, Rivers JK, MacDonald N, Wiggin J, Lui H. Paradoxical hypertrichosis and pseudo-hypertrichosis following laser epilation. J Am Acad Dermatol 2005; 53:85-88. Park SW, Yong SL, Martinka M, Shapiro J. Rapp-Hodgkin syndrome: A review of the aspects of hair and hair color. J Am Acad Dermatol 2005;53(4):729-35. Zhou, Dr. Youwen Zhou Y, Dai D, Martinka M, Su M, Zhang Y, Campos E, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho, V, Li G. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005. Afifi T, de Gannes G, Huang C, Zhou Y. Topical therapies for psoriasis. Evidence-based review. Can Fam Physician 2005;51:519-525. Zloty, Dr. David M Cohen JL, Barankin B, Zloty DM, Mikhail GR. Metastatic zosteriform squamous cell carcinoma in an immunocompetent patient. J Cutan Med 2005 (published online July 7/05). Murray CA, Zloty D, Warshawski L. The evolution of soft tissue fillers in clinical practice. Dermatologic Clinics 2005; 23(2): 343-363.
ENDOCRINOLOGY Finegood, Dr. Diane T Maree AF, Kublik R, Finegood DT, Edelstein-Keshet L. Modelling the onset of type 1 diabetes: Can impaired macrophage phagocytosis make the difference between health and disease? Philosophical Transactions of the Royal Society A on Biomathematical Modelling. 233: 533-551, 2005. Maree AF, Komba M, Dyck C, Labecki M, Finegood DT, Edelstein-Keshet L. Quantifying macrophage defects in type 1 diabetes. J Theor Biol. 233: 533-551, 2005. UBC Department of Medicine Page 160 Annual Report 2005
Fung, Dr. Michelle A Warnock GL, Meloche RM, Thompson D, Shapiro RJ, Fung M, Ao Z, Ho S, He Z, Dai LJ, Young L, Blackburn L, Kozak S, Kim PT, Al-Adra D, Johnson JD, Liao YH, Elliott T, Verchere CB. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus. Archives of Surgery. 140(8):735-44, Aug 2005. Gill, Dr. Sabrina Wesley JK, Singer J, Gill S, Kreisman S, Mase MR, Antoinette B, Pottinger M, Tildesley HD: The Clinical Utility of a Non-Mydriatic Retinal Camera in a Diabetes Clinic. International J Endocrinology & Metabolism 2005;2:74-79. Kendler, Dr. David L Anthony B. Hodsman, Douglas C. Bauer, David Dempster, Larry Dian, David A. Hanley, Steven T. Harris, David Kendler, Michael R. McClung, Paul D. Miller, Wojciech P. Olszynski, Eric Orwoll, and Chui Kin Yuen. Parathyroid Hormone and Theriparatide for the Treatment of Osteoporosis: A Review Of The Evidence And Suggested Guidelines For Its Use. Endocr Rev e-published March 15, 2005.
Prior, Dr. Jerilynn C Prior JC. Ovarian Aging and the Perimenopausal Transition-the paradox of endogenous ovarian hyperstimulation. Endocrine. 26 (3): 297-300 Apr 2005. Papaioannou A, Joseph L, Ioannidis G, Berger C, Anastassiades T, Brown J P, Hanley D A, Hopman W, Josse R G, Kirkland S, Murray T M, Olszynski W, Pickard L, Prior J C, Siminoski K, Adachi J D, CaMOS Research Group. Risk Factors Associated with Incident Clinical Vertebral and Non-Vertebral Fractures in Postmenopausal Women: The Canadian Multicentre Osteoporosis Study (CaMOS). Osteoporos Int. 2005 May;16(5):568-578. Epub 2004 Oct 27. Sawka A M, Thabane L, Papaioannou A, Gafni A, Ioannidis G, Papadimitropoulos EA, Hopman WM, Cranney, Hanley DA, Pickard L, Adachi JD, Prior, JC.CaMOS Canadian Multicentre Osteoporosis Study. Health-Related Quality of life measurements in elderly Canadians with osteoporosis compared to other chronical medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporosis International Online Aug 18, 2005. Prior JC. Clearing confusion about Perimenopause. BC. Med J. 2005, 47(10): 534-538. Prior JC. Premenopausal Osteoporosis. The Female Patient. 2005, 30:45-48. Sirrs, Dr. Sandra M Bennett MT, Sirrs S, Yeung JK, and Smith CA. Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole. Leukemia and Lymphoma. 2005;46(12):1829-31. Tildesley, Dr. Hugh D The Clinical Utility of a Non-Mydriatic Camera in a Diabetes Clinic. Johns K, Singer J, Gill S, Kreisman S, Mase R, Pottinger B & Tildesley H. International Journal of Endocrinology and Metabolism, June 2005 Vol 3, No 2 pp. 74-79. Metformin’s Contraindications Should be Contraindicated. McCormack J, Johns K, Tildesley H. Canadian Medical Association Journal. Vol 173, No 5, August 30, 2005, pp. 502-504. Wilkins, Dr. Graeme E Piper H, Bugis S, Wilkins G, Walker B, Wiseman S, Baliski C. Detecting and Defining Hypothyroidis after Hemithyroidectomy. American Journal of Surgery 189: 587-591, 2005.
UBC Department of Medicine Page 161 Annual Report 2005
GASTROENTEROLOGY Bressler, Dr. Brian Bressler B, El-Ashry D, Pinto R, Heathcote EJ. Which Patients with Primary Biliary Cirrhosis or Primary Sclerosing Cholangitis Should Undergo Endoscopic Screening for Esophageal Varices Detection? Gut. 2005 Mar;54(3):407-10. Byrne, Dr. Michael F
Ho JK, Byrne MF. What's up in GERD? Canadian Journal of Diagnosis 2005, March, pp. 71-73. Fishman, Dr. Martin J Andrews CN, Levy A, Fishman M, et al. Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: A multicentre comparative study. Can J Gastro 2005; 19(11):667-71. Freeman, Dr. Hugh J Freeman HJ. Collagenous mucosal inflammatory disorders of the gastrointestinal tract. Gastroenterology 2005; 159:338-350. Freeman HJ. Crohn’s disease in the eighth decade in three sisters. Can J Gastroenterol 2005; 19; 251-252. Freeman HJ, Flak B. Demyelination-like syndrome in Crohn’s disease after infliximab therapy. Can J Gastroenterol 2005; 19: 313-316. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn’s disease. Can J Gastroenterol 2005; 19:603-606. Freeman HJ. Lymphoproliferative disorders in collagenous colitis. Inflamm Bowel Dis 2005; 11:781-782. Freeman HJ. Endoscopic excision of a prolapsing malignant polyp which caused intermittent gastric outlet obstruction. World J Gastroenterol 2005; 11: 5245-5247. Freeman HJ. Long-term clinical behavior of jejunoileal involvement in Crohn's disease. Can J Gastroenterol 2005; 19:575-578. Freeman HJ. C-ANCA/PR-3 positive colitis may be a distinctive form of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2005; 41:135. Freeman HJ, Noble MA. Lack of evidence for Mycobacterium avium subspecies paratuberculosis in Crohn's disease. Inflamm Bowel Dis 2005; 11:782-783. Freeman HJ. Age-dependent phenotypic clinical expression of Crohn's disease. J Clin Gastroenterol 2005; 774-777. Ramji, Dr. Alnoor Chatur N, Ramil A, Bain V, Ma M, Marotta P, Ghent C, Lilly L, Heathcote J, Deschenes M, Lee S, Steinbrecher U, Yoshida E. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: The Canadian Association for the study of the Liver (CASL) experience with Mycophenolate Mofetil and Tacrolimus. Liver International. 2005 Aug;25(4):723-7. Salh, Dr. Baljinder Singh Gomez-Munoz A, Kong JY, Parhar K, Wang SW, Gangoiti P, Gonzalez M, Eivemark S, Salh B, Duronio V, Seinbrecher UP. Ceramide 1 phosphate promotes cell survial through activation of the phosphatidylinositol 3-kinase/protein kinase B pathway. FEBS Lett 2005; 579:3744-50.
Tai, Dr. Isabella T Tai IT, M Dai and LB Chen. Periostin induction in tumor cell line explants and inhibition of in-vitro cultured cell growth by anti-periostin antibodies. Carcinogenesis, 2005; 26(5):908-15.
UBC Department of Medicine Page 162 Annual Report 2005
Tai IT, M Dai, DA Owen and LB Chen. Genome-wide expression analysis of therapy resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest, 2005; 115(6):1492-1502. Yoshida, Dr. Eric M Tung D, Yoshida EM, Wang CSK, Steinbrecher UP. Severe Desflurane Hepatotoxicity after Colon Surgery in an Elderly Patient. Canadian Journal of Anaesthesia 2005; 52:133-136. Arbour L, Field L, Ross PL, Erikson A, Henderson H, Rupps R, Yoshida EM. Characteristics of Primary Biliary Cirrhosis in British Columbia's First Nations People. Canadian Journal of Gastroenterology 2005; 19: 305-10 Ho SGF, Phillips AJ, Legiehn GM, Yoshida EM, Davis JE, Chung SW, Scudamore CH. Recurrent Hepatocellular Carcinoma after Liver Transplantation Mimicking Post-Transplant Lymphoproliferative Disease. Australasian Radiology 2005; 49: 315-18. Farley JD, Wong VK, Chung HV, Lim E, Walters G, Farley TA, Yoshida EM. Treatment of Chronic Hepatitis C in Canadian Prison Inmates. Canadian Journal of Gastroenterology 2005; 19:153-56. Ho JK, Tha SPL, Coupland R, Dalal BI, Bowie WR, Sreenivasan GM, Krajden M, Yoshida EM. Parovirus B19 in an Immunocompetent Patient with Acute Liver Dysfunction: An Underdiagnosed Cause of Acute Non-A-E Viral Hepatitis. Canadian Journal of Gastroenterology 2005; 19:19: 161-62. Chatur N, Ramji A, Bain VG, MA MM, Marotta PJ, Ghent CN, Lilly LB, Heathcote EJ, Deschenes M, Lee SS, Steinbrecher UP, Yoshida EM. Transplant Immunosuppressive Agents in Non-Transplant Chronic Autoimmune Hepatitis: the Canadian Association for the Study of Liver (CASL) Experience with Mycophenolate Mofetil & Tacrolimus. Liver International 2005: 25:723-77. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal Reactivation of Hepatitis B Post-Chemotherapy for Lymphoma in a Hepatitis B Surface Antigen Negative, Hepatitis B Core Antibody Positive Patient: Potential Implications for Future Prophylaxis Recommendations. Leukemia & Lymphoma 2005: 46: 1085-89 Cheung J, Lee TK, The C-Z, Wang CYM, Kwan WCP, Yoshida EM. Cross-Sectional Study of Hepatitis B Awareness among Chinese and Asian-Canadians in the Vancouver-Richmond Community. Canadian Journal of Gastroenterology 2005; 19: 245-49. Wong VK, Cheong-Lee C, Ford JE, Yoshida EM. Acute Sensorineural Hearing Loss Associated with Peginterferon & Ribavirin Combination Therapy During Hepatitis C Treatment: Outcome after Resumption of Therapy. World Journal of Gastroenterology 2005; 34: 5392-93. Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Peltekian KM, Cantarovich M, Lilly B, Scudamore CH, Bain VG, Wall WJ, Balshaw RF, Barkun JST. Evaluation of Renal Function in Lver Transplant Recipients Receiving Daclizumab (Zenapax) and Mycophenolate Mofetil and a Delayed, Low-Dose Tacrolimus Regimen versus a Standard Dose Tacrolimus-based Regimen. Liver Transplantation 2005; 11: 1064-72. Greanya ED, Partovi N, Conci M, Shapiro RJ, Yoshida EM, Levy RD, Sherlock CH, Stephens GM. Role of Cytomegalovirus (CMV) Antigenemia Assay for Detection of Presence of CMV Syndrome/Disease after Solid Organ Transplantation: A Review of the British Columbia Experience. Canadian Journal of Infectious Diseases & Medical Microbiology 2005; 16: 335-41. Ghali P, Marotta PJ, Yoshida EM, Vincent GB, Marleau D, Peltekian K, Metrakos P, Deschenes M. Liver Transplantation for Incidental Cholangiocarcinoma: Analysis of the Canadian Experience. Liver Transplantation 2005; 11: 1412-16.
GENERAL INTERNAL MEDICINE Broder, Dr. Sarah S Broder. Jumping to conclusions: Things are never what they seem. Can Respir J 2005;12(3): 149- 150.
UBC Department of Medicine Page 163 Annual Report 2005
Dunne, Dr. James V Prevalence of elevated pulmonary arterial pressures measured by Echocardiography in a Multicentre study of patients with systemic sclerosis. Pope JE, Lee P, Baron M, Dunne J, Smith D, et al. J Rheum, 2005; 32:1273-8. Hatala, Dr Rose Hatala R, Keitz S, Wyer P, Guyatt G, et al. Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ 2005; 172:661-665. Hatala R, Kassen BO, Nishikawa J, Cold G, Issenberg SB. Incorporating simulation technology in a Canadian national specialty examination: a descriptive report. Academic Medicine. 2005;80(6):554- 6.
Holmes Boulton, Dr. Cheryl L Holmes CL. Vasoactive Drugs in the Intensive Care Unit. Current Opinion in Critical Care 2005; 11:413-417. Kassen, Dr. Barry O Hatala R, Kassen BO, Nishikawa J, Cole G, Issenberg SB. Incorporating Simulation Technology in a Canadian Internal Medicine Specialty Examination: A Descriptive Report. Acad Med. 2005 Jun;80(6):554-6. Khan, Dr. Nadia A N Khan, D Wardman, NR Campbell. Differences in need for antihypertensive drugs among those aware and unaware of their hypertensive status: a cross sectional survey. BMC Cardiovasc Disord. 2005 Feb 3;5(1):4. Khan N, Finlay A. McAlister, Norman RC Campbell, Ross D Feldman, Jeff Mahon, Richard Lewanczuk, Simon W Rabkin, Kelly B. Zarnke, Brenda Hemmelgarn, Marcel Lebel, Mitchell Levine, Carol Herbert, for the Canadian Hypertension Education Program. The 2005 Canadian Recommendations for the Management of Hypertension: Therapy. Canadian Journal of Cardiology. 2005; 20(1):31-40. Ma, Dr. Irene W Gill JS, Ma I, Landsberg D, Johnson N, Levin A. Cardiovascular events and investigations in patients awaiting cadaveric kidney transplantation. Journal of the American Society of Nephrology 16(3):808-16, 2005. Cowie SE, Ma I, Lee SK, Smith RM, Hsiang YN. Nosocomical MRSA infection in vascular surgery patients: impact on patient outcome. Vasc Endovascular Surg. 2005 Jul-Aug;39(4):327-34. Magee, Dr. Laura A Hayter MA, Anderson L, Claydon J, Magee LA, Little R, Liston RM, Lee SK, von Dadelszen P, and the Canadian Neonatal Network. Variations in early and intermediate neonatal outcomes for inborn infants admitted to a Canadian NICU and born of hypertensive pregnancies. JOGC 2005;27(1):25-32. Magee LA, Miremadi S, Li J, Cheng C, Ensom M, Carleton B, Coté AM, von Dadelszen P. Does therapy with both MgSO4 and nifedipine increase the risk of Mg-induced neuromuscular weakness in women with preeclampsia? Am J Obstet Gynecol 2005;193:153-63. Goswami D, Tannetta D, Magee LA, Fuchisawa A, Redman CWG, Sargent IL, von Dadelszen P. Excess syncytiotrophoblast microparticle shedding is a feature of pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 2005;27:56-61. Magee LA, Côté AM, von Dadelszen P. Nifedipine for severe hypertension in pregnancy: emotion or evidence? JOGC 2005;27(3):260-262.
UBC Department of Medicine Page 164 Annual Report 2005
von Dadelszen P, Magee LA, Taylor EL, Muir JC, Stewart SD, Sherman P, Lee SK for the Canadian Neonatal Network. Maternal hypertension and neonatal outcome among small for gestational age infants. Obstet Gynecol 2005;106(2):335-339 [Reported in Reuters Health 08-04-2005 13:15:11 – 0400 by W Boggs]. von Dadelszen P, Menzies J, Magee LA. The complications of hypertension in pregnancy. Minerva Medica 2005;96(4):287-302. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy (Cochrane Review). In: The Renal Health Library, 2005. Oxford: Update Software Ltd. Available from http://www.update-software.com. (Reprinted from The Cochrane Library, Issue 2, 2005. Chicester, UK: John Wiley & Sons, Ltd.) von Dadelszen P, Magee LA. Antihypertensive medications in management of gestational hypertension-preeclampsia. Clin Obstet Gynecol 2005;48(2):441-59. Palepu, Dr. Anita Kuyper LM, Palepu A, Kerr T, Li K, Miller CL, Spittal PM, Hogg RS, Montaner JSG, Wood E. Factors associated with sex-trade involvement among injection drug users in a Canadian setting. Addiction Research and Theory 2005; 13(2):193-199. Palepu A, Raj A, Horton NJ, Tibbetts N, Meli S, Samet JH. Substance abuse treatment and risk behaviors among HIV-infected persons with alcohol problems. Journal of Substance Abuse Treatment 2005;28(1):3-9. Palepu A, Horton NB, Tibbetts N, Meli Seville, Samet JH. Substance abuse treatment and hospitalization among a cohort of HIV-infected persons with alcohol problems. Alcohol and Clinical Experimental Medicine 2005;29(3):389-94. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naïve HIV-infected injection drug users. AIDS 2005; 19(8):837-839. Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, Hogg R, Wood E. Determinants of HAART discontinuation among injection drug users. AIDS Care 2005; 17(5):539:549. Wood E, Li K, Palepu A, Marsh DC, Schechter MT, Hogg RS, Montaner JSG. Socio-demographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users. Substance Use and Misuse 2005; 40(8): 1153-67. Wood E, Kerr T, Palepu A, Zhang R, Strathdee SA, Tyndall MW, Montaner JS, Hogg RS. Slower uptake of HIV antiretroviral therapy by Aboriginal drug users. Journal of Infection 2005; Sept 16 E-publication ahead of print. Hubley A, Russell LB, Palepu A. Injection Drug use Quality of Life scale (IDUQOL): A validation study. Health and Quality of Life Outcomes 2005: 19; 3(1):43.
GERIATRIC MEDICINE Lee, Dr. Philip E Sundeep S, Gill A, Rochon A, Hermann N, Lee PE, Sykora K, Gunraj N, Normand S-L, Gurwitz JH, Marras C, Wodchis WP, Mamdani M. Atypical Antipsychotic Drugs and Risk of Ischemic Stroke: Population Based Retrospective Cohort Study. BMJ Feb 26th, 2005; 330(7489):445.
Madden, Dr. Kenneth M. Madden KM, Levy WC, Stratton JK. Exercise training and heart rate variability in older adult female subjects. Clinical Investigative Medicine. 2006; 29(1):20-8. McElhaney, Dr. Janet E McElhaney JE, Hooton JW, Hooton N Bleackley. Effect of booster versus single dose influenza UBC Department of Medicine Page 165 Annual Report 2005
vaccination on humoral and cellular immune responses. Vaccine 23:3294-3300, 2005. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine. 2005 Jul 8;23 Suppl 1:S10-25. Gravenstein S, Drinka P, Osterweil D, Schilling M, Krause P, Elliott M, Shult P, Ambrozaitis A, Kandel R, Binder E, Hammond J, McElhaney J, Flack N, Daly J, Keene O. Inhaled Zanamivir Versus Rimantadine for the Control of Influenza in a Highly Vaccinated Long-term Care Population. Journal of the American Medical Directors Association. 2005; 6(6):359-66. Meneilly, Dr. Graydon S Trimble LA, Sundberg S, Markham L, Janicijevic S, Beattie BL, Meneilly GS. Older Adults / Value of the clock test to predict problems with insulin skills. Canadian Journal of Diabetes 29:102-103 (2005). Meneilly GS, Elahi D. Metabolic alterations in middle-aged and elderly lean patients with type 2 diabetes. Diabetes Care 28:1498-1499 (2005). Meneilly GS. Diabetes is common in elderly persons. Journal of Gerontology 60:1145-1146 (2005) Meneilly GS, Veldhuis JD, Elahi D. Deconvolution analysis of rapid insulin pulses before and after 6 weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes. J Clin Endocrinol Metab 90:6251-6256 (2005). Meneilly GS. Should subclinical hypothyroidism in elderly patients be treated? CMAJ 172:633 (2005). Wong, Dr. Roger Y Wong RYM. A practical approach to advanced Alzheimer's disease. BC Medical Journal 2005; 47(9): 494-498.
HEMATOLOGY Barnett, Dr. Michael J Eisterer W, Jiang X, Christ O, Glimm H, Lee K, Pang E, Lambie K, Shaw G, Holyoake TL, Petzer Al, Auewarakul C, Barnett MJ, Eaves CJ & Eaves AC. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19: 435-441, 2005. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA & Lipton J. Myeloablative allografting for chronic lymphocytic leukemia and prolymphocytic leukemia: Evidence for a potent graft-versus-leukemia effect associated with chronic graft-versus-host disease. Bone Marrow Transplant 36: 825-830, 2005. Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotranplants for Acute Myeloid Leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Gordon AC, Oakervee HE, Kaya B, Thomas JM, Barnett MJ, Rohatiner AZS, Lister TA, Cavenagh JD, Hinds CJ. Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care. Anaesthesia 60: 340-347, 2005. Lavoie JC, Connors JM, Phillips G, Reece D, Barnett MJ, Forrest D, Gascoyne R, Hogge D, Nantel SH, Shepherd JD, Smith C, Song KW, Sutherland H, Toze C, Voss NJ, Nevill T. Ten-year follow-up of patients having received high-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin's disease. Blood 106: 1473-1478, 2005.
UBC Department of Medicine Page 166 Annual Report 2005
Forrest DL, Hogge DE, Nevill TJ, Lavoie JC, Nantel SH, Barnett MJ, Shepherd JD, Smith CA, Song KW, Sutherland H, Toze CL, Voss NJ, Gascoyne R, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005.
Eaves, Dr. Allen C Chalandon Y, Jiang X, Christ O, Loutet S, Thanopoulou E, Eaves A & Eaves C. BCR-ABL- transduced human cord blood cells produce abnormal populations in immunodeficient mice. Leukemia 19: 442-448, 2005. Eisterer W, Jiang X, Christ O, Glimm H, Lee K, Pang E, Lambie K, Shaw G, Holyoake TL, Petzer AL, Auewarakul C, Barnett MJ, Eaves CJ & Eaves AC. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19: 435-441, 2005. Peters CE, Woodside SM & Eaves AC. Isolation of subsets of immune cells. Methods Mol Biol 302: 95-116, 2005. Forrest, Dr. Donna L Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotranplants for Acute Myeloid Leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase risk of second neoplasms for patients with Hodgkin’s Lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJS, Nevill TJ. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-1478, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-host effect associated with graft-versus-host disease. Bone Marrow Transplant 36: 825-830, 2005. Hogge, Dr. Donna Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of
UBC Department of Medicine Page 167 Annual Report 2005
karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leuk Lymph 46: 525-531, 2005. Lavoie JC, Connors JM, Phillip G, Reece D, Barnett MJ, Forrest D, Gascoyne R, Hogge D, Nantel SN, Shepherd JD, Smith C, Song KW, Sutherland H, Toze C, Voss NJ & Nevill T. Ten-year follow-up of patients having received high-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin's disease. Blood 106: 1473-1478, 2005. Forrest DL, Hogge DE, Nevill TJ, Lavoie JC, Nantel SN, Barnett MJ, Shepherd JD, Smith CA, Song KW, Sutherland H, Toze CL, Voss NJ, Gascoyne R & Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase the risk of second neoplasms for patients with hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-host effect associated with graft-versus-host disease. Bone Marrow Transplant 36: 825-830, 2005. Humphries, Dr. Richard Keith Milson MD, Duxbury R, Gagen D, Humphries RK, Schmidt M, von-Ka C, Fairbairn LJ. Overexpression of HOXB4 confers a myelo-erythroid differentiation delay in vitro. Leukemia 19: 148-153, 2005. Abramovich C & Humphries RK. Hox regulation of normal and leukemic hematopoietic stem cells. Curr Opin Hematol 12: 210-216, 2005. Palmqvist L, Glover CH, Bossen B, Hsu L, Lu M, Piret JM, Humphries RK* & Helgason CD. Correlation of murine embryonic stem cell gene expression profiles with functional measures of pluripotency. Stem Cells 23: 663-680, 2005. (*co-senior author) Pineault N, Abramovich C & Humphries RK. Transplantable cell lines generated with NUP98-Hox fusion genes undergo leukemic progression by Meis1 independent of its binding to DNA. Leukemia 19: 636-643, 2005. Ferrell CM, Dorsam ST, Ohta H, Humphries RK, Derynck MK, Haqq C, Largman C & Lawrence HJ. Activation of stem-cell specific genes by HOXA9 and HOXA10 homeodomain proteins in CD34+ human cord blood cells. Stem Cells 23: 644-655, 2005. Lansdorp, Dr. Peter M Ly H, Calado RT, Allard P, Baerlocher GM, Lansdorp PM, Young NS & Parslow TG. Functional characterization of telomerase RNA variants found in patients with hematological disorders. Blood 105(6): 2332-2339, 2005. Masutomi K, Possemato R, Wong JMY, Currier JL, Tothova Z, Manola JB, Ganesan S, Lansdorp PM, Collins K & Hahn WC. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci USA 102: 8222-8227, 2005. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, Lansdorp PM & Young NS. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352: 1413-1424, 2005. Lansdorp PM. Major cutbacks at chromosome ends. Trends Biochem Sci 30:388-395, 2005. Ly H, Schertzer M, Jastaniah W, Davis J, Yong SL, Ouyang Q, Blackburn EH, Parslow TG & Lansdorp PM. Identification and functional characterization of two variant alleles of the telomerase
UBC Department of Medicine Page 168 Annual Report 2005
RNA template gene (TERC) in a patient with Dyskeratosis Congenita. Blood 106:1246-1252, 2005. Roth A, Baerlocher GM, Schertzer M, Chavez E, Duhrsen U & Lansdorp PM. Telomere loss, senescence and genetic instability in CD4+ T lymphocytes overexpressing hTERT. Blood 106: 43-50, 2005. Zhdanova NS, Karamisheva TV, Minina J, Astakhova NM, Lansdorp PM, Kammori M, Rubtsov NB, Searle JB. Unusual distribution pattern of telomeric repeats in the shrews Sorex araneus and Sorex granarius. Chromosome Res. 13:617-25, 2005. Wang JCY, Warner JK, Erdmann N, Lansdorp PM, Harrington L & Dick JE. Dissociation of telomerase activity and telomere length maintenance in primitive human hematopoietic cells. Proc Natl Acad Sci USA 102: 14398-14403, 2005. Lavoie, Dr. Julye C Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJS, Nevill TJ. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-1478, 2005. Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase risk of second neoplasms for patients with Hodgkin’s Lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-host effect associated with graft-versus-host disease. Bone Marrow Transplant 36: 825-830, 2005. Leitch, Dr. Heather A Leitch HA & Connors JM. Vaccine therapy for non-Hodgkin’s lymphoma and other B-cell malignancies. Curr Opin on Investig Drugs 6: 597-604, 2005. Nantel, Dr. Stephen H Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotranplants for Acute Myeloid Leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase risk of second neoplasms for patients with Hodgkin’s Lymphoma: A comparison of conventional therapy alone versus conventional
UBC Department of Medicine Page 169 Annual Report 2005
therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJS, Nevill TJ. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-1478, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-host effect associated with graft-versus-host disease. Bone Marrow Transplant 36: 825-830, 2005. Nevill, Dr. Thomas J Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA & Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-host effect associated with graft-versus-host disease. Bone Marrow Transplant 36: 825-830, 2005. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ & Nevill TJ. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-1478, 2005. Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotranplants for Acute Myeloid Leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase risk of second neoplasms for patients with Hodgkin’s Lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Schrader, Dr. John W Guo X, Schrader KA, Xu Y & Schrader JW. Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras. Oncogene 24: 2330-42, 2005. McLean G, Torres M, Trotter B, Noseda M, Bryson S, Pai EF, Schrader JW & Casadevall A. A point mutation in the CH3 domain of human IgG3 inhibits antibody secretion without affecting antigen
UBC Department of Medicine Page 170 Annual Report 2005
specificity. Molecular Immunology 42: 1111-9, 2005. McLean GR, Olsen OA, Watt IN, Rathanaswami P, Leslie KB, Babcook JS & Schrader JW. Recognition of HCMV by human primary immunoglobins identifies as innate foundation to an adaptive immune response. J Immunology 174: 4768-78, 2005. Wang B, David M, and Schrader JW. Absence of Caprin-1 results in defects in cellular proliferation. J Immunol 175: 4274-81, 2005. David M, Cochrane CL, Duncan SK, and Schrader JW. Pure lipopolysaccharide or synthetic Lipid A induces activation of p21Ras in primary macrophages through a pathway dependent on Src family kinases and PI3K. J Immunol 175: 8236-41, 2005. Shepherd, Dr. John D Lavoie JC, Connors JM, Phillip G, Reece D, Barnett MJ, Forrest D, Gascoyne R, Hogge D, Nantel SN, Shepherd JD, Smith C, Song KW, Sutherland H., Toze C, Voss NJ and Nevill T. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-1478, 2005. Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotranplants for Acute Myeloid Leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase risk of second neoplasms for patients with Hodgkin’s Lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-host effect associated with graft-versus-host disease. Bone Marrow Transplant 36: 825-830, 2005. van der Holt B, Lowenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, Verhoef GE, Ferrant A, Crump M, Selleslag D, Theobald M, Fey MF, Vellenga E, Dugan M, Sonneveld P. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106: 2646-2654, 2005. Smith, Dr. Clayton A Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase risk of second neoplasms for patients with Hodgkin’s Lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJS, Nevill TJ.
UBC Department of Medicine Page 171 Annual Report 2005
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-1478, 2005. Storms R, Green PD, Safford KM, Niedzwicki D, Cogle CR, Colvin MO, Rice H and Smith C. Distinct human hematopoietic compartments are delineated by expression of aldehyde dehydrogenase and CD34. Blood 106: 95-102, 2005. Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotranplants for Acute Myeloid Leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Bennet M, Sirrs S, Yeung J and Smith C. Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole. Leuk Lymphoma 46: 1829-1831, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-host effect associated with graft-versus-host disease. Bone Marrow Transplant 36: 825-830, 2005. Song, Dr. Kevin W Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotranplants for Acute Myeloid Leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJS, Nevill TJ. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-1478, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s Lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23:7994-8002, 2005. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-host effect associated with graft-versus-host disease. Bone Marrow Transplant 36:825-830, 2005. Song KW, Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant 36:183-191, 2005.
UBC Department of Medicine Page 172 Annual Report 2005
Sreenivasan, Dr. Gayatri M Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, Farinha P, Horsman DE, Gascoyne RD. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clinical Cancer Research 11: 1065-1072, 2005. Ho JK, Tha SP, Coupland R, Dalal BI, Bowie WR, Sreenivasan GM, Krajden M, Yoshida EM. Parvovirus B19 in an immunocompetent adult patient with acute liver failure: an underdiagnosed cause of acute non-A-E viral hepatitis. Can J Gastroenterol 19: 161-2, 2005. Sutherland, Dr. Heather J Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotranplants for Acute Myeloid Leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-host effect associated with graft-versus-host disease. Bone Marrow Transplant 36: 825-830, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest , Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJS, Nevill TJ. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-1478, 2005. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase risk of second neoplasms for patients with Hodgkin’s Lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Toze, Dr. Cynthia L Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplantation 36: 825-830 2005. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem cell transplantation does not increase risk of second neoplasms for patients with Hodgkin’s Lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 23: 7994-8002, 2005. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJS, Nevill TJ. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed
UBC Department of Medicine Page 173 Annual Report 2005
Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-1478, 2005. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131: 223-230, 2005. Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M & Keating A. Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leuk Lymphoma 46: 525-531, 2005. Vickars, Dr. Linda M Rock G, Anderson D, Clark W, Leblond P, Palmer D, Sternbach M, Sutton D, Wells G, members of the Canadian Apheresis Group (including Vickars LM) and members of the Canadian Association of Apheresis Nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. British Journal of Haematology 129: 79-86, 2005.
INFECTIOUS DISEASES Av-Gay, Dr. Yossef Y Karisgot Hestvik AL, Hmama Z, Av-Gay Y (2005). Mycobacterial manipulation of the Host Cell. FEMS Microbiology Reviews, 29:1041-1050. Papavinasasundaram KG, Chan B, Chung JH, Colston MJ, Davis EO, Av-Gay Y. (2005) Delection of the Mycobacterium tuberculosis pknH gene confers a higher bacillary load during chronic phase of infection in BALB/c mice. J Bacteriol, 187:5751-5760. Dosanjh NS, Chung JH, Rawat M, Av-Gay Y. (2005) Thiol Specific Oxidative Stress Response in Mycobacteria. FEMS Microbiology Letters. 249:87-94. Sendide K, Deghmane A, Av-Gray Y, Talal A, Hmama Z. (2005) Mycobacterium bovis BCG Attenuates Surface Expression of Mature Class II Molecules through Interleukin-10-Dependent inhibition of Cathepsin S 3. J Immunology 8:5324-5332. Bowie, Dr. William R Marra F, Patrick DM, White R, Ng H, Bowie WR, Hutchinson JM. Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia. Journal of Antimicrobial Chemotherapy 2005: 55: 95-101. Brunham, Dr. Robert C Rey-Ladino J, Koochesfahani KM, Zaharik ML, Shen C, Brunham R. A live and inactivated chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct. Infection and Immunity. 73.3 (March 2005): 1568- 1577. Pourbohloul B, Meyers LA, Skowronski DM, Krajden M, Patrick DM, Brunham R. Modeling control strategies of respiratory pathogens. Emerging Infectious Diseases 11.8 (Aug 2005) 1249-1256. Cohen CR, Koochesfahani KM, Meier AS, Shen C, Karunakaran K, Ondondo B, Kinyari T, Mugo NR, Nguti R, Brunham R. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon-gamma. Journal of Infectious Diseases. 192.4 (August 2005): 591-599. Jolly, Moffatt, Fast, Brunham. Sexually Transmitted Disease Thresholds in Manitoba, Canada. Annals of Epidemiology. 15.10 (Nov 2005): 781-788.
UBC Department of Medicine Page 174 Annual Report 2005
Brunham RC, Babak P, Mak S, White R and Rekart ML. "The Unexpected Impact of a Chlamydia trachomatis Infection Control Program on Susceptibility to Reinfection.". Journal of Infectious Diseases. 192.10 (Nov 15, 2005): 1836-1844. Brunham RC. "Parran Award Lecture: insights into the epidemiology of sexually transmitted diseases from Ro = betacD.". Sexually Transmitted Diseases. 32.12 (Dec, 2005): 722-724. Lena S, Pourbohloul B, Brunham RC. Effect of Immune Response on Transmission Dynamics for Sexually Transmitted Infections. J Infec Dis 2005 Jan 191 Suppl 1. (Feb 1, 2005): S78-S84. Luo M, Bamforth J, Gill K, Cohen C, Brunham RC, Plummer FA. High resolution sequence-based DPA1 typing identified two novel DPA1 alleles, DPA1*010103 and DPB1*0303, from a Kenyan population. Tissue Antigens 2005 Jan 1; 65(1):120-122. Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper R, Talbot PJ, Tam T, Babiuk L. Severe Acute Respiratory Syndrome (SARS): A year in review. Annual Rev Med 2005 Feb 18; 56:357-381. Meyers LA, Pourbohloul B, Newman MEJ, Skowronski DM, Brunham RC. Network theory and SARS: Predicting outbreak diversity. J Theoretical Biol 2005 Jan 7;232(1):71-81. Brunham RC, Rey-Ladino J. Immunology of Chlamydia Infection: Implications for a Chlamydia trachomatis vaccine. Nat Rev Immun 2005 Feb 5(2):149-161. Cherkasov, Dr. Artem A. Cherkasov, D. Nandan, N.E. Reiner. Selective Targeting of Indel-inferred Differences in 3D Structures of Highly Homologous Proteins. Proteins: Structure, Function and Bioinformatics, 58, 950- 4 (2005). A. Cherkasov. Inductive QSAR Desriptors. Distinguishing Compounds with Antibacterial Activity by Artificial Neural Networks International Journal of Molecular Sciences. (2005), 6, 63-86, (Invited contribution for issue in honour of Professor Marwin Charton). A. Cherkasov. Review on the Third Edition of “Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins” by Andreas D. Baxevanis and B. F. Francis Ouellette. ChemBioChem: a European Journal of Chemical Biology. 6, 1128-1129, (2005). A. Cherkasov. Review on Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins. The American Journal of Human Biology, 17, 287-289 (2005). A. Cherkasov, Z. Shi, M. Fallahi, G. Hammond. Successful in Silico Discovery of Novel Non- Steroidal Ligands for Human Sex Hormone Binding Globulin (SHBG). Journal of Medicinal Chemistry, 48, 3203-3213 (2005). A. Cherkasov. ‘Inductive’ Descriptors. 10 Successful Years in QSAR. Current Computer-Aided Drug Design, 1, 21-42 (2005). V. Astakhov, A. Cherkasov. Use of Bayesian Networks for Predicting HLA-A2 (MHC-I) Binding Peptides. Bioinformation, 1(2), 58-63 (2005). A. Cherkasov, Z. Shi, Y. Li, S.M. Jones, M. Fallahi, G.L. Hammond. ‘Inductive’ Charges on Atoms in Proteins: Comparative Docking with the Extended Steroid Benchmark Set and Discovery of a Novel SHBG Ligand. Journal of Chemical Information and Modelling, 45, 1842-1853 2005. Chow, Dr. Anthony W Hull MW, Chow AW: An approach to oral infections and their management. Curr Infect Dis Rep 7:17-27, 2005. Grigg, Dr. Michael J.P.J. Saeij*, J.P. Boyle*, M.E. Grigg, G. Arrizabalaga, and J.C. Boothroyd. (2005) Bioluminescence imaging of Toxoplasma infection in living mice reveals dramatic differences between strains. Infect. Immun. 73(2):695-702. *joint first authors.
UBC Department of Medicine Page 175 Annual Report 2005
Hmama, Dr. Zakaria Sendide K, Reiner NE, Lee JSI, Bourgoin S, Talal A, Hmama Z. Cross-talk between CD14 and CR3 promotes phagocytosis of mycobacteria: regulation by phosphatidylinositol 3-kinase and cyohesin-1. J Immunol, 174: 210-9, 2005. Hestvik ALK, Z Hmama, Y Av-Gay. Mycobacterial manipulation of the host cell. FEMS Microbiol Rev. 2005 Jul 21; [Epub ahead of print]. Kerr, Dr. Thomas H Kerr T, Wood E, Grafstein E, Ishida T, Shannon K, Montaner J, Tyndall MW. High rates of primary care and emergency room use among injection drug users in Vancouver. Journal of Public Health, 2005; 27(1):62-66. Kerr T, Marshall A, Walsh J, Tyndall M, Hogg R, Montaner J, Wood E. Determinants of highly active antiretroviral therapy discontinuation among injection drug users. AIDS Care, 2005; 17(5):539-549. Wood E, Li K, Miller C, Hogg RS, Montaner JS, Schechter MT, Kerr T. Baseline self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a prospective cohort of injection drug users. International Journal of Epidemiology, 2005; 34(1):152-158. Wood E, Small W, Li K, Montaner J, Schechter M, Kerr T. Recent incarceration independently predicts syringe sharing among injection drug users. Public Health Reports, 2005; 120(2):150-156. Kuyper LM, Palepu A, Kerr T, Li K, Miller CL, Spittal PM, Hogg RS, Montaner JSG, Wood E. Factors associated with sex-trade involvement among female injection drug users in a Canadian setting. Addiction Research and Theory, 2005; 13(2):193-199. Kerr T, Oleson M, Tyndall MW, Montaner J, Wood E. A description of a peer-run supervised injection site for injection drug users. Journal of Urban Health, 2005; 82: 267-275. Wood E, Kerr T. Measuring the public health impact of police activities on illicit drug users. International Journal of Drug Policy, 2005; 16: 148-149. Elliott R, Csete J, Palepu A, Kerr T. Reason and rights in global drug control policy. Canadian Medical Association Journal, 2005; 72(5): 655-656. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users. AIDS, 2005; 19(8): 837-839. Collins CLC, Kerr T, Kuyper LM, Li K, Tyndall MW, Marsh DC, Montaner JS, Wood E. Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use. Journal of Urban Health, 2005; 82(2): 276-284. Kerr T, Marsh D, Li K, Montaner J, Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug and Alcohol Dependence, 2005; Jun 16; [Epub ahead of print]. Wood E, Tyndall MW, Li K, Lloyd-Smith E, Small W, Montaner JS, Kerr T. Do supervised injection facilities attract high risk injection drug users. American Journal of Preventative Medicine, 2005; 29(2):126-130. Wood E, Kerr T, Qui Z, Montaner J, Tyndall MW. Prevalence and correlated of hepatitis C infection among users of North America’s first medically supervised injection facility. Journal of Public Health, 2005; 119(12): 1111-1115. O’Connell JM, Kerr T, Li K, Tyndall MW, Hogg RS, Montaner JS, Wood E. Requiring help injecting independently predicts incident HIV infection among injection drug users. Canadian Journal of Infectious Diseases, 2005; 16(Suppl A): 348P. Miller C, Strathdee S, Kerr T, Li K, Wood E. Factors associated with early adolescent initiation into injection drug use: Implications for injection drug use intervention programs. Canadian Journal of Infectious Diseases, 2005; 16(Suppl A): 326P. Kerr T, Small W, Wood E. The public health and social impacts of drug market enforcement: A review of the evidence. International Journal of Drug Policy, 2005, 16(4): 210-220.
UBC Department of Medicine Page 176 Annual Report 2005
Wood E, Tyndall M, Stoltz J, Small W, Zhang R, O’Connell J, Montaner J, Kerr T. Safer injection education for HIV prevention within a medically supervised safer injection facility. International Journal of Drug Policy, 2005, 16:281-284. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet, 2005, 366:316-318. Kuyper LM, Collins CLC, Kerr T, Hogg RS, Li K, Tyndall MW, Montaner JSG, Wood E. The prevalence and incidence of sexually transmitted infections in a prospective cohort of injection drug users in Vancouver, British Columbia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2005; 16(4): 225-229. Elliott R, Kerr T, Csete J, Wood E. Harm reduction, HIV/AIDS, and the human rights challenge to global drug control policy. Health and Human Rights, 2005; 8(2):104-138. Collins CL, Kerr T, Tyndall MW, Marsh DC, Kretz P, Montaner JS, Wood E. Is there a rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users? Canadian Journal of Public Health, 2005; 96(5):344-347. Kerr T, Stoltz J, Strathdee S, Hogg R, Li K, Montaner J, Kerr T. The impact of sex partners’ HIV status on HIV seroconversion among a cohort of injection drug users. Canadian Journal of Infectious Diseases, 2005; 16(Suppl A): 161. Kerr T, Walsh J, Lloyd-Smith E, Wood E. Measuring adherence to antiretroviral therapy: Implications for research and practice. Current HIV Reports, 2005; 2(4): 200-205. Kerr T, Kaplan K, Suwannawong P, Wood E. The Thai Drug Users' Network: Its proposal to the global Fund. Health and Human Rights, 2005; 8(2). Fairbairn N, Wood E, Small W, Stoltz J, Li K, Kerr T. Risk profile of individuals who provide assistance with illicit drug injections. Drug and Alcohol Dependence, 2005 Sep 5; [Epub ahead of print]. Hogg R, Strathdee S, Kerr T, Wood E, Remis R. Prevalence of HIV/AIDS among Aboriginal British Colymbians. Harm Reduction Journal, 2005; 2(1); 26 [Epub ahead of print]. Wood E, Kerr T, Palepu A, Zhang R, Strathdee SA, Tyndall MW, Montaner JS, Hogg RS. Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users. J Infec. 2005 Sep 16; [Epub ahead of print]. Kerr T, Marshall A, Walsh J, Tyndall M, Hogg R, Montaner J, Wood E. Determinants of HAART discontinuation among injection drug users. AIDS Care, 2005; 17(5): 539-549. Lloyd-Smith E, Kerr T, Hogg TS, Li K, Montaner JS, Wood E. Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduction Journal, 2005; 2(1):24. Wood E, Montaner J, Kerr T. HIV risks in incarcerated injection-drug users. Lancet, 2005; 366: 1834-1835. Wood E, Tyndall MW, Stolz J, Small W, Lloyd-Smith E, Zhang R, Montaner JSG, Kerr T. Factors associated with syrings sharing among users of a medically supervised safer injecting facility. American Journal of Infectious Diseases, 2005; 1(1):50-54. Tyndall MW, Kerr T, Shang R, King E, Montaner JG, Wood E. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug and Alcohol Dependence, 2005 Dec 12; [Epub ahead of print]. Montaner, Dr. Julio S Harrigan PR, Hogg RS, Dong WWY, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, Alexander CS, Montaner JSG. Predictors of HIV drug resistance mutations in a large drug- naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005;191:339-347. Braitstein P, Yip P, Montessori V, Moore D, Montaner JSG, Hogg RS. Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naïve HIV-positive patients. CMAJ 2005;173(2):160-64.
UBC Department of Medicine Page 177 Annual Report 2005
Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JSG, Harrigan PR. Molecular and clinical epidemiology of CXCR4 using HIV-1 in a large population of therapy naïve individuals. J Infect Dis 2005;192(3):466-474. Collins CLC, Kerr T, Kuyper LM, Li K, Tyndall MW, Marsh DC, Montaner JSG, Wood E. Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use. J Urban Health 2005;82(2)276-84. Harrigan PR, Wynhoven B, Brumme ZL, Brumme CL, Sattha B, Major JC, de la Rosa R, Montaner JSG. HIV-1 drug resistance: Degress of underestimation by a cross-sectional versus lonitudinal testing approach. J Infec Dis 2005;191(8):1325-30. Kerr T, Oleson M, Tyndall MW, Montaner J, Wood E. A description of a peer-run supervised injection site for injection drug users. J Urban Health 2005;82(2):267-75. Kerr T, Wood E, Grafstein E, Ishida T, Shannon K, Lai C, Montaner JS, Tyndall M. High rates of primary care and emergency department use among injection drug users in Vancouver. J Public Health Med 2005:27:62-66. O'Connell JM, Kerr T, Li K, Tyndall MW, Hogg RS, Montaner JS, Wood E. Requiring help injecting independently predicts incident HIV infection among injection drug users. JAIDS 2005;40(1):83-8. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, Montaner JSG. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. JAIDS 2005;40():288-93. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JSG, D'Hearn M, Piliero P, Ryenes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Kuritzkes DR, Lange J, Stellbrink H, Delfraissy J, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Fuimares D, DeMasi R, Chung J, Salgo MP. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. JAIDS 2005;40(4):404-12. Normen L, Chan K, Braitstein P, Anema A, Bondy G, Montaner JSG, Hogg RS. Food insecurity and hunger are prevalent among HIV-positive individuals in British Columbia, Canada. J Nutrition 2005;135(4):820-5. Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, O'Shaughnessy MV, Montaner JSG. Non- tuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: Spectrum of disease and long term follow-up. Clin Infec Dis 2005;41(10):1483-97. Toulson AR, Harrigan R, Heath K, Yip B, Brumme ZL, Harris M, Hogg RS, Montaner JSG. Treatment interruption of antiretroviral therapy among patients with nadir CD4 cell counts >200 cells/mm3. J Infect Dis 2005:192(10)1787-93. Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy J, Stellbrink H, Lange J, Kuritzkes D, Eron JJ, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Fuimaraes D, Drobnes C, Bader-Weder S, DeMasi R, Smiley L, Salgo M. Safety of enfuvirtide in combination with an optimized backround of antiretrovirals in treatment-experienced HIV-1 infected adults over 48 weeks. JAIDS 2005;40(4):413- 20. Wainberg MA, Sawyer JPC, Montaner JSG, Murphy RL, Kuritzkes DR, Raffi F. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection-Review. Antiviral Therapy 2005;10(1):13-28. Wood E, Hogg RS, Yip B, Dong WWY, Wynhoven B, Mo T, Brumme CJ, Montaner JSG, Harrigan PR. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005;19(11):1189-95. Wood E, Hogg RS,Yip B, Harrigan PR, Montaner JSG. Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr 2005;38(3):289-95.
UBC Department of Medicine Page 178 Annual Report 2005
Wood E, Hogg RS, Harrigan PR, Montaner JSG. When to initiate antiretroviral therapy in HIV-1 infected adults: A review for clinicians and patients. Lancet Infect Dis 2005;5:407-14. Wood E, Tyndall MW, Stoltz JA, Small W, Zhang R, O'Connell J, Montaner JS, Kerr T. Safer injecting education for HIV prevention within a medically supervised safer injecting facility. Internat J Drug Policy 2005;16(4):281-4. Montessori, Dr. Valentina C Braitstein P, Montessori V, Chan K, Montaner JSG, Schechter M, O'Shaughnessy MV, Hogg RS. Quality of life, depression, and fatigue among persons co-infected with HIV and hepatitis C: Outcomes from a population-based cohort. AIDS Care May 2005; 17(4):505-515. Braitstein P, Yip B, Montessori V, Moore D, Montaner JS, Hogg RS. Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naïve HIV-positive patients. CMAJ 2005;173(2):160-4.
Moore, Dr. David M Braitstein P, Yip B, Montessori V, Moore D, Montaner JS, Hogg RS. Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naïve HIV-positive patients. CMAJ 2005 Jul 19;173(2):160-4. Lem M, Moore D, Marion S, Bonner S, Chan K, O'Connell J, Montaner JSG, Hogg RS. Back to Work: Correlates of Employment Among Persons Receiving Highly Active Antiretrovial Therapy. AIDS Care 2005 Aug; 17 (6):740-6. Moore D, Montaner J. Total lymphocyte counts and ART in resource-limited settings. Lancet. 2005 Nov 26; 366(9500):1831-2. Yassi A, Moore D, FitzGerald JM, Bigelow P, Hon CY, Bryce E and other members of The BC Interdisciplinary Respiratory Protection Study Group. Research gaps in protecting healthcare workers from SARS and other respiratory pathogens: An interdisciplinary, multi-stakeholder, evidence-based approach. J Occup Environ Med. 2005 47(1):41-50. Moore D, Gamage B, Bryce E, Copes R, Yassi A and other members of The BC Interdisciplinary Respiratory Protection Study Group. Protecting Healthcare Workers From SARS and Other Respiratory Pathogens: Organizational and Individual Factors that Affect Adherence to Infection Control Guidelines. Am J Inf Cont 2005 33(2): 88-96. Gamage B, Moore D, Yassi A, Copes R, Bryce E, and other members of The BC Interdisciplinary Respiratory Protection Study Group. Protecting Health Care Workers from SARS and Other Respiratory Pathogens: A Critical Review of the Infection Control Literature. Am J Inf Cont 2005 33(2): 114-121. Moore D, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, Montaner JSG. Discordant immunologic and virologic responses to HAART are assoicated with increased mortality and poor adherence to therapy. JAIDS 2005 40(3):288-293. Nandan, Dr. Devki Nandan D and NE Reiner (2005). Leishmania donovani engages in regulatory interference by targeting macrophage protein tyrosine phosphatase SHP-1, Clin. Immunol. 114(3): 266-77. Leon C, Nandan D, M Lopez and NE Reiner (2005). Annexin V associates with the interferon-gamma receptor and regulates IFN-gamma signaling (In second review with J. Exp. Med). Cherkasov A, Nandan D, and NE Reiner (2005). Selective Targeting of Indel - Inferred – Differences in Spatial Structures of Highly Homologous Proteins. PROTEINS Structure, Function, and Bioinformatics 58(4) 950-4.
Patrick, Dr. David M Marra F, Patrick DM, White R, Ng H, Bowie WR, Hutchinson JM. Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia. Journal of Antimicrobial
UBC Department of Medicine Page 179 Annual Report 2005
Chemotherapy. 2005: 55: 95-101. CA. Kay C, Patrick DM, Keystone J, Bodie-Collins M, Riera C, Puello J, Jelinek T, Freedman D, Kozarsky GP, Parise M, Nguyen-Dinh P, Steketee R, Eliades M. Transmission of Malaria in Resort Areas -- Dominican Republic, 2004 MMWR 2005; 53(51 & 52); 1195-1198. CA. Phillips, Dr. Elizabeth J Mills, EJ, Montori VM, Perri D, Phillips E, Koren G. Natural Health Products -- HIV Drug Interactions: a systematic review. International Journal of STD and AIDS 2005;16(3):181-6. Mills E, Foster B, van Heeswijk R, Phillips E, Wilson K, Leonard B, Kosuge K, Kanfer I. Impact of African herbal medicines on antiretroviral metabolism. AIDS 2005;19(1):95-97. Martin A, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen F, Mallal S. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4+ T cell counts. AIDS 2005;19(1):97-99. Mills EJ, Wilson K, Clarke MJ, Foster B, Walker SE, Rachlis B, DeGroot N, Gold W, Phillips E, Myers SP, Gallicano K. Milk thistle and indinavir: a randomized controlled pharmacokinetics study. Eur J of Clin Pharm 2005;6(1):1-7. Phillips E, Wong G, Kaul R, Shahabi K, Mallal S, Nolan D, Knowles S, Martin A, Shear N. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005;19:979-81. Knowles S, Wong G, Rahim S, Binkley K, Phillips E, Shear N. An underrecognized, yet serious adverse drug reaction: hydrochlorothiazide-induced non cardiogenic pulmonary edema. Pharmacotherapy 2005:25:1258-65. Thistle P, Gottesman M, Pilon R, Glazier RH, Arbess G, Phillips EJ, Ward RL. A randomized control trial of an Ultra-Short zidovudine regimen in the prevention of perinatal HIV transmission in rural Zimbabwe. Cent Afr J Med. 2004 Sept-Oct;50(9-10):79-84. Notman MJ, Phillips EJ, Knowles SR, Weber EA, Shear NH. Clindamycin skin testing has limited diagnostic potential. Contact dermatitis 2005;53:335-8. van Heeswijk RP, Cooper CL, Foster BC, Chauhan B, Shirazi F, Seguin I, Phillips EJ, Mills E. The effect of high-dose vitamin C on hepatic CYP3A4 activity. Pharmacotherapy 2005;25:1725-8. Antoniou T, Tseng A, van Heeswijk R, Walker S, Giguere P, Phillips EJ. Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/ritonavir combination therapy in antiretroviral experienced patients. Ther Drug Monit 2005;27:779-781. Reiner, Dr. Neil E Cherkasov, A, D Nandan and NE Reiner (2005) Selective targeting of Indel - Inferred Differences in Spatial Structures of Highly Homologous Proteins, PROTEINS: Structure, Function, and Bioinformatics 58(4):950-954. Reiner, NE (2005) Targeting cell regulation promotes pathogen survival in macrophages, Clin. Immunol. 114:213-215. Nandan, D and NE Reiner (2005) Leishmania donovani engages in regulatory interference by targeting macrophage protein tyrosine phosphatase SHP-1, Clin. Immunol. 114:266-277. Farajnia, S, F Mahboudi, S Ajdari, NE Reiner and MH Alimohammadian (2005) Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote Class I nuclease with a predominant Th1-like response, Clinical and Experimental Immunology, 139:498-505. Sendide, K, NE Reiner, JSI Lee, S Bourgoin, A Talal, and Z Hmama (2005) Cross-talk between CD14 and complement receptor 3 promotes phagocytosis of mycobacteria: regulation by phosphatidylinositol 3-kinase and cytohesin-1, J Immunol. 174(7):4210-9. Cherkasov, A, SJ Lee, D Nandan and NE Reiner (2005) Large-scale survey for potentially targetable indels in bacterial and protozoan proteins, PROTEINS: 62(2):371-380. Rekart, Dr. Michael L Rekart ML, Wong T, Wong E, Hutchinson K, Ogilvie GS. The impact of syphilis mass treatment one year later: self-reported behaviour change among participants. International Journal of STD and AIDS UBC Department of Medicine Page 180 Annual Report 2005
2005; 16: 571-578(8). Ogilvie GS, Knowles L, Taylor D, Tigchelaar J, Brunt C, James L, Wong E, Maginley J, Jones H, Rekart ML. Incorporating a social networking approach (SNA) to enhance contact tracing in a heterosexual outbreak of syphilis. Sexually Transmitted Infections 2005 81: 124-127. Jones HD, Taylor D, Montgomery CA, Patrick DM, Money D, Vipond JCF, Morshed MG, Ruissard DA, Rekart ML. Prenatal and Congenital Syphilis in British Columbia. Journal of Obstetrics and Gynaecology Canada 2005; 27(5): 467-472. Brunham CR, Pourbohloul B, Mak S, White R, Rekart ML. The Unexpected Impact of Chlamydia trachomatis Infection Control Program on Susceptibility to Reinfection. The Journal of Infectious Diseases. 2005; 192:1836-1844. Steiner, Dr. Theodore S Crellin NK, Garcia RV, Hadisfar O, Allen SE, Steiner TS, and Levings MK. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J. Immunol. 175 (2005):8051-8059. Tyndall, Dr. Mark W Wood E, Kerr T, Palepu A, Zhang R, Strathdee S, Tyndall M, Montaner JS, Hogg R. Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users. J Infect. 2005; Sep 16 [Epub ahead of print]. Tyndall MW, Kerr T, Zhang R, King E, Montaner JG, Wood E. Attendance, drug use patterns, and referrals made from North America’s first supervised injection facility. Drug Alcohol Depend. 2005 Dec12; [Epub ahead of print]. Kerr T, Oleson M, Tyndall MW, Montaner JS, Wood E. An evaluation of a peer-run safer injection site for injection drug users. J Urban Health. 2005; 82(2):267-75. Kerr T, Tyndall MW, Li K, Montaner J, Wood E. Safer injection faclitiy use and syringe sharing among injection drug users. Lancet. 2005; 366(9482):316-8. Wood E, Kerr T, Stoltz J, Qui Z, Zhang R, Montaner JS, Tyndall MW. Prevalence and correlates of Hepatitis C infection among users of North America’s first medically supervised safer injection facility. Public Health 2005; 119 (12):1111-19. Leri F, Stewart J, Fischer B, Jurgen R, Marsh DC, Brissette S, Bruneau J, El-Guebaly N, Noel L, Tyndall M, Wild TC. Patterns of opioid and cocaine co-use: a descriptive study in a Canadian sample of untreated opioid-dependent individuals. Exp Clin Psychopharmacol 2005; 13(4):303-10. Moore D, Hogg R, Yip B, Wood E, Tyndall M, Braitstein P, Montaner JS. Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy. J Acquir Immune Defic Syndr. 2005;40(3):288-293. Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, Hogg R, Wood E. Determinants of HAART discontinuation among injection drug users. AIDS Care. 2005;17(5): 539-549. Wood E, Tyndall MW, Stoltz J, Small W, Zhang R, O’Connell J, Montaner JS, Kerr T. Safer injecting education for HIV prevention within a medically supervised safer injecting facility. Int J Drug Pol. 2005;29(2):126-130. O'Connell JM, Kerr T, Li K, Tyndall MW, Hogg RS, Montaner JS, Wood E. Requiring Help Injecting Independently Predicts Incident HIV Infection Among Injection Drug Users. J Acquir Immune Defic Syndr. 2005, 40(1):83-8. Shannon K, Bright V, Duddy J, Tyndall MW. Access and Utilization of HIV Treatment and Services Among Women Sex Workers in Vancouver's Downtown Eastside. J Urban Health. 2005; 82(3):488- 97. Tyndall M. Avoiding simplistic interpretations: Comment on Degenhardt et al. Addiction 2005,100(7):923-4. Wild C, el-Guebaly N, Fischer B, Brissette S, Brochu S, Bruneau J, Noel L, Rehm J, Tyndall M, Nun P, Comorbid depression amond untreated illicit opiate users: Results from a mulitsite Canadian study. Can J Psychiatry 2005;50:512-18. UBC Department of Medicine Page 181 Annual Report 2005
Wood E, Tyndall MW, Li K, Lloyd-Smith E, Small W, Montaner JS, Kerr T. Do supervised injecting facilities attract higher-risk injection drug users. Am J Prev Med. 2005, 29(2):126-30. Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Noel L, Tyndall MW, Wild C, Mun P, Baliunas D, Illicit Opioid Use in Canada: Comparing Social, Health, and Drug Use Characteristics of Untreated Users in Five Cities (OPICAN Study). J Urban Health. 2005; 82(2):250-66. Collins CL, Kerr T, Kuyper LM, Li K, Tyndall MW, Marsh DC, Montaner JS, Wood E, Potential Uptake and Correlates of Willingness to Use a Supervised Smoking Facility for Non-injection Illicit Drug Use. J Urban Health. 2005; 82(2):276-84. Kerr T, Oleson M, Tyndall MW, Montaner JSG, Wood E, An evaluation of a peer-run safer injection site for injection drug users. J Urban Health. 2005;82(2):267-75. Kerr T, Tyndall MW, Li K, Montaner JSG, Wood E, Safer injection facility use and syringe sharing among injection drug users. Lancet. 2005; 366(9482):316-8. Kerr T, Wood E, Grafstein E, Ishida T, Shannon K, Lai C, Montaner JSG, Tyndall MW, High rates of primary care and emergency department use among injection drug users in Vancouver. J Public Health. 2005; 27(1):62-6. Wood, Dr. Evan Wood E, Li K, Miller C, Hogg RS, Montaner JS, Schechter MT, Kerr T. Baseline self-perceived risk of HIV infection predicts subsequent seroconversion among a cohort of injection drug users. International Journal of Epidemiology. 2005;34(1):152-158. Wood E, Hogg RS, Yip B, Harrigan RP, O'Shaughnessy MV, Montaner JS. Why are baseline plasma HIV RNA levels > 100,000 copies/mL associated with mortality after the initiation of antiretroviral therapy. J Acquir Immune Defic Syndr. 2005;38(3):289-295. Kerr T, Small W, Wood E. Public health and social impacts of drug market enforcement: a review of the evidence. International Journal of Drug Policy, 2005: 16(4):210-220. Kuyper L, Palepu A, Kerr T, Spittal P, Li K, Hogg RS, Schechter MT, Wood E. Factors associated with sex-trade involvement among female injection drug users in a Canadian setting. Addiction Research and Theory, 2005;13(2):193-199. Collins CL, Kerr T, Tyndall MW, Marsh DC, Kretz P, Montaner JS, Wood E. Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users. Can J Pub Health, 2005; 96(5):344-347. Kerr T, Tyndall MW, Li K, Montaner JS, Wood E. Safer injecting facility use and syringe sharing in injection drug users. Lancet, 2005; 366(9482):316-8. Kuyper LM, Collins LC, Kerr T, Li K, Tyndall MW, Montaner JS, Wood E. The prevalence and incidence of sexually transmitted infections in a prospective cohort of injection drug users in Vancouver, British Columbia. Can J Infect Dis & Med Microbi, 2005; 16(4):225-229. Collins CL, Kuyper L, Kerr T, Tyndall MW, Marsh DC, Montaner JS, Wood E. Potential uptake and correlates of willingness to use a supervised smoking facility for non-injection illicit drug use. J Urban Health 2005;82(2);276-284. Wood E, Kerr T, Qui Z, Zhang R, Montaner JS, Tyndall MW. Prevalence and correlates of hepatitis C infection among users of North America’s first medically supervised safer injecting facility. J Pub Health, 2005; 119(12): 1111-1115. Wood E, Hogg RS, Yip B, Montaner JS, Harrigan PR. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS, 2005;19(11):1189-1195. Miller CL, Spittal PM, Frankish JC, Li K, Schechter MT, Wood E. HIV and hepatitis C outbreaks among high-risk youths in Vancouver demand a public health response. Can J Public Health, 2005; 96(2):107-108. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naïve HIV-infected injection drug users. AIDS, 2005; 19(8):837-839.
UBC Department of Medicine Page 182 Annual Report 2005
Kerr T, Oleson M, Tundall MW, Montaner J, Wood E. A description of a peer-run supervised injection site for injection drug users. J Urban Health, 2005; 82(2); 267-275. Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate antiretroviral therapy in HIV-1 infected adults: A review for clinicians and patients. Lancet Infec Dis, 2005;5(7):407-414. Wood E, Tyndall MW, Li K, Lloyd-Smith E, Small W, Montaner J, Hogg R, Wood E. Detrminants of HAART discontinuation among injection drug users. AIDS Care, 2005;17(5):539-549. Lloyd-Smith E, Kerr T, Hogg RS, Li K, Montaner JS, Wood E. Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduction Journal, 2005;2(1):24. Wood E, Kerr T. Measuring the public health impact of police activities on illicit drug users. Int J Drug Pol, 2005;16:148-149. Wood E. The role of supply reduction in an evidence-based illicit drug strategy. Addiction, 2005; 100(8):1194-1195. Wood E, Li K, Palepu A, Marsh DC, Schechter MT, Hogg R, Montaner J, Kerr T. Socio-demographic disparities in access to addiction treatment among a cohort of injection drug users. Substance Use and Misuse, 2005;40(8): 1153-1167. Wood E, Tyndall MW, Small W, Stoltz J, Zhang R, O'Connell J, Montaner J, Wood E. Requiring help injecting independently predicts incident HIV infection among injection drug users. J Acquir Immune Defic Syndr, 2005;40:83-88. Petrar S, McKnight B, Hogg RS, Montaner JS, Wood E. Baseline HIV RNA levels, virological response rates, and mortality after the initiation of antiretroviral therapy. Contagion, 2005;2(7):311- 316. Kerr T, Marsh D, Li K, Montaner J, Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug and Alcohol Dependence, 2005;80(3):329-335. Fairbairn N, Wood E, Small W, Stoltz J, Li K, Kerr T. Risk profile of individuals who provide assistance with illicit drug injections. Drug Alcohol Depend. 2005 Sep 7 [Epub ahead of print] Elliott R, Csete J, Wood E, Kerr T. Harm reduction, HIV/AIDS and the human rights challenge to global drug control policy. Health and Human Rights, 2005; 8(2): 104-138. Kerr T, Kaplan K, Suwannawong P, Wood E. The Thai Drug Users' Network: Its proposal to the global Fund. Health and Human Rights, 2005;8(2). Moore DM, Hogg RS, Yip B, Wood E. Tyndall M, Braitstein P, Montaner JS. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr, 2005; 40(3): 288- 293. Wood E, Kerr T, Palepu A, Zhang R, Strathdee SA, Tyndall MW, Montaner JSG, Hogg RS. Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users. Journal of Infection, 2005 Sep 16; [Epub ahead of print]. Kerr T, Walsh J, Lloyd-Smith E, Wood E. Measuring adherence to highly active antiretroviral therapy: Implications for research and practice. Current HIV/AIDS Reports, 2005:2(4):200-205. Wood E, Tyndal MW, Small W, Lloyd-Smith E, Zhang R, Montaner JS, Kerr T. Faactors associated with syrings sharing among users of a medically supervised safer injecting facility. Am J Infect Dis. 1(1):50-54, 2005. Wood E, Montarner J, Kerr T. HIV risks in incarcerated injection-drug users. Lancet, 2005; 366:1834-1834. Tyndall MW, Kerr T, Zhang R, King E, Montaner JG, Wood E, Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug and Alcohol Dependence, 2005 Dec 12; [Epub ahead of print]. Hogg RS, Strathdee S, Kerr T, Wood E, Remis R. Prevalence of HIV/AIDS among Aboriginal British Columbians. Harm Reduction Journal, 2005;2(1):26 [Epub ahead of print].
UBC Department of Medicine Page 183 Annual Report 2005
MEDICAL ONCOLOGY Chi, Dr. Kim N Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, Gelmon KA. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093 in combination with Paclitaxel in patients with advanced cancer. Investigational New Drugs, 23(4):311-315, August 2005. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD. Identification of serus amyloid as a biomarker to distinguish prostate cancer patients with bone lesions. Clinical Chemistry. 51(4):695-707, 2005. Chi KN. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World Journal of Urology 23(1):33-7, 2005. Winquist E, Moore MJ, Chi KN, Ernst DS, Hirte H, North S, Powers J, Walsh W, Boucher T, Patton R, Seymour L. A multinominal Phase II Study of Ionafarnib (SCH 66336) in patients with Refractory Urothelial Cancer. Urol Oncol 2005 23(3):143-9. Gelmon KA, Belanger K, Soulieres D, Britten C, Chia S, Carpentier D, Chi K, Powers J, Walsh W, Seymour L. A Phase I study of T900607 given once every three weeks in patients with advanced refractory cancers; national Cancer Institute of Canada Clinical Trials Group 9NCIC-CTG) IND 130. Investigational New Drugs, 23:445-453, 2005. Eigl BJ, Eggener SE, Baybik J, Ettinge S, Chi KN, Nlson C, Wang Z, Gleave ME. Timing is Everything: Preclinical Evidence Supporting Simultaneous rather than Sequential Chemohormonal Therapy for Prostate Cancer. Clin Ca Research 11(13):4905-11, 2005 Jul 1. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Tompson I, Berg K D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rownsky E. A phase II Pharmacokinetic, and Biological Correlative study of Oblimersen Sodium and Docetaxel in patients with Hormone Refractory Prostate Cancer. Clin Ca Research 11(10):3854-61, 2005 May 15. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized Phase II Study of Two Doses of Gefitinib in Hormone Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group. Journal of Clinical Oncology 23(3):455-60, 2005. Chi KN, Eisenhauer E, Fazil L, jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. A Phase 1 Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2'-Methoxyethyl Antisense Oligonucleotide to Clusterin in Patients with Localized Prostate Cancer. Journal of the National Cancer Institute, 97(17):1287-96, 2005. Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemotherapy & Pharmacology, 56 Suppl 7:47-57, 2005. Al-Tourah AJ, Murray N, Coppin C, Kollmannsberger C, Man A, Chi KN. Minimizing Treatment Without Compromising Cure With Primary Surveillance for Clinical Stage 1 Embryonal Predominant Non-Seminomatous Testicular Cancer: A Population-Based Analysis from British Columbia. Journal of Urology, 174(6):2209-13, 2005. Chia, Dr. Stephen K Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon K and Bally MB. Trastuzumab and liposomal doxorubicin in the treatment of MCF-7 xenograft tumour bearing mice: combination does not affect drug serum levels. Pharmaceutical Res 2005;22:915-22. Dabiri SH, Huntsman D, Makretsov N, Cheang M, Gilks CB, Badjik C, Gelmon K, Chia S and Hayes MM. The Presence of Stromal Mast Cells Identifies a Subset of Invasive Breast Cancers with avorablePrognosis. Modern Pathology 2004;17:690-5. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GH, Chia SK and Gelmon KA. Population-Based Validation of the Prognostic Model ADJUVANT! For Early Breast Cancer. J Clin Oncol 2005;23:2716-2725. Prentice LM, Shadeo A, Lestou VS, Miller MA, Deleeuw RJ, Makretsov N, Turbin D, Brown LA, UBC Department of Medicine Page 184 Annual Report 2005
Macpherson N, Yorida E, Cheang MC, Bentley J, Chia S, Nielsen TO, Gilks CB, Lam W, Huntsman DG. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene 2005 Jul 18; [Epub ahead of print] Gelmon KA, Belanger K, Soulieres D, Britten C, Chia S, Charpentier D, Chi K, Powers J, Walsh W and Seymour L. A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group IND 130. Investigation New Drugs 2005;23:445-453. Connors, Dr. Joseph M Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, Farinha P, Horsman DE, Gascoyne RD. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res, 2005;11:1065-72 Shenkier TN, Voss N, Chhanabhai M, Fairey R, Gascoyne RD, Hoskins P1, Klasa R, Morris J, O’Reilly SE, Pickles T; Sehn L, Connors JM. The treatment of primary central nervous system lymphoma (PCNSL) in 122 immunocompetent patients: A population-based study of successively treated cohorts from the British Columbia Cancer Agency (BCCA). Cancer, 2005;103:1008-13 Looi A, Gascoyne RD, Chhanabhai M, Connors JM, Rootman J, White VA. Mantle cell lymphoma in the ocular adnexal region. Ophthalmology 2005;112:114-119. Knezevich S, Ludkovski O, Salski C, Lestou V, Chhanabhai M, Lam W, Klasa R, Connors JM, Dyer MJ, Gascoyne RD, Horsman DE. Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia 2005;19:659-663. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bexjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE. A randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma. J Clin Oncol 2005;23:4634-42. Au WY, Gascoyne RD, Klasa RD, Connors JM, Gallagher RP, Le ND, Loong F, Law CK, Liang R. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol 2005;128(6):792-6. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, Connors JM. Promary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005;23(10):2233-9. Connors JM. Radioimmunotherapy - hot new treatment for lymphoma. N Engl J Med 2005;352(5):496-8. Sehn LH, Connors JM. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective. Oncology (Huntingt) 2005;19:26-34. Shenkier TN, Voss N, Chhanabhai M, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Morris J, O'Reilly SE, Pickles T, Sehn L, Connors JM. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Cancer 2005;103:1008-17. Connors JM. Alemtuzumab for B-cell chronic lymphocytic leukemia. Issues in Emerging Health Technologies 2005; issue 66. Connors JM. State of the art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005;23:6400-08. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopex-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival preditcion. Blood 2005;106:3183-90. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, Macpherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of combined CHOP
UBC Department of Medicine Page 185 Annual Report 2005
plus rituximab therapy dramatically improved oucome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33. Connors JM. ABVD, the Stanford V regimen, and BEACOPP for Hodgkin's lymphoma: what should an oncologist do? Clin Lymphoma 2005:6:50-1. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Shepherd LE. Radiotherapy and Hodgkin's lymphoma. J Clin Oncol 2005;22:8914 (letter). Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of controversial therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 2005;23:7994-8002. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005;131:223-30. Gill, Dr. Karamjit K Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K et al. Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. Journal of Clinical Oncology. 23(22):5027-33, 2005. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 106(6):2169-2174, 2005. Lafferty J, Gill K, et al. Proficiency Testing of Reticulocyte Counting in Ontario. Laboratory Hematology. 11:185-189, 2005. Gill, Dr. Sharlene Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, Fitch TR, Steen P, Kim GP and Gill S. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Annals of Oncology, 16(10):1654-61 (Epub ahead of print Aug 5, 2005). Gill S, Lindor NM et al. Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation. Clinical Cancer Research, 2005; 11(18): 6466-71 Sept 15, 2005. Gill S, Burgart L, Lindor N, Goldberg RM and Thibodeau S. hPMS2 Expression in Colorectal Cancers with Microsatellite Instability: Clinical Cancer Research, 2005;11(18):6466-71 Sept 15, 2005. Gill S. Advances in the Treatment of Metastatic Colorectal Cancer, Oncology Exchange, Oct 2005; 4(5):6-9. Gill S and Sinicrope F. Colorectal Cancer Prevention - Is an ounce of prevention worth a pound of cure? Seminars in Oncology, Feb 2005, 32(1). Gill S, Goldberg RM. Duration of Adjuvant Chemotherapy for Colon Cancer - Viewpoint, Nature Clinical Practice Oncology, June 2005, 2(6). Gill S. New Developments in Therapy for Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2005, 1:13-17. Ho C, Ng K, O’Reilly S and Gill S. Outcomes in Older Patients with Advanced Colorectal Cancer: A Population-Based Analysis, Clinical Colorectal Cancer, 2005; 5(4): 279-82. Hoskins, Dr. Paul J Law JKY, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen negative. Hepatitis B core antibody positive patient: implications for future prophylaxis recommendations. Leuk Lymphoma 46, 1085-89, 2005.
UBC Department of Medicine Page 186 Annual Report 2005
Lee CH, Huntsman D, Cheang MCU, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB. Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gyne Path 24, 147-152, 2005. Shenkier TN, Voss N, Chhanabhai M, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Morris J, O’Reilly SE, Pickles T, Sehn L and Connors C. The treatment of primary central nervous system lymphoma (PCNSL) in 122 immunocompetent patients: A population-based study of successively treated cohorts from the British Columbia Cancer Agency (BCCA). Cancer 103, 1008-1017, 2005. Tinker A, Bhagat K, Swenerton KD, Hoskins PJ. Carboplatin and Paclitaxel for advanced and recurrent cervical cancer. Gynecol Oncol 98, 54-58, 2005. Hoskins PJ, Le N. Identifying patients unlikely to benefit further chemotherapy: A descriptive study of outcome at each relapse in ovarian cancer. Gynecol Oncol 97, 862-869, 2005. Knowling, Dr. Margaret (Meg) A Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin C, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M (2005). "Locoregional radiation therapy in patients witih high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial." Journal of the National Cancer Institute 97(2):116-126. Melosky, Dr. Barbara L Couture F, Turner AT, Melosky B, Xiu L, Plante RK, Lau CY, Quirt I. "Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management". The Oncologist 2005; Vol 10(1): 63-71. Murray, Dr. Robert Nevin C Singh S, Parulekar W, Murray N, et al. Influence of sex on toxicity and treatment outcome in small- cell lung cancer. J Clin Oncol 23:850-856, 2005. Ho C, Murray N, Laskin J, Melosky B, Anderson H, Bebb G. Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced and non-small cell carcinoma of the lung in North America. Lung Cancer 225-231, 2005. Al-Tourah A, Murray N, Coppin C, Kollmannsberger C, Man A, Chi K. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant non-seminomatous testicular cancer: a population based analysis from British Columbia. J Urol 174:2209-2213, 2005. Ho C, Davis J, Anderson F, Bebb G, Murray N. Hepatitis following treatment with gefitinib. J Clin Oncol 23;8531-8532, 2005. Norris, Dr. Brian D Savage C, Pater J, Dongsheng T, Norris B. How well do common toxicity criteria and quality of life agree on patient symptoms? Accepted for publication in the Journal of Clinical Oncology. Savage, Dr. Kerry J Feurerhake, F, Kutok JL, Monti S, Cattoretti, G, Kurtin P, Pinkus, GS, de Leval, L, Harris NL, Savage KJ, Habermann T, Dalla-Favera, R, Golub TR, Aster JC, Shipp, MA. NF{kappa}B activity, function and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. August 2005;106(4). Savage KJ, A Nasser, Voss N, Paltiel C, Klasa R, Gascoyne RD and Connors JM. Favourable Outcome of Primary Mediastinal Large B-cell Lymphoma: The British Columbia Experience. Annals of Oncology. 2005 Oct 19 (EPub). Monti S*, Savage KJ*, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RCT, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann T, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5):1851-1861. *shared co-first authorship. UBC Department of Medicine Page 187 Annual Report 2005
Savage KJ and Gascoyne RD. Molecular Signatures of Lymphoma. International Journal of Hematology. 2005. International Journal of Hematololgy. 2004;80(5):401- 409. Smith PG, Wang F, Wilkinson KN, Savage KJ, Neuberg D, Shipp MA, Aguiar RCT. The Phosphodiesterase PDE4B Controls Cell Proliferation and Apoptosis in DLBCL via the PI3K/AKT Pathway. Blood. 2005;105(1):308-316. Rodig S, Savage KJ, Pinkus G, Shipp MA, Aster JA, Kutok JL. Distinct patterns of TRAF-1 expression and c-rel activation in Nodular Sclerosis Hodgkin’s Lymphoma and Anaplastic Large Cell Lymphoma. Am J Surg Path. 2005;29(2):196-203. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM. Primary Paranasal Sinus Lymphoma: Natural History and Improved Outcome with Central Nervous System Chemoprophylaxis. Leukemia and Lymphoma. 2005;46(12):1721-1727. Savage KJ. Aggressive Peripheral T-cell lymphomas (Specified and Unspecifed types). Hematology (American Society of Hematology Education Program). 2005;267-77. Shah, Dr. Amil M Dranitsaris, G, Maroun H, Shah, A. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol 19(2): 83-87, 2005. Dranitsaris G, Maroun J, Shah A. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Supportive Care in Cancer 13(5): 318-324, 2005. Shenkier, Dr. Tamara N Shenkier TN, Voss N, Chhanabhai M, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Morris J, O'Reilly SD, Pickles T, Sehn L, Connors JM. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients. Cancer 2005;103(5):1008-17. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJM, Ponzoni M, O'Brien P, Rubenstein J, Connors JM. Primary CNS Lymphoma of T cell origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group. J Clin Oncol 2005;23(10):2233-9. Panades M, Olivotto IA, Speers Ch, Chenkier TN, Olivotto TA, Weir L, Allan SJ, Truong PT. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol 2005;23(0):1941-50. Shenkier TN. Unusual variants of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005;19(4):651-64, vi. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23(22):5034-43. Swenerton, Dr. Kenneth D Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L and Eisenhauer E. Randomised trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, OSI-211, in women with relapsed epithelial ovarian cancer. J Clin Oncol 2005; 23:1859- 1866. Le LH, Swenerton KD, Elit L, Provencher DM, Stuart GCE, Le T, Lee U, Rogers A, Pond GR, Hu H and Oza AM. Phase II multicentre open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. Int J Gyn Cancer 2005;15:4. Lea RH, Provencher DM, Jeffery JF, Oza A, Reid RL, Swenerton KD. Breast Cancer and Abortion. JOGC 2005, 158:253. Tinker AW, Bhagat K, Swenerton KD and Hoskins PJ. Carboplatin and paclitaxel for advanced cervical carcinoma: the BCCA experience. Gynecol Oncol 2005; 98: 54-58.
UBC Department of Medicine Page 188 Annual Report 2005
Wilson, Dr. Kenneth S Ragaz JR, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CML, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, and Manji M. Loco-regional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial. J Natl Cancer Inst 2005; 97: 116-126.
NEPHROLOGY Duncan, Dr. John A Duncan JA, Levin A. Sex Hemoglobin and Kidney Disease: New Perspectives. European Journal of Clinical Investigation. 35; Suppl 3:52-57, 2005. Gill, Dr. John S M. Tonelli, B. Hemmelgarn, B. Manns, S. Davison, C. Bohm, S. Gourishankar, G. Pylypchuk, K. Yeates, J.S. Gill. Use and outcomes of peritoneal dialysis among Aboriginal people in Canada. Journal of the American Society of Nephrology 2005 Feb; 16(2): 482-8. Gill JS, Ma I, Johnson N, Landsberg D, Levin A. Cardiovascular Events and Investigation In Patients Awaiting Cadaveric Kidney Transplantation. Journal of the American Society of Nephrology 2005 March; 16(3):808-16. Wu M, Gill JS, Johnson N, Pereira BJG, Hariharan S. The Advanced Age Deceased Kidney Donor: Current Outcomes and Future Opportunities. Kidney International 2005 Jun;67(6): 473-80. Gill JS, Jonelli M, Johnson N, Kiberd B, Landsberg D, Pereira BJG. The Impact of Waiting Time and Comorbid Conditions On The Survival Benefit of Kidney Transplantation. Kidney International 2005 November; 68(5):2345-51. Jastrzebski, Dr. Jacek Shalansky KF & Jastrzebski J: Complete Switch to Darbopoietin in a Hemodialysis Unit. Journal of Clinical Nephrology 64 (pp55-64) 2005. Haymond J, Shalansky K, Jastrzebski J: Efficacy of low-dose alteplase for treatment of hemodialysis catheter occlusions. Journal of Vascular Access 2005; 6:76-82. Chen JC, Kamal D, Jastrzebski J, Taylor D: Venovenostomy for outflow venous obstruction in patients with upper extremity autogenous hemodialysis arteriovenous access. Ann Vasc Surg. 2005 Sept;19(5):629-35. Kiaii, Dr. Mercedeh MacRae JM, Ahmed A, Johnson N, Levin A, Kiaii M. "Central Vein Stenosis: A common problem in patients on hemodialysis" ASAIO J. 2005 Jan-Feb, 51(1): 77-81. Landsberg, Dr. David N Gill JS, Ma I, Johnson N, Landsberg D, Levin A. Cardiovascular Events and Investigation In Patients Awaiting Cadaveric Kidney Transplantation. Journal of the American Society of Nephrology 2005 March; 16(3):808-16. Gill JS, Tonelli M, Johnson N, Kiberd B, Landsberg D, Pereira BJG. The Impact Of Waiting Time And Comorbid Conditions On The Survival Benefit Of Kidney Transplantation. Kidney International 2005 Nov: 68(5): 2345-51. Landsberg DN. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. Can. Med. Assoc. J., Nov 2005; 173: 1181-1884. Quamme, Dr. Gary A Goytain A, and GA Quamme. Functional characterization of human SLC41A1, a Mg2+ transporter with similarity to prokaryotic MgtE Mg2+ transporters. Physiol. Genomics, 21:337-342, 2005.
UBC Department of Medicine Page 189 Annual Report 2005
Goytain A, and GA Quamme. Identification and characterization of a novel Mg2+ transporter with channel-like properties. BMC Genomics, 2005 Apr 1;6(1):48 [Epub ahead of print]. Goytain A and GA Quamme. Functional characterization of the human solute carrier, SLC41A2. Biochem Biophys Res Commun, 330:701-705, 2005. Goytain A and GA Quamme. Functional characterization of ACDP2 (ancient conserved domain Mg2+ transporter that is differentially regulated by magnesium) Physiol. Genomics, 2005 May 17;[Epub ahead of print] PMID: 15899945. Taylor, Dr. Paul Andrade Jason, Taylor Paul A, Love Janet M, Levin Adeera, “Successful Reintroduction of a Different Erythropoietic Stimulating Agent after Pure Red Cell Aplasia: Relapse after successful therapy with prednisone”, NDT.
NEUROLOGY
Anderson, Dr. Duncan • Bassett K, Anderson DP: RESIO revisited: visual function assessment and cataract surgery in British Columbia Can J Ophthalmo 2005;40:27-33.
Barton, Dr. Jason J Barton JJS, Lindgren KS, Cherkasova MV, Goff DC, Manoach DS. What is perseverated in schizophrenia? Evidence of abnormal response plasticity in the saccadic system. J Abnormal Psychol 2005; 114: 75-84. Malcolm GL, Leung C, Barton JJS. Regional variation in the inversion effect for faces: different patternsfor feature shape, spatial relations, and external contour. Perception, 2005; 34:1221-31. Barton JJS, Hefter RL, Chang B, Schomer D, Drislane F. The field defects of anterior temporal lobectomy: a quantitative re-assessment of Meyer’s loop. Brain 2005; 128: 2123-33. Barton JJS, Cherkasova MV. Impaired spatial coding within-objects but not between-objects in prosopagnosia. Neurology 2005; 65: 270-4. Hefter R, Manoach DS, Barton JJS. Perception of facial expression and facial identity in patients with developmental social processing disorders. Neurology 2005; 65: 1620-5.
Polli FE, Barton JJS, Cain MS, Thakkar KN, Rauch SL, Manoach DS. Rostral and dorsal anterior cingulate cortex make dissociable contributions during antisaccade error commission. Proc Nat Acad Sci 2005; 102: 15700-5. Edelman J, Valenzuela N, Barton J. Antisaccade velocity, but not latency, depends on the presence of a visible target. Vision Res 2005; Oct 28 epub. Barton JJS, Raoof M, Jameel O, Manoach DS. Task-switching with antisaccades versus no-go trials: a comparison of inter-trial effects. Exp Brain Res, 2005; epub. Barton JJS, Kuzin A, Polli F, Manoach DS. The use of working memory by task prediction: what benefits accrue from different types of foreknowledge? Neuroscience 2005: Dec 1 epub.
Briemberg, Dr. Hannah Briemberg HR, Amato AA. Inflammatory Neuropathies. Current Neurology and Neuroscience Reports 2005;5(1):66-71. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA. Interferon Mediated Innate Immune Mechanisms in Dermatomyositis. Annals of Neurology; 2005;57:664-678. Briemberg HR. 10 Most Commonly Asked Questions About Idiopathic Inflammatory Myopathies. Neurologist; 2005 Jul;11(4):250-3.
UBC Department of Medicine Page 190 Annual Report 2005
Calne, Dr. Donald Calne D, Schulzer M, Mak E, Stoessl AJ (2005). Treatment for the progression of Parkinson's disease. Lancet Neurol; 4:206 (commentary). Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ (2005). PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128: 2777-2785.
Cashman, Dr. Neil Mazzoni IE, Ledebur HC, Paramithiotis E, Cashman NR. Lymphoid signal transduction mechanisms linked to the cellular prion protein. Biochemistry and Cell Biology, 2005 Oct;83(5):644-53. Griffin JK, Cashman NR. Progress in Prion Vaccines and Immunotherapies. Expert Opin Biol Ther 5(1):97-110, 2005. Trojan DA, Cashman NR. Postpoliomyelitis Syndrome. Muscle Nerve 31(1):6-19, 2005.
Curt, Dr. Armin Curt A. Reply to R Jaeger et al.. (Letter to the Editor). Spinal Cord 2005; 43:64. Schmid DM, Curt A, Hauri D, Schurch B. Motor evoked potentials (MEP) and evoked pressure curves (EPC) from the urethral compressive musculature (UCM) by functional magnetic stimulation in healthy volunteers and patients with neurogenic incontinence. Neurourol Urodyn. 2005; 24(2): 117-27. Mangold S., Keller T., Curt A., and Dietz V. Transcutaneous functional electrical stimulation for grasping in subjects with cervical spinal cord injury. Spinal Cord, 2005; 43: 1-13. Alkadhi H, Brugger P, Hotz Boendermaker S, Crelier G, Curt A, Hepp Reymond MC, Kollias S. What disconnection tells about motor imagery. Evidence from paraplegic patients. Cerebral Cortex 2005; 15: 131-40. Hao Z, Reitz A, Kollias S, Summers P, Curt A, Schurch B. A fMRI study of the role of suprapontine brain structures in the voluntary control of voiding. Neuro-Image 2005; 24: 174-80. Curt A. Neurological and functional assessment of recovery from spinal cord injury. Der Orthopäde 2005; 34: 106-112. Curt A, Dietz V. Controversial treatments for spinal cord injuries – first reply (Correspondence). Lancet 2005; 5: 841. Karsenty G, Werth E, Knapp P, Curt A, Schurch B and Bassetti CL. Sleep-related painful erections. Nature Clinical Practice Urology 2005; 2: 256-260. Diehl P, Kliesch U, Dietz V, Curt A. Impaired facilitation of motor evoked potentials in incomplete spinal cord injury. J Neurology 2005 Jul 27 (Epub ahead of print). Paul C, Belotti M, Jezernik S, Curt A. Development of a human neuro-muskulo-skeletal model for investigation of spinal cord injury. BioL Cybern 2005; 93: 153-70.
Devonshire, Dr. Virginia Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65:1919-1923.
Doudet, Dr. Doris V Sossi, G Tropini, D Doudet, M-L Camborde, A Rahim, TJ Ruth. The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET R4: a phantom study. Phys Med Biol. 2005;50:2859-69. Strome EM, Clark CM, Zis AP, Doudet DJ. “Electroconvulsive shock decreases binding to 5-HT2 receptors in non-human primates: an in vivo PET study with [18f]setoperone1" In revision Biological Psychiatry, 57:1004-1010 (2005).
UBC Department of Medicine Page 191 Annual Report 2005
DJ Doudet, TJ Ruth, JE Holden. Sequential vs non-sequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: 2: Divergence in the effects of DAT inhibitors. JCBF. On line June 2005.
Feldman, Dr. Howard Rockwood K, Song X, Hogan DB, Black SE, Gauthier S, MacKnight C, Vandorpe R, Guzman A, Montgomery P, Kertesz A, Bouchard RM, and Feldman H. Clinical and radiographic subtypes of Vascular Cognitive Impairment in a clinical-based cohort study. J Neurol Sci 2005; 240(1-2): 7-14. Shobab L, Hsiung R G-Y, and Feldman H. The Role of Cholesterol in the Pathogenesis of Alzheimer’s Disease. Lancet Neurology. 2005; 4(12): 841-52. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda J, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CH, Boeve B, Burn DJ, Costa D, Del Ser T, Bubois B, Galasko D, Gauthier S, Goetz C, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria R, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee V, Lees A, Litvan I, Londos E, Lopez O, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska E, Pasquier F, Perry RH, Schulz J, Trojanowski J, Yamada M, for the Consortium on DLB. Dementia with Lewy Bodies: Diagnosis and Management: Third Report of the DLB Consortium. Neurology. 2005; 65(12): 1863-72. Feldman H and Woodward M. The Staging and Assessment of Moderate to Severe Alzheimer’s Disease Neurology. 2005; 65(6): S3: S10-S17. Mackenzie IRA and Feldman H. Ubiquitin Immunohistochemistry in Classical MND, MND with Dementia and FTD-MND Type. Journal of Neuropathology & Experimental Neurology. 2005; 64(8): 730-739. Feldman H and Jacova C. Mild Cognitive Impairment. American Journal of Geriatric Psychiatry. 2005; 13(8): 645-655. Feldman H, Gauthier SG, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM and the Donepezil MSAD Study Investigators Group. Efficacy and Safety of Donepezil in Patients with Severe Alzheimer's Disease: evidence from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry. 2005; 20: 559-569. Feldman H and Jacova C: Assessing Mental Status in Dementia: The Behavioral Neurology Assessment. Canadian Journal of Neurological Science .2005; 32(2): 138-139 (Invited Editorial). Peters KR, Graf P, Hayden S, and Feldman H. Neuropsychological Subgroups of Cognitively- Impaired-Not-Demented (CIND) Individuals: Delineation, Reliability and Predictive Validity. Journal of Clinical and Experimental Neuropsychology. 2005; 27:164-188. Feldman H, Hux M, and Schwam EM. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2005; 64(7):1320 (Author Reply). Feldman H, Van Baelen V, Kavanagh SM and Torfs K. Cognition, function and caregiving time patterns in patients with mild-tomoderate Alzheimer disease: a 12-month analysis. Alzheimer Disease and Associated Disorders. 2005; 19(1): 29-36.
Hallam, Dr. Bradley Wecker, N. S., Kramer, J. H., Hallam, B. J., & Delis, D. C. (2004). Mental flexibility: Age effects on switching. Neuropsychology, 19, 345-52.
Hsiung, Dr. Gyk (Robin) Shobab L, Hsiung GR, Feldman H. Cholesterol metabolism and Alzheimer’s Disease. Lancet Neurol. 2005 Dec;4(12):841-52. Spacey S, Vanmolkot K, Murphy C, van den Maagdenberg A, Hsiung GR. Familial hemiplegic migraine presenting as recurrent encephalopathy in a Native Indian family. Headache. 2005 Oct;45(9):1244-9.
UBC Department of Medicine Page 192 Annual Report 2005
Kim, Dr. Seung U Ryu MY, Lee MA, Ahn JH, Cho KG, Kim SU. Brain transplantation of genetically modified neural stem cells in parkinsonian rat. Cell Transplant 14, 193-202, 2005. Lee K, Jeon K, Kim JM, Kim VN, Choi DH, Kim SU, Kim SY. Downregulation of GFAP, TSP-1 and p53 in human glioblastoma cell line, U373MG, by IE1 protein from cytomegalovirus: Implication for the possible role for IE1 in the pathogenesisg of glioma. Glia 51, 1-12, 2005. Lee ST, Chu K, Park JE, Lee K, Kang L, Kim SU, Kim M. Intravenous administration of human neural stem cells induces functionalrecovery in Huntington's disease rat model. Neurosci Res 52, 243- 249, 2005. Jung YS, Lee BK, Park HS, Shim JK, Kim SU, Lee SH, Baik EJ, Moon CH. Activation of protein kinase C-delta attenuates kainate-induced cell death of cortical neurons. Neuroreport 16, 741-744, 2005. Park HS, Lee BK, Park S, Kim SU, Lee SH, Baik EJ, Lee S, Yi KY, Yoo SE, Moon CH, Jung YS. Effects of sabiporide, a specific Na+/H+ exchanger inhibitor, on neuronal cell death and brain ischemia. Brain Res 1061, 67-71, 2005. Choi SH, Lee da Y, Kim SU, Jin BK. Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase. J Neurosci 25, 4082-4090, 2005. Kim YH, Lee DS, Kang JH, Lee YJ, Chung JK, Roh JK, Kim SU, Lee MC. Reversing the silencing of reporter sodium/iodide symporter transgene for stem cell tracking. J Nucl Med 46, 305-311, 2005. Kim SR, Lee DY, Chung ES, Oh UT, Kim SU, Jin BK. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J Neurosci 25, 662-671, 2005. Franciosi S, Choi HB, Kim SU, McLarnon JG. IL-8 enhancement of amyloid-beta (Abeta 1-42)- induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. J Neuroimmunol 59, 66-74, 2005. Kim EH, Kim SU, Choi KS. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene. 24, 838-849, 2005. Kim SS, Choi JM, Kim JW, Ham DS, Ghil SH, Kim MK, Kim-Kwon Y, Hong SY, Ahn SC, Kim SU, Lee YD, Suh-Kim H. cAMP induces neuronal differentiation of mesenchymal stem cells via activation of extracellular signal-regulated kinase/MAPK. Neuroreport 16, 1357-1361, 2005. Schmidt NO, Przylecki W, Yang W, Ziu M, Teng Y, Kim SU, Black PM, Aboody KS, Carroll RS. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia 7, 623-629, 2005. Kim EH, Kim HS, Kim SU, Noh EJ, Lee JS, Choi KS. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 24, 6877-6889, 2005. Kim SU, de Vellis J. (Editors) Microglia special issue. J Neurosci Res 81(3), 2005. de Vellis J, Kim SU. Foreword. J Neurosci Res 81, 301, 2005. Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res 81, 302-313, 2005. Nagai A, Mishima S, Ishida Y, Ishikura H, Harada T, Kobayashi S, Kim SU. Immortalized human microglial cell line: Phenotypic expression. J Neurosci Res 81, 342-348, 2005. Park KW, Lee DY, Joe EH, Kim SU, Jin BK. Neuroprotective role of microglia expressing interleukin-4. J Neurosci Res 81, 397-402, 2005. McLarnon JG, Choi HB, Lue LF, Walker DG, Kim SU. Perturbations in calcium-mediated signal transduction in microglia from Alzheimer's disease patients. J Neurosci Res 81, 426-435, 2005. Lee EM, Kim JY, Cho BR, Chung WK, Yoon BW, Kim SU, Lee BC, Hwang WS, Moon SY, Lee JS, Ahn C. Down-regulation of MHC class I expression in human neuronal stem cells using viral stealth mechanism. Biochem Biophys Res Commun 326, 825-835, 2005.
UBC Department of Medicine Page 193 Annual Report 2005
Krieger, Dr. Charles Shan, X., Hu, J.H., Cayabyab, F.S. and Krieger, C. (2005) Increased phospho-adducin immunoreactivity in a murine model of amyotropic lateral sclerosis. Neuroscience, 134:833-846.
Leavitt, Dr. Blair Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF. (2005) Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. Journal of Neurochemistry 95: 553-562. Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. (2005) Ethyl-EPA in Huntington disease: a double- blind, randomized, placebo-controlled trial. Neurology. 2005 Jul 26;65(2):286-92. Devon RS, Schwab C, Topp JD, Orban PC, Yang Y, Pape TD, Helm JR, Davidson TL, Rogers DA, Gros-Louis F, Rouleau G, Horazdovksy BF, Leavitt BR, Hayden MR. (2005) Cross-Species Characterization of the ALS2 Gene and Analysis of its Pattern of Expression in Development and Adulthood. Neurobiology of Disease Mar;18(2):243-57. Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR. (2005) Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington’s Disease. Journal of Neuroscience Apr 20;25(16)4169-80. Slow EJ, Graham RK, Osmand A, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. (2005) Absence of Behavioural Abnormalities and Neurodegeneration in vivo despite Widespread Neuronal Huntingtin Inclusions. Proc Natl Acad Sci U S A. 2005 102(32)11402-11407. Missirlis PI, Mead CL, Butland SL, Ouellette BF, Devon RS, Leavitt BR, and Holt RA. (2005) Satellog: A Database for the Identification and Prioritization of Satellite Repeats in Disease Association Studies. BMC Bioinformatics. Jun 10;6(1):145. Van Raamsdonk JM, Pearson J, Rogers D, Bissada N, Vogl AW, Hayden MR, Leavitt BR. (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Human Molecular Genetics 14(10)1379-92. Pinto JT, Van Raamsdonk J, Leavitt, BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJ. (2005) Treatment of YAC128 Mice with Cystamine Does not Lead to Its Accumulation in Plasma or Brain: Implications for the Treatment of Huntington Disease. Journal of Neurochemistry 2005 Aug;94(4):1087-101. Van Raamsdonk JM, Pearson J, Bailey CDC, Rogers DA, Johnson GVW, Hayden MR, Leavitt BR. (2005) Cystamine Treatment is Neuroprotective in the YAC128 Mouse Model of Huntington’s Disease. Journal of Neurochemistry J Neurochem. Oct;95(1):210-20. Van Raamsdonk JM, Pearson J, Rogers D, Lu G, Hayden MR and Leavitt BR. (2005) Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol. 2005 Aug 27 [Epub ahead of print]. Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA. (2005) Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2005 Sep 13; [Epub ahead of print]. Graham RK, Slow EJ, Deng Y, Bissada N, Lu G, Pearson J, Shehadeh J, Leavitt BR, Raymond LA, and Hayden MR. (2005) Levels of mutant huntingtin influence the phenotypic severity of Huntington Disease in YAC128 mouse models. Neurobiology of Disease Oct. 13; [Epub ahead of print] Van Raamsdonk JM, Murphy Z, Slow E, Leavitt BR, Hayden MR. (2005) Selective Degeneration and Nuclear Localization of Mutant Huntingtin in the YAC128 Mouse Model of Huntington Disease. Human Molecular Genetics 2005 Nov 8; [Epub ahead of print]
UBC Department of Medicine Page 194 Annual Report 2005
Lee, Dr. Chong Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ (2005). PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128: 2777-2785. Li, Dr. David Schwid SR, Thorpe J, Sharief M, Sandberg-Wolheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G for the EVIDENCE Study Group and the UBC MS/MRI Research Group: Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis: The EVIDENCE Study. Arch Neurol 62: 785-794, 2005. Barkhof F, Held U, Simon JH, Daumer M, Fazekas F, Filippi M, Frank JA, Kappos L, Li DKB, Menzler S, Miller DH, Petkau J, Wolinsky JS: Predicting gadolinium-enhancement status in MS patients eligible for randomized clinical trials. Neurology 65:1447-1454, 2005. Brief E, Whittall KP, Li DKB, MacKay AL: Proton T2 relaxation of cerebral metabolites of normal human brain over large TE range. NMR in Biomedicine 18:14-18, 2005. Traboulsee A, Zhao GJ, Li DKB. Neuroimaging in Multiple Sclerosis. Neurol Clin 23: 131-148, 2005. Brief,E, Whittall, K, Li, D, MacKay,A, “Proton T2 Relaxation of cerebral metabolites of normal human brain over a large TE range, NMR in Biomedicine, 18, 14-18, 2005.
McKeown, Dr. Martin Liao, Rui, Jeffrey L Krolik and Martin J McKeown. "An information-theoretic criterion for intrasubject alignment of FMRI time series: motion corrected independent component analysis.". IEEE TRANSACTIONS ON MEDICAL IMAGING. 24.1 (Jan, 2005): 29 - 44. Buffington, Angela L H, Colleen A Hanlon and Martin J McKeown. "Acute and persistent pain modulation of attention-related anterior cingulate fMRI activations.". PAIN. 113.1-2 (Jan, 2005): 172 - 184. Hanlon, C.A., A.L.H. Buffington and M.J. McKeown. "Altered sensorimotor processing during ipsilesional arm movement after MCA stroke.". NEUROLOGY. 64 (2005): 114 - 120. Hanlon, Colleen A, Angela L H Buffington and Martin J McKeown. "New brain networks are active after right MCA stroke when moving the ipsilesional arm.". Journal with ISSN: 1526-632X. 64.1 (Jan 11, 2005): 114 - 120.
Murphy, Dr. Colleen Spacey SD, Vanmolkot KR, Murphy C, van den Maagdenberg AM, Hsiung RG. Familial hemiplegic migraine presenting as recurrent encephalopathy in a native Indian family. Headache. 2005 Oct;45(9):1244-9. Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, Freeman TB, Stoessl AJ (2005). Longitudinal study by PET after fetal tissue transplants in Huntington’s Disease. Ann. Neurol. 58(2):331-7.
Oger, Dr. Joel Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005 Aug;11(4):398-402. Oger J, Francis G, Chang P; On behalf of the PRISMS Study Group. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: The PRISMS study. J Neurol Sci. 2005 Oct 15;237 (1-2):45-52. J. Oger. In memoriam Don Paty. Neurology 2005:65:984-985.
UBC Department of Medicine Page 195 Annual Report 2005
Pelech, Dr. Steve Djeha, H., Todryk, S.M., Pelech, S., Wrighton, C.J., Irvine, A.S., Mountain, A. & Lipinski, K.S. Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70. Cancer Gene Therapy 12:560-571 (2005). Jia, Z., Barbier, L., Amraei, M., Pelech, S., Dennis, J.W., Metalnikov, P., O¹Donnell, P.O. & Nabi, I. R. Tumor cell pseudopodial protrusions: Localized signalling domains coordinating cytoskeleton remodelling, cell adhesion, glycolysis, RNA translocation, and protein translation. J Biol Chem. 280:30564-30573 (2005). Adams, G., Coffee Jr., R.L., Zhang, H., Pelech, S.L., Strack, S. & Wadzinski, B.E. Positive regulation of Raf/MEK/ERK signaling by protein serine/threonine phosphatase 2A holoenzymes. J. Biol Chem. 280:42644-42654 (2005).
Raymond, Dr. Lynn Hogarth, P., Kayson, E., Kieburtz, K., Marder, K., Oakes, D., Rosas, D., Shoulson, I., Wexler, N.S., Young, A.B., Zhao, H., the U.S.-Venezuala Huntington’s Disease Collaborative Research Group, and the Huntington Study Group. (2005) Interrater Agreement in the Assessment of Motor Manifestations of Huntington’s Disease. Movement Disorders, 20:293-297. (My name appears among those in the Huntington Study Group in appendix of contributors to research described in the paper) Raymond, L.A. and Goumeniouk, A.D. (2005) Huntington Disease: Targeting the Triad. The Canadian Journal of Diagnosis, 22(4):82-87.
Ruth, Dr. Thomas V. Sossi, K. R. Buckley, P. Piccioni, A. Rahmim, M.-L. Camborde, S. Lapi, T. J. Ruth. Printed Sources For Positron Emission Tomography (PET) IEEE NS; 52, (2005): 114 - 118. AR Studenov, MJ Adam, JS Wilson, TJ Ruth. New radiolabelling chemistry: Synthesis of phosphorus-[18F]fluorine compounds. J Label. Comp. Radiopharm. 48: 497-500 (2005). V Sossi, G Tropini, D Doudet, M-L Camborde, A Rahim, TJ Ruth. The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET R4: a phantom study. Phys Med Biol. 2005;50:2859-69. R Ting, MJ Adam, TJ Ruth, DM Perrin. Arylfluoroborates and Alkylfluorosilicates as Potential PET Imaging Agents: High Yielding Aqueous Biomolecular 18F-Labeling. J. Am. Chem. Soc. (2005), 127: 13094-13095. DJ Doudet, TJ Ruth, JE Holden. Sequential vs non-sequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: 2: Divergence in the effects of DAT inhibitors. JCBF. On line June 2005. V Sossi, TJ Ruth, Small animal PET imaging: in-vivo biochemistry. J. Neural Transmission. 112: 319 - 330 (2005). Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ (2005). PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128: 2777-2785.
Sadovnick, Dr. Adele D Willer CJ, Dyment DA, Sadovnick AD, Ebers GC. Maternal-offspring HLA compatibility in multiple sclerosis. Tissue Antigens 66:44-47, 2005.
Dyment, DA, Herrera BM, Cader Z, Willer CJ, Lincoln MR, Sadovnick AD, Risch N, Ebers GC. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol. Genet. (Epub June 2005) 14:2019-2026.
UBC Department of Medicine Page 196 Annual Report 2005
Sadovnick AD, Yee IML, Ebers GC for The Canadian Collaborative Study Group. Multiple Sclerosis and Birth Order. Lancet Neurology (online) 2005; doi:10.1016/S1474-4422(05)70170-8; Lancet Neurology 4:611-617, 2005. Waubant E, Sadovnick AD. Interferon babies. EDITORIAL. Neurology 2005; 65:788-789. Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M, Ferretti V, Tienari PJ, Sadovnick AD, Peltonen L, Ebers GC, Hudson TJ. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis.Nat Genet. 2005 Oct;37(10):1108-12. Epub 2005 Sep 25. Evans L, Akiskal HS, Keck PE Jr, McElroy SL, Sadovnick AD, Remick RA, Kelsoe JR. Familiality of temperament in bipolar disorder: support for a genetic spectrum. J Affect Disord. 2005 Mar;85(1- 2):153-68. Nievergelt CM, Kripke DF, Remick RA, Sadovnick AD, McElroy SL, Keck PE Jr, Kelsoe JR. Examination of the clock gene Cryptochrome 1 in bipolar disorder: mutational analysis and absence of evidence for linkage or association. Psychiatr Genet. 2005 Mar;15(1):45-52. Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC; Canadian Collaborative Study Group. Timing of birth and risk of multiple sclerosis: population based study. BMJ. 2005 Jan 15;330(7483):120. Epub 2004 Dec 7.
Sossi, Dr. Vesna V. Sossi, K. R. Buckley, P. Piccioni, A. Rahmim, M.-L. Camborde, S. Lapi, T. J. Ruth. Printed Sources For Positron Emission Tomography (PET) IEEE NS; 52, (2005): 114 - 118. V Sossi, G Tropini, D Doudet, M-L Camborde, A Rahim, TJ Ruth. The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET R4: a phantom study. Phys Med Biol. 2005;50:2859-69. V Sossi, TJ Ruth, Small animal PET imaging: in-vivo biochemistry. J. Neural Transmission. 112: 319 - 330 (2005). Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, Freeman TB, Stoessl AJ (2005). Longitudinal study by PET after fetal tissue transplants in Huntington’s Disease. Ann. Neurol. 58(2):331-7. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ (2005). PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128: 2777-2785.
Spacey, Dr. Sian Spacey SD, Vanmolkot KR, Murphy C, van den Maagdenberg AM, Hsiung RG. Familial hemiplegic migraine presenting as recurrent encephalopathy in a native Indian family. Headache. 2005 Oct;45(9):1244-9. Spacey SD, Materek LA, Szczwgielski Bi, Bird TD. Two novel CACNA1A gene mutations associated with episodic ataxia type 2 and interictal dystonia. Arch Neurol. 2005 Feb;62(2):314-6. TM Spacey SD. Adams P. Familial Paroxysmal Kinesigenic Dyskinesia. GeneReviews at the GeneTests-GeneClinic Web site. Available at http://www.geneclinics.org (2005). TM Spacey SD. Adams P. Familial Paroxysmal Non-Kinesigenic Dyskinesia. GeneReviews at the GeneTests-GeneClinic Web site. Available at http://www.geneclinics.org (2005).
Stoessl, Dr. Jon Au WL, Adams JR, Troiano AR, Stoessl AJ (2005). Parkinson's disease: In vivo assessment of disease progression using Positron Emission Tomography (PET). Mol. Brain Res. 134: 24-33. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, Gwinn-Hardy K, McFarland H, Innis R, Katz RG, Kieburtz K, Kish SJ, Lange N, Langston JW, Marek K, Morin L, Moy C, Murphy D, Oertel WH, Oliver G, Palesch Y, Powers W,
UBC Department of Medicine Page 197 Annual Report 2005
Seibyl J, Sethi KD, Shults CW, Sheehy P, Stoessl AJ, Holloway R (2005). The role of radiotracer imaging in Parkinson disease. Neurology 64: 208-215. Stoessl AJ, McGeer PL (2005). Hot spots: can positron emission tomography offer insights into the pathogenesis of PD? Ann. Neurol. 57: 161-162 (Editorial). Calne D, Schulzer M, Mak E, Stoessl AJ (2005). Treatment for the progression of Parkinson's disease. Lancet Neurol; 4:206 (commentary). Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, Freeman TB, Stoessl AJ (2005). Longitudinal study by PET after fetal tissue transplants in Huntington’s Disease. Ann. Neurol. 58(2):331-7. Lang AE, Miyasaki J, Olanow CW, Stoessl AJ, Schowersky O (2005). A forum on the early management of Parkinson's disease. Can J Neurol Sci 32:277-286. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ (2005). PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128: 2777-2785. Lidstone SC, de la Fuente-Fernandez R, Stoessl AJ (2005). The placebo response as a reward mechanism. Sem. Pain Medicine 3: 37-42 (invited paper).
Teal, Dr. Philip Hill MD, Buchan AM, for the CASES Investigators: Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for stroke effectiveness study. CMAJ 2005;172:1307-12. Teal P, Silver FL, Simard D. Safety, Tolerability, and Dose-finding of Repinotan in Acute Stroke. The Canadian Journal of Neuroscience. 2005;32:61-67. 3. Muir KW, Teal PA. Why have neuroprotectants failed? Lessons learned from stroke trials. J Neurol. 2005 August 25;[Epub ahead of print].
Traboulsee, Dr. Anthony Traboulsee A, Zhao GJ, Li DKB. Neuroimaging in Multiple Sclerosis. Neurol Clin 23: 131-148, 2005. Tremlett HL, Traboulsee T. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology; 2005; 64(1):174.
Tremlett, Dr. Helen Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65:1919-1923. Banwell, B and Tremlett H Coming of Age: The Use of Immunomodulatory Therapy in Paediatric Multiple Sclerosis. Neurology 2005; 64:778-779. Tremlett HL, Traboulsee T. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology; 2005; 64(1):174.
Wang, Dr. Yu Tian Brebner K, TP Wong, L Liu, Y Liu, P Campsall, S Gray, L Phelps, AG Phillips, YT Wang, Nucleus Accumbens Long-Term Depression and the Expression of Behavioral Sensitization, Science, 310:1340-1343, 2005. Levinson JN, N Chéry, K Huang, TP Wong, K Gerrow, R Kang, O Prange, YT Wang and A El- Husseini, Neuroligins mediate excitatory and inhibitory synapse formation: involvement of PSD-95 and neurexin-1 beta in neuroligin-induced synaptic specificity. J. Biol. Chem. 280:17312-17319, 2005. Mielke JG, C Taghibiglou, L Liu, Y Zhang, Z Jia, K Adeli and YT Wang, A biochemical and functional characterization of diet-induced brain insulin resistance. J. Neurochem. 93:1568-1578, 2005.
UBC Department of Medicine Page 198 Annual Report 2005
Kim MJ, AW Dunah, YT Wang and M Sheng, Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signalling and AMPA receptor trafficking. Neuron 46:745-760, 2005. Mielke JG and YT Wang, Insulin exerts neuroprotection by counteracting the decrease in cell-surface GABAA receptors following oxygen-glucose deprivation in cultured cortical neurons. J. Neurochem. 92:103-113, 2005. Lise MF, Wong TP, Trinh A, Hines RM, Liu L, Kang R, Hines DJ, Lu J, Goldenring JR, Wang YT, A El-Husseini. Involvement of myosin Vb in glutamate receptor trafficking, J. Biol. Chem. Online published in Dec. 2005.
PHYSICAL & REHAB MEDICINE Hughes, Dr. Barbara L Hughes BL, Sawatzky BJ, Hol AT. 2004. A comparison of Spinergy vs standard steel-spoke wheelchair wheels. Archives of Physical Medicine and Rehabilitation, 2005; 86(3):596-601.
RESPIRATORY MEDICINE Ayas, Dr. Najib T F Scheer, JM Zeitzer, NT Ayas, R Brown, CA Czeisler, SA Shea. Reduced Sleep Efficiency In Cervical Spinal Cord Injury; Association With Abolished Nighttime Melatonin Secretion: Preliminary Communication. Spinal Cord Medicine Aug 2005. 1-4. Zeitzer JM, Ayas NT, Shea SA, Wu AD, Czeisler CA, Brown R. Bilateral oculosympathetic paresis associated with loss of nocturnal melatonin secretion in patients with spinal cord injury. J Spinal Cord Med. 2005; 28(1):55-9. Tachibana N, Ayas NT, White DP. An Analysis of Sleep Laboratory Activity in the United States. Journal Clinical Sleep Medicine 2005; 1:1-4. Bajwa E, Ayas NT, Schulzer M, Mak E, Ryu J, Malhotra A. Interferon Gamma-1b Therapy in Idiopathic Pulmonary Fibrosis: A Metaanalysis. Chest 2005; 128:203-206. Barger LK, Cade BE, Ayas NT, Cronin JW, Rosner B, Speizer F, Czeisler CA. Impact of Extended Duration Work shifts (>=24 hours) on Intern Sleep and Risk of Motor Vehicle Crashes. New England Journal of Medicine 2005; 352: 125-34. [subject of editorial] Wang CS, Fitzgerald JM, Schulzer M, Mak E, Ayas NT. Does This Dyspneic Patient in the Emergency Department Have Congestive Heart Failure? JAMA 2005. 294:1944-56. Brauer, Dr. Michael Smargiassi A, Baldwin M, Pilger C, Dugandzic R, Brauer M. Small scale spatial variability of particle concentrations and traffic levels in Montreal: a pilot study. Sci Total Environ. 2005 Feb 15;338(3):243-51. Varuguese S, Teschke K, Brauer M, Chow Y, van Netten C, Kennedy S. Effects of theatrical smokes and fogs on respiratory symptoms and lung function. American Journal of Industrial Medicine. 2005 May;47(5):411-8. Teschke K, Chow Y, van Netten C, Varughese S, Kennedy S, Brauer M. Exposures to atmospheric effects in the entertainment industry. Journal of Occupational and Environmental Hygiene. 2005 May;2(5):277-84. Ebelt St, Wilson WE, Brauer M. Exposure to ambient and nonambient componoents of particulate matter: A comparison of health effects. Epidemiology. 2005;16(3):396-405. Cohen, Dr. Richard D Cohen RD, Murnaghan L, Collins J, Pratt D. An Update on Masters Degrees in Medical Education. Medical Teacher 2005; 27: 686-692.
UBC Department of Medicine Page 199 Annual Report 2005
Cook, Dr. Victoria J Cook VJ, Hernandez-Garduno E, Kunimoto D, Hershfield ES, Fanning A, Hoeppner VH, Elwood RK, FitzGerald JM and the Canadian Molecular Epidemiology of Tuberculosis Study Group. The lack of association between bacille Calmette-Guerin vaccination and clustering of Aboriginals with tuberculosis in western Canada. Can Respir J. 2005 Apr;12(3):134-8. Duronio, Dr. Vincent Jamil, S, Soboutti R, Hojabrpour P, Raj M, Kast J and Duronio V. A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth via interaction with Cdk1. Biochem J. 387, 659-667, 2005. Wang S, Denny TA, Steinbrecher, UP and Duronio V. Investigations of Bad phosphorylation in hemopoietic cells. Apoptosis 10, 341-348, 2005. Scott A, Khan KM and Duronio V. IGF-I activates PKB and prevents anoxic apoptosis in Achilles tendon cells. J Orthopaedic Res., 23, 1219-1225, 2005. Scott A, Hkan KM, Heer J, Cook, JL, Lian O, Duronio V. High strain mechanical loading rapidly induces tendon apoptosis: An ex-vivo rat tibialis anterior model. British J. Sports Medicine 39, e25 (4 pages) 2005. Gomez-Munoz A, Kong JY, Parhar K, Wang S, Gangoiti P, Gonzalez M, Eivemark S, Salh B, Duronio V, Steinbrecher UP. Ceramide 1-phosphate promotes cell survival through activation of the phosphatidylinositol 3-kinase/protein kinase B Pathway. FEBS Letters, 579, 3744-50 (2005). Chiu D, Ma K, Scott A, Duronio V. Acute activation of Erk1/Erk2 and PKB/Akt proceed by independent pathways in multiple cell types. FEBS Journal, 272, 4372-4384 (2005). Khalil N, Xu YD, O'Connor R, Duronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by TGF-ß induced release of extracellular FGF-2 and phosphorylation of p38 MAPK and JNK. J. Biol. Chem., published online, Oct. 2005. Elwood, Dr. Richard K Mansouri D, Adimi P. Mirsaedi M, Mansouri N, Tabarsi P, Amiri M, Jamaati HR, Motavasseli M, Baghaii N, Cheraghvandi A, Rouhi R, Roozbahany NA, Zahirifard S, Mohammadi F, Masjedi MR, Velayati AA, Casanova JL, Speert DP, Elwood RK, Schellenberg R, Turvey SE. Primary Immune Deficiencies Presenting in Adults: Seven Years of Experience from Iran. J Clin Immuno Vol. 25 No. 4, July 2005. Marra F, Marra CA, Moadebi S, Shi P, Elwood RK, Stark G, FitzGerald JM. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005 Sept;128(3):1406-13. Elwood RK, Cook VJ, Hernández-Garduño E. Risk of tuberculosis in children from smear negative source cases. Int J Tuberc Lung Dis 2005;9(1): 49-50. Cook VJ, Hernández-Garduño E, Kunimoto D, Hershfield ES, Fanning EA, Hoeppner VH, Elwood RK, FitzGerald MJ and the Canadian Molecular Epidemiology of Tuberculosis Study Group. The lack of association between bacilli Calmette-Guérin vaccination and clustering of Aboriginals with tuberculosis in western Canada. Can Respir J 2005:12(3)134-138. FitzGerald, Dr. J. Mark Oosterbrink JB, Maureen PMH, Rutten-van Molken, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost effectiveness of bronchodilator therapy in COPD patients in different countries. Value in Health 2005;8:32-46. Yassi A, Moore D, FitzGerald JM, Bigelow P, Hon C-Y, Bryce E and the BC Inter disciplinary respiratory protection study group. Research gaps in protecting health care workers from SARS and other respiratory pathogens: an interdisciplinary, multi-stakeholder, evidence based approach. Journal of Occupational and Environmental Medicine 2005 47:41-50. Ogilvie G, Patrick DM, Schulzer M, Sellors JS, Petric M, Chambers K, White R, FitzGerald JM. Diagnostic accuracy of self collected cervico vaginal samples for human papillomavirus vs. clinician collected samples: a meta analysis. Sex Transm Infect 2005;81:207-212.
UBC Department of Medicine Page 200 Annual Report 2005
Marra F, Marra C, Moadebi S, Shi P, Elwood RK, Stark G, FitzGerald JM. Levofloxacin Treatment of Active Tuberculosis and the Risk of Adverse Events. Chest 2005; 128:1406-1413. Dennis R, Solarte I, FitzGerald JM. Asthma. Clinical Evidence. McGregor MJ, FitzGerald JM, Reid RJ, Levy AR, Schulzer M, Jung D, Groshaus HE, Cox M. Determinants of Hospital Length of Stay Among Pneumonia Admissions To A Large Canadian Hospital Over the Past Decade. Can Resp J 2005 12:365-370. Wang C, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 2005;294:1944-1956. FitzGerald J M, Boulet Louis-Philippe LP, Follows RMA. CONCEPT: A one year, multi centre, randomized double blind , double-dummy comparison of salmeterol/fluticasone propionate using a stable dosing regimen with formoterol/budesonide using an adjustable maintenance regimen in adults persistent asthma. Clinical Therapeutics 2005;27:1-14. Moore D, Gamage B, Bryce E, Copes R, Yassi A and members of The BC Interdisciplinary Respiratory Protection Study Group. Protecting health care workers from SARS and other respiratory pathogens: Organizational and individual factors that affect adherence to infection control guidelines. American Journal of Infection Control 2005;33 (2):88-96. Levy AR, Sobolev BG, Hayden R, Kiely M, FitzGerald M, Schechter MT et al. Time on wait lists for coronary bypass surgery in British Columbia, Canada, 1991 – 2000. BMC Health Services Research 2005;5-22. Alvarez G, Schulzer M, FitzGerald JM. Risk factors for near fatal asthma - a meta analytic review. Can Resp J 2005;5:265-270. Etminan M, FitzGerald JM, Gleave M, Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta analysis. Cancer Causes and Control 2005;16:1125-1131. Becker A, Lemiere C, Berube D, Boulet L-P, Ducharme F, FitzGerald JM, Kovesi T on behalf of the Asthma Guidelines working group of the Canadian Network for Asthma Care and the Canadian Thoracic Society. CMAJ 2005;173:S1-S11. Weiner M, Benatar D, Burman W et al and the Tuberculosis Clinical Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40:1481-91. Henderson WR, Chittock D, Dhingra V,Doyle-Waters M, FitzGerald M, Ronco J. Intensive insulin therapy and strict glucose control for critically ill patients. Cochrane Database of Systematic Reviews. 3, 2005. American Thoracic Society/Centres of Disease Control and prevention/Infectious Disease Society of America: Controlling Tuberculosis in the United States. Am J Respir Crit Care Med 2005;172:1169-1227. Etminan M, Gill S, FitzGerald M, Samii A. Challenges and opportunities for pharmacoepidemiology in drug therapy and decision making. J Clin Pharmacol 2005;45:450-453. Fleetham, Dr John A Tsuiki S, Lowe AA, Almeida FR, Su J, Fleetham JA The interaction between changes in upright mandibular position and supine airway size in obstructive sleep apnea patients. Am J Orthod Dento Orthop, 128(4):504-512, 2005. Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K, Belenkie I, Pfieffer M, Fleetham J, Hanly P, Smilovitch M, Tomlinson G, Floras JS. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med. 353: 2025-33, 2005. Khalil, Dr. Nasreen Mancini, G.B. and Khalil, N. Angiotensin Type 1 Receptor Blocker Inhibits Pulmonary Injury, Clin Invest Med, 2005 ;28:118-126.
UBC Department of Medicine Page 201 Annual Report 2005
Lam, Dr. Stephen C Sin DD, Man SF, McWilliams A, Lam S. Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med 2005. Coe BP, Henderson LJ, Garnis C, Tsao M-S, Gazdar A, Minna J, Lam S, MacAulay C, Lam WL. High resolution chromosome 5p array CGH analysis of small cell lung carcinoma cell lines. Genes Chromosomes and Cancer 2005. 42(3): p. 308-313. Henderson LJ, Coe BP, Lee E, Girard L, Gazdar AF, Minna JD, Lam S, MacAulay C, Lam WL. Genomic and gene expression profiling of minute alterations of chromosome arm 1p in small-cell lung carcinoma cells. Brit J Cancer 2005. 92(8):p. 1553-60. Coe BP et al. Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small cell lung cancer cell lines. Genes Chromosomes Cancer. 2005. Aug 29 [Epub ahead of print]. Garnis C et al. Chromosome 5p aberrations and glial cell line-derived neurotrophic factor activation are early events in lung cancer. Oncogene. 2005. 24:p. 4806-12. Garnis C, et al. High resolution analysis of non-small cell cancer cells line by whole genome tiling path array CGH. Int J Cancer. 2005. Sep 26 [Epub ahead of print]. Garnis C, Campbell J, Davies JJ, Lam S, MacAulay C, Lam WL. Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis. Hum Mol Genet 2005;14(4)475-482. Tichelaar JW, Zhang Y, leRiche JC, Biddinger PW, Lam S, Anderson MW. Increased staining for phosopho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer 2005,5:155. 06 Dec 2005. Sin DD, Man Paul SF, McWilliams A, Lam S. Progression of Airway Dysplasia and C-reactive Protein in Smokers at High Risk of Lung Cancer. Respiratory and Critical Care Medicine. 2005. Dec 9 [Epub ahead of print]. Guillaud M, leRiche J, Daw C, Korbelik J, Coldman A, Wistuba I, Park IW, Fazdar A, Lam S, MacAulay C. Nuclear morphometry as a Biomarker for Bronchial Intraepithelial Neoplasia: Correlation with Genetic Damage and Cancer Development. Cytometry Part A (1):34-40, 2005. Levy, Dr. Robert D Stephenson, A, Flint J, English J, Bedal S, Fradet G, Chittock D, Levy RD. Interpretation of transbronchial lung biopsies from lung transplant recipients: Inter- and intra-observer agreement. Can Respir J 2005;12:75-77. Maltais F, Bourbeau J, Lacasse Y, Shapiro S, Perrault H, Penrod JR, Baltzan M, Rouleau M, Julien M, Paradis B, Audet R, Hernandez P, Levy RD, Camp P, Lecours R, Picard D, Bernard S. A Canadian, multicentre randomized clinical trial of home-based pulmonary rehabilitation in COPD: rationale and methods. Can Resp J 2005;12:193-98.
Man, Dr. S. F. P Sin D, Man SFP, Marrie T. Arterial Carbon Dioxide Tension On Admission As A Marker Of In-Hospital Mortality In Community-Acquired Pneumonia. Am. Journ. Med. 2005; 118:145-150. Sin DD, and Man SFP. COPD: A Novel Risk Factor for Cardiovascular Disease. Can J Physiol and Pharmacol. 2005 83:8-13. Gan WQ, Man SFP, and Sin DD. The Interactions Between Cigarette Smoking and Reduced Lung Function on Systemic Inflammation. Chest 2005; 127: 558-564. Gan WQ, Man SFP, and Sin DD. Effects of Inhaled Corticosteroids on Sputum Cell Counts in Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. BMC Pulmonary Medicine 2005: 5:(1-14). Sin DD, and Man SFP. Can Inhaled Steroids Mend a Broken Heart in Chronic Obstructive Pulmonary Disease? An Editorial. Eur. Respir. J. 2005; 25: 589-590. Man SFP, and Sin DD. Inhaled Cortico-steroids in COPD: Is there a Clinical Benefit? Drugs 2005; 65:579-91.
UBC Department of Medicine Page 202 Annual Report 2005
Sin D, Wu L, and Man SFP. The Relationship Between Reduced Lung Function and Cardiovascular Mortality. A Systematic Review of the Literature. Chest 2005;127:1952-1959. Wasswa-Kintu S, Gan WQ, Man SFP, Pare P, and Sin DD. The Relationship Between Reduced Forced Expiratory Volume in One Second and The Risk of Lung Cancer: A Systematic Review and Meta-Analysis. Thorax 2005;60:570-5. Borszcz PD, Befus AD, Moqbel R, Sin DD, Man SFP, and Lacy P. Effects of Clarithromycin on Inflammatory Cell Mediator Release and Survival. Chemotherapy 2005;51:206-210. Pare, Dr. Peter D Nakano Y, Wong JC, de Jong PA, Buzatu L, Nagao T, Coxson HO, Elliott WM, Hogg JC, Pare PD. The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med; 171(2): 142-6, 2005 (Epub Oct 29, 2004). De Jong PA, Nakano Y, Hop WC, Long FR, Coxson HO, Pare PD, Tiddens HA. Changes in airway dimensions on computed tomography scans of children with cystic fibrosis; Am J Respir Crit Care Med (Epub ahead of print April 14 2005). Herrera AM, McParland BE, Bienkowska A, Tait R, Pare PD, Seow CY. 'Sarcomeres' of smooth muscle: functional characteristics and ultrastructural evidence. J Cell Sci; 118(pt 11):2381-2392, 2005. de Jong PA, Muller NL, Pare PD, Coxson HO. Computed tomographic imagine of the airways: relationship to structure and function. Eur Respir J. 2005 Jul;26(1):140-52. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005 Jul;60(7);570-585. Road, Dr. Jeremy Sheel W & Road J. Effects of physical activity on exercise capacity in twins with Alpha-1 antitrypsin deficiency. Clin J Sport Med. 15:183-185, 2005. Ryan, Dr. Francis (Frank) C Ryan CF. Obstructive sleep apnea hypopnea syndrome: an approach to treatment including upper airway surgery. Thorax 60:595-604, 2005. Al-Alawi A, Ryan CF, Flint JD, Muller NL. Aspergillus-related lung disease. Canadian Respir J 2005; 12:377-387. Kwiatkowska M, Ayas N, Ryan F. Evaluation of clinical prediction rules using a convergence of knowledge-driven and data-driven methods: a semio-fuzzy approach. Proceedings of the Sixth International Conference on Data Mining, Text Mining and their Business Applications. Champion P, Ryan F. A case of congenital cutis laza (generalized elastolysis) Can Respir J 12:151-2, 2005. Lam B, Ip MSM, Tench E, Ryan CF. Craniofacial profile in Asians and whites with obstructive sleep apnea. Thorax 60: 504-510, 2005. De Almeida FR, Lowe AA, Tsuiki S, Otsuka R, Wong M, Ryan CF. Longterm compliance and side effects of oral appliances used for the treatment of snoring and obstructive sleep apnea syndrome. J Clin Sleep Med 1:143-149, 2005. Sandford, Dr. Andrew J Zhang X, Ding L, Sandford AJ. Selection of reference genes for gene expression studies in human neutrophils by real-time PCR. BMC Mol. Biol. 2005;6:4. Kasuga I, Ruan J, Connett JE, Anthonisen NR, Sandford AJ. Lack of association of human leukocyte antigen-B7 with COPD and rate of decline in lung function. Respir. Med. 2005;99:1528-33. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwaia M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR. Genetic modifiers of lung disease in cystic fibrosis. N Engl. J. Med.
UBC Department of Medicine Page 203 Annual Report 2005
2005;353:1443-53. Sin, Dr. Donald D Sin DD, and Man SFP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proceedings of the American Thoracic Society 2005;2:8-11. Sin DD, Marrie TJ, and Man SFP. PC02 and mortality in pneumonia. American Journal of Medicine 2005;118:145-50. Sin DD, and Man SFP. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Canadian Journal of Physiology and Pharmacology 2005;83:1-13. Gan WQ, Man SFP, and Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005;127:558-64. Gan WQ, Man SFP, and Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BioMed Central Pulmonary Medicine 2005; 5:3. Man SFP, and Sin DD. Inhaled corticosteroids in chronic obstructive pulmonary disease (COPD): is there a clinical benefit? Drugs 2005;65:579-91. Sin DD, and Man SFP. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Canadian Journal of Physiology and Pharmacology 2005;83:1-13. Tsuyuki RT, Sin DD, Sharpe HM, Cowie RL, Man SFP. Management of asthma among community-based physicians. Journal of Asthma 2005;42:163-7. Wassa-Kintu S, Gan WG, Man SFP, Pare PD, and Sin DD. The relationship between forced expiratory volume in one second and the risk of lung cancer: a systematic review and a meta-analysis. Thorax 2005;60:570-5. Sin DD, Wu L, and Man SFP. The relationship between reduced lung function and cardiovascular mortality: a systematic review of the literature. Chest 2005;127:1952-9. Tkacova R, Toth S, Sin DD. Inhaled corticosteroids and survival in COPD patients receiving long- term home oxygen therapy. Respir Med 2005 [Epub ahead of print Aug]. Man SFP, Sin DD. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2005;2-78-82. Tebbutt, Dr. Scott J Tebbutt, S.J., Opushnyev, I.V., Tripp, B.W., Kassamali, A., Andersen, M. SNP Chart: an integrated platform for visualization and interpretation of microarray genotyping data. Bioinformatics 21:124- 127 (2005). Van Eeden, Dr. Stephan F Haddrell AE, Ishii H, van Eeden SF, Agnes GR. Apparatus for preparing mimics of suspended particles in the troposphere and their controlled deposition onto individual lung cells in culture with measurement of downstream biological response. Anal Chem. Jun 1;77(11):3623-8, 2005. Shih CH, Whalen BA, Goto Y, Hogg JC, van Eeden SF. Flow cytometric method for enumeration and characterization of newly released polymorphonuclear leukocytes from the bone marrow using 5'-Bromo-2'-deoxyrudine. Am J Physiol Apr 27; [Epub ahead of print] 2005. Yeung, Dr. Moira M Tsang KWT, Lo PL, Tan KC, Ooi BC, Ho JC, Mak J, Tipoe GL, Wu AY, Ip MS, Lam WK, Chan-Yeung M. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005. Ho SP, Chan-Yeung M, Chow K, Ip MS, Mak JC. Antioxidant enzyme activities in healthy Chinese adults: influence of age, gender and smoking. Respirology 2005.
UBC Department of Medicine Page 204 Annual Report 2005
RHEUMATOLOGY Choi, Dr. Hyon K Choi HK, Atkinson K, Karlson E, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men - The Health Professionals Follow-up Study. Arch Intern Med 2005;165:1-7. Choi HK, Liu S, Willett W, Curhan G. Intake of purine-rich foods, protein, dairy product, and serum uric acid level - The Third National Health and Nutritional Examination Survey. Arthritis Rheum 2005;52:283-9. Choi HK, Willett WC, Stampfer M, Rimm E, Hu FB. Dairy consumption and risk of Type 2 diabetes mellitus in men – a prospective study. Arch Intern Med 2005;165:742-748. Modawal A, Choi HK, Ferrer M, Caron JA. A meta-analysis on the efficacy of intra-articular viscosupplementation therapy for knee osteoarthritis. Fam Pract 2005;54:758-767. Matteson EL, Choi HK, Poe DS, et al. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum 2005;53:337-342. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005;53:528-535. Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005;32:1013-1019. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis: the Third National Health and Nutrition Examination Survey. J Rheumatol 2005;32:2311-6. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6396 persons with rheumatoid arthritis. J Rheumatol 2005;32:1875-83. Choi KH, Mount DB, Reginato AM, American College of Physicians, American Physiological Society. Pathogenesis of gout. Ann Intern Med 2005;143:499-516. Modawal A, Ferrer M, Choi KH, Castle JA. Hyaluronic acid injections relieve knee paid. J Fam Pract 2005;54:758-67. Choi HK. Diet, alcohol and gout: how do we advise patients given recent developments? Curr Rheumatol Rep 2005;7:220-6. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-5. Choi HK. Dietary risk factors for rheumatic diseases. Curr Opin Rheumatol 2005;17:141-6.
Cibere, Dr. Jolanda Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lobanok T, Ionescu M, Poole AR, Esdaile JM. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: Randomized discontinuation trial results employing biomarkers. J Rheumatol 2005; 32:896-902.
Ensworth, Dr. Stephanie Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Gordon C, Barr S, Edworthy S, Bae SC, Petri M, Sibley J, Isenberg D, Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcon GS, Hanly J, Sturfelt G, Nived O, Pope J, Ensworth S, Rajan R, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A, Ramsay-Goldman R. Race/ethnicity and cancer occurance in systemic lupus erythematosus. Arthritis Rheum 2005;53:781-4. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcon GS, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St. Pierre Y, Ramsay-Goldman R,Clarke A. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481- 90.
UBC Department of Medicine Page 205 Annual Report 2005
Esdaile, Dr. John M American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria (JM Esdaile, member). The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2005;50:3418-3426. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus (JM Esdaile, member). Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting. Arthritis Rheum 2005;50:3427-31. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, Esdaile JM, Anis AH. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82. Lacaille D, Anis A, Guh D, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005;53:241-8. Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, Brazier JE, Fortin PR, Anis AH. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005;14:1333-1344. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, and The METGO Study Team. A 48-week, randomized, double-blind, double-observer, placebo-controlled trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis. Arthritis Rheum 2005;52:1360-1370. Cibere J, Anona T, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lonescu M, Poole R, Esdaile JM. Glucosamine and type II collagen degradation: Results from a clinical trial. J Rheumatol 2005;32:896-902. Wong J, Esdaile JM. Methotrexate in systemic lupus erythematosus. Lupus 2005;13:101-5. Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, Penrod J, Joseph L, St. Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet JT, Choquette D, Grodzicky T, Esdaile JM, Clarke AE for the Tri-Nation Study Group. The systemic lupus erythematosus Tri-Nation study: Longitudinal changes in physical and mental well-being. Rheumatology 2005;44:751-5. Anis AH, Guh DP, Lacaille D, Marra CA, Rashidi AA, Li X, Esdaile JM. The unintended effects of cost-sharing for drugs among patients with rheumatoid arthritis. CMAJ 2005; 173:1355-1340. Anis AH, Guh DP, Lacaille D, Marra CA, Rashidi AA, Li X. When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. CMAJ 2005;173:1335-40. Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 2005;65:473-496.
Gillies, Dr. Jean Bent H, Ratzlaff CR, Goligher EC, Kopec JA, Gillies JH. Computer-administered BATH ankylosing spondylitis and Quebec Scale outcome questionnaires for low back pain: agreement with traditional paper format. J Rheumatol 2005;32:669-72.
Klinkhoff, Dr. Alice Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, and The METGO Study Team. A 48-week, randomized, double-blind, double-observer, placebo-controlled trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis. Arthritis Rheum 2005;52:1360- 1370. Klinkhoff A. An editorial is a golden opportunity. J Rheumatol 2005;32:978-9.
UBC Department of Medicine Page 206 Annual Report 2005
Almoallim H, Klinkhoff A. Longterm outcome of treatment of Felty’s syndrome with intramuscular gold: case reports and recommendations for management. J Rheumatol 2005;32:20-6.
Lacaille, Dr. Diane Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, and The METGO Study Group. A 48-week randomized, double-blind, double-observer, placebo-controlled multicentre trial of combination methotrexate and intramuscular gold in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005;52:1360-1370. Anis A, Guh D, Lacaille D, Marra C, Rashidi A, Li X, Esdaile JM. The unintended effects of cost- sharing for drugs among patients with rheumatoid arthritis. CMAJ 2005;173:1335-1344. Anis AH, Guh DP, Lacaille D, Marra CA, Rashidi AA, Li X. When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. CMAJ 2005;173:1335-40. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005;53:241-8. Lacaille D. Arthritis and employment research: where are we? Where do we need to go? J Rheumatol Suppl 2005;72:42-5. Patterson, Dr. A. Caroline Almoallim H, Patterson C. Microscopic polyangiits sparing the kidneys in a long-term survivor after allogeneic bone marrow transplantation and graft-versus host disease, Clin Rheumatol 2005;24:439- 441. Shojania, Dr. Kamran Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 2005;654:473-496. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, Esdaile JM, Anis AH. A comparison of generic, indirect utitlity measures (the HU12, HU13, SF-6D, and the EQ 5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;607:1571-82. Stein, Dr. Howard B Stein H, Gal-Or N: The debate on Canadian campuses: Bringing back debate and the spirit of Scholarship: inroads. Can J Opin 2005;6:44-51.
Wade, Dr. John Neustadt D, Caldwell J, Bell M, Wade J, Gimbel J. Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee: a randomized, controlled, multicenter trial. J Rheumatol 2005;32:1928-36.
UBC Department of Medicine Page 207 Annual Report 2005
GRANTS AND RESEARCH AWARDS
UBC Department of Medicine Page 208 Annual Report 2005